<SEC-DOCUMENT>0001140361-12-023627.txt : 20120508
<SEC-HEADER>0001140361-12-023627.hdr.sgml : 20120508
<ACCEPTANCE-DATETIME>20120508162726
ACCESSION NUMBER:		0001140361-12-023627
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120508
DATE AS OF CHANGE:		20120508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942756657
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14710
		FILM NUMBER:		12821773

	BUSINESS ADDRESS:	
		STREET 1:		2910 SEVENTH ST
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5106441170

	MAIL ADDRESS:	
		STREET 1:		2910 SEVENTH ST
		CITY:			BERKLEY
		STATE:			CA
		ZIP:			94710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10q.htm
<DESCRIPTION>XOMA CORPORATION 10-Q 03-31-2012
<TEXT>
<html>
<head>
    <title>form10q.htm</title>
    <!--Licensed to: Thomson Reuters-->
    <!--Document Created using EDGARizer 2020 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Washington, D.C.&#160;&#160;20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the quarterly period ended March 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">or</font></div>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the transition period from __________to__________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission File No. 0-14710</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">52-2154066</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of incorporation or organization)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S.&#160;&#160;Employer Identification No.)</font></div>
</td>
</tr><tr>
<td valign="middle" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="51%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2910 Seventh Street, Berkeley,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">California 94710</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(510) 204-7200</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices, </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">including zip code)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Telephone Number)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;&#160;No&#160;<font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;&#160;No&#160;<font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;(Do not check if a smaller </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">reporting company)</font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act of 1934).&#160;&#160;Yes&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Class</font></font></div>
</td>
<td valign="middle" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Outstanding at May 4, 2012</font></font></div>
</td>
</tr><tr>
<td valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock, $0.0075 par value</font></div>
</td>
<td valign="top" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">68,083,980</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="toc">TABLE OF CONTENTS</a></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Page</font></font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART&#160;I&#160;&#160;&#160;&#160; FINANCIAL INFORMATION</font></td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><!--efplaceholder-->Item&#160;1.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i1">Condensed Consolidated Financial Statements (unaudited)</a></font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#bs">Condensed Consolidated Balance Sheets as of March 31, 2012 and December 31, 2011</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#sop">Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2012 and 2011</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#cf">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2012 and 2011</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#notes">Notes to Condensed Consolidated Financial Statements</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;2.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;3.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i3">Quantitative and Qualitative Disclosures About Market Risk</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;4.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i4">Controls and Procedures</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td colspan="2" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART&#160;II&#160;&#160;&#160;&#160; OTHER INFORMATION</font></td>
<td valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;1.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i21">Legal Proceedings</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;1A.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i21a">Risk Factors</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;2.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i23">Unregistered Sales of Equity Securities and Use of Proceeds</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;3.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i22">Defaults Upon Senior Securities</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;4.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i24">Mine Safety Disclosure</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></font></div>
</div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;5.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#i24">Other Information</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;6.</font></div>
</td>
<td align="left" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#exhi">Exhibits</a></font></div>
</td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="2" valign="bottom" width="95%"><a href="#sig"><!--efplaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Signatures</font></a></td>
<td align="right" valign="bottom" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">- i -</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I - FINANCIAL INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1.&#160;&#160;CONDENSED CONSOLIDATED FINANC<a name="i1">IAL</a> STATEMENTS (unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED B<a name="bs">ALANC</a>E SHEETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands, except share and per share amounts)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Note 1)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current assets:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="range!a6"><!--efplaceholder--></a>Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trade and other receivables, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,164</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,674</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,019</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">88,725</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,695</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,329</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,709</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,268</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,632</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,322</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,036</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,852</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,128</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued and other liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,297</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,012</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,912</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,695</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest bearing obligation &#8211; current</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,796</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,796</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,857</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,631</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenue &#8211; long-term</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,207</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,539</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest bearing obligations &#8211; long-term</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,569</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,524</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contingent warrant liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other liabilities - long term</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,079</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">952</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">63,025</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock, $0.05 par value, 1,000,000 shares authorized</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.0075 par value, 92,666,666 shares authorized, 68,076,152 and 35,107,007 shares outstanding at March 31, 2012 and December 31, 2011, respectively</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">511</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">935,455</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,801</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(916,478</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(886,053</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,488</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,011</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,322</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,036</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Note 1) The condensed consolidated balance sheet as of December 31, 2011 has been derived from the audited financial statements as of that date included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEM<a name="sop">ENTS</a> OF OPERATIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands, except per share amounts)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three months ended March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License and collaborative fees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,014</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,827</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract and other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,851</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,768</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,865</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,595</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,771</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,347</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,679</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,369</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restructuring</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,227</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,716</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss from operations</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,362</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,121</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income (expense):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,042</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(664</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,057</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revaluation of contingent warrant liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,357</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss before taxes</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(30,425</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,320</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provision for income tax expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(30,425</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,335</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted net loss per share of common stock</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.69</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.22</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares used in computing basic and diluted net loss per share of common stock</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,353</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,180</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STAT<a name="cf">EMENTS </a>OF CASH FLOWS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash flows from operating activities:</font></div>
</td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="range!a5"><!--efplaceholder--></a>Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(30,425</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,335</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,265</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,346</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock contribution to 401(k)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,134</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,046</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">674</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,772</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued interest on interest bearing obligations</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">394</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">231</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revaluation of contingent warrant liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,357</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restructuring charge related to long-lived assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,707</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of discount and final payment fee on debt and debt issuance costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">467</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">298</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unrealized loss on foreign currency exchange</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">376</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,619</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unrealized loss on foreign exchange options</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">276</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other non-cash adjustments</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(43</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in assets and liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trade and other receivables, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,168</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,631</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,651</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">247</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,221</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,429</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">884</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,156</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(37</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(90</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,675</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash flows from investing activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(548</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(548</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash flows from financing activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of common stock, net of issuance costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39,480</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,129</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of long-term debt</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,102</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principal payments of debt</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(714</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38,766</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,231</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effect of exchange rate changes on cash</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(573</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase in cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,543</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,143</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at the beginning of the period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,304</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at the end of the period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56,874</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Supplemental Cash Flow Information:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid during the quarter for:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income taxes</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-cash investing and financing activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Discount on long-term debt</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,899</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of contingent warrant liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,386</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest added to principal balances on long-term debt</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">398</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO <a name="notes">CONDENSED CONSOLIDATED </a>FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of Business</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">XOMA Corporation (&#8220;XOMA&#8221; or the &#8220;Company&#8221;), a Delaware corporation, combines a portfolio of late-stage clinical programs and research activities to develop innovative therapeutic antibodies with its recently launched commercial operations.&#160; XOMA focuses its scientific research on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.&#160;&#160;XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (&#8220;Servier&#8221;) through a global Phase 3 program and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA&#8217;s scientific research also has produced the XMet platform, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators that could offer new approaches in the treatment of diabetes.&#160;&#160;In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier&#8217;s ACEON&#174; (perindopril erbumine) and certain U.S. rights to a patent-protected portfolio of fixed dose combination product candidates where perindopril is combined with other active ingredients to treat cardiovascular disease.&#160;XOMA has the right to develop and commercialize one of these product candidates and options to develop and commercialize two more product candidates, all for the U.S. market.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Presentation and Significant Accounting Policies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Presentation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The condensed consolidated financial statements include the accounts of XOMA and its subsidiaries. All intercompany accounts and transactions were eliminated during consolidation. The unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 14, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are necessary to present fairly the Company&#8217;s consolidated financial position as of March 31, 2012, the consolidated results of the Company&#8217;s operations and the Company&#8217;s cash flows for the three months ended March 31, 2012 and 2011. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year or future periods.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of Estimates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, research and development expense, long-lived assets, restructuring liabilities, derivative instruments and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company&#8217;s billing under government contracts. Under the Company&#8217;s contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), the Company bills using NIH provisional rates and thus are subject to future audits at the discretion of NIAID&#8217;s contracting office. These audits can result in an adjustment to revenue previously reported.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Option Pricing Model (&#8220;Black-Scholes Model&#8221;) used to calculate the fair value of its contingent warrant liabilities. The Company changed its assumption from an estimate of volatility based on historical stock price volatility observed on XOMA&#8217;s underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions, which was determined to be a more precise indicator for the fair value calculation of the Company&#8217;s warrants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reclassifications</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain reclassifications of prior period amounts have been made to the financial statements and accompanying notes to conform to the current period presentation. Prior period presentation of contingent warrant liabilities has been reclassified from current liabilities to long-term liabilities based on the contingent nature of these obligations. These contingent warrant liabilities represent a conditional obligation of the Company to repurchase certain warrants for cash in the event of a change in control. In addition, gain or loss on revaluation of the contingent warrant liabilities included in the other income (expense) line of the condensed consolidated statement of operations in the prior period has been reclassified to the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. These reclassifications had no impact on the Company&#8217;s previously reported net loss or cash flows.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-lived Assets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company reviews the carrying values and depreciation estimates of its long-lived assets whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the estimated future net cash flows expected to result from the use of an asset is less than its carrying amount. Long-lived assets include property and equipment and building and leasehold improvements. During the three months ended March 31, 2012, the Company recorded an impairment loss of $0.8 million and accelerated depreciaton of $0.9 million&#160;on long-lived assets in connection with the Company&#8217;s 2012 streamlining plan. See <font style="FONT-STYLE: italic; DISPLAY: inline">Note 6: Streamlining and Restructuring Charges</font> for additional disclosure on the 2012 streamlining plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Concentration of Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash equivalents and receivables are financial instruments, which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents such as money market funds. The Company has not encountered such issues during 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2012, two customers represented 49% and 40% of total revenue and 63% and 37% of the accounts receivable balance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2011, these two customers represented 51% and 44% of total revenues. As of December 31, 2011, there were receivables outstanding from these two customers representing 57% and 43% of the accounts receivable balance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Newly Adopted Accounting Pronouncements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2011, Accounting Standards Codification Topic 820, <font style="FONT-STYLE: italic; DISPLAY: inline">Fair Value Measurement</font> was amended to develop common requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. generally accepted accounting principles and international financial reporting standards. The Company adopted this guidance as of January 1, 2012 on a retrospective basis and this adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June 2011, Accounting Standards Codification Topic 220, <font style="FONT-STYLE: italic; DISPLAY: inline">Comprehensive Income</font> was amended to increase the prominence of items reported in other comprehensive income. Accordingly, a company can present all nonowner changes in stockholders&#8217; equity either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The Company adopted this guidance as of January 1, 2012 on a retrospective basis and this adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Condensed Consolidated Financial Statement Detail</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comprehensive Loss</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Comprehensive loss is equal to net loss for both the three months ended March 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss Per Share of Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic and diluted net loss per share of common stock is based on the weighted average number of shares of common stock outstanding during the period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Potentially dilutive securities are excluded from the calculation of earnings per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock options and restricted stock units</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,722</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,638</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible preferred stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">254</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants for common stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,457</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,607</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,179</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,499</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2012 and 2011, all outstanding securities were considered anti-dilutive, and therefore the calculation of basic and diluted net loss per share was the same.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2012 cash equivalents consisted of demand deposits of $14.4 million, money market funds of $50.5 million, and U.S. government securities of $10.0 million with maturities of less than 90 days at the date of purchase. At December 31, 2011, cash equivalents consisted of demand deposits of $21.1 million and money market funds of $27.2 million with maturities of less than 90 days at the date of purchase.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Foreign Exchange Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company holds debt and may incur expenses denominated in foreign currencies, which exposes it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and the Euro. The Company is required to make principal and accrued interest payments in Euros on its &#8364;15.0 million loan from Servier (See <font style="FONT-STYLE: italic; DISPLAY: inline">Note 7: Long-Term Debt and Other Financings</font>). In order to manage its foreign currency exposure related to these payments, in May 2011, the Company entered into two foreign exchange option contracts to buy &#8364;15.0 million and &#8364;1.5 million on January 2016 and January 2014, respectively. By having these option contracts in place, the Company&#8217;s foreign exchange rate risk is reduced if the U.S. dollar weakens against the Euro. However, if the U.S. dollar strengthens against the Euro, the Company is not required to exercise these options, but will not receive any refund on premiums paid.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upfront premiums paid on these foreign exchange option contracts totaled $1.5 million. The fair values of these option contracts are re-valued at each reporting period and are estimated based on pricing models using readily observable inputs from actively quoted markets. The fair values of these option contracts are included in other assets on the condensed consolidated balance sheet and changes in fair value on these contracts are included in other income (expense) on the condensed consolidated statements of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The foreign exchange options were revalued at March 31, 2012 and had an aggregate fair value of $0.9 million resulting in a related loss of $0.3 million for the three months ended March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued Liabilities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accrued liabilities consisted of the following at March 31, 2012 and December 31, 2011 (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued payroll and other benefits</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,155</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,007</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued management incentive compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">996</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,096</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued restructuring costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">891</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued professional fees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">917</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued severance payments</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">551</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,207</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">944</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">715</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,297</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,012</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contingent Warrant Liabilities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of XOMA&#8217;s common stock at an exercise price of $1.76 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in March 2012 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At issuance, the fair value of the warrant liability was estimated to be $6.4 million using the Black-Scholes Model. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded an increase in the fair value of $14.7 million as a loss in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, 14,832,827 of these warrants were outstanding and had a fair value of $21.1 million. This increase in liability is primarily due to the excess of the market value of the Company&#8217;s common stock at March 31, 2012 compared to the warrant exercise price. See <font style="FONT-STYLE: italic; DISPLAY: inline">Note 4: Fair Value Measurements </font>for further disclosure regarding the fair value of this warrant liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, in connection with an underwritten offering, the Company issued five-year warrants to purchase 1,260,000 shares of XOMA&#8217;s common stock at an exercise price of $10.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in February 2010 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.3 million using the Black-Scholes Model. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA&#8217;s underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.3 million as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding. See <font style="FONT-STYLE: italic; DISPLAY: inline">Note 4: Fair Value Measurements </font>for further disclosure regarding the fair value of this warrant liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June 2009, the Company issued warrants to certain institutional investors as part of a registered direct offering. The warrants represent the right to acquire an aggregate of up to 347,826 shares of XOMA&#8217;s common stock over a five year period beginning December 11, 2009 at an exercise price of $19.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in June 2009 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.1 million using the Black-Scholes Model. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA&#8217;s underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.1 million as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding. See <font style="FONT-STYLE: italic; DISPLAY: inline">Note 4: Fair Value Measurements </font>for further disclosure regarding the fair value of this warrant liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value Measurements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies ASC 820, which establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 1 &#8211; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Quoted prices in active markets for identical assets or liabilities.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 2 &#8211;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Observable inputs other than quoted prices in active markets for similar assets or liabilities.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 3 &#8211; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unobservable inputs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents) and liabilities measured at fair value on a recurring basis as of March 31, 2012 and December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial assets and liabilities carried at fair value as of March 31, 2012 and December 31, 2011 were classified as follows (in thousands):</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value Measurements at March 31, 2012 Using</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quoted Prices in </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Active Markets for </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Identical Assets</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Significant </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Observable </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inputs</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Significant </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unobservable </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inputs</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Level&#160;1)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Level&#160;2)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Level&#160;3)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Money market funds <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,523</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,523</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. government securities <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,999</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,999</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Foreign exchange options</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">926</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">926</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,522</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">926</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,448</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contingent warrant liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value Measurements at December 31, 2011 Using</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quoted Prices in </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Active Markets for </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Identical Assets</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Significant </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Observable </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inputs</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Significant </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unobservable </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inputs</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Level&#160;1)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Level&#160;2)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Level&#160;3)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Money market funds <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,222</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,222</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Foreign exchange options</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,202</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,202</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,222</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,202</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,424</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contingent warrant liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;Included in cash and cash equivalents</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value of the foreign exchange options at March 31, 2012 and December 31, 2011 was determined using readily observable market inputs from actively quoted markets obtained from various third party data providers. These inputs, such as spot rate, forward rate and volatility have been derived from readily observable market data, meeting the criteria for Level 2 in the fair value hierarchy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value of the contingent warrant liabilities was determined at March 31, 2012 and December 31, 2011 using the Black-Scholes Model, which requires inputs such as the expected term of the warrants, volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA&#8217;s underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. A market-based volatility rate was determined to be a more precise indicator for the fair value calculation of the Company&#8217;s warrants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value of the contingent warrant liabilities was estimated using the following range of assumptions at March 31, 2012 and December 31, 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="60%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">102.1% - 103.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-free interest rate</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.5% - 1.05</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected term</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.7 - 4.9 years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.9 - 3.1 years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table provides a summary of changes in the fair value of the Company&#8217;s Level 3 financial liabilities for the three months ended March 31, 2012 (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contingent warrant liabilities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December&#160;31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Initial fair value of warrants issued in March 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification of contingent warrant liability to equity upon exercise of warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase in fair value of contingent warrant liabilities upon revaluation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,357</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at March 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The net increase of $14.4 million in the estimated fair value of the contingent warrant liabilities was recognized as a loss in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of operations for the three months ended March 31, 2012.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2011, the Company recognized a net decrease of $2.4 million in the estimated fair value of the contingent warrant liabilities as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Licensing, Collaborative and Other Arrangements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Servier &#8211; U.S. Perindopril Franchise</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 17, 2012, the Company announced that it had acquired certain U.S. rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON&#174; (perindopril erbumine), a currently marketed ACE inhibitor, and three fixed-dose combination (&#8220;FDC&#8221;) product candidates where a form of proprietary perindopril (perindopril arginine) is combined with another active ingredient(s), such as a calcium channel blocker. The Company assumed commercialization activities for ACEON&#174; in January 2012 following the transfer from Servier&#8217;s previous licensee.&#160;&#160;In late February 2012, the Company initiated enrollment in a Phase 3 trial for perindopril arginine and amlodipine besylate, the first FDC product candidate. The trial, named PATH (<font style="DISPLAY: inline; FONT-WEIGHT: bold">P</font>erindopril <font style="DISPLAY: inline; FONT-WEIGHT: bold">A</font>mlodipine for the <font style="DISPLAY: inline; FONT-WEIGHT: bold">T</font>reatment of <font style="DISPLAY: inline; FONT-WEIGHT: bold">H</font>ypertension), is expected to enroll approximately 816 patients with hypertension to determine the safety and efficacy of the FDC versus either perindopril or amlodipine alone. Based on regulatory interaction to date, if&#160;the trial generates positive results, it is expected to be the only&#160;efficacy trial needed to complement&#160;existing clinical data&#160;and will&#160;support&#160;the submission of an application to the FDA seeking approval for this product candidate. Partial funding for the PATH trial was provided by Servier; the balance of study expenses, consisting primarily of costs generated by the Company&#8217;s contract research organization, are expected to be paid over time from the profits generated by the Company&#8217;s ACEON&#174; sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the original agreement, the Company paid a $1.5 million license fee to Servier in the third quarter of 2010. The Company also is required to pay a royalty on ACEON&#174; sales at a rate that is tiered based on sales levels and ranges from a mid-single digit to a mid-teen percentage rate. If approved, the Company also will pay a royalty on sales of the FDC product candidates in the mid-teen percentage rate. The FDC royalty rate is subject to reduction in the event of generic competition or if other intellectual property rights are required. The Company may be required to pay the following milestones: development milestones aggregating $8.5 million (assuming the Company exercises its options on the additional FDCs) and sales milestones of up to an aggregate $15.1 million, in each case for all of the FDC product candidates. The Company also may be required to make certain additional payments if the FDC product candidates receive FDA approval but certain minimum sales levels are not reached. The Company generally will be responsible for its development and commercialization expenses, but Servier has agreed to partially fund development of the first FDC product candidate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Streamlining and Restructuring Charges</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January 2012, the Company implemented a streamlining of operations, which resulted in a restructuring plan designed to sharpen its focus on value-creating opportunities led by gevokizumab and its unique antibody discovery and development capabilities. The restructuring plan included a reduction of XOMA&#8217;s personnel by 84 positions, or 34%, of which 52 were eliminated immediately and the remainder eliminated as of April 6, 2012. These staff reductions resulted primarily from the Company&#8217;s decisions to utilize a contract manufacturing organization for Phase 3 and commercial antibody production and to eliminate internal research functions that are non-differentiating or that can be obtained cost-effectively by contract service providers.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the three months ended March 31, 2012, in connection with this streamlining of operations, the Company recorded charges of $2.1 million related to severance, other termination benefits and outplacement services. The Company expects to incur an additional $0.1 million restructuring charge in the second quarter of 2012 related to severance, other termination benefits and outplacement services.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company plans to vacate two of its leased buildings in 2012 related to manufacturing operations and internal research functions. The Company did not incur any restructuring charges during the first quarter of 2012 in connection with the exit of these leased buildings as they are still in use; however, it expects to incur restructuring charges of approximately $1.2 million in the remainder of 2012, primarily related to the net present value of future minimum lease payments at the cease-use date, less potential estimated future sublease income.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2012, the Company performed an impairment analysis of property and equipment and leasehold improvements related to its manufacturing operations. Since the estimated undiscounted future cash inflows from a&#160;certain group of these assets were less than the carrying value, the Company determined that&#160;these assets&#160;were impaired and recorded a restructuring charge of $0.8 million. Further, the Company changed the useful life of certain property and equipment and leasehold improvements impacted by XOMA<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s plans to vacate two leased buildings. As a result, the Company recorded accelerated depreciation of $0.9 million as a restructuring charge.&#160;The Company expects to incur additional restructuring charges of approximately $0.7 million in the remainder of &#160;2012 related to the&#160;accelerated depreciation&#160;of leasehold improvements.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The current and long-term portions of the outstanding restructuring liabilities are included in accrued and other liabilities and other liabilities &#8211; long-term on the condensed consolidated balance sheets and are based upon restructuring charges recognized as of March&#160;31, 2012 and December 31, 2011 in connection with the 2009 and 2012 restructuring plans. As of March&#160;31, 2012, the components of these liabilities are shown below (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employee Severance </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Other Benefits</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Facility Charges</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Asset </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Impairment <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">162</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">162</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restructuring charges</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,070</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,707</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash payments</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,258</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,281</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,707</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,699</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at March 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">812</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">147</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">959</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;Restructuring charges include non-cash impairments of property and equipment and leasehold improvements. However, these amounts are not included in the restructuring accrual.</font><br>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The restructuring charges the Company expects to incur in connection with the 2012 streamlining of operations are subject to various assumptions, and actual results may differ.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-Term Debt and Other Financings</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-Term Debt</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Novartis Note</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2005, the Company executed a secured note agreement with Novartis (then Chiron Corporation), which is due and payable in full in June 2015. Under this note agreement, the Company borrowed semi-annually to fund up to 75% of the Company&#8217;s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50 million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus 2%, which was equal to 2.80% at March 31, 2012, and is payable semi-annually in June and December of each year. At the Company&#8217;s election, the semi-annual interest payments can be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $50 million. The Company has made this election for all interest payments thus far. Loans under the note agreement are secured by the Company&#8217;s interest in the collaboration with Novartis, including any payments owed to it thereunder.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2012 and December 31, 2011, the outstanding principal balance under this note agreement was $14.0 million. Pursuant to the terms of the arrangement as restructured in November 2008, the Company will not make any additional borrowings under the Novartis note. Due to the structure of the secured note agreement with Novartis and since there is no liquid market for this obligation, there is no practical method to estimate fair value of this long-term debt.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Servier Loan</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2010, in connection with the license and collaboration agreement entered into with Servier, the Company executed a loan agreement with Servier, which provided for an advance of up to &#8364;15 million. The loan was fully funded in January 2011, with the proceeds converting to approximately $19.5 million. The loan is secured by an interest in XOMA&#8217;s intellectual property rights to all gevokizumab indications worldwide, excluding certain rights in the U.S. and Japan. Interest is calculated at a floating rate based on a Euro Inter-Bank Offered Rate (&#8220;EURIBOR&#8221;) and subject to a cap. The interest rate for the initial interest period was 3.22%. The interest rate has been reset to 3.83% for the six-month period from July 2011 through January 2012 and 3.54% for the six-month period from January 2012 through July 2012. Interest is payable semi-annually; however, the loan agreement provides for a deferral of interest payments over a period specified in the agreement. During the deferral period, accrued interest will be added to the outstanding principal amount for the purpose of interest calculation for the next six-month interest period. On the repayment commencement date, all unpaid and accrued interest shall be paid to Servier and thereafter, all accrued and unpaid interest shall be due and payable at the end of each six-month period. The loan matures in 2016; however, after a specified period prior to final maturity, the loan is to be repaid (i) at Servier's option, by applying up to a significant percentage of any milestone or royalty payments owed by Servier under the Company&#8217;s collaboration agreement and (ii) using a significant percentage of any upfront, milestone or royalty payments the Company receives from any third party collaboration or development partner for rights to gevokizumab in the U.S. and/or Japan.&#160; In addition, the loan becomes immediately due and payable upon certain customary events of default. At March 31, 2012 and December 31, 2011, the outstanding principal balance under this loan was $20.0 million and $19.4 million, respectively, using the Euro to US Dollar (&#8220;USD&#8221;) exchange rate at each such date. For the three months ended March 31, 2012 and 2011, the Company recorded unrealized foreign exchange losses of $0.6 million and $1.6 million, respectively, related to the re-measurement of the loan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The loan has a stated interest rate lower than the market rate based on comparable loans held by similar companies, which represents additional value to the Company. The Company recorded this additional value as a discount to the face value of the loan amount, at its fair value of $8.9 million. The fair value of this discount, which was determined using a discounted cash flow model, represents the differential between the stated terms and rates of the loan, and market rates. Based on the association of the loan with the collaboration arrangement, the Company recorded the offset to this discount as deferred revenue.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The loan discount is amortized under the effective interest method over the expected five-year life of the loan.&#160;&#160;The Company recorded non-cash interest expense of $0.3 million in the three months ended March 31, 2012 and 2011, resulting from the amortization of the loan discount. At March 31, 2012 and December 31, 2011, the net carrying value of the loan was $13.2 million and $12.5 million, respectively. For the three months ended March 31, 2012, the Company recorded an unrealized foreign exchange loss of $0.2 million related to the re-measurement of the loan discount as of March 31, 2012.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company believes that realization of the benefit and the associated deferred revenue is contingent on the loan remaining outstanding over the five-year contractual term of the loan. If the Company were to stop providing service under the collaboration arrangement and the arrangement is terminated, the maturity date of the loan would be accelerated and a portion of measured benefit would not be realized. As the realization of the benefit is contingent, in part, on the provision of future services, the Company is recognizing the deferred revenue over the expected five-year life of the loan. The deferred revenue is amortized under the effective interest method, and the Company recorded $0.3 million of related non-cash revenue during both the three months ended March 31, 2012 and 2011.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General Electric Capital Corporation Term Loan</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2011, the Company entered into a loan agreement (the &#8220;Loan Agreement&#8221;) with General Electric Capital Corporation (&#8220;GECC&#8221;), under which GECC agreed to make a term loan in an aggregate principal amount of $10 million (the &#8220;Term Loan&#8221;) to XOMA (US) LLC, a wholly owned subsidiary of the Company, and upon execution of the Loan Agreement, GECC funded the Term Loan. The Term Loan is guaranteed by the Company and its two other principal subsidiaries, XOMA Ireland Limited and XOMA Technology Ltd.&#160;&#160;As security for their obligations under the Loan Agreement, the Company, XOMA (US) LLC, XOMA Ireland Limited and XOMA Technology Ltd. each granted a security interest pursuant to a guaranty, pledge and security agreement in substantially all of their existing and after-acquired assets, excluding their intellectual property assets (such as those relating to the Company&#8217;s gevokizumab and anti-botulism products). The Company incurred debt issuance costs of approximately $1.3 million in connection with the Term Loan and will make an additional payment equal to 5% of the Term Loan (the &#8220;Final Payment Fee&#8221;) on the maturity date, or such earlier date as the Term Loan is paid in full. The debt issuance costs and Final Payment Fee are being amortized and accreted, respectively, to interest expense over the term of the Term Loan using the effective interest method.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Term Loan accrues interest at a fixed rate of 11.71% per annum. We are required to repay the principal amount of the Term Loan over a period of 42 consecutive equal monthly installments of principal and accrued interest, commencing on January 4, 2012, and thereafter on the first calendar day of each succeeding month.&#160;&#160;The Term Loan matures and is due and payable in full on June 30, 2015.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including restrictions on the ability to incur indebtedness, grant liens, make investments, dispose of assets, enter into transactions with affiliates and amend existing material agreements, in each case subject to various exceptions.&#160;&#160;In addition, the Loan Agreement contains customary events of default that entitle GECC to cause any or all of the indebtedness under the Loan Agreement to become immediately due and payable. The events of default include any event of default under a material agreement or certain other indebtedness. Upon an event of default, the Term Loan and other obligations under the Loan Agreement will, at the election of GECC, bear interest from and after the occurrence and during the continuation of an event of default at a rate equal to the lesser of 5.0% above the stated rate of interest or the maximum rate allowed by law.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company may voluntarily prepay the Term Loan in full, but not in part, and any voluntary and certain mandatory prepayments are subject to a prepayment premium of 3% in the first year of the loan, 2% in the second year and 1% thereafter, although mandatory prepayments in connection with entering into certain exclusive licenses, granting certain negative pledges or incurring certain collaboration-related indebtedness will not be subject to such prepayment premium.&#160;&#160;The Company will also be required to pay the Final Payment Fee in connection with any voluntary or mandatory prepayment. At March 31, 2012 and December 31, 2011, the outstanding principal balance under the Loan Agreement was $9.3 million and $10.0 million respectively.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2011, pursuant to the loan agreement, the Company issued to GECC unregistered stock purchase warrants, which entitle GECC to purchase up to an aggregate of 263,158 unregistered shares of XOMA common stock at an exercise price equal to $1.14 per share. These warrants are immediately exercisable and will expire on December 30, 2016. The Company allocated the aggregate proceeds of the GECC Term Loan between the warrants and the debt obligation based on their relative fair values.&#160;&#160;The fair value of the warrants issued to GECC was determined using the Black-Scholes Model. The warrants fair value of $0.2 million is recorded as a discount to the debt obligation and is being amortized over the term of the loan using the effective interest method. If the maturity of the debt is accelerated in connection with any voluntary or mandatory prepayment, then the remaining discount amortization would be recognized immediately.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest expense for the Servier loan, GECC loan and Novartis note are shown below (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest expense</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Servier loan</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">516</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GECC term loan</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">417</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Novartis note</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">84</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,042</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Financings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATM Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 4, 2011, the Company entered into an At Market Issuance Sales Agreement (the &#8220;2011 ATM Agreement&#8221;), with McNicoll, Lewis &amp; Vlak LLC (now known as MLV &amp; Co. LLC, &#8220;MLV&#8221;), under which it may sell shares of its common stock from time to time through the MLV, as the agent for the offer and sale of the shares, in an aggregate amount not to exceed the amount that can be sold under the Company&#8217;s registration statement on Form S-3 (File No. 333-172197) filed with the SEC on February 11, 2011 and amended on March 10, 2011, June 3, 2011 and January 3, 2012, which was most recently declared effective by the SEC on January 17, 2012. MLV may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for the Company&#8217;s common stock or to or through a market maker. MLV may also sell the shares in privately negotiated transactions, subject to the Company&#8217;s prior approval. From the inception of the 2011 ATM Agreement through March 31, 2012, the Company sold a total of 7,572,327 shares of common stock under this agreement for aggregate gross proceeds of $14.6 million, including 2,285,375 shares of common stock sold in the first quarter of 2012 for aggregate gross proceeds of $3.3 million. Total offering expenses incurred related to sales under the 2011 ATM Agreement from inception to March 31, 2012, were $0.4 million, including $0.1 million incurred in the first quarter of 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Underwritten Offering and Amendment to Shareholder Rights Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 9, 2012, the Company completed an underwritten public offering of 29,669,154 shares of its common stock, and accompanying warrants to purchase one half of a share of common stock for each share purchased, at a public offering price of $1.32 per share. Total gross proceeds from the offering were approximately $39.2 million, before deducting underwriting discounts and commissions and estimated offering expenses totaling approximately $2.9 million. The warrants, which represent the right to acquire an aggregate of up to 14,834,577 shares of common stock, are immediately exercisable and have a five-year term and an exercise price of $1.76 per share.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has amended its shareholder rights agreement to provide that it will not apply to any person or entity who becomes the beneficial owner of 20% or more but less than 40% of its outstanding common stock with the prior approval of its board of directors, and its board has approved purchasers in&#160;the March 2012 public offering becoming beneficial owners of 20% or more but less than 40% of its outstanding common stock as a result of their participation in the offering.&#160; As a result, such ownership by any such purchaser will not trigger the provisions of the rights agreement that would give each holder of the rights the right to receive upon exercise that number of common stock equivalents having a market value of two times the exercise price.&#160;&#160;The board's approval in this regard only applies to purchasers in&#160;such offering.&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company did not recognize any income tax expense for the three months ended March 31, 2012 and income tax expense was not material for the three months ended March 31, 2011. The Company&#8217;s effective tax rate will fluctuate from period to period due to several factors inherent in the nature of the Company&#8217;s operations and business transactions. The factors that most significantly impact this rate include the variability of licensing transactions in foreign jurisdictions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-based Compensation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the first quarter of 2012, the Board of Directors of the Company approved grants under the Long Term Incentive Plan for an aggregate of 940,900 stock options and an aggregate of 343,115 restricted stock units (&#8220;RSUs&#8221;) to certain employees of the Company. The options vest monthly over four years and the RSUs vest annually over three years in equal increments.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. This model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues. The forfeiture rate impacts the amount of aggregate compensation for both stock options and RSUs. To establish an estimate of forfeiture rate, the Company considers its historical experience of option forfeitures and terminations.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value of stock-based awards was estimated based on the following weighted average assumptions for the three months ended March 31, 2011 and 2010:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend yield</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">92</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">86</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-free interest rate</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.05</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.20</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected term</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.6 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="3" valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.6 years</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock option activity for the three months ended March 31, 2012 was as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="42%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise Price </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Per Share</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Remaining </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual Life </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in years)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Aggregate </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intrinsic Value </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options outstanding at December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,053,435</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12.55</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.89</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">940,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.45</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(24,730</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.69</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited, expired or cancelled</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(167,484</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21.65</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options outstanding at March 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,802,121</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.53</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.28</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options exercisable at March 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,567,292</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14.96</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.45</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">867</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The valuation of RSUs is determined at the date of grant using the closing stock price. To establish an estimate of forfeiture rate, the Company considers its historical experience of forfeitures and terminations.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unvested RSU activity for the three months ended March 31, 2012 is summarized below:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted-</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="56%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average Grant-</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date Fair Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unvested balance at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">903,874</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.69</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">343,115</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.29</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(132,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.69</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unvested balance at March 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,114,414</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.57</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2012 and 2011 (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">385</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">289</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">711</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="56%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stock-based compensation expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">674</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,772</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10.&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Legal Proceedings, Commitments and Contingencies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 9, 2009, a complaint was filed in the Superior Court of Alameda County, California, in a lawsuit captioned Hedrick et al. v. Genentech, Inc. et al, Case No. 09-446158. The complaint asserts claims against Genentech, the Company and others for alleged strict liability for failure to warn, strict product liability, negligence, breach of warranty, fraudulent concealment, wrongful death and other claims based on injuries alleged to have occurred as a result of three individuals&#8217; treatment with RAPTIVA&#174;. The complaint seeks unspecified compensatory and punitive damages. Since then, additional complaints have been filed in the same court, bringing the total number of filed cases to seventy seven.&#160; The cases have been consolidated as a coordinated proceeding. &#160;All of the complaints allege the same claims and seek the same types of damages based on injuries alleged to have occurred as a result of the plaintiffs' treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of all but one of the cases pending in Alameda County Superior Court.&#160; The one Alameda County case not included in this settlement agreement is Kilzer v. Genentech, Inc., et al, Case No. RG-10-502461.&#160; The Company&#8217;s agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.&#160;&#160; The Company believes the claims against it to be without merit and intends to defend against them vigorously.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 4, 2010, a petition was filed in the District Court of Dallas County, Texas in a case captioned McCall v. Genentech, Inc., et al., No. 10-09544.&#160; The defendants filed a Notice of Removal to the United States District Court for the Northern District of Texas on September 3, 2010.&#160; The removed case is captioned McCall v. Genentech, Inc., et al., No. 3:10-cv-01747-B. The petition asserts personal injury claims against Genentech, the Company and others arising out of plaintiff&#8217;s treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; The Company&#8217;s agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 7, 2011, a complaint was filed in the United States District Court for the Northern District of Texas in a case captioned Massa v. Genentech, Inc., et al., No. 4:11CV70. This complaint alleges the same claims against Genentech, the Company and others and seeks the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; The Company&#8217;s agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 11, 2011, a complaint was filed in the United States District Court for the District of Massachusetts in a case captioned Sylvia, et al. v. Genentech, Inc., et al., No. 1:11-cv-10054-MLW.&#160; On June 13, 2011, a complaint was filed in the Supreme Court for the State of New York, Onondaga County.&#160; Defendants removed the case to the United States District Court for the Northern District of New York on November 3, 2011. &#160;These two complaints allege the same claims against Genentech, the Company and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; No trial date has been set in either case. The Company&#8217;s agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which the Company believes is applicable to these matters. The Company believes the claims against it to be without merit and intends to defend against them vigorously.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 8, 2011, four complaints were filed in the United States District Court for the Eastern District of Michigan.&#160; The cases are captioned:&#160; Muniz v. Genentech, et al., 5:11-cv-11489-JCO-RSW; Tifenthal v. Genentech, et al., 2:11-cv-11488-DPH-LJM; Blair v. Genentech, et al., 2:11-cv-11463-SFC-MJH; and Marsh v. Genentech, et al., 2:11-cv-11462-RHC-MKM.&#160; The complaints allege the same claims against Genentech, the Company and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; All four cases were transferred to the United States District Court for the Western District of Michigan.&#160; On October 26, 2011, the Court granted the Motions to Dismiss filed by Genentech and the Company in all four actions.&#160; On October 31, 2011, Plaintiffs filed a Notice of Appeal in each case in the United States Court of Appeal for the Sixth Circuit.&#160; The Company&#8217;s agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which the Company believes is applicable to these matters. The Company believes the claims against it to be without merit and intends to defend against them vigorously.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANA<a name="i2">LY</a>SIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts in our condensed consolidated financial statements and accompanying notes. On an on-going basis, we evaluate our estimates including, but not limited to, those related to terms of revenue recognition, long-lived assets, contingent warrant liabilities and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a leader in the discovery and development of innovative antibody-based therapeutics. Our lead drug candidate is gevokizumab (formerly XOMA 052), a humanized antibody that binds to the inflammatory cytokine interleukin-1 beta (&#8220;IL-1 beta&#8221;).&#160;&#160;In collaboration with our partner, Les Laboratoires Servier (&#8220;Servier&#8221;), gevokizumab is expected to enter global Phase 3 clinical development in 2012 for non-infectious uveitis (&#8220;NIU&#8221;) and Beh&#231;et&#8217;s uveitis.&#160;&#160;We anticipate Servier will enter gevokizumab into a Phase 2 study in a cardiovascular disease indication during 2012.&#160;&#160;Separately we have launched a Phase 2 proof-of-concept program for gevokizumab to evaluate additional indications for further development, including a clinical trial in moderate-to-severe inflammatory acne, which began enrolling patients in December 2011, and a clinical trial in erosive osteoarthritis of the hand, for which we plan to initiate enrollment in the second quarter of 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have entered into a license and collaboration agreement with Servier to jointly develop and commercialize gevokizumab in multiple indications.&#160;&#160;Gevokizumab is designed to inhibit the pro-inflammatory cytokine IL-1 beta, which is believed to be a primary trigger of pathologic inflammation in multiple diseases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our proprietary preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo and represent potential new therapeutic approaches to the treatment of diabetes.&#160;&#160;We have developed these and other antibodies using some or all of our ADAPT&#8482; antibody discovery and development platform, our ModulX&#8482; technologies for generating allosterically modulating antibodies, and our OptimX&#8482; technologies for optimizing biophysical properties of antibodies, including affinity, immunogenicity, stability and manufacturability.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January 2012, we announced that we had acquired certain U.S. rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON&#174; (perindopril erbumine), a currently marketed angiotensin converting enzyme (&#8220;ACE&#8221;) inhibitor, and three fixed-dose combination (&#8220;FDC&#8221;) product candidates where perindopril is combined with another active ingredient(s), such as a calcium channel blocker. The proprietary form of perindopril in each of the combination product candidates provides patent protection until December 2023. We assumed commercialization activities for ACEON&#174; in January 2012 following the transfer from Servier&#8217;s previous licensee.&#160;&#160;In late February 2012, we initiated enrollment in a Phase 3 trial for perindopril arginine and amlodipine besylate, the first FDC product candidate.&#160;&#160;Partial funding for the Phase 3 trial will be provided by Servier; the balance of study expenses, consisting primarily of costs generated by our contract research organization, are expected to be paid by us over time from any profits generated by our ACEON&#174; sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our biodefense initiatives currently include a $65.0 million multiple-year contract funded by the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), to support our ongoing development of anti-botulism antibody product candidates, of which the first, XOMA 3AB, is in a Phase 1 clinical trial.&#160;&#160;This contract is the third that NIAID has awarded us for the development of botulinum antitoxins.&#160;&#160;In October 2011, we announced that we had been awarded a fourth contract for up to $28.0 million over five years to develop broad-spectrum antitoxins for the treatment of human botulism poisoning, bringing the program&#8217;s total potential awards to approximately $120 million.&#160;&#160;In January 2012, we announced that we will complete NIAID biodefense contracts currently in place but will not actively pursue future contracts. Should the government choose to acquire XOMA 3AB or other biodefense products in the future, we expect to be able to provide these antibodies through an outside manufacturer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We also have developed antibody product candidates with premier pharmaceutical companies including Novartis AG (&#8220;Novartis&#8221;) and Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;).&#160;&#160;Two antibodies developed with Novartis, LFA102 and HCD122 (lucatumumab), are in Phase 1 and/or 2 clinical development by Novartis for the potential treatment of breast or prostate cancer and hematological malignancies, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Significant Developments in the First Quarter of 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Perindopril Franchise</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 45pt">
<div style="TEXT-ALIGN: center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 17, 2012, we announced that we had acquired certain U.S. rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON&#174;, a currently marketed ACE inhibitor, and three FDC product candidates where a proprietary form of perindopril (perindopril arginine) is combined with another active ingredient(s), such as a calcium channel blocker. We assumed commercialization activities for ACEON&#174; in January 2012 following the transfer from Servier&#8217;s previous licensee.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 45pt">
<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2012, we initiated enrollment in a Phase 3 trial for perindopril arginine and amlodipine besylate, the first FDC product candidate. The trial is expected to enroll approximately 816 patients with hypertension to determine the safety and efficacy of the FDC versus either perindopril or amlodipine alone. Based on regulatory interaction to date, if the trial generates positive results, it is expected to be the only efficacy trial needed to complement existing clinical data and will support the submission of an application to the FDA seeking approval for this product candidate. Partial funding for the PATH trial was provided by Servier; the balance of study expenses, consisting primarily of costs generated by our contract research organization, are expected to be paid over time from the profits generated by our ACEON&#174; sales.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Streamlining and Restructuring Charges</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 45pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></font></font></div>
</div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 5, 2012, we implemented a streamlining of operations, which resulted in a restructuring designed to sharpen our focus on value-creating opportunities led by gevokizumab and our unique antibody discovery and development capabilities. The restructuring plan included a reduction of our personnel by 84 positions, or 34%, of which 52 were eliminated immediately and the remainder eliminated as of April 6, 2012. These staff reductions resulted primarily from our decisions to utilize a contract manufacturing organization for Phase 3 and commercial antibody production and to eliminate internal research functions that are non-differentiating or that can be obtained cost-effectively by contract service providers. As a result, we expect to reduce ongoing internal spending by approximately $14 million in 2012 compared to the 2011 level. In connection with the streamlining of operations, we incurred restructuring charges of $2.1 million related to severance, other termination benefits and outplacement services and $1.7 million related to the impairment and accelerated depreciation&#160;of various assets and leasehold improvements in the first quarter of 2012. In the remainder of 2012, we anticipate incurring an additional $0.1 million in severance charges and approximately $1.2 million in facility charges related to this streamlining of operations.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Management Change</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 45pt">
<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 4, 2012, the Company&#8217;s Board of Directors appointed John Varian, a current Board member and the interim Chief Executive Officer, as Chief Executive Officer. W. Denman Van Ness continues to serve as Chairman of the Board.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 45pt">
<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the first quarter of 2012, we sold 2,285,375 shares of common stock through McNicoll, Lewis &amp; Vlak LLC (now known as MLV &amp; Co. LLC, &#8220;MLV&#8221;), under our At Market Issuance Sales Agreement dated February 4, 2011 (the &#8220;2011 ATM Agreement&#8221;), for aggregate gross proceeds of $3.3 million.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 45pt">
<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2012, we completed an underwritten public offering of 29,669,154 shares of our common stock, and accompanying warrants to purchase one half of a share of common stock for each share purchased, for gross proceeds of $39.2 million.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenues</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Total revenues for the three months ended March 31, 2012 and 2011, were as follows (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center">
<table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Decrease)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License and collaborative fees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,014</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,827</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,813</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract and other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,851</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,768</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(917</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,865</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,595</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,730</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">License and Collaborative Fees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">License and collaborative fee revenue includes fees and milestone payments related to the out-licensing of our products and technologies. The decrease in license and collaborative fee revenue for the three months ended March 31, 2012, as compared to the same period of 2011, was primarily due to $5.5 million in revenue recognized in the first quarter of 2011 related to the collaboration and license agreement with Servier to jointly develop and commercialize gevokizumab in multiple indications. This decrease was partially offset by an increase in other licensing fees of $0.6 million. The generation of future revenue related to license fees and other collaborative arrangements is dependent on our ability to attract new licensees to our antibody technologies and new collaboration partners. We expect our revenues from license and collaborative fees in 2012 to remain comparable to 2011 levels.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contract and Other Revenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contract and other revenues include agreements where we provide contracted research and development services to our contract and collaboration partners, including NIAID and Servier. The following table shows the activity in contract and other revenue for the three months ended March 31, 2012 and 2011 (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Decrease)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NIAID</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,837</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,884</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,047</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Servier</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,649</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,082</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">365</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">802</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(437</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total contract and other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,851</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,768</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(917</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The decrease in NIAID revenue is primarily due to decreased activity under NIAID Contract No. HHSN272200800028C (&#8220;NIAID 3&#8221;). This decrease in NIAID 3 contract revenue is partially offset by the recognition of $2.0 million in revenue related to an adjustment to previously-reported revenue from NIAID resulting from an audit by NIAID&#8217;s contracting office. This revenue, which was previously deferred, was recognized upon the completion of negotiations with and approval by the NIH in March 2012. Also partially offsetting the decrease in contract and other revenue was an increase in gevokizumab clinical development and CMC activity under the collaboration with Servier and $0.5 million in activity under Contract No. HHSN272201100031C (&#8220;NIAID 4&#8221;), which was executed in October 2011.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on expected levels of revenue generating activities related to contract and other revenue, we expect a slight decrease in contract and other revenue in 2012 compared to 2011.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expenses</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Biopharmaceutical development includes a series of steps, including <font style="FONT-STYLE: italic; DISPLAY: inline">in vitro</font> and <font style="FONT-STYLE: italic; DISPLAY: inline">in vivo</font> preclinical testing, and Phase 1, 2 and 3 clinical studies in humans. Each of these steps is typically more expensive than the previous step, but actual timing and the cost to us depends on the product being tested, the nature of the potential disease indication and the terms of any collaborative or development arrangements with other companies or entities. After successful conclusion of all of these steps, regulatory filings for approval to market the products must be completed, including approval of manufacturing processes and facilities for the product. Our research and development expenses currently include costs of personnel, supplies, facilities and equipment, consultants, third party costs and other expenses related to preclinical and clinical testing.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses were $15.7 million for the three months ended March 31, 2012, compared with $17.3 million for the same period of 2011. The decrease of $1.6 million for the three months ended March 31, 2012, as compared to the same period in 2011, was primarily due to a decrease in salaries and related personnel costs.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Salaries and related personnel costs are a significant component of research and development expenses. We recorded $7.0 million in research and development salaries and employee-related expenses for the three months ended March 31, 2012, as compared with $8.8 million for the same period of 2011. The decrease of $1.8 million was primarily due to a decrease of $1.0 million in salaries and benefits due to decreased headcount in manufacturing as result of the 2012 streamlining of operations, and a $0.7 million decrease in stock-based compensation.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our research and development activities can be divided into earlier stage programs and later stage programs. Earlier stage programs include molecular biology, process development, pilot-scale production and preclinical testing. Also included in earlier stage programs are costs related to excess manufacturing capacity, which we expect will decrease in 2012 due to our streamlining objectives to utilize a contract manufacturing organization. Later stage programs include clinical testing, regulatory affairs and manufacturing clinical supplies. Certain research and development segment reclassifications have been made to previously reported amounts to conform to the current year's presentation. The costs associated with these programs approximate the following (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="60%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earlier stage programs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,333</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,383</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Later stage programs</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,438</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,964</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,771</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,347</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our research and development activities can also be divided into those related to our internal projects and those projects related to collaborative and contract arrangements. Certain research and development segment reclassifications have been made to previously reported amounts to conform to the current year's presentation. The costs related to internal projects versus collaborative and contract arrangements approximate the following (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="60%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Internal projects</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,682</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,408</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Collaborative and contract arrangements</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,089</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,939</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,771</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,347</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2012, the program upon which we incurred the largest amount of expense (gevokizumab) accounted for more than 40% but less than 50% of our total research and development expense, one development program (NIAID) accounted for more than 20% but less than 30%, and one development program (XMet) accounted for more than 10% but less than 20% of our total research and development expense. All remaining development programs accounted for less than 10% of our total research and development expense for the three months ended March 31, 2012. For the three months ended March 31, 2011, the program upon which we incurred the largest amount of expense (NIAID) accounted for more than 40% but less than 50%, and one development program (NIAID) accounted for more than 30% but less than 40% of our total research and development expenses. All remaining development programs accounted for less than 10% of our total research and development expense for the three months ended March 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We expect our research and development spending in 2012 will increase primarily due to the expected initiation of our Phase 3 clinical program for gevokizumab for the NIU indication, the initiation of our Phase 2 proof-of-concept program for gevokizumab to evaluate moderate-to-severe inflammatory acne and the expected initiation of our Phase 2 proof-of-concept program for erosive osteoarthritis of the hand, all under our license and collaboration agreement with Servier. In addition, we plan to announce the final proof-of-concept indication later in 2012. Also contributing to the expected increase is the initiation of a Phase 3 trial for perindopril arginine in combination with amlodipine besylate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Future research and development spending may be impacted by potential new licensing or collaboration or development arrangements, as well as the termination of existing agreements. Beyond this, the scope and magnitude of future research and development expenses are difficult to predict at this time.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selling, General and Administrative Expenses</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Selling, general and administrative expenses include salaries and related personnel costs, facilities costs and professional fees. Selling, general and administrative expenses were $4.7 million for the three months ended March 31, 2012, compared with $5.4 million for the same period of 2011. The $0.7 million decrease for the first quarter of 2012, as compared to the same period of 2011, was primarily due to a decrease of $0.6 million in salary and related personnel costs, including a $0.4 million decrease in stock-based compensation.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Streamlining and Restructuring Charges</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January 2012, we implemented a streamlining of operations, which resulted in a restructuring designed to sharpen our focus on value-creating opportunities led by gevokizumab and its unique antibody discovery and development capabilities. The restructuring plan included a reduction of XOMA&#8217;s personnel by 84 positions, or 34%, of which 52 were eliminated immediately and the remainder eliminated as of April 6, 2012. These staff reductions result primarily from our decision to utilize a contract manufacturing organization for Phase 3 and commercial antibody production and to eliminate internal research functions that are non-differentiating or that can be obtained cost-effectively by contract service providers.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the three months ended March 31, 2012, in connection with this streamlining of operations, we recorded charges of $2.1 million related to severance, other termination benefits and outplacement services. We expect to incur an additional $0.1 million restructuring charge in the second quarter of 2012 related to severance, other termination benefits and outplacement services.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We plan to vacate two of our leased buildings in 2012 related to manufacturing operations and internal research functions. We did not incur any restructuring charges during the first quarter of 2012 in connection with the exit of these leased buildings as they were still in use; however, we expect to incur restructuring charges of approximately $1.2 million in the remainder of 2012, primarily related to the net present value of future minimum lease payments at the cease-use date, less potential estimated future sublease income.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2012, we performed an impairment analysis of property and equipment and leasehold improvements related to&#160;our manufacturing operations. Since the estimated undiscounted future cash inflows from a certain&#160;group of these assets were less than the carrying value, we determined that&#160;these assets&#160;were impaired and recorded a related restructuring charge of approximately $0.8 million. Further,&#160;we changed the useful life of certain property and equipment and leasehold improvements impacted by our&#160;plans to vacate two leased buildings. As a result,&#160;we recorded accelerated depreciation of $0.9 million as a restructuring charge.&#160;We expect to incur additional restructuring charges of approximately $0.7 million in the remainder of&#160;2012 related to the&#160;accelerated depreciation&#160;of leasehold improvements.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="FIS_LIQUIDITY_CAPITAL"><!--EFPlaceholder--></a>Other Income (Expense)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest expense and amortization of debt issuance costs are shown below for the three months ended March 31, 2012 and 2011 (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;(Decrease)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest expense</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Servier loan</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">516</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GECC term loan</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">417</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">417</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Novartis note</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">84</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,042</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">510</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The increase of $0.5 million in interest expense in 2012 as compared to 2011 was primarily due to interest expense related to the loan with GECC, which was funded in December 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other expense primarily consisted of unrealized and realized (losses) gains. The following table shows the activity in other expense for the three months ended March 31, 2012 and 2011 (in thousands):</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table cellpadding="0" cellspacing="0" width="80%" style="TEXT-ALIGN: left; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: left;">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" nowrap valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Decrease)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unrealized foreign exchange loss <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,617</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,215</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Realized foreign exchange gain <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(2)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">560</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unrealized loss on foreign exchange options</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(276</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(276</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(664</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,057</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">393</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unrealized foreign exchange gain (loss) for the three months ended March 31, 2012 and 2011 primarily relates to gains (losses) on the re-measurement of the &#8364;15 million Servier loan.</font></div>
</td>
</tr></table>
</div>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Realized foreign exchange gain for the three months ended March 31, 2011 primarily relates to the conversion into U.S. dollars of the &#8364;15 million cash proceeds received from Servier in January of 2011.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revaluation of Contingent Warrant Liabilities</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2012, in connection with an underwritten offering, we issued five-year warrants to purchase 14,834,577 shares of XOMA&#8217;s common stock at an exercise price of $1.76 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate us to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Option Pricing Model (the &#8220;Black-Scholes Model&#8221;) on the date of such change in control. We believe the likelihood of a change in control prior to the expiration of the warrants is remote; however, due to these provisions, we are required to account for the warrants issued in March 2012 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At issuance, the fair value of the warrant liability was estimated to be $6.4 million using the Black-Scholes Model. We revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded an increase in the fair value of $14.7 million as a loss in the revaluation of contingent warrant liabilities line of our condensed consolidated statement of operations. As of March 31, 2012, 14,832,827 of these warrants were outstanding and had a fair value of $21.1 million. This increase in liability is primarily due to the excess of the market value of the Company&#8217;s common stock at March 31, 2012 compared to the warrant exercise price.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, in connection with an underwritten offering, we issued five-year warrants to purchase 1,260,000 shares of XOMA&#8217;s common stock at an exercise price of $10.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate us to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model the date of such change in control. We believe the likelihood of a change in control prior to the expiration of the warrants is remote; however, due to these provisions, we are required to account for the warrants issued in February 2010 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.3 million using the Black-Scholes Model. At March 31, 2012, we changed our expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA&#8217;s underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. We revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.3 million as a gain in the revaluation of contingent warrant liabilities line of our condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding.</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June 2009, we issued warrants to certain institutional investors as part of a registered direct offering. The warrants represent the right to acquire an aggregate of up to 347,826 shares of XOMA&#8217;s common stock over a five year period beginning December 11, 2009 at an exercise price of $19.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate us to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. We believe the likelihood of a change in control prior to the expiration of the warrants is remote; however, due to these provisions, we are required to account for the warrants issued in June 2009 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.1 million using the Black-Scholes Model. At March 31, 2012, we changed our expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA&#8217;s underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. We revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.1 million as a gain in the revaluation of contingent warrant liabilities line of our condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table provides a summary of the changes in fair value of contingent warrant liabilities for the three months ended March 31, 2012 (in thousands):</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 9pt" align="center">
<table cellpadding="0" cellspacing="0" width="60%" style="TEXT-INDENT: 9pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-INDENT: 9pt;">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contingent warrant liabilities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="48%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December&#160;31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Initial fair value of warrants issued in March 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="48%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification of contingent warrant liability to equity upon exercise of warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase in fair value of contingent warrant liabilities upon revaluation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,357</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at March 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We did not recognize any income tax expense for the three month ended March 31, 2012 and income tax expense was not material for the three months ended March 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accounting Standards Codification Topic 740<font style="FONT-STYLE: italic; DISPLAY: inline">,</font> <font style="FONT-STYLE: italic; DISPLAY: inline">Income Taxes</font> provides for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes our historical operating performance and carry-back potential, we have determined that total deferred tax assets should be fully offset by a valuation allowance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We did not have unrecognized tax benefits as of March 31, 2012 and do not expect this to change significantly over the next twelve months. We will recognize future interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&#160;As of March 31, 2012, we have not accrued interest or penalties related to uncertain tax positions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes our cash and cash equivalents, our working capital and our cash flow activities as of the end of, and for each of, the periods presented (in thousands):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Change</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,543</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Working Capital</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">69,868</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,064</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,804</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="44%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Change</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="44%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,675</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,475</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(548</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">340</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38,766</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,231</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,535</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effect of exchange rate changes on cash</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(573</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">573</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="44%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase in cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,543</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,973</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Working Capital</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The increase in working capital was primarily due to an increase of $26.5 million in cash and cash equivalents, primarily due to the March 2012 underwritten public offering of 29,669,154 shares of our common stock and accompanying warrants for gross proceeds of $39.2 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash Used in Operating Activities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in operating activities was $11.7 million for the three months ended March 31, 2012, compared with $3.2 million for the same period in 2011. Net cash used in operating activities was $8.5 million higher in the first quarter of 2012 because a $15.0 million license fee was received in the first quarter of 2011 as consideration for the collaboration with Servier. In addition, accounts payable decreased and prepaid expenses increased.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash Used in Investing Activities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in investing activities was $0.5 million for the three months ended March 31, 2012, compared with $0.9 million for the same period of 2011. Cash used in investing activities for the three months ended March 31, 2012 and 2011 primarily consisted of fixed asset purchases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash Provided by Financing Activities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash provided by financing activities was $38.8 million for the three months ended March 31, 2012, compared with $24.2 million for the same period of 2011. Cash provided by financing activities in the first quarter of 2012 related to net proceeds received from the issuance of common stock and warrants of $36.2 million in the March 2012 underwritten public offering and net proceeds of $3.2 million received from the issuance of common stock under the 2011 ATM Agreement, offset by $0.7 million principal payments on our loan with GECC. Cash provided by financing activities in the first quarter of 2011 related to proceeds received from the Servier loan for $20.1 million and the net proceeds of $4.1 million received from the issuance of common stock under the our previous at market issuance sales agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Underwritten Offering and Amendment to Shareholder Rights Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 9, 2012, we completed an underwritten public offering of 29,669,154 shares of our common stock, and accompanying warrants to purchase one half of a share of common stock for each share purchased, at a public offering price of $1.32 per share. Total gross proceeds from the offering were approximately $39.2 million, before deducting underwriting discounts and commissions and estimated offering expenses totaling approximately $2.9 million. The warrants, which represent the right to acquire an aggregate of up to 14,834,577 shares of common stock, are immediately exercisable and have a five-year term and an exercise price of $1.76 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have amended our shareholder rights agreement to provide that it will not apply to any person or entity who becomes the beneficial owner of 20% or more but less than 40% of our outstanding common stock with the prior approval of our board of directors, and our board has approved purchasers in&#160;the March 2012 public offering becoming beneficial owners of 20% or more but less than 40% of our outstanding common stock as a result of their participation in the offering.&#160; As a result, such ownership by any such purchaser will not trigger the provisions of the rights agreement that would give each holder of the rights the right to receive upon exercise that number of common stock equivalents having a market value of two times the exercise price.&#160;&#160;The board's approval in this regard only applies to purchasers in&#160;such offering.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATM Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 4, 2011, we entered into the 2011 ATM Agreement with MLV, under which we may sell shares of our common stock from time to time through the MLV, as our agent for the offer and sale of the shares, in an aggregate amount not to exceed the amount that can be sold under our registration statement on Form S-3 (File No. 333-172197) filed with the SEC on February 11, 2011 and amended on March 10, 2011, June 3, 2011 and January 3, 2012, which was most recently declared effective by the SEC on January 17, 2012.&#160;&#160;MLV may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for our common stock or to or through a market maker.&#160;&#160;MLV may also sell the shares in privately negotiated transactions, subject to our prior approval.&#160;&#160;From the inception of the 2011 ATM Agreement through May 4, 2012, we sold a total of 7,572,327 shares of common stock under this agreement for aggregate gross proceeds of $14.6 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net proceeds received during the first quarter of 2012 from the March 2012 public offering and 2011 ATM Agreement were used to continue development of our gevokizumab product candidate and for other working capital and general corporate purposes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have incurred significant operating losses and negative cash flows from operations since our inception. At March 31, 2012, we had cash and cash equivalents of $74.9 million. During 2012, we expect to continue using our cash and cash equivalents to fund ongoing operations. Additional licensing, antibody discovery and development collaboration agreements, government funding and financing arrangements may positively impact our cash balances. Based on our cash reserves and anticipated spending levels, revenue from collaborations including the gevokizumab license and collaboration agreement with Servier, funding from the loan agreement with GECC, our March 2012 public offering, biodefense contracts and licensing transactions and other sources of funding that we believe to be available, we estimate that we have sufficient cash resources to meet our anticipated net cash needs into 2014. Any significant revenue shortfalls, increases in planned spending on development programs or more rapid progress of development programs than anticipated, as well as the unavailability of anticipated sources of funding, could shorten this period.&#160;&#160;If adequate funds are not available, we will be required to delay, reduce the scope of, or eliminate one or more of our product development programs and further reduce personnel-related costs. Progress or setbacks by potentially competing products may also affect our ability to raise new funding on acceptable terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Estimates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Critical accounting estimates are those that require significant judgment and/or estimates by management at the time that the financial statements are prepared such that materially different results might have been reported if other assumptions had been made. We consider certain accounting policies including, but not limited to, revenue recognition, research and development expense, long-lived assets, contingent warrant liabilities, derivative instruments and stock-based compensation to be critical policies. There have been no significant changes in our critical accounting estimates during the three months ended March 31, 2012, as compared with those previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the SEC on March 14, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Information and Cautionary Factors That May Affect Future Results</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain statements contained herein related to the anticipated size of clinical trials, the anticipated timing of initiation of clinical trials, continued sales of approved products, regulatory approval of unapproved product candidates, anticipated restructuring charges, the sufficiency of our cash resources and the amounts of certain revenues and certain costs in comparison to prior years, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Among other things, clinical trials may not reach their anticipated size if trials are not initiated or due to enrollment issues such as unavailability of patients, competing product candidates or unanticipated safety issues; the timing of initiation of clinical trials may be delayed or may never occur as a result of actions or inaction by regulators or our present or future collaboration partners, complications in the design, implementation or third-party approval of clinical trials, complications in the collection or interpretation of statistical data or unanticipated safety issues; continued sales of approved products may be impacted by XOMA's ability to implement its marketing efforts, competition or unanticipated safety issues; regulatory approval of unapproved product candidates may be affected by the results of future clinical trials, actions or inaction by the FDA or unanticipated safety issues; restructuring charges may be other than as anticipated if we have not estimated them properly or if we implement additional or different streamlining activities; the period for which our cash resources are sufficient could be shortened if expenditures are made earlier or in larger amounts than anticipated or are unanticipated, if anticipated revenue or cost sharing arrangements do not materialize, or if funds are not otherwise available on acceptable terms; and our revenues may be lower than anticipated, and our costs may be higher than expected, due to actions or inactions by regulatory authorities or our present or future collaboration partners, unanticipated safety issues or unavailability of additional financing, licensing or collaboration opportunities. These and other risks, including those related the generally unstable nature of current economic and financial market conditions; the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the Food and Drug Administration, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); changes in the status of existing collaborative or licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations and their discretion in decision-making; our ability to meet the demands of the United States government agency with which we have entered our government contracts; competition; market demand for products; scale-up, manufacturing and marketing capabilities; availability of additional licensing or collaboration opportunities; international operations; share price volatility; our financing needs and opportunities; uncertainties regarding the status of biotechnology patents; and uncertainties as to the costs of protecting intellectual property are described in more detail in <font style="FONT-STYLE: italic; DISPLAY: inline">Part II &#8212;&#160;&#160;Item 1A: Risk Factors</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE D<a name="i3">ISCLOS</a>URES ABOUT MARKET RISK</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Rate Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our exposure to market rate risk for changes in interest rates relates primarily to our investment portfolio and our loan facilities. By policy, we make our investments in high quality debt securities, limit the amount of credit exposure to any one issuer and limit duration by restricting the term of the instrument. We generally hold investments to maturity, with a weighted average portfolio period of less than twelve months. However, if the need arose to liquidate such securities before maturity, we may experience losses on liquidation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We hold interest-bearing instruments that are classified as cash, cash equivalents and short-term investments. Fluctuations in interest rates can affect the principal values and yields of fixed income investments. If interest rates in the general economy were to rise rapidly in a short period of time, our fixed income investments could lose value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table presents the amounts and related weighted average interest rates of our cash and cash equivalents at March 31, 2012 and December 31, 2011 (in thousands, except interest rates):</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="39%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td nowrap valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Maturity</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Carrying </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Rate</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="39%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2012</font></div>
</td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="39%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Daily to 90 days</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.07</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="39%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="39%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2011</font></div>
</td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="39%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Daily to 90 days</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2012, we have an outstanding principal balance on our note with Novartis of $14.0 million, which is due in 2015. The interest rate on this note is charged at a rate of USD six-month LIBOR plus 2%, which was 2.80% at March 31, 2012. No further borrowing is available under this note.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2012, we have an outstanding principal balance on our loan with Servier of &#8364;15.0 million, which converts to approximately $20.0 million at March 31, 2012. The interest rate on this loan is charged at a floating rate based on a Euro Inter-Bank Offered Rate (&#8220;EURIBOR&#8221;) and subject to a cap. The interest rate for the initial interest period was 3.22%. The interest rate has been reset to 3.83% for six-month period from July 2011 through January 2012 and 3.54% for the six-month period from January 2012 through July 2012. No further borrowing is available under this loan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2012, we have an outstanding principal balance on our loan with GECC of $9.3 million, which is to be repaid over a period of 39 consecutive equal monthly installments. The loan accrues interest at a fixed rate of 11.71% per annum. No further borrowing is available under this note.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The variable interest rate related to our long-term debt instruments is based on LIBOR for our Novartis note and EURIBOR for our Servier loan. We estimate that a hypothetical 100 basis point change in interest rates could increase or decrease our interest expense by approximately $0.3 million on an annualized basis. Our loan with GECC is not subject to interest rate risk as it accrues interest at a fixed rate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Foreign Currency Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.65pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We hold debt, may incur expenses, and may be owed milestones denominated in foreign currencies. The amount of debt owed, expenses incurred, or milestones owed to us will be impacted by fluctuations in these foreign currencies. When the U.S. dollar weakens against foreign currencies, the U.S. dollar value of the foreign-currency denominated debt, expense, and milestones increases, and when the U.S. dollar strengthens against these currencies, the U.S. dollar value of the foreign-currency denominated debt, expense, and milestones decreases. Consequently, changes in exchange rates will affect the amount we are required to repay on our &#8364;15.0 million loan from Servier and may affect our results of operations. Our loan from Servier was fully funded in January 2011, with the proceeds converting to approximately $19.5 million using the January 13, 2011 Euro to USD exchange rate.&#160;&#160;At March 31, 2012, the &#8364;15.0 million outstanding principal balance under this loan agreement would have equaled approximately $20.0 million using the March 31, 2012 Euro to USD exchange rate. In May 2011, in order to manage our foreign currency exposure relating to our principal and interest payments on our loan from Servier, we entered into two foreign exchange option contracts to buy &#8364;15.0 million and &#8364;1.5 million on January 2016 and January 2014, respectively. Upfront premiums paid on these foreign exchange option contracts totaled $1.5 million and they had an aggregate fair value of $0.9 million at March 31, 2012. Our use of derivative financial instruments represents risk management; we do not enter into derivative financial contracts for trading purposes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 4.&#160;&#160;CONTR<a name="i4">OLS</a> AND PROCEDURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Evaluation of Controls and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and our Vice President, Finance and Chief Financial Officer (our principal financial and principal accounting officer), we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and our Vice President, Finance and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report in timely alerting them to material information relating to us and our consolidated subsidiaries required to be included in our periodic SEC filings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in Internal Control</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There have been no changes in our internal controls over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II &#8211; OTHER INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LE<a name="i21">GAL </a>PROCEEDINGS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 9, 2009, a complaint was filed in the Superior Court of Alameda County, California, in a lawsuit captioned Hedrick et al. v. Genentech, Inc. et al, Case No. 09-446158. The complaint asserts claims against Genentech, us and others for alleged strict liability for failure to warn, strict product liability, negligence, breach of warranty, fraudulent concealment, wrongful death and other claims based on injuries alleged to have occurred as a result of three individuals&#8217; treatment with RAPTIVA&#174;. The complaint seeks unspecified compensatory and punitive damages. Since then, additional complaints have been filed in the same court, bringing the total number of filed cases to seventy seven.&#160; The cases have been consolidated as a coordinated proceeding. &#160;All of the complaints allege the same claims and seek the same types of damages based on injuries alleged to have occurred as a result of the plaintiffs' treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of all but one of the cases pending in Alameda County Superior Court.&#160; The one Alameda County case not included in this settlement agreement is Kilzer v. Genentech, Inc., et al, Case No. RG-10-502461.&#160; Our agreement with Genentech provides for an indemnity of XOMA and payment of legal fees and funding of this settlement agreement by Genentech, which we believe is applicable to these matters.&#160;&#160; We believe the claims against us to be without merit and intend to defend against them vigorously.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 4, 2010, a petition was filed in the District Court of Dallas County, Texas in a case captioned McCall v. Genentech, Inc., et al., No. 10-09544.&#160; The defendants filed a Notice of Removal to the United States District Court for the Northern District of Texas on September 3, 2010.&#160; The removed case is captioned McCall v. Genentech, Inc., et al., No. 3:10-cv-01747-B. The petition asserts personal injury claims against Genentech, us and others arising out of plaintiff&#8217;s treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; Our agreement with Genentech provides for an indemnity of XOMA and payment of legal fees and funding of this settlement agreement by Genentech, which we believe is applicable to these matters.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 7, 2011, a complaint was filed in the United States District Court for the Northern District of Texas in a case captioned Massa v. Genentech, Inc., et al., No. 4:11CV70. This complaint alleges the same claims against Genentech, us and others and seeks the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; Our agreement with Genentech provides for an indemnity of XOMA and payment of legal fees and funding of this settlement agreement by Genentech, which we believe is applicable to these matters.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 11, 2011, a complaint was filed in the United States District Court for the District of Massachusetts in a case captioned Sylvia, et al. v. Genentech, Inc., et al., No. 1:11-cv-10054-MLW.&#160; On June 13, 2011, a complaint was filed in the Supreme Court for the State of New York, Onondaga County.&#160; Defendants removed the case to the United States District Court for the Northern District of New York on November 3, 2011. &#160;These two complaints allege the same claims against Genentech, us and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; No trial date has been set in either case. Our agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which we believe is applicable to these matters. We believe the claims against us to be without merit and intend to defend against them vigorously.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">On April 8, 2011, four complaints were filed in the United States District Court for the Eastern District of Michigan.&#160; The cases are captioned:&#160; Muniz v. Genentech, et al., 5:11-cv-11489-JCO-RSW; Tifenthal v. Genentech, et al., 2:11-cv-11488-DPH-LJM; Blair v. Genentech, et al., 2:11-cv-11463-SFC-MJH; and Marsh v. Genentech, et al., 2:11-cv-11462-RHC-MKM.&#160; The complaints allege the same claims against Genentech, us and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; All four cases were transferred to the United States District Court for the Western District of Michigan.&#160; On October 26, 2011, the Court granted the Motions to Dismiss filed by Genentech and us in all four actions.&#160; On October 31, 2011, Plaintiffs filed a Notice of Appeal in each case in the United States Court of Appeal for the Sixth Circuit.&#160; Our agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which we believe is applicable to these matters. We believe the claims against us to be without merit and intend to defend against them vigorously</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1A.</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RISK FA<a name="i21a">CTO</a>RS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following risk factors and other information included in this quarterly report should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us also may impair our business operations. If any of the following risks occur, our business, financial condition, operating results and cash flows could be materially adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because our product candidates are still being developed, we will require substantial funds to continue; we cannot be certain that funds will be available and, if they are not available, we may have to take actions that could adversely affect your investment and may not be able to continue operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;We will need to commit substantial funds to continue development of our product candidates and we may not be able to obtain sufficient funds on acceptable terms, or at all.&#160;&#160;If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Any debt financing or additional equity that we raise may contain terms that are not favorable to our stockholders or us. If we raise additional funds through collaboration and licensing arrangements with third parties, we may be required to relinquish some rights to our technologies or our product candidates, grant licenses on terms that are not favorable to us or enter into a collaboration arrangement for a product candidate at an earlier stage of development or for a lesser amount than we might otherwise choose.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available on a timely basis, we may:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">terminate or delay clinical trials for one or more of our product candidates;</font></div>
</td>
</tr></table>
</div>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">further reduce our headcount and capital or operating expenditures; or</font></div>
</td>
</tr></table>
</div>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">curtail our spending on protecting our intellectual property.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We finance our operations primarily through our multiple revenue streams resulting from discovery and development collaborations, biodefense contracts, the licensing of our antibody technologies, and sales of our common stock.&#160;&#160;In September 2009, we sold our royalty interest in LUCENTIS&#174; to Genentech, Inc., a wholly-owned member of the Roche Group (&#8220;Genentech&#8221;) for gross proceeds of $25.0 million, including royalty revenue from the second quarter of 2009.&#160;&#160;These proceeds, along with other funds, were used to fully repay our loan from Goldman Sachs Specialty Lending Holdings, Inc. (&#8220;Goldman Sachs&#8221;).&#160;&#160;As a result, we no longer have a royalty interest in LUCENTIS&#174;.&#160;&#160;In August 2010, we sold our royalty interest in CIMZIA&#174; for gross proceeds of $4.0 million, including royalty revenue from the second quarter of 2010.&#160;&#160;As a result, we no longer have a royalty interest in CIMZIA&#174;.&#160;&#160;We received revenue from this royalty interest of $0.5 million in 2010 and $0.5 million in 2009.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on our cash reserves and anticipated spending levels, revenue from collaborations including our gevokizumab (formerly referred to as XOMA 052) collaboration agreement with Les Laboratoires Servier (&#8220;Servier&#8221;), funding from our loan agreements with Servier and General Electric Capital Corporation (&#8220;GECC&#8221;), our March 2012 public offering, biodefense contracts and licensing transactions and other sources of funding that we believe to be available, we believe that we have sufficient cash resources to meet our anticipated net cash needs into 2014. &#160;Any significant revenue shortfalls, increases in planned spending on development programs or more rapid progress of development programs than anticipated, as well as the unavailability of anticipated sources of funding, could shorten this period or otherwise have a material adverse impact on our ability to finance our continued operations.&#160;&#160;If adequate funds are not available, we will be required to delay, reduce the scope of, or eliminate one or more of our product development programs and further reduce personnel-related costs.&#160;&#160;Progress or setbacks by potentially competing products may also affect our ability to raise new funding on acceptable terms.&#160;&#160;As a result, we do not know when or whether:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">operations will generate meaningful funds,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="TEXT-ALIGN: justify;">
<td style="TEXT-ALIGN: justify; WIDTH: 36pt">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="TEXT-ALIGN: justify; WIDTH: 18pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify; WIDTH: 18pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">additional agreements for product development funding can be reached,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="TEXT-ALIGN: justify;">
<td style="TEXT-ALIGN: justify; WIDTH: 36pt">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="TEXT-ALIGN: justify; WIDTH: 18pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify; WIDTH: 18pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">strategic alliances can be negotiated, or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="TEXT-ALIGN: justify;">
<td style="TEXT-ALIGN: justify; WIDTH: 36pt">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="TEXT-ALIGN: justify; WIDTH: 18pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify; WIDTH: 18pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">adequate additional financing will be available for us to finance our own development on acceptable terms, or at all.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash balances and operating cash flow are influenced primarily by the timing and level of payments by our licensees, collaboration and development partners, as well as by our operating costs.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Global credit and financial market conditions may reduce our ability to access capital and cash and could negatively impact the value of our current portfolio of cash equivalents and our ability to meet our financing objectives.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Traditionally, we have funded a large portion of our research and development expenditures through raising capital in the equity markets.&#160;&#160;Recent events, including failures and bankruptcies among large commercial and investment banks, have led to considerable declines and uncertainties in these and other capital markets and have led to new regulatory and other restrictions that may broadly affect the nature of these markets.&#160;&#160;These circumstances could severely restrict the raising of new capital by companies such as us in the future.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Volatility in the financial markets has also created liquidity problems in investments previously thought to bear a minimal risk.&#160;&#160;For example, money market fund investors, including us, have in the past been unable to retrieve the full amount of funds, even in highly-rated liquid money market accounts, upon maturity.&#160;&#160;Although as of March 31, 2012, we have received the full amount of proceeds from money market fund investments, an inability to retrieve funds from money market fund investments as they mature in the future could have a material and adverse impact on our business, results of operations and cash flows.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our cash and cash equivalents are maintained in highly liquid investments with remaining maturities of 90&#160;days or less at the time of purchase.&#160;&#160;While as of the date of this filing, we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents since March 31, 2012, no assurance can be given that further deterioration in conditions of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because all of our product candidates are still being developed, we have sustained losses in the past and we expect to sustain losses in the future.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have experienced significant losses and, as of March 31, 2012, we had an accumulated deficit of $916.5 million.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2012, we had a net loss of approximately $30.4 million or $0.69 per share of common stock (basic and diluted). For the three months ended March 31, 2011, we had a net loss of approximately $6.3 million or $0.22 per share of common stock (basic and diluted).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our ability to achieve profitability is dependent in large part on the success of our development programs, obtaining regulatory approval for our product candidates and entering into new agreements for product development, manufacturing and commercialization, all of which are uncertain.&#160;&#160;Our ability to fund our ongoing operations is dependent on the foregoing factors and on our ability to secure additional funds.&#160;&#160;Because our product candidates are still being developed, we do not know whether we will ever achieve sustained profitability or whether cash flow from future operations will be sufficient to meet our needs.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have received negative results from certain of our clinical trials, and we face uncertain results of other clinical trials of our product candidates.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2011, we announced that our Phase 2b trial of gevokizumab in Type 2 diabetes in 421 patients did not achieve the primary endpoint of reduction in hemoglobin A1c (&#8220;HbA1c&#8221;) after six monthly treatments with gevokizumab compared to placebo.&#160;&#160;In June 2011, we announced top line trial results from our six-month Phase 2a trial of gevokizumab in Type 2 diabetes in 74 patients, and there were no differences in glycemic control between the drug and placebo groups as measured by HbA1c levels.&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Many of our product candidates, including gevokizumab and XOMA 3AB, will require significant additional research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any commercial sales.&#160;&#160;This process is lengthy and expensive, often taking a number of years.&#160;&#160;As clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly.&#160;&#160;As a result, it is uncertain whether:&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our future filings will be delayed,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our preclinical and clinical studies will be successful,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">we will be successful in generating viable product candidates to targets,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">we will be able to provide necessary additional data,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">results of future clinical trials will justify further development, or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">we will ultimately achieve regulatory approval for any of these product candidates.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The timing of the commencement, continuation and completion of clinical trials may be subject to significant delays relating to various causes, including completion of preclinical testing and earlier-stage clinical trials in a timely manner, scheduling conflicts with participating clinicians and clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria, and shortages of available drug supply.&#160;&#160;Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments.&#160;&#160;Regardless of the initial size or relative complexity of a clinical trial, the costs of such trial may be higher than expected due to increases in duration or size of the trial, changes in the protocol pursuant to which the trial is being conducted, additional or special requirements of one or more of the healthcare centers where the trial is being conducted, changes in the regulatory requirements applicable to the trial or in the standards or guidelines for approval of the product candidate being tested or for other unforeseen reasons.&#160;&#160;In addition, we will conduct clinical trials in foreign countries in the future which may subject us to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign clinical research organizations, as well as expose us to risks associated with foreign currency transactions insofar as we might desire to use U.S. dollars to make contract payments denominated in the foreign currency where the trial is being conducted.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All of our product candidates are prone to the risks of failure inherent in drug development.&#160;&#160;Preclinical studies may not yield results that would satisfactorily support the filing of an Investigational New Drug application (&#8220;IND&#8221;) (or a foreign equivalent) with respect to our product candidates.&#160;&#160;Even if these applications would be or have been filed with respect to our product candidates, the results of preclinical studies do not necessarily predict the results of clinical trials.&#160;&#160;Similarly, early-stage clinical trials in healthy volunteers do not predict the results of later-stage clinical trials, including the safety and efficacy profiles of any particular product candidates.&#160;&#160;In addition, there can be no assurance that the design of our clinical trials is focused on appropriate indications, patient populations, dosing regimens or other variables which will result in obtaining the desired efficacy data to support regulatory approval to commercialize the drug.&#160;&#160;Preclinical and clinical data can be interpreted in different ways.&#160;&#160;Accordingly, Food and Drug Administration (&#8220;FDA&#8221;) officials or officials from foreign regulatory authorities could interpret the data in different ways than we or our collaboration or development partners do which could delay, limit or prevent regulatory approval.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Administering any of our products or potential products may produce undesirable side effects, also known as adverse effects.&#160;&#160;Toxicities and adverse effects that we have observed in preclinical studies for some compounds in a particular research and development program may occur in preclinical studies or clinical trials of other compounds from the same program.&#160;&#160;Such toxicities or adverse effects could delay or prevent the filing of an IND (or a foreign equivalent) with respect to such products or potential products or cause us to cease clinical trials with respect to any drug candidate.&#160;&#160;In clinical trials, administering any of our products or product candidates to humans may produce adverse effects.&#160;&#160;These adverse effects could interrupt, delay or halt clinical trials of our products and product candidates and could result in the FDA or other regulatory authorities denying approval of our products or product candidates for any or all targeted indications.&#160;&#160;The FDA, other regulatory authorities, our collaboration or development partners or we may suspend or terminate clinical trials at any time.&#160;&#160;Even if one or more of our product candidates were approved for sale, the occurrence of even a limited number of toxicities or adverse effects when used in large populations may cause the FDA to impose restrictions on, or stop, the further marketing of such drugs.&#160;&#160;Indications of potential adverse effects or toxicities which may occur in clinical trials and which we believe are not significant during the course of such clinical trials may later turn out to actually constitute serious adverse effects or toxicities when a drug has been used in large populations or for extended periods of time.&#160;&#160;Any failure or significant delay in completing preclinical studies or clinical trials for our product candidates, or in receiving and maintaining regulatory approval for the sale of any drugs resulting from our product candidates, may severely harm our reputation and business.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June 2011, Novartis announced that an advisory committee of the FDA voted in favor of the overall efficacy but not the overall safety of Ilaris&#174; (canakinumab), a fully-human monoclonal antibody that, like gevokizumab, targets IL-1 beta, to treat gouty arthritis attacks in patients who cannot obtain adequate relief with non-steroidal anti-inflammatory drugs or colchicine.&#160;&#160;Novartis also stated that in two pivotal Phase 3 studies of canakinumab in gouty arthritis patients, a higher percentage of patients had adverse events with canakinumab than with the standard treatment for gouty arthritis, and more serious adverse events were reported by patients treated with canakinumab compared to patients receiving the standard treatment.&#160;&#160;In August 2011, Novartis announced that the FDA had issued a Complete Response letter requesting additional information, including clinical data to evaluate the benefit risk profile of canakinumab in refractory gouty arthritis patients.&#160;&#160;We have not yet determined what impact, if any, these developments may have on the development of gevokizumab.&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If our therapeutic product candidates do not receive regulatory approval, neither our third party collaborators nor we will be able to manufacture and market them.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our product candidates (including gevokizumab, perindopril arginine in combination with amlodipine besylate (&#8220;FDC1&#8221;) and XOMA 3AB) cannot be manufactured and marketed in the United States and other countries without required regulatory approvals.&#160;&#160;The United States government and governments of other countries extensively regulate many aspects of our product candidates, including:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">testing,</font></div>
</td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">manufacturing,</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">promotion and marketing, and</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">exporting.&#160;</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act.&#160;&#160;At the present time, we believe that many of our product candidates (including gevokizumab and XOMA 3AB) will be regulated by the FDA as biologics and that some of our product candidates (including FDC1) will be regulated by the FDA as drugs.&#160;&#160;Initiation of clinical trials requires approval by health authorities.&#160;&#160;Clinical trials involve the administration of the investigational new drug to healthy volunteers or to patients under the supervision of a qualified principal investigator.&#160;&#160;Clinical trials must be conducted in accordance with FDA and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices and the European Clinical Trials Directive under protocols that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy criteria to be evaluated.&#160;&#160;Other national, foreign and local regulations may also apply.&#160;&#160;The developer of the drug must provide information relating to the characterization and controls of the product before administration to the patients participating in the clinical trials.&#160;&#160;This requires developing approved assays of the product to test before administration to the patient and during the conduct of the trial.&#160;&#160;In addition, developers of pharmaceutical products must provide periodic data regarding clinical trials to the FDA and other health authorities, and these health authorities may issue a clinical hold upon a trial if they do not believe, or cannot confirm, that the trial can be conducted without unreasonable risk to the trial participants.&#160;&#160;We cannot assure you that U.S. and foreign health authorities will not issue a clinical hold with respect to any of our clinical trials in the future.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The results of the preclinical studies and clinical testing, together with chemistry, manufacturing and controls information, are submitted to the FDA and other health authorities in the form of a New Drug Application (&#8220;NDA&#8221;) for a drug, and in the form of a Biologic License Application (&#8220;BLA&#8221;) for a biological product, requesting approval to commence commercial sales.&#160;&#160;In responding to an NDA or BLA, the FDA or foreign health authorities may grant marketing approvals, request additional information or further research, or deny the application if it determines that the application does not satisfy its regulatory approval criteria.&#160;&#160;Regulatory approval of an NDA, BLA, or supplement is never guaranteed, and the approval process can take several years and is extremely expensive.&#160;&#160;The FDA and foreign health authorities have substantial discretion in the drug and biologics approval processes.&#160;&#160;Despite the time and expense incurred, failure can occur at any stage, and we could encounter problems that cause us to abandon clinical trials or to repeat or perform additional preclinical, clinical or manufacturing-related studies.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional regulations or statutes, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.&#160;&#160;State regulations may also affect our proposed products.&#160;&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The FDA and other regulatory agencies have substantial discretion in both the product approval process and manufacturing facility approval process and, as a result of this discretion and uncertainties about outcomes of testing, we cannot predict at what point, or whether, the FDA or other regulatory agencies will be satisfied with our or our collaborators&#8217; submissions or whether the FDA or other regulatory agencies will raise questions which may be material and delay or preclude product approval or manufacturing facility approval.&#160;&#160;In light of this discretion and the complexities of the scientific, medical and regulatory environment, our interpretation or understanding of the FDA&#8217;s or other regulatory agencies&#8217; requirements, guidelines or expectations may prove incorrect, which could also further delay or increase the cost of the approval process.&#160;&#160;As we accumulate additional clinical data, we will submit it to the FDA and other regulatory agencies, as appropriate and such data may have a material impact on the approval process.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Given that regulatory review is an interactive and continuous process, we maintain a policy of limiting announcements and comments upon the specific details of regulatory review of our product candidates, subject to our obligations under the securities laws, until definitive action is taken.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Even if the FDA, the European Commission or another regulatory agency approves a product candidate for marketing, the approval may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials, and the FDA, European Commission or other regulatory agency may subsequently withdraw approval based on these additional trials. As the current holder of the ACEON&#174; NDA, we are required to submit annual reports to the FDA and are responsible for pharmacovigilance activities related to the product.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Even for approved products, the FDA, European Commission or other regulatory agency may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furthermore, a marketing approval of a product may be withdrawn by the FDA, the European Commission or another regulatory agency or such a product may be voluntarily withdrawn by the company marketing it based, for example, on subsequently-arising safety concerns.&#160;&#160;In February 2009, the European Medicines Agency (&#8220;EMA&#8221;) announced that it had recommended suspension of the marketing authorization of RAPTIVA&#174; in the European Union and that its Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) had concluded that the benefits of RAPTIVA&#174; no longer outweigh its risks because of safety concerns, including the occurrence of progressive multifocal leukoencephalopathy (&#8220;PML&#8221;) in patients taking the medicine.&#160;&#160;In the second quarter of 2009, Genentech announced and carried out a phased voluntary withdrawal of RAPTIVA&#174; from the U.S. market, based on the association of RAPTIVA&#174; with an increased risk of PML.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The FDA, European Commission and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may issue additional equity securities and thereby materially and adversely affect the price of our common stock.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are authorized to issue, without stockholder approval, 1,000,000 shares of preferred stock, of which none were issued and outstanding as of May 4, 2012, which may give other stockholders dividend, conversion, voting, and liquidation rights, among other rights, which may be superior to the rights of holders of our common stock.&#160;&#160;In April 2011, the 2,959 Series B convertible preference shares previously issued to Genentech were converted by Genentech into 254,560 shares of common stock.&#160;&#160;In addition, we are authorized to issue, generally without stockholder approval, up to 92,666,666 shares of common stock, of which 68,083,980 were issued and outstanding as of May 4, 2012.&#160;&#160;If we issue additional equity securities, the price of our common stock may be materially and adversely affected.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the third quarter of 2009, we had entered into an At Market Issuance Sales Agreement (the &#8220;2009 ATM Agreement&#8221;), with Wm Smith &amp; Co. (&#8220;Wm Smith&#8221;), under which we could sell up to 1.7 million shares of our common stock from time to time through Wm Smith, as the agent for the offer and sale of the shares.&#160;&#160;Wm Smith could sell these shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), including but not limited to sales made directly on The NASDAQ Global Market, on any other existing trading market for our common stock or to or through a market maker.&#160;&#160;Wm Smith could also sell the shares in privately negotiated transactions, subject to our approval.&#160;&#160;From the inception of the 2009 ATM Agreement through October 27, 2010, we sold a total of 1,666,666 shares of common stock through Wm Smith, constituting all of the shares available for sale under the agreement, for aggregate gross proceeds of $12.2 million.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, we completed an underwritten offering of 2.8 million units, with each unit consisting of one share of our common stock and a warrant to purchase 0.45 of a share of common stock, for gross proceeds of approximately $21.0 million, before deducting underwriting discounts and commissions and estimated offering expenses of $1.7 million.&#160;&#160;The investors purchased the units at a price of $7.50 per unit.&#160;&#160;The warrants, which represent the right to acquire an aggregate of up to 1.26 million shares of common stock, are exercisable beginning six months and one day after issuance and have a five-year term and an exercise price of $10.50 per share.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2010, we entered into a common stock purchase agreement with Azimuth Opportunity, Ltd. (&#8220;Azimuth&#8221;), pursuant to which we obtained a committed equity line of credit facility under which we could sell up to $30.0 million of our registered shares of common stock to Azimuth over a 12-month period, subject to certain conditions and limitations.&#160;&#160;In August 2010, we sold a total of 3,421,407 shares under this facility for aggregate proceeds of $14.2 million, representing the maximum number of shares that could be sold under this facility.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In October 2010, we entered into an At Market Issuance Sales Agreement (the &#8220;2010 ATM Agreement&#8221;), with Wm Smith and McNicoll, Lewis &amp; Vlak LLC (the &#8220;Agents&#8221;), under which we could sell shares of our common stock from time to time through the Agents, as our agents for the offer and sale of the shares, in an aggregate amount not to exceed the amount that can be sold under our registration statement on Form S-3 (File No. 333-148342) filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on December 26, 2007 and declared effective by the SEC on May 29, 2008.&#160;&#160;The Agents could sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for our common stock or to or through a market maker.&#160;&#160;The Agents could also sell the shares in privately negotiated transactions, subject to our prior approval.&#160;&#160;From the inception of the 2010 ATM Agreement through May 2011, we sold a total of 7.6 million shares of common stock under this agreement for aggregate gross proceeds of $34.0 million, including 0.8 million shares sold in 2011 for aggregate gross proceeds of $4.4 million.&#160;&#160;In May 2011, the 2010 ATM Agreement expired by its terms, and there will be no further issuances under this facility.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 4, 2011, we entered into an At Market Issuance Sales Agreement (the &#8220;2011 ATM Agreement&#8221;) with McNicoll, Lewis &amp; Vlak LLC (now known as MLV &amp; Co. LLC, &#8220;MLV&#8221;), under which we may sell shares of our common stock from time to time through the MLV, as our agent for the offer and sale of the shares, in an aggregate amount not to exceed the amount that can be sold under our registration statement on Form S-3 (File No. 333-172197) filed with the SEC on February 11, 2011 and amended on March 10, 2011, June 3, 2011 and January 3, 2012, which was most recently declared effective by the SEC on January 17, 2012.&#160;&#160;MLV may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for our common stock or to or through a market maker.&#160;&#160;MLV may also sell the shares in privately negotiated transactions, subject to our prior approval.&#160;&#160;From the inception of the 2011 ATM Agreement through May 4, 2012, we sold a total of 7,572,327 shares of common stock under this agreement for aggregate gross proceeds of $14.6 million.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 9, 2012, we completed an underwritten public offering of 29,669,154 shares of our common stock, and accompanying warrants to purchase one half of a share of common stock for each share purchased, at a public offering price of $1.32 per share. Total gross proceeds from the offering were approximately $39.2 million, before deducting underwriting discounts and commissions and estimated offering expenses totaling approximately $2.9 million. The warrants, which represent the right to acquire an aggregate of up to 14,834,577 shares of common stock, are immediately exercisable and have a five-year term and an exercise price of $1.76 per share.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The financial terms of future collaborative or licensing arrangements could result in dilution of our share value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Funding from collaboration partners and others has in the past and may in the future involve issuance by us of our shares.&#160;&#160;We cannot be certain how the purchase price of such shares, the relevant market price or premium, if any, will be determined or when such determinations will be made.&#160;&#160;Any such issuance could result in dilution in the value of our issued and outstanding shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our share price may be volatile and there may not be an active trading market for our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There can be no assurance that the market price of our common stock will not decline below its present market price or that there will be an active trading market for our common stock.&#160;&#160;The market prices of biotechnology companies have been and are likely to continue to be highly volatile.&#160;&#160;Fluctuations in our operating results and general market conditions for biotechnology stocks could have a significant impact on the volatility of our common stock price.&#160;&#160;We have experienced significant volatility in the price of our common stock.&#160;&#160;From January 1, 2011 through May 4, 2012, the share price of our common stock has ranged from a high of $7.71 to a low of $1.12.&#160;&#160;Factors contributing to such volatility include, but are not limited to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">results of preclinical studies and clinical trials,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">information relating to the safety or efficacy of products or product candidates,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">developments regarding regulatory filings,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">announcements of new collaborations,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">failure to enter into collaborations,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">developments in existing collaborations,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our funding requirements and the terms of our financing arrangements,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">technological innovations or new indications for our therapeutic products and product candidates,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">introduction of new products or technologies by us or our competitors,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">sales and estimated or forecasted sales of products for which we receive royalties, if any,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">government regulations,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">developments in patent or other proprietary rights,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the number of shares issued and outstanding,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the number of shares trading on an average trading day,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">announcements regarding other participants in the biotechnology and pharmaceutical industries, and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 54pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">market speculation regarding any of the foregoing.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If we are unable to continue to meet the requirements for continued listing on The NASDAQ Global Market, then we may be de-listed.&#160;&#160;In March 2010, we received a Staff Determination letter from The NASDAQ Stock Market LLC (&#8220;NASDAQ&#8221;) indicating that we had not regained compliance with the minimum $1.00 per share requirement for continued inclusion on The NASDAQ Global Market, pursuant to NASDAQ Listing Rule 5450(a)(1).&#160;&#160;On August 18, 2010, we effected a reverse split of our common stock in order to regain compliance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be successful in commercializing our products, which could also affect our development efforts.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We began commercializing our first product, ACEON<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, in January 2012, and we have limited experience in the sales, marketing and distribution of pharmaceutical products.&#160;&#160;There can be no assurance that we will be able to maintain the arrangements we have with third-party suppliers, distributors and other service providers that are necessary for us to perform these activities or that our efforts will be successful.&#160;&#160;Maintaining or expanding these arrangements, or developing our own capabilities, may divert attention and resources from or otherwise negatively affect our development programs.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our rights to commercialize ACEON<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> are licensed from Servier, and we are obligated to develop and commercialize the products covered by our agreement in accordance with the terms and conditions of that agreement.&#160;&#160;Our ability to satisfy some of these obligations is dependent on factors that are outside of our control, and our agreement may be terminated if we materially breach our obligations and fail to cure such breach or for other reasons.&#160;&#160;If our agreement is terminated, we would have no further rights to develop and commercialize these products.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furthermore, because we intend to use revenues generated by sales of ACEON&#174; in part to fund development of FDC1, lower than expected revenues from such sales could adversely affect our ability to fund the costs of such development.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of ACEON</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"> or our product candidates and could subject us to significant fines and penalties.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operations may be directly or indirectly subject to various state and federal healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act and HIPAA/HITECH. These laws may impact, among other things, the commercial operations for ACEON or any of our product candidates that may be approved for commercial sale.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The federal Anti-Kickback Statute prohibits persons from knowingly and willingly soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs. The Physician Payments Sunshine Act also has several state equivalents, which require, and under which the federal government will require in 2013, disclosure of payments we make to physicians for consulting and other services.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend a False Claims Act action. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Various states have also enacted laws modeled after the federal False Claims Act.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters and was amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information.&#160;&#160;In order to comply with these laws, we have implemented a compliance program to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems and by promoting a culture of compliance. Although we take our obligation to maintain our compliance with these various laws and regulations seriously and our compliance program is designed to prevent the violation of these laws and regulations, if we are found to be in violation of any of the laws and regulations described above or other applicable state and federal healthcare fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our operations, all of which could have a material adverse effect on our business and results of operations.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Certain of our technologies are in-licensed from third parties, so our capabilities using them are restricted and subject to additional risks.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We license technologies from third parties.&#160;&#160;These technologies include but are not limited to phage display technologies licensed to us in connection with our bacterial cell expression technology licensing program.&#160;&#160;However, our use of these technologies is limited by certain contractual provisions in the licenses relating to them and, although we have obtained numerous licenses, intellectual property rights in the area of phage display are particularly complex.&#160;&#160;If the owners of the patent rights underlying the technologies we license do not properly maintain or enforce those patents, our competitive position and business prospects could be harmed.&#160;&#160;Our success will depend in part on the ability of our licensors to obtain, maintain and enforce our in-licensed intellectual property.&#160;&#160;Our licensors may not successfully prosecute the patent applications to which we have licenses, or our licensors may fail to maintain existing patents.&#160;&#160;They may determine not to pursue litigation against other companies that are infringing these patents, or they may pursue such litigation less aggressively than we would.&#160;&#160;Our licensors may also seek to terminate our license, which could cause us to lose the right to use the licensed intellectual property and adversely affect our ability to commercialize our technologies, products or services.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Even if products in which we have an interest receive approval in the future, they may not be accepted in the marketplace.&#160;&#160;In addition, we or our collaborators or licensees may experience difficulties in launching new products, many of which are novel and based on technologies that are unfamiliar to the healthcare community.&#160;&#160;We have no assurance that healthcare providers and patients will accept such products, if developed.&#160;&#160;For example, physicians and/or patients may not accept a product for a particular indication because it has been biologically derived (and not discovered and developed by more traditional means) or if no biologically derived products are currently in widespread use in that indication.&#160;&#160;Similarly, physicians may not accept a product if they believe other products to be more effective or more cost-effective or are more comfortable prescribing other products.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Safety concerns may also arise in the course of on-going clinical trials or patient treatment as a result of adverse events or reactions.&#160;&#160;For example, in February 2009, the EMA announced that it had recommended suspension of the marketing authorization of RAPTIVA&#174; in the European Union and EMD Serono Inc., the company that marketed RAPTIVA&#174; in Canada (&#8220;EMD Serono&#8221;) announced that, in consultation with Health Canada, the Canadian health authority (&#8220;Health Canada&#8221;), it would suspend marketing of RAPTIVA&#174; in Canada.&#160;&#160;In March 2009, Merck Serono Australia Pty Ltd, the company that marketed RAPTIVA&#174; in Australia (&#8220;Merck Serono Australia&#8221;), following a recommendation from the Therapeutic Goods Administration, the Australian health authority (&#8220;TGA&#8221;), announced that it was withdrawing RAPTIVA&#174; from the Australian market.&#160;&#160;In the second quarter of 2009, Genentech announced and carried out a phased voluntary withdrawal of RAPTIVA&#174; from the U.S. market, based on the association of RAPTIVA&#174; with an increased risk of PML. As a result, sales of RAPTIVA&#174; ceased in the second quarter of 2009.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients.&#160;&#160;Such guidelines or recommendations can be very influential and may adversely affect the usage of any products we may develop directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy or a government entity withdrawing its recommendation to screen blood donations for certain viruses) or indirectly (for example, by recommending a competitive product over our product).&#160;&#160;Consequently, we do not know if physicians or patients will adopt or use our products for their approved indications.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Even approved and marketed products are subject to risks relating to changes in the market for such products.&#160;&#160;Introduction or increased availability of generic versions of products can alter the market acceptance of branded products, such as ACEON<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>.&#160;&#160;In addition, unforeseen safety issues may arise at any time, regardless of the length of time a product has been on the market.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our third party collaborators, licensees, suppliers or contractors may not have adequate manufacturing capacity sufficient to meet market demand.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upon approval of any of our product candidates or in the event of increased demand for marketed products, we do not know whether the capacity of the manufacturing facilities of our existing or future third-party collaborators, licensees, suppliers or contractors will be available or can be increased to produce sufficient quantities of our products to meet market demand.&#160;&#160;Also, if we or our third party collaborators, licensees, suppliers or contractors need additional manufacturing facilities to meet market demand, we cannot predict that we will successfully obtain those facilities because we do not know whether they will be available on acceptable terms.&#160;&#160;In addition, any manufacturing facilities acquired or used to meet market demand must meet the FDA&#8217;s quality assurance guidelines.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our agreements with third parties, many of which are significant to our business, expose us to numerous risks.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our financial resources and our marketing experience and expertise are limited.&#160;&#160;Consequently, our ability to successfully develop products depends, to a large extent, upon securing the financial resources and/or marketing capabilities of third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April 1996, we entered into an agreement with Genentech whereby we agreed to co-develop Genentech&#8217;s humanized monoclonal antibody product RAPTIVA&#174;.&#160;&#160;In April 1999, March 2003, and January 2005, the companies amended the agreement.&#160;&#160;In October 2003, RAPTIVA&#174; was approved by the FDA for the treatment of adults with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and, in September 2004, Merck Serono announced the product&#8217;s approval in the European Union.&#160;&#160;In January 2005, we entered into a restructuring of our collaboration agreement with Genentech which ended our existing cost and profit sharing arrangement related to RAPTIVA&#174; in the United States and entitled us to a royalty interest on worldwide net sales.&#160;&#160;In February 2009, the EMA announced that it had recommended suspension of the marketing authorization of RAPTIVA&#174; in the European Union and EMD Serono announced that, in consultation with Health Canada, it would suspend marketing of RAPTIVA&#174; in Canada.&#160;&#160;In March 2009, Merck Serono Australia, following a recommendation from the TGA, announced that it was withdrawing RAPTIVA&#174; from the Australian market.&#160;&#160;In the second quarter of 2009, Genentech announced and carried out a phased voluntary withdrawal of RAPTIVA&#174; from the U.S. market, based on the association of RAPTIVA&#174; with an increased risk of PML.&#160;&#160;As a result, sales of RAPTIVA&#174; ceased in the second quarter of 2009.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div>
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></font></font></div>
</div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2004, we announced we had agreed to collaborate with Chiron Corporation (now Novartis) for the development and commercialization of antibody products for the treatment of cancer.&#160;&#160;In April 2005, we announced the initiation of clinical testing of the first product candidate out of the collaboration, HCD122, an anti-CD40 antibody, in patients with advanced chronic lymphocytic leukemia.&#160;&#160;In October 2005, we announced the initiation of the second clinical trial of HCD122 in patients with multiple myeloma.&#160;&#160;In November 2008, we announced the restructuring of this product development collaboration, which involved six development programs including the ongoing HCD122 and LFA102 programs.&#160;&#160;In exchange for cash and debt reduction on our existing loan facility with Novartis, Novartis has control over the HCD122 and LFA102 programs and the additional ongoing program, as well as the right to expand the development of these programs into additional indications outside of oncology.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2005, we entered into a contract with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;) to produce three monoclonal antibodies designed to protect United States citizens against the harmful effects of botulinum neurotoxin used in bioterrorism.&#160;&#160;In July 2006, we entered into an additional contract with NIAID for the development of an appropriate formulation for human administration of these three antibodies in a single injection.&#160;&#160;In September 2008, we announced that we were awarded an additional contract with NIAID to support our on-going development of drug candidates toward clinical trials in the treatment of botulism poisoning.&#160;&#160;In October 2011, we announced we had been awarded an additional contract with NIAID to develop broad-spectrum antitoxins for the treatment of human botulism poisoning.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2010, we entered into a license and collaboration agreement with Servier, to jointly develop and commercialize gevokizumab in multiple indications.&#160;&#160;Under the terms of the agreement, Servier has worldwide rights to diabetes and cardiovascular disease indications and rights outside the U.S. and Japan to Beh&#231;et&#8217;s uveitis and other inflammatory and oncology indications.&#160;&#160;We retain development and commercialization rights for Beh&#231;et&#8217;s uveitis and other inflammatory disease and oncology indications in the U.S. and Japan, and have an option to reacquire rights to diabetes and cardiovascular disease indications from Servier in these territories.&#160;&#160;Should we exercise this option, we will be required to pay Servier an option fee and partially reimburse their incurred development expenses.&#160;&#160;The agreement contains customary termination rights relating to matters such as material breach by either party, safety issues and patents.&#160;&#160;Servier also has a unilateral right to terminate the agreement on a country-by-country basis or in its entirety on six months&#8217; notice.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2010, we also entered into a loan agreement with Servier, which provides for an advance of up to &#8364;15.0 million and was fully funded in January 2011 with the proceeds converting to approximately $19.5 million using the January 13, 2011 Euro to USD exchange rate.&#160;&#160;This loan is secured by an interest in our intellectual property rights to all gevokizumab indications worldwide, excluding the U.S. and Japan.&#160;&#160;The loan has a final maturity date in 2016; however, after a specified period prior to final maturity, the loan is required to be repaid (i) at Servier&#8217;s option, by applying up to a significant percentage of any milestone or royalty payments owed by Servier under our collaboration agreement and (ii) using a significant percentage of any upfront, milestone or royalty payments we receive from any third party collaboration or development partner for rights to gevokizumab in the U.S. and/or Japan.&#160;&#160;In addition, the loan becomes immediately due and payable upon certain customary events of default.&#160;&#160;At March 31, 2012, the &#8364;15.0 million outstanding principal balance under this loan agreement would have equaled approximately $20.0 million using the March 31, 2012 Euro to USD exchange rate.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2011, we entered into a loan agreement with GECC, under which GECC agreed to make a term loan in an aggregate principal amount of $10 million to XOMA (US) LLC, our wholly owned subsidiary, and upon execution of the loan agreement, GECC funded the term loan. The term loan is guaranteed by us and our two other principal subsidiaries, XOMA Ireland Limited and XOMA Technology Ltd.&#160;&#160;As security for our obligations under the loan agreement, we, XOMA (US) LLC, XOMA Ireland Limited and XOMA Technology Ltd. each granted a security interest pursuant to a guaranty, pledge and security agreement in substantially all of our existing and after-acquired assets, excluding our intellectual property assets (such as those relating to our gevokizumab and anti-botulism products). We are required to repay the principal amount of the Term Loan over a period of 42 consecutive equal monthly installments of principal and accrued interest.&#160;&#160;The term loan matures on June 30, 2015, and at maturity, we will make an additional payment equal to 5% of the term loan (&#8220;Final Payment Fee&#8221;). The loan agreement contains customary representations and warranties and customary affirmative and negative covenants, including restrictions on the ability to incur indebtedness, grant liens, make investments, dispose of assets, enter into transactions with affiliates and amend existing material agreements, in each case subject to various exceptions.&#160;&#160;In addition, the loan agreement contains customary events of default that entitle GECC to cause any or all of the indebtedness under the loan agreement to become immediately due and payable. The events of default include any event of default under a material agreement or certain other indebtedness.&#160;&#160;We may voluntarily prepay the term loan in full, but not in part, and any voluntary and certain mandatory prepayments are subject to a prepayment premium of 3% in the first year of the loan, 2% in the second year and 1% thereafter, with certain exceptions.&#160;&#160;We will also be required to pay the Final Payment Fee in connection with any voluntary or mandatory prepayment.&#160;&#160;Pursuant to the loan agreement, we issued to GECC unregistered stock purchase warrants, which entitle GECC to purchase up to an aggregate of 263,158 unregistered shares of XOMA common stock at an exercise price equal to $1.14 per share, are immediately exercisable and expire on December 30, 2016.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div>
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective in January 2012, we entered into an amended and restated agreement with Servier for the U.S. commercialization rights to ACEON&#174; and the development and commercialization in the U.S. of up to three products combining perindopril with other cardiovascular drugs in fixed-dose combinations, or FDCs.&#160;&#160;This agreement, together with a related trademark license agreement, provides us with exclusive U.S. rights to ACEON&#174; and the first FDC product, and options on two additional FDCs.&#160;&#160;The arrangement also provides that Servier will supply to us, and we will purchase exclusively from Servier, the active ingredients in ACEON&#174; and the FDCs, in some cases for a limited period.&#160;&#160;The agreement contains customary termination rights relating to matters such as material breach by either party, insolvency of either party or safety issues.&#160;&#160;Each party also has the right to terminate the arrangement if the first FDC product does not receive FDA approval by December 31, 2014.&#160;&#160;Servier also has the right to terminate the arrangement if certain aspects of our commercialization strategy are not successful and Servier does not consent to an alternative strategy or, as to the FDCs, if we breach our obligations to certain of our service providers.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have licensed our bacterial cell expression technology, an enabling technology used to discover and screen, as well as develop and manufacture, recombinant antibodies and other proteins for commercial purposes, to over 60 companies.&#160;&#160;As of May 4, 2012, we were aware of two antibody products manufactured using this technology that have received FDA approval, Genentech&#8217;s LUCENTIS&#174; (ranibizumab injection) for treatment of neovascular wet age-related macular degeneration and UCB&#8217;s CIMZIA&#174; (certolizumab pegol) for treatment of Crohn&#8217;s disease and rheumatoid arthritis.&#160;&#160;In the third quarter of 2009, we sold our LUCENTIS&#174; royalty interest to Genentech.&#160;&#160;In the third quarter of 2010, we sold our CIMZIA&#174; royalty interest.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because our collaborators, licensees, suppliers and contractors&#160;&#160;are independent third parties, they may be subject to different risks than we are and have significant discretion in, and different criteria for, determining the efforts and resources they will apply related to their agreements with us.&#160;&#160;If these collaborators, licensees, suppliers and contractors do not successfully perform the functions for which they are responsible, we may not have the capabilities, resources or rights to do so on our own.&#160;&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not know whether we, our collaborators or licensees will successfully develop and market any of the products that are or may become the subject of any of our collaboration or licensing arrangements.&#160;&#160;In some cases these arrangements provide for funding solely by our collaborators or licensees, and in other cases, such as our arrangement with Servier for gevokizumab, all of the funding for certain projects and a significant portion of the funding for other projects is to be provided by our collaborator or licensee.&#160;&#160;Even when we have a collaborative relationship, other circumstances may prevent it from resulting in successful development of marketable products.&#160;&#160;In addition, third party arrangements such as ours also increase uncertainties in the related decision-making processes and resulting progress under the arrangements, as we and our collaborators or licensees may reach different conclusions, or support different paths forward, based on the same information, particularly when large amounts of technical data are involved.&#160;&#160;Furthermore, our contracts with NIAID contain numerous standard terms and conditions provided for in the applicable federal acquisition regulations and customary in many government contracts.&#160;&#160;Uncertainty exists as to whether we will be able to comply with these terms and conditions in a timely manner, if at all.&#160;&#160;In addition, we are uncertain as to the extent of NIAID&#8217;s demands and the flexibility that will be granted to us in meeting those demands.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although we continue to evaluate additional strategic alliances and potential partnerships, we do not know whether or when any such alliances or partnerships will be entered into.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Products and technologies of other companies may render some or all of our products and product candidates noncompetitive or obsolete.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Developments by others may render our products, product candidates, or technologies obsolete or uncompetitive.&#160;&#160;Technologies developed and utilized by the biotechnology and pharmaceutical industries are continuously and substantially changing.&#160;&#160;Competition in antibody-based technologies is intense and expected to increase in the future as a number of established biotechnology firms and large chemical and pharmaceutical companies advance in these fields.&#160;&#160;Many of these competitors may be able to develop products and processes competitive with or superior to our own for many reasons, including that they may have:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">37</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">significantly greater financial resources,</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">larger research and development and marketing staffs,</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">larger production facilities,</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">entered into arrangements with, or acquired, biotechnology companies to enhance their capabilities, or</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td align="right" style="WIDTH: 27pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">extensive experience in preclinical testing and human clinical trials.&#160;</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These factors may enable others to develop products and processes competitive with or superior to our own or those of our collaborators.&#160;&#160;In addition, a significant amount of research in biotechnology is being carried out in universities and other non-profit research organizations.&#160;&#160;These entities are becoming increasingly interested in the commercial value of their work and may become more aggressive in seeking patent protection and licensing arrangements.&#160;&#160;Furthermore, many companies and universities tend not to announce or disclose important discoveries or development programs until their patent position is secure or, for other reasons, later; as a result, we may not be able to track development of competitive products, particularly at the early stages.&#160;&#160;Positive or negative developments in connection with a potentially competing product may have an adverse impact on our ability to raise additional funding on acceptable terms.&#160;&#160;For example, if another product is perceived to have a competitive advantage, or another product&#8217;s failure is perceived to increase the likelihood that our product will fail, then investors may choose not to invest in us on terms we would accept or at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The examples below pertain to competitive events in the market which we review quarterly and are not intended to be representative of all existing competitive events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Gevokizumab</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We, in collaboration with Servier, are developing gevokizumab, a potent anti-inflammatory monoclonal antibody targeting IL-1 beta.&#160;&#160;Other companies are developing other products based on the same or similar therapeutic targets as gevokizumab and these products may prove more effective than gevokizumab.&#160;&#160;We are aware that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 36pt">
<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Novartis markets and is developing Ilaris&#174; (canakinumab, ACZ885), a fully human monoclonal antibody that selectively binds to and neutralizes IL-1 beta. Since 2009, canakinumab has been approved in over 50 countries for the treatment of children and adults suffering from Cryopyrin-Associated Periodic Syndrome (&#8220;CAPS&#8221;).&#160;&#160;Novartis has filed for regulatory approval of canakinumab in the U.S. and Europe for the treatment acute attacks in gouty arthritis. In August 2011, Novartis announced that the FDA had issued a Complete Response letter requesting additional information, including clinical data to evaluate the benefit risk profile of canakinumab in refractory gouty arthritis patients.&#160;&#160;In September 2011, Novartis announced positive results of a pivotal Phase 3 trial of canakinumab in patients with systemic juvenile idiopathic arthritis and that it plans to seek regulatory approval for this indication in 2012. Novartis is also pursuing other diseases in which IL-1 beta may play a prominent role, such as systemic secondary prevention of cardiovascular events.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Eli Lilly and Company (&#8220;Lilly&#8221;) is developing a monoclonal antibody to IL-1 beta in Phase 1 development for the treatment of cardiovascular disease. In June 2011, Lilly reported results from a Phase 2 study of LY2189102 in 106 patients with Type 2 diabetes, showing a significant (p&lt;0.05), early reduction in C reactive protein, moderate reduction in HbA1c and anti-inflammatory effects. We do not know whether LY2189102 remains in development.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2008, Swedish Orphan Biovitrum obtained from Amgen the global exclusive rights to Kineret&#174; (anakinra) for rheumatoid arthritis as currently indicated in its label. In November 2009, the agreement regarding Swedish Orphan Biovitrum&#8217;s Kineret&#174; license was expanded to include certain orphan indications.&#160;&#160;Kineret&#174; is an IL-1 receptor antagonist (IL-1ra) which has been evaluated in multiple IL-1 mediated diseases, including indications we are considering for gevokizumab.&#160;&#160;In addition to other on-going studies, a proof-of-concept clinical trial in the United Kingdom investigating Kineret&#174; in patients with a certain type of myocardial infarction, or heart attack, has been completed.&#160;&#160;In August 2010, Biovitrum announced that the FDA had granted orphan drug designation to Kineret&#174; for the treatment of CAPS.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">38</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 36pt">
<div>&#160;</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2008, Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;) announced it had received marketing approval from the FDA for ARCALYST&#174; (rilonacept) Injection for Subcutaneous Use, an interleukin-1 blocker or IL-1 Trap, for the treatment of CAPS, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome in adults and children 12 and older.&#160;&#160;In September 2009, Regeneron announced that rilonacept was approved in the European Union for CAPS.&#160;&#160;In June 2010 and February 2011, Regeneron announced positive results of two Phase 3 clinical trials of rilonacept in gout.&#160;&#160;In November 2011, Regeneron announced that the FDA had accepted for review Regeneron&#8217;s supplemental BLA for ARCALYST&#174; for the prevention and treatment of gout. A meeting of an FDA advisory panel to review this supplemental BLA is scheduled for May 2012.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Amgen has been developing AMG 108, a fully-human monoclonal antibody that targets inhibition of the action of IL-1.&#160;&#160;In April 2008, Amgen discussed results from a Phase 2 study in rheumatoid arthritis.&#160;&#160;AMG 108 showed statistically significant improvement in the signs and symptoms of rheumatoid arthritis and was well tolerated.&#160;&#160;In January 2011, MedImmune, the worldwide biologics unit for AstraZeneca PLC, announced that Amgen granted it rights to develop AMG 108 worldwide except in Japan.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 36pt">
<div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June 2009, Cytos Biotechnology AG announced the initiation of an ascending dose Phase 1/2a study of CYT013-IL1bQb, a therapeutic vaccine targeting IL-1 beta, in Type 2 diabetes.&#160;&#160;In 2010, this study was extended to include two additional groups of patients.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></div>
</td>
<td style="WIDTH: 36pt">
<div>&#160;</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are aware that the following companies have completed or are conducting or planning Phase 3 clinical trials of the following products for the treatment of uveitis: Abbott - HUMIRA&#174; (adalimumab); Lux Biosciences, Inc. - LUVENIQ (voclosporin); Novartis - Myfortic&#174; (mycophenalate sodium) and Santen Pharmaceutical Co., Ltd. - Sirolimus (rapamycin).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Perindopril</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are currently selling ACEON, an angiotensin converting enzyme (&#8220;ACE&#8221;) inhibitor, and developing FDC1, a fixed-dose combination product candidate comprised of perindopril arginine and amlodipine besylate, a calcium channel blocker.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The ACE inhibitor market is highly genericized with all options being available generically.&#160;&#160;We are aware that:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The number one product (based on annual sales) within the ACE inhibitor category is lisinopril, formerly marketed by Astra-Zeneca Pharmaceuticals LP under the brand ZESTRIL&#174; and by Merck &amp; Co. under the brand Prinivil&#174;.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are multiple options in the fixed-dose combination market combining ACE inhibitors with diuretics, and two options combining an ACE inhibitor with a calcium channel blocker.&#160;&#160;Current options with a calcium channel blocker are benazepril/amlodipine, formerly marketed by Novartis Pharmaceuticals as Lotrel&#174;, and trandolapril/verapamil, formerly marketed by Abbot Laboratories as Tarka&#174;.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ACE inhibitors are a segment of the larger Renin Angiotensin Aldosterone System, or RAAS, market.&#160;&#160;This market is comprised of ACE inhibitors and angiotensin receptor blockers (ARB).&#160;&#160;Both classes act on the RAAS in different ways to control blood pressure.&#160;&#160;We are aware that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The most successful of the ARBs (in terms of annual sales) is valsartan, trade name Diovan&#174;, which is marketed by Novartis.&#160;&#160;This compound, along with other ARBs, has been developed in multiple fixed-dose combination products: with a diuretic, a calcium channel blocker (amlodipine) and as a triple combining all three.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our perindopril franchise will compete directly with fixed-dose combinations containing an ACE inhibitor and secondarily with fixed-dose combinations containing an ARB.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">XOMA 3AB</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins.&#160;&#160;Other companies are developing other products targeting botulism poisoning and these products may prove more effective than XOMA 3AB.&#160;&#160;We are aware that:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">39</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cangene Corporation&#160;&#160;has a contract with the U.S. Department of Health &amp; Human Services, expected to be for $423.0 million, to manufacture and supply an equine heptavalent botulism anti-toxin.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Emergent BioSolutions, Inc. is currently in development of a botulism immunoglobulin candidate that may compete with our anti-botulinum neurotoxin monoclonal antibodies.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing risks and inefficiencies may adversely affect our ability to manufacture products for ourselves or others.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To the extent we continue to provide manufacturing services for our own benefit or to third parties, we are subject to manufacturing risks.&#160;&#160;Additionally, unanticipated fluctuations in customer requirements have led and may continue to lead to manufacturing inefficiencies, which if significant could lead to an impairment on our long-lived assets or restructuring activities.&#160;&#160;We must utilize our manufacturing operations in compliance with regulatory requirements, in sufficient quantities and on a timely basis, while maintaining acceptable product quality and manufacturing costs.&#160;&#160;Additional resources and changes in our manufacturing processes may be required for each new product, product modification or customer or to meet changing regulatory or third party requirements, and this work may not be successfully or efficiently completed.&#160;&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Manufacturing and quality problems may arise in the future to the extent we continue to perform these manufacturing activities for our own benefit or for third parties.&#160;&#160;Consequently, our development goals or milestones may not be achieved in a timely manner or at a commercially reasonable cost, or at all.&#160;&#160;In addition, to the extent we continue to make investments to improve our manufacturing operations, our efforts may not yield the improvements that we expect.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure of our products to meet current Good Manufacturing Practices standards may subject us to delays in regulatory approval and penalties for noncompliance.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our contract manufacturers are required to produce ACEON&#174; and our clinical product candidates under current Good Manufacturing Practices, or cGMP, in order to meet acceptable standards for use in our clinical trials and for commercial sale, as applicable. If such standards change, the ability of contract manufacturers to produce ACEON&#174; and our product candidates on the schedule we require for our clinical trials or to meet commercial requirements may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with us or may discontinue their business before the time required by us to successfully produce clinical and commercial supplies of ACEON&#174; and our product candidates. We and our contract manufacturers are subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer&#8217;s compliance with these regulations and standards. Any difficulties or delays in our contractors&#8217; manufacturing and supply of ACEON&#174; and our product candidates or any failure of our contractors to maintain compliance with the applicable regulations and standards could increase our costs, cause us to lose revenue, make us postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and corresponding state and foreign authorities, prevent the import and/or export of ACEON&#174; and our product candidates, or cause ACEON&#174; and any of our product candidates that may be approved for commercial sale to be recalled or withdrawn.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because many of the companies we do business with are also in the biotechnology sector, the volatility of that sector can affect us indirectly as well as directly.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a biotechnology company that collaborates with other biotechnology companies, the same factors that affect us directly can also adversely impact us indirectly by affecting the ability of our collaborators, partners and others we do business with to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For example, in connection with our licensing transactions relating to our bacterial cell expression technology, we have in the past and may in the future agree to accept equity securities of the licensee in payment of license fees.&#160;&#160;The future value of these or any other shares we receive is subject both to market risks affecting our ability to realize the value of these shares and more generally to the business and other risks to which the issuer of these shares may be subject.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As we do more business internationally, we will be subject to additional political, economic and regulatory uncertainties.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may not be able to successfully operate in any foreign market.&#160;&#160;We believe that, because the pharmaceutical industry is global in nature, international activities will be a significant part of our future business activities and that, when and if we are able to generate income, a substantial portion of that income will be derived from product sales and other activities outside the United States.&#160;&#160;Foreign regulatory agencies often establish standards different from those in the United States, and an inability to obtain foreign regulatory approvals on a timely basis could put us at a competitive disadvantage or make it uneconomical to proceed with a product or product candidate&#8217;s development.&#160;&#160;International operations and sales may be limited or disrupted by:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">40</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">imposition of government controls,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">export license requirements,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">political or economic instability,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">trade restrictions,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">changes in tariffs,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">restrictions on repatriating profits,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">exchange rate fluctuations,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">withholding and other taxation, and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">difficulties in staffing and managing international operations.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to foreign currency exchange rate risks.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to foreign currency exchange rate risks because substantially all of our revenues and operating expenses are paid in U.S. dollars, but we pay interest and principal obligations with respect to our loan from Servier in Euros.&#160;&#160;To the extent that the U.S. dollar declines in value against the Euro, the effective cost of servicing our Euro-denominated debt will be higher.&#160;&#160;Changes in the exchange rate result in foreign currency gains or losses.&#160;&#160;Although we have managed some of our exposure to changes in foreign currency exchange rates by entering into foreign exchange option contracts, there can be no assurance that foreign currency fluctuations will not have a material adverse effect on our business, financial condition, liquidity or results of operations.&#160;&#160;In addition, our foreign exchange option contracts are re-valued at each financial reporting period, which may also result in gains or losses from time to time.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we and our partners are unable to protect our intellectual property, in particular our patent protection for our principal products, product candidates and processes, and prevent its use by third parties, our ability to compete in the market will be harmed, and we may not realize our profit potential.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We rely on patent protection, as well as a combination of copyright, trade secret, and trademark laws to protect our proprietary technology and prevent others from duplicating our products or product candidates.&#160;&#160;However, these means may afford only limited protection and may not:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">prevent our competitors from duplicating our products,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">prevent our competitors from gaining access to our proprietary information and technology, or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">permit us to gain or maintain a competitive advantage.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because of the length of time and the expense associated with bringing new products to the marketplace, we and our collaboration and development partners hold and are in the process of applying for a number of patents in the United States and abroad to protect our product candidates and important processes and also have obtained or have the right to obtain exclusive licenses to certain patents and applications filed by others.&#160;&#160;However, the mere issuance of a patent is not conclusive as to its validity or its enforceability.&#160;&#160;The United States Federal Courts or equivalent national courts or patent offices elsewhere may invalidate our patents or find them unenforceable.&#160;&#160;In addition, the laws of foreign countries may not protect our intellectual property rights effectively or to the same extent as the laws of the United States.&#160;&#160;If our intellectual property rights are not adequately protected, we may not be able to commercialize our technologies, products, or services, and our competitors could commercialize our technologies, which could result in a decrease in our sales and market share that would harm our business and operating results.&#160;&#160;Specifically, the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions.&#160;&#160;The legal standards governing the validity of biotechnology patents are in transition, and current defenses as to issued biotechnology patents may not be adequate in the future.&#160;&#160;Accordingly, there is uncertainty as to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">41</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">whether any pending or future patent applications held by us will result in an issued patent, or that if patents are issued to us, that such patents will provide meaningful protection against competitors or competitive technologies,</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">whether competitors will be able to design around our patents or develop and obtain patent protection for technologies, designs or methods that are more effective than those covered by our patents and patent applications, or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the extent to which our product candidates could infringe on the intellectual property rights of others, which may lead to costly litigation, result in the payment of substantial damages or royalties, and/or prevent us from using technology that is essential to our business.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have established a portfolio of patents, both United States and foreign, related to our bacterial cell expression technology, including claims to novel promoter sequences, secretion signal sequences, compositions and methods for expression and secretion of recombinant proteins from bacteria, including immunoglobulin gene products.&#160;&#160;Most of the more important European patents in our bacterial cell expression patent portfolio expired in July 2008 or earlier.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If certain patents issued to others are upheld or if certain patent applications filed by others issue and are upheld, we may require licenses from others in order to develop and commercialize certain potential products incorporating our technology or we may become involved in litigation to determine the proprietary rights of others.&#160;&#160;These licenses, if required, may not be available on acceptable terms, and any such litigation may be costly and may have other adverse effects on our business, such as inhibiting our ability to compete in the marketplace and absorbing significant management time.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the uncertainties regarding biotechnology patents, we also have relied and will continue to rely upon trade secrets, know-how and continuing technological advancement to develop and maintain our competitive position.&#160;&#160;All of our employees have signed confidentiality agreements under which they have agreed not to use or disclose any of our proprietary information.&#160;&#160;Research and development contracts and relationships between us and our scientific consultants and potential customers provide access to aspects of our know-how that are protected generally under confidentiality agreements.&#160;&#160;These confidentiality agreements may be breached or may not be enforced by a court.&#160;&#160;To the extent proprietary information is divulged to competitors or to the public generally, such disclosure may adversely affect our ability to develop or commercialize our products by giving others a competitive advantage or by undermining our patent position.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Litigation regarding intellectual property can be costly and expose us to risks of counterclaims against us.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may be required to engage in litigation or other proceedings to protect our intellectual property.&#160;&#160;The cost to us of this litigation, even if resolved in our favor, could be substantial.&#160;&#160;Such litigation could also divert management&#8217;s attention and resources.&#160;&#160;In addition, if this litigation is resolved against us, our patents may be declared invalid, and we could be held liable for significant damages.&#160;&#160;In addition, we may be subject to a claim that we are infringing another party&#8217;s patent.&#160;&#160;If such claim is resolved against us, we or our collaborators may be enjoined from developing, manufacturing, selling or importing products, processes or services unless we obtain a license from the other party.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Such license may not be available on reasonable terms, thus preventing us from using these products, processes or services and adversely affecting our revenue.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be unable to effectively price our products or obtain adequate reimbursement for sales of our products, which would prevent our products from becoming profitable.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If we or our third party collaborators or licensees succeed in bringing our product candidates to the market, they may not be considered cost-effective, and reimbursement to the patient may not be available or may not be sufficient to allow us to sell our products on a competitive basis.&#160;&#160;In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of reimbursement to the patient from third-party payors, such as government and private insurance plans.&#160;&#160;Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services.&#160;&#160;Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means.&#160;&#160;In the United States, there have been and will continue to be a number of federal and state proposals to implement government controls on pricing.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">42</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the emphasis on managed care in the United States has increased and will continue to increase the pressure on the pricing of pharmaceutical products.&#160;&#160;We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our business.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could impact our business<a name="SendMailTemp"><!--EFPlaceholder--></a>.&#160;&#160;In March&#160;2010, the U.S. Congress enacted and President Obama signed into law the Patient Protection and Affordable Care Act, which includes a number of healthcare reform provisions.&#160;&#160;Assuming this law survives on-going calls for its repeal, the reforms imposed by the law would significantly impact the pharmaceutical industry, most likely in the area of pharmaceutical product pricing.&#160;&#160;While the law may increase the number of patients who have insurance coverage for our products or product candidates, its cost containment measures could also adversely affect reimbursement for our existing or potential products; however, the full effects of this law cannot be known until these provisions are implemented and the relevant federal and state agencies issue applicable regulations or guidance.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The pharmaceutical and biotechnology industries are subject to extensive regulation, and from time to time legislative bodies and governmental agencies consider changes to such regulations that could have significant impact on industry participants.&#160;&#160;For example, in light of certain highly-publicized safety issues regarding certain drugs that had received marketing approval, the U.S. Congress has considered various proposals regarding drug safety, including some which would require additional safety studies and monitoring and could make drug development more costly.&#160;&#160;We are unable to predict what additional legislation or regulation, if any, relating to safety or other aspects of drug development may be enacted in the future or what effect such legislation or regulation would have on our business.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The business and financial condition of pharmaceutical and biotechnology companies are also affected by the efforts of governments, third-party payors and others to contain or reduce the costs of healthcare to consumers.&#160;&#160;In the United States and various foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the healthcare system, such as proposals relating to the reimportation of drugs into the U.S. from other countries (where they are then sold at a lower price) and government control of prescription drug pricing.&#160;&#160;The pendency or approval of such proposals could result in a decrease in the share price of our common stock or limit our ability to raise capital or to obtain strategic collaborations or licenses.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are exposed to an increased risk of product liability claims, and a series of related cases is currently pending against us.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The testing, marketing and sales of medical products entails an inherent risk of allegations of product liability.&#160;&#160;In the event of one or more large, unforeseen awards of damages against us, our product liability insurance may not provide adequate coverage.&#160;&#160;A significant product liability claim for which we were not covered by insurance or indemnified by a third party would have to be paid from cash or other assets, which could have an adverse affect on our business and the value of our common stock.&#160;&#160;To the extent we have sufficient insurance coverage, such a claim would result in higher subsequent insurance rates.&#160;&#160;In addition, product liability claims can have various other ramifications including loss of future sales opportunities, increased costs associated with replacing products, and a negative impact on our goodwill and reputation, which could also adversely affect our business and operating results.&#160; As examples, following are summaries of certain product liability related complaints to which we are a party.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 9, 2009, a complaint was filed in the Superior Court of Alameda County, California, in a lawsuit captioned Hedrick et al. v. Genentech, Inc. et al, Case No. 09-446158. The complaint asserts claims against Genentech, us and others for alleged strict liability for failure to warn, strict product liability, negligence, breach of warranty, fraudulent concealment, wrongful death and other claims based on injuries alleged to have occurred as a result of three individuals&#8217; treatment with RAPTIVA&#174;. The complaint seeks unspecified compensatory and punitive damages. Since then, additional complaints have been filed in the same court, bringing the total number of filed cases to seventy seven.&#160; The cases have been consolidated as a coordinated proceeding. &#160;All of the complaints allege the same claims and seek the same types of damages based on injuries alleged to have occurred as a result of the plaintiffs' treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of all but one of the cases pending in Alameda County Superior Court.&#160; The one Alameda County case not included in this settlement agreement is Kilzer v. Genentech, Inc., et al, Case No. RG-10-502461.&#160; Even though Genentech has agreed to indemnify us in connection with these matters, there can be no assurance that these or other products liability lawsuits will not result in liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">43</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 4, 2010, a petition was filed in the District Court of Dallas County, Texas in a case captioned McCall v. Genentech, Inc., et al., No. 10-09544.&#160; The defendants filed a Notice of Removal to the United States District Court for the Northern District of Texas on September 3, 2010.&#160; The removed case is captioned McCall v. Genentech, Inc., et al., No. 3:10-cv-01747-B. The petition asserts personal injury claims against Genentech, us and others arising out of plaintiff&#8217;s treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; Even though Genentech has agreed to indemnify us in connection with these matters, there can be no assurance that these or other products liability lawsuits will not result in liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 7, 2011, a complaint was filed in the United States District Court for the Northern District of Texas in a case captioned Massa v. Genentech, Inc., et al., No. 4:11CV70. This complaint alleges the same claims against Genentech, us and others and seeks the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; Even though Genentech has agreed to indemnify us in connection with these matters, there can be no assurance that these or other products liability lawsuits will not result in liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 11, 2011, a complaint was filed in the United States District Court for the District of Massachusetts in a case captioned Sylvia, et al. v. Genentech, Inc., et al., No. 1:11-cv-10054-MLW.&#160; On June 13, 2011, a complaint was filed in the Supreme Court for the State of New York, Onondaga County.&#160; Defendants removed the case to the United States District Court for the Northern District of New York on November 3, 2011. &#160;These two complaints allege the same claims against Genentech, us and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; No trial date has been set in either case. Even though Genentech has agreed to indemnify us in connection with these matters, there can be no assurance that these or other products liability lawsuits will not result in liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 8, 2011, four complaints were filed in the United States District Court for the Eastern District of Michigan.&#160; The cases are captioned:&#160; Muniz v. Genentech, et al., 5:11-cv-11489-JCO-RSW; Tifenthal v. Genentech, et al., 2:11-cv-11488-DPH-LJM; Blair v. Genentech, et al., 2:11-cv-11463-SFC-MJH; and Marsh v. Genentech, et al., 2:11-cv-11462-RHC-MKM.&#160; The complaints allege the same claims against Genentech, us and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; All four cases were transferred to the United States District Court for the Western District of Michigan.&#160; On October 26, 2011, the Court granted the Motions to Dismiss filed by Genentech and us in all four actions.&#160; On October 31, 2011, Plaintiffs filed a Notice of Appeal in each case in the United States Court of Appeal for the Sixth Circuit.&#160; Even though Genentech has agreed to indemnify us in connection with these matters, there can be no assurance that these or other products liability lawsuits will not result in liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The loss of key personnel, including our Chief Executive Officer, could delay or prevent achieving our objectives.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our research, product development and business efforts could be adversely affected by the loss of one or more key members of our scientific or management staff, particularly our executive officers: John Varian, our Chief Executive Officer; Patrick J. Scannon, M.D., Ph.D., our Executive Vice President and Chief Scientific Officer; Fred Kurland, our Vice President, Finance and Chief Financial Officer; Christopher J. Margolin, our Vice President, General Counsel and Secretary; and Paul D. Rubin, M.D., our Senior Vice President, Research and Development and Chief Medical Officer.&#160;&#160;We currently have no key person insurance on any of our employees.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our ability to use our net operating loss carry-forwards and other tax attributes will be substantially limited by Section 382 of the Internal Revenue Code.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section 382 of the Internal Revenue Code of 1986, as amended, generally limits the ability of a corporation that undergoes an &#8220;ownership change&#8221; to utilize its net operating loss carry-forwards (&#8220;NOLs&#8221;) and certain other tax attributes against any taxable income in taxable periods after the ownership change.&#160;&#160;The amount of taxable income in each taxable year after the ownership change that may be offset by pre-change NOLs and certain other pre-change tax attributes is generally equal to the product of (a) the fair market value of the corporation&#8217;s outstanding shares (or,&#160;&#160;in the case of a foreign corporation, the fair market value of items treated as connected with the conduct of a trade or business in the United States) immediately prior to the ownership change and (b) the long-term tax exempt rate (i.e., a rate of interest established by the IRS that fluctuates from month to month).&#160;&#160;In general, an &#8220;ownership change&#8221; occurs whenever the percentage of the shares of a corporation owned, directly or indirectly, by &#8220;5-percent shareholders&#8221; (within the meaning of Section 382 of the Internal Revenue Code) increases by more than 50 percentage points over the lowest percentage of the shares of such corporation owned, directly or indirectly, by such &#8220;5-percent shareholders&#8221; at any time over the preceding three years.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">44</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on our initial analysis under Section 382 (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to an annual limitation), we experienced an ownership change in 2009, which would substantially limit the future use of our pre-change NOLs and certain other pre-change tax attributes per year. We have and will continue to evaluate alternative analyses permitted under Section 382 and IRS notices in order to determine whether or not any ownership changes have occurred and may occur (and if so, when they occurred) that would result in limitations on our NOLs or certain other tax attributes.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not realize the expected benefits of our initiatives to reduce costs across our operations, and we may incur significant charges or write-downs as part of these efforts.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have pursued and may continue to pursue a number of initiatives to reduce costs of our operations. In January 2012, we implemented a workforce reduction of approximately 34% in order to improve our cost structure. This workforce reduction resulted primarily from our decisions to utilize a contract manufacturing organization for Phase 3 and commercial antibody production and to eliminate internal research functions that are non-differentiating or that can be obtained cost-effectively by contract service providers. As a result, we expect to reduce ongoing internal spending by approximately $14 million in 2012 compared to the 2011 level.&#160;&#160;In the first quarter of 2012, as a result of our streamlining of operations, we incurred restructuring and related severance costs totaling approximately $3.8 million, of which $2.1 million were cash charges. For the remainder of 2012, we expect to incur an additional $2.1 million in restructuring and severance costs, of which $1.4 million are expected to result in cash charges.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may not realize some or all of the expected benefits of our current and future initiatives to reduce costs. In addition to restructuring or other charges, we may experience disruptions in our operations as a result of these initiatives.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we are a relatively small biopharmaceutical company with limited resources, we may not be able to attract and retain qualified personnel.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success in developing marketable products and achieving a competitive position will depend, in part, on our ability to attract and retain qualified scientific and management personnel, particularly in areas requiring specific technical, scientific or medical expertise.&#160;&#160;We had approximately 157 employees as of May 4, 2012. We may require additional experienced executive, accounting, research and development, legal, administrative and other personnel from time to time in the future.&#160;&#160;There is intense competition for the services of these personnel, especially in California.&#160;&#160;Moreover, we expect that the high cost of living in the San Francisco Bay Area, where our headquarters and manufacturing facilities are located, may impair our ability to attract and retain employees in the future.&#160;&#160;If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our operations may suffer and we may be unable to implement our current initiatives or grow effectively.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business and operations would suffer in the event of system failures.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Despite the implementation of security measures, our internal computer systems and those of our current and any future collaborators, licensees, suppliers, contractors and consultants are vulnerable to damage from cyber&#8722;attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.&#160;&#160;We could experience failures in our information systems and computer servers, which could be the result of a cyber&#8722;attack and could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy.&#160;&#160;System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our development programs, commercialization activities and other business operations.&#160;&#160;The loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.&#160;&#160;Similarly, we rely on third parties to supply components for and manufacture our product and product candidates, conduct clinical trials of our product candidates and warehouse and distribute ACEON<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, and similar events relating to their computer systems could also have a material adverse effect on our business.&#160;&#160;To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of gevokizumab, FDC1 or any of our other product candidates and the commercialization of ACEON<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> could be delayed or otherwise adversely affected.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calamities, power shortages or power interruptions at our Berkeley headquarters and manufacturing facility could disrupt our business and adversely affect our operations.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our principal operations are located in Northern California, including our corporate headquarters and manufacturing facility in Berkeley, California.&#160;&#160;This location is in an area of seismic activity near active earthquake faults.&#160;&#160;Any earthquake, terrorist attack, fire, power shortage or other calamity affecting our facilities may disrupt our business and could have material adverse effect on our business and results of operations.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">45</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">We have a significant stockholder, which may limit other stockholders&#8217; ability to influence corporate matters and may give rise to conflicts of interest.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Entities controlled by Felix J. Baker and Julian C. Baker beneficially own approximately 30.6% of our outstanding common stock as of May 4, 2012.&#160;&#160;Accordingly, these entities may exert significant influence over us and any action requiring the approval of the holders of our stock, including the election of directors and approval of significant corporate transactions. We have agreed to allow a representative of these investors to receive information and attend meetings of our board of directors as an observer. These entities have indicated that they may be interested in nominating a member of our board of directors at some future date, but that no decision has been made on whether or not to make such a request.&#160;&#160;Furthermore, conflicts of interest could arise in the future between us, on the one hand, and these entities, on the other hand, concerning potential competitive business activities, business opportunities, the issuance of additional securities and other matters.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our shareholder rights agreement and organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2003, we adopted a new shareholder rights agreement (to replace the shareholder rights agreement that had expired), which could make it considerably more difficult or costly for a person or group to acquire control of us in a transaction that our Board of Directors opposes.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our charter and by-laws:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: center; WIDTH: 63pt">
<div style="TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#9679;</font></font></font></div>
</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">authorize our Board of Directors to issue up to 1,000,000 shares of preferred stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board of Directors may determine.&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), that may prohibit large stockholders, in particular those owning 15% or more of our outstanding common stock, from merging or combining with us.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These provisions of our shareholder rights agreement, our organizational documents and the DGCL, alone or in combination with each other, may discourage transactions involving actual or potential changes of control, including transactions that otherwise could involve payment of a premium over prevailing market prices to holders of common stock, could limit the ability of stockholders to approve transactions that they may deem to be in their best interests, and could make it considerably more difficult for a potential acquirer to replace management.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNREGISTE<a name="i23">RED </a>SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="tx49578_13"><!--EFPlaceholder--></a>ITEM 3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DEFAULTS <a name="i22">UPON SENIOR </a>SECURITIES</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="tx49578_14"><!--EFPlaceholder--></a>ITEM 4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MINE SAFE<a name="i24">TY</a> DISCLOSURES</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="tx49578_15"><!--EFPlaceholder--></a><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER INFORMATION</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">46</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 6.</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIB<a name="exhi">ITS</a></font></font></td>
</tr><tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Number</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31_1.htm">31.1</a></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of John Varian, filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31_2.htm">31.2</a></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Fred Kurland, filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex32_1.htm">32.1</a></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of John Varian, furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex32_2.htm">32.2</a></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Fred Kurland, furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex99_1.htm">99.1</a></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release dated May 8, 2012, furnished&#160;&#160;herewith</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Instance Document</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Schema Document</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Calculation Linkbase Document</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.DEF</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Definition Linkbase Document</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Label Linkbase Document</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Presentation Linkbase Document</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">47</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><a href="#toc">Table of Contents</a></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIG<a name="sig">NA</a>TURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block" align="left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XOMA Corporation</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;May 8, 2012</font></font></div>
</td>
<td valign="top" width="5%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ JOHN VARIAN</font></font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">John Varian</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer (principal executive officer) and </font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">Director</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">&#160;</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 8, 2012</font></font></td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></font></div>
</td>
<td valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ FRED KURLAND</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fred Kurland</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vice President, Finance and Chief Financial Officer</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(principal financial and principal accounting officer)</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">48</font></div>

<div>
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>ex31_1.htm</title>
    <!--Licensed to: TR-->
    <!--Document Created using EDGARizer 2020 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 31.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant To Section 302 Of The Sarbanes-Oxley Act Of 2002</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Chapter 63, Title 18 U.S.C.&#160;&#160;Section 1350(A) And (B))</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, John Varian, certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))) for the registrant and we have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="49%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;May 8, 2012</font></font></div>
</div>
</td>
<td valign="top" width="2%" style="BORDER-BOTTOM: #ffffff solid">&#160;</td>
<td align="left" nowrap valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;&#160;&#160;JOHN VARIAN</font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John Varian</font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title>ex31_2.htm</title>
    <!--Licensed to: TR-->
    <!--Document Created using EDGARizer 2020 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 31.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant To Section 302 Of The Sarbanes-Oxley Act Of 2002</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Chapter 63, Title 18 U.S.C.&#160;&#160;Section 1350(A) And (B))</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Fred Kurland, certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))) for the registrant and we have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="49%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;May 8, 2012</font></font></div>
</div>
</td>
<td valign="top" width="2%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;&#160;&#160;FRED KURLAND</font></font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fred Kurland</font></font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President, Finance and Chief Financial Officer</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">

<div>&#160;</div>

<div>&#160;</div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>ex32_1.htm</title>
    <!--Licensed to: TR-->
    <!--Document Created using EDGARizer 2020 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 32.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Chapter 63, Title 18 U.S.C.&#160;&#160;Section 1350(A) And (B))</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chapter 63, Title 18 U.S.C.&#160;&#160;Section 1350(a) and (b)), the undersigned hereby certifies in his capacity as an officer of XOMA Corporation (the &#8220;Company&#8221;) that the quarterly report of the Company on Form 10-Q for the period ended March 31, 2012, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of and for the periods covered by such report.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="49%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;&#160;May 8, 2012</font></div>
</td>
<td valign="top" width="2%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;&#160;&#160;JOHN VARIAN</font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John Varian</font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief Executive Officer</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This certification will not be deemed filed for purposes of Section 18 of the Exchange Act (15 U.S.C. 78), or otherwise subject to the liability of that section.&#160;&#160;Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32_2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
    <title>ex32_2.htm</title>
    <!--Licensed to: TR-->
    <!--Document Created using EDGARizer 2020 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 32.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Chapter 63, Title 18 U.S.C.&#160;&#160;Section 1350(A) And (B))</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chapter 63, Title 18 U.S.C.&#160;&#160;Section 1350(a) and (b)), the undersigned hereby certifies in his capacity as an officer of XOMA Corporation (the &#8220;Company&#8221;) that the quarterly report of the Company on Form 10-Q for the period ended March 31, 2012, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of and for the periods covered by such report.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="49%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;&#160;May 8, 2012</font></div>
</td>
<td valign="top" width="2%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="49%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;&#160;&#160;FRED KURLAND</font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fred Kurland</font></div>
</td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice President, Finance and Chief Financial Officer</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This certification will not be deemed filed for purposes of Section 18 of the Exchange Act (15 U.S.C. 78), or otherwise subject to the liability of that section.&#160;&#160;Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">

<div>&#160;</div>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>ex99_1.htm</title>
    <!--Licensed to: Thomson Reuters NY-->
    <!--Document Created using EDGARizer 2020 5.4.2.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="logo.jpg" alt="Graphic"></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="100%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XOMA Reports Financial Results for First Quarter 2012 and <font style="DISPLAY: inline">Highlights Recent Achievements</font><font id="TAB2" style="LETTER-SPACING: 3pt; COLOR: black">&#160;</font></font></font></td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8211; XOMA&#8217;s cash position enhanced by the $36.2 million raised in recent equity offering &#8211;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BERKELEY, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, today reported its financial results and operational highlights for the quarter ended March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">XOMA reported total revenues of $9.9 million in the first quarter of 2012, compared with $15.6 million in the corresponding period of 2011.&#160;&#160;The decrease in 2012 revenues was due to revenue recognized in 2011 from the up-front payment received from Les Laboratoires Servier (Servier) upon the execution of the collaboration agreement to develop and commercialize gevokizumab in multiple indications.&#160;&#160;The net loss for the first quarter of 2012 included a non-cash charge of $14.4 million (or $0.33 per share), as a result of the accounting rules relating to the valuation and classification of warrants.&#160;&#160;For the quarter ended March 31, 2012, XOMA had a net loss of $30.4 million (or $0.69 per share), compared with a net loss of $6.3 million, or $0.22 per share, for the quarter ended March 31, 2011.&#160;&#160;Excluding the increase in the non-cash revaluation of contingent warrant liabilities, which resulted primarily from the appreciation of XOMA&#8217;s stock price, net loss in the first quarter of 2012 was $16.0 million (or $0.36 per share).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The first quarter of 2012 was of significant importance to XOMA&#8217;s future.&#160;&#160;We implemented our strategy to focus directly on value-creating activities, primarily the gevokizumab Phase 3 non-infectious uveitis clinical program and the proof-of-concept studies.&#160;&#160;Our strategic decisions and the potential of gevokizumab&#160;to treat multiple inflammatory diseases drew the attention of some of the leading investors in biotechnology.&#160;&#160;Their support resulted in our ability to add&#160;over $36 million of cash to our balance sheet, which we expect will enable us to fund all of our operations well into 2014. This in turn allows our team to focus on building shareholder value by executing and delivering clinical results,&#8221; stated John Varian, Chief Executive Officer.&#160;&#160;&#8220;We remain on track to initiate both our Phase 3 non-infectious uveitis trial and our Phase 2 proof-of-concept study for erosive osteoarthritis of the hand by the end of June.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January 2012, XOMA announced a streamlining of its operations and an associated reduction in personnel, which are reflected in the reduction of the company&#8217;s expenses during the first quarter of 2012.&#160;&#160;Research and development expenses for the first quarter of 2012 were $15.8 million, compared with $17.3 million in the corresponding period of 2011.&#160;&#160;General and administrative expenses were $4.7 million in the first quarter of 2012, a 13 percent reduction from $5.4 million incurred in the first quarter of 2011.&#160;&#160;As a result of the company&#8217;s streamlining activities, XOMA took a charge of $3.8 million during the first quarter of 2012.&#160;&#160;The company currently anticipates the streamlining activities will result in total charges of $5.9 million, of which $3.0 million will be cash charges in 2012.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 31, 2012, XOMA had cash and cash equivalents of $74.9 million, including proceeds from the company&#8217;s March 2012 equity offering.&#160;&#160;The Company ended December 31, 2011, with cash and cash equivalents of $48.3 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">First Quarter 2012 Operational Actions and Achievements</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 5, XOMA announced the appointment of John Varian as Chief Executive Officer, in addition to his continued position as a member of the Board of Directors.&#160;&#160;Concurrently, Mr. Varian announced the streamlining of XOMA&#8217;s operations to focus on value-creating activities, primarily the expansion of gevokizumab&#8217;s clinical development program.&#160;&#160;The streamlining resulted in</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a personnel reduction of 84 positions</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the decision to outsource Phase 3 and commercial-scale manufacturing</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the elimination of internal research functions that were non-differentiated or obtainable cost-effectively through contract service providers</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">an anticipated reduction in G&amp;A spending of 20%, versus the prior year, to support the leaner organization</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the decision to complete the biodefense contracts XOMA has in place but not actively pursue future contracts.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 17, XOMA announced the launch of its commercial operations through the acquisition of U.S. development and commercialization rights to ACEON&#174; (perindopril erbumine) and a portfolio of fixed-dose combination product candidates incorporating a patent-protected version of perindopril from Servier.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February, XOMA enrolled its first patient in the PATH (Perindopril Amlodipine for the Treatment of Hypertension) trial.&#160;&#160;The three-arm trial is expected to enroll approximately 816 patients with hypertension to determine the safety and efficacy of the fixed-dose combination versus either perindopril or amlodipine alone.&#160;&#160;Based on regulatory interaction to date, if the trial generates positive results, it is expected to be the only efficacy trial needed to complement existing clinical data and will support the submission of an application to the FDA seeking approval for perindopril amlodipine candidate.&#160;&#160;The study will be funded in part through a co-development arrangement with Servier with the balance expected to be provided by the profits generated from U.S. ACEON&#174; sales.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 9, XOMA completed the sale of 29,669,154 shares of its common stock, and accompanying warrants to purchase one half of a share of common stock for each share purchased, at a public offering price of $1.32 per share.&#160;&#160;Gross proceeds from the offering were approximately $39.2 million and net proceeds were approximately $36.2 million.&#160;&#160;Full details related to the accounting of warrants and changes in valuation can be found in the company&#8217;s Form 10-Q filed with Securities and Exchange Commission.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 14, XOMA communicated its intention to initiate the second gevokizumab Phase 2 proof-of-concept study in erosive osteoarthritis of the hand (EOA) during the second quarter of 2012.&#160;&#160;EOA is caused by the breakdown of the body&#8217;s natural balance between cartilage formation and degradation, which leads to the narrowing of the space between the first and second joints in the fingers.&#160;&#160;Patients experience significant pain, stiffness, and ultimately loss of function.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012 Guidance</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company reaffirmed the anticipated cash used in ongoing operating activities during 2012 to be approximately $35 million, as announced on January 5, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investor Conference Call and Webcast</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">XOMA will host a conference call and webcast today, May 8, 2012, at 4:30 p.m. ET.&#160;&#160;The webcast can be accessed via the Investors section of XOMA's website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://investors.xoma.com/events.cfm</font> and will be available for replay until close of business on August 8, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international).&#160;&#160;A telephonic replay will be available beginning approximately two hours after the conclusion of the call until close of business on May 15, 2012.&#160;&#160;Telephone numbers for the replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international), passcode 72993480.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations.&#160;&#160;XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.&#160;&#160;XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (Servier) through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases.&#160;&#160;XOMA&#8217;s scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.&#160;&#160;In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier&#8217;s ACEON&#174; (perindopril erbumine) and a patent-protected portfolio of product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">More detailed information can be found at www.xoma.com.&#160;&#160;The XOMA Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">** Tables Follow **</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain statements contained herein concerning timing of initiation of clinical trials, anticipated size of clinical trials, continued sales of approved products, regulatory approval of unapproved product candidates, anticipated restructuring charges, anticipated expense reductions, sufficiency of our cash resources and anticipated levels of cash utilization, or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.&#160;&#160;These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Among other things, the timing of initiation of clinical trials may be delayed or may never occur as a result of actions or inaction by regulators or present or future collaboration partners, complications in the design, implementation or third-party approval of clinical trials, complications in the collection or interpretation of statistical data or unanticipated safety issues; clinical trials may not reach their anticipated size if they are not initiated or due to enrollment issues such as unavailability of patients, competing product candidates or unanticipated safety issues; continued sales of approved products may be impacted by XOMA's ability to implement its marketing efforts, competition or unanticipated safety issues; regulatory approval of unapproved product candidates may be affected by the results of future clinical trials, actions or inaction by the FDA or unanticipated safety issues; restructuring charges may be other than as anticipated if we have not estimated them properly or if we implement additional or different streamlining activities; expense reductions may not be realized if anticipated savings are offset by other expenses or if we make other changes in our business; the period for which our cash resources are sufficient could be shortened if expenditures are made earlier or in larger amounts than anticipated or are unanticipated, if anticipated revenue or cost sharing arrangements do not materialize, or if funds are not otherwise available on acceptable terms; and anticipated levels of cash utilization may be other than as expected due to unavailability of additional licensing or collaboration opportunities, inability to obtain the services of contract manufacturing or service providers on anticipated terms, higher than expected costs for clinical trials, outsourced manufacturing or other services, the effects of the pace of development spending in light of the terms of XOMA's existing collaboration arrangements, or unanticipated changes in XOMA's research and development programs or other businesses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These and other risks, including those related to current economic and financial market conditions; the results of discovery and pre-clinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); changes in the status of existing collaborative or licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations and their discretion in decision-making; XOMA's ability to meet the demands of the United States government agency with which it has entered into its government contracts; competition; market demand for products; scale-up, manufacturing and marketing capabilities; availability of additional licensing or collaboration opportunities; international operations; share price volatility; XOMA's financing needs and opportunities; uncertainties regarding the status of biotechnology patents; and uncertainties as to the costs of protecting intellectual property, are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands, except per share amounts)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">License and collaborative fees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,014</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,827</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract and other</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">8,851</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">9,768</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">9,865</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">15,595</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,771</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,347</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,679</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,369</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restructuring</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">3,777</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">24,227</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">22,716</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss from operations</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,362</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,121</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income (expense):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,042</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other (expense) income</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(664</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,057</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revaluation of contingent warrant liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(14,357</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2,390</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss before taxes</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(30,425</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,320</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provision for income tax expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(15</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(30,425</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(6,335</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted net loss per share of common stock</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(0.69</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">(0.22</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares used in computing basic and diluted net loss per share of common stock</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">44,353</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">29,180</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(in thousands)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(unaudited)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current assets:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="range!a8"><!--efplaceholder--></a>Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trade and other receivables, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,164</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">3,674</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2,019</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">88,725</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,695</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,329</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,709</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2,268</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2,632</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">101,322</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">78,036</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="white">
<td colspan="8" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,852</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,128</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued and other liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,297</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,012</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,912</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,695</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest bearing obligation &#8211; current</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2,796</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2,796</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,857</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,631</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenue &#8211; long-term</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,207</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,539</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest bearing obligations &#8211; long-term</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,569</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,524</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contingent warrant liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other liabilities &#8211; long term</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">1,079</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">952</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">81,834</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">63,025</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">19,488</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">15,011</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders' equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">101,322</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">78,036</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contingent warrant liabilities</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Initial fair value of warrants issued in March 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification to equity upon exercise of warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase in fair value of contingent warrant liabilities upon revaluation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,357</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at March 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CONTACT: XOMA Corporation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Company and Investor Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ashleigh Barreto</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;510-204-7482</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline">barreto@xoma.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Juliane Snowden</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Oratorium Group, LLC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">jsnowden@oratoriumgroup.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Media Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Canale Communications</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Carolyn Hawley</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;619-849-5375</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline">carolyn@canalecomm.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>xoma-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:curr="http://xbrl.sec.gov/currency/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:xoma="http://xoma.com/20120331" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="xoma-20120331.xsd" />
  <xbrli:context id="c20120101to20120331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120504">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-05-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20110101to20110331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20101231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20110331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20120331" unitRef="U002" decimals="-3">935455000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-1">900801000</us-gaap:AdditionalPaidInCapital>
  <!--Amortization of discount and final payment fee on debt and debt issuance costs-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20120101to20120331" unitRef="U002" decimals="-3">467000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Amortization of discount and final payment fee on debt and debt issuance costs-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20110101to20110331" unitRef="U002" decimals="-3">298000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Unrealized Gain (Loss) on Derivatives-->
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-276000</us-gaap:UnrealizedGainLossOnDerivatives>
  <!--Unrealized Gain (Loss) on Derivatives-->
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c20110101to20110331" unitRef="U002" decimals="-3">0</us-gaap:UnrealizedGainLossOnDerivatives>
  <!--Restructuring charge related to long-lived assets-->
  <us-gaap:AssetImpairmentCharges contextRef="c20120101to20120331" unitRef="U002" decimals="-3">1707000</us-gaap:AssetImpairmentCharges>
  <!--Restructuring charge related to long-lived assets-->
  <us-gaap:AssetImpairmentCharges contextRef="c20110101to20110331" unitRef="U002" decimals="-3">0</us-gaap:AssetImpairmentCharges>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20120331" unitRef="U002" decimals="-3">74887000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-2">48344000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20101231" unitRef="U002" decimals="-3">37304000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, at Carrying Value-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20110331" unitRef="U002" decimals="-3">56874000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-3221000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-5429000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20120101to20120331" unitRef="U002" decimals="-3">1651000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-247000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Trade and other receivables, net-->
  <us-gaap:IncreaseDecreaseInReceivables contextRef="c20120101to20120331" unitRef="U002" decimals="-3">2168000</us-gaap:IncreaseDecreaseInReceivables>
  <!--Trade and other receivables, net-->
  <us-gaap:IncreaseDecreaseInReceivables contextRef="c20110101to20110331" unitRef="U002" decimals="-3">10631000</us-gaap:IncreaseDecreaseInReceivables>
  <!--Commitments and Contingencies Disclosure [Text Block]-->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;10.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Legal Proceedings, Commitments and Contingencies&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On April 9, 2009, a complaint was filed in the Superior Court of Alameda County, California, in a lawsuit captioned Hedrick et al. v. Genentech, Inc. et al, Case No. 09-446158. The complaint asserts claims against Genentech, the Company and others for alleged strict liability for failure to warn, strict product liability, negligence, breach of warranty, fraudulent concealment, wrongful death and other claims based on injuries alleged to have occurred as a result of three individuals' treatment with RAPTIVA&amp;#174;. The complaint seeks unspecified compensatory and punitive damages. Since then, additional complaints have been filed in the same court, bringing the total number of filed cases to seventy seven.&amp;#160; The cases have been consolidated as a coordinated proceeding. &amp;#160;All of the complaints allege the same claims and seek the same types of damages based on injuries alleged to have occurred as a result of the plaintiffs' treatment with RAPTIVA&amp;#174;.&amp;#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of all but one of the cases pending in Alameda County Superior Court.&amp;#160; The one Alameda County case not included in this settlement agreement is Kilzer v. Genentech, Inc., et al, Case No. RG-10-502461.&amp;#160; The Company's agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.&amp;#160;&amp;#160; The Company believes the claims against it to be without merit and intends to defend against them vigorously.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On August 4, 2010, a petition was filed in the District Court of Dallas County, Texas in a case captioned McCall v. Genentech, Inc., et al., No. 10-09544.&amp;#160; The defendants filed a Notice of Removal to the United States District Court for the Northern District of Texas on September 3, 2010.&amp;#160; The removed case is captioned McCall v. Genentech, Inc., et al., No. 3:10-cv-01747-B. The petition asserts personal injury claims against Genentech, the Company and others arising out of plaintiff's treatment with RAPTIVA&amp;#174;.&amp;#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&amp;#160; The Company's agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On January 7, 2011, a complaint was filed in the United States District Court for the Northern District of Texas in a case captioned Massa v. Genentech, Inc., et al., No. 4:11CV70. This complaint alleges the same claims against Genentech, the Company and others and seeks the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&amp;#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&amp;#160; The Company's agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On January 11, 2011, a complaint was filed in the United States District Court for the District of Massachusetts in a case captioned Sylvia, et al. v. Genentech, Inc., et al., No. 1:11-cv-10054-MLW.&amp;#160; On June 13, 2011, a complaint was filed in the Supreme Court for the State of New York, Onondaga County.&amp;#160; Defendants removed the case to the United States District Court for the Northern District of New York on November 3, 2011. &amp;#160;These two complaints allege the same claims against Genentech, the Company and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&amp;#160; No trial date has been set in either case. The Company's agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which the Company believes is applicable to these matters. The Company believes the claims against it to be without merit and intends to defend against them vigorously.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On April 8, 2011, four complaints were filed in the United States District Court for the Eastern District of Michigan.&amp;#160; The cases are captioned:&amp;#160; Muniz v. Genentech, et al., 5:11-cv-11489-JCO-RSW; Tifenthal v. Genentech, et al., 2:11-cv-11488-DPH-LJM; Blair v. Genentech, et al., 2:11-cv-11463-SFC-MJH; and Marsh v. Genentech, et al., 2:11-cv-11462-RHC-MKM.&amp;#160; The complaints allege the same claims against Genentech, the Company and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&amp;#160; All four cases were transferred to the United States District Court for the Western District of Michigan.&amp;#160; On October 26, 2011, the Court granted the Motions to Dismiss filed by Genentech and the Company in all four actions.&amp;#160; On October 31, 2011, Plaintiffs filed a Notice of Appeal in each case in the United States Court of Appeal for the Sixth Circuit.&amp;#160; The Company's agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which the Company believes is applicable to these matters. The Company believes the claims against it to be without merit and intends to defend against them vigorously.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20120331" unitRef="U001" decimals="0">92666666</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20111231" unitRef="U001" decimals="0">92666666</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20120331" unitRef="U001" decimals="0">68076152</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20111231" unitRef="U001" decimals="0">35107007</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, $0.0075 par value, 92,666,666 shares authorized, 68,076,152 and 35,107,007 shares outstanding at March 31, 2012 and December 31, 2011, respectively-->
  <us-gaap:CommonStockValue contextRef="c20120331" unitRef="U002" decimals="-3">511000</us-gaap:CommonStockValue>
  <!--Common stock, $0.0075 par value, 92,666,666 shares authorized, 68,076,152 and 35,107,007 shares outstanding at March 31, 2012 and December 31, 2011, respectively-->
  <us-gaap:CommonStockValue contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-3">263000</us-gaap:CommonStockValue>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20120331" unitRef="U002" decimals="-3">18857000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-4">20631000</us-gaap:LiabilitiesCurrent>
  <!--Debt Instrument, Increase, Accrued Interest-->
  <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-394000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <!--Debt Instrument, Increase, Accrued Interest-->
  <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-231000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <!--Debt Instrument, Unamortized Discount-->
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c20110331" unitRef="U002" decimals="-3">8899000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <!--Deferred Revenue, Current-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20120331" unitRef="U002" decimals="-3">6912000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred Revenue, Current-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-5">5695000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue - long-term-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20120331" unitRef="U002" decimals="-3">7207000</us-gaap:DeferredRevenueNoncurrent>
  <!--Deferred revenue - long-term-->
  <us-gaap:DeferredRevenueNoncurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-6">7539000</us-gaap:DeferredRevenueNoncurrent>
  <!--Basic and diluted net loss per common stock (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20120101to20120331" unitRef="U003" decimals="2">-0.69</us-gaap:EarningsPerShareDiluted>
  <!--Basic and diluted net loss per common stock (in dollars per share)-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20110101to20110331" unitRef="U003" decimals="2">-0.22</us-gaap:EarningsPerShareDiluted>
  <!--Effect of exchange rate changes on cash-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20120101to20120331" unitRef="U002" decimals="-3">0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-573000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20120101to20120331" unitRef="U002" decimals="-3">674000</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20110101to20110331" unitRef="U002" decimals="-3">1772000</us-gaap:ShareBasedCompensation>
  <!--Income Tax Disclosure [Text Block]-->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;8.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Income Taxes&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company did not recognize any income tax expense for the three months ended March 31, 2012 and income tax expense was not material for the three months ended March 31, 2011. The Company's effective tax rate will fluctuate from period to period due to several factors inherent in the nature of the Company's operations and business transactions. The factors that most significantly impact this rate include the variability of licensing transactions in foreign jurisdictions.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20120101to20120331" unitRef="U002" decimals="-3">1042000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20110101to20110331" unitRef="U002" decimals="-3">532000</us-gaap:InterestExpense>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20120331" unitRef="U002" decimals="-3">81834000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-7">63025000</us-gaap:Liabilities>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20120331" unitRef="U002" decimals="-3">101322000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-8">78036000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Interest bearing obligation - current-->
  <us-gaap:LongTermDebtCurrent contextRef="c20120331" unitRef="U002" decimals="-3">2796000</us-gaap:LongTermDebtCurrent>
  <!--Interest bearing obligation - current-->
  <us-gaap:LongTermDebtCurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-9">2796000</us-gaap:LongTermDebtCurrent>
  <!--Interest bearing obligations - long-term-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20120331" unitRef="U002" decimals="-3">33569000</us-gaap:LongTermDebtNoncurrent>
  <!--Interest bearing obligations - long-term-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-10">33524000</us-gaap:LongTermDebtNoncurrent>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20120101to20120331" unitRef="U002" decimals="-3">38766000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20110101to20110331" unitRef="U002" decimals="-3">24231000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-548000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-888000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-11675000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-3200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-30425000</us-gaap:NetIncomeLoss>
  <!--Net loss-->
  <us-gaap:NetIncomeLoss contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-6335000</us-gaap:NetIncomeLoss>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20120101to20120331" unitRef="U002" decimals="-3">26543000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20110101to20110331" unitRef="U002" decimals="-3">20143000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-14362000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-7121000</us-gaap:OperatingIncomeLoss>
  <!--Revenues-->
  <us-gaap:Revenues contextRef="c20120101to20120331" unitRef="U002" decimals="-3">9865000</us-gaap:Revenues>
  <!--Revenues-->
  <us-gaap:Revenues contextRef="c20110101to20110331" unitRef="U002" decimals="-3">15595000</us-gaap:Revenues>
  <!--Other expense-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-664000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other expense-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-1057000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other Postretirement Benefits Payments-->
  <us-gaap:OtherPostretirementBenefitsPayments contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-1134000</us-gaap:OtherPostretirementBenefitsPayments>
  <!--Other Postretirement Benefits Payments-->
  <us-gaap:OtherPostretirementBenefitsPayments contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-1046000</us-gaap:OtherPostretirementBenefitsPayments>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20120331" unitRef="U001" decimals="0">1000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20111231" unitRef="U001" decimals="0">1000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20120331" unitRef="U003" decimals="INF">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20111231" unitRef="U003" decimals="INF">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Proceeds from issuance of common stock, net of issuance costs-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20120101to20120331" unitRef="U002" decimals="-3">39480000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from issuance of common stock, net of issuance costs-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20110101to20110331" unitRef="U002" decimals="-3">4129000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from issuance of long-term debt-->
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c20120101to20120331" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <!--Proceeds from issuance of long-term debt-->
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c20110101to20110331" unitRef="U002" decimals="-3">20102000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <!--Property and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20120331" unitRef="U002" decimals="-3">10329000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-11">12709000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20120101to20120331" unitRef="U002" decimals="-3">548000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20110101to20110331" unitRef="U002" decimals="-3">888000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Receivables, Net, Current-->
  <us-gaap:ReceivablesNetCurrent contextRef="c20120331" unitRef="U002" decimals="-3">10164000</us-gaap:ReceivablesNetCurrent>
  <!--Receivables, Net, Current-->
  <us-gaap:ReceivablesNetCurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-12">12332000</us-gaap:ReceivablesNetCurrent>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20120101to20120331" unitRef="U002" decimals="-3">714000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20110101to20110331" unitRef="U002" decimals="-3">0</us-gaap:RepaymentsOfLongTermDebt>
  <!--Restructuring-->
  <us-gaap:RestructuringCharges contextRef="c20120101to20120331" unitRef="U002" decimals="-3">3777000</us-gaap:RestructuringCharges>
  <!--Restructuring-->
  <us-gaap:RestructuringCharges contextRef="c20110101to20110331" unitRef="U002" decimals="-3">0</us-gaap:RestructuringCharges>
  <!--Restructuring and Related Activities Disclosure [Text Block]-->
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;6.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Streamlining and Restructuring Charges&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In January 2012, the Company implemented a streamlining of operations, which resulted in a restructuring plan designed to sharpen its focus on value-creating opportunities led by gevokizumab and its unique antibody discovery and development capabilities. The restructuring plan included a reduction of XOMA's personnel by 84 positions, or 34%, of which 52 were eliminated immediately and the remainder eliminated as of April 6, 2012. These staff reductions resulted primarily from the Company's decisions to utilize a contract manufacturing organization for Phase 3 and commercial antibody production and to eliminate internal research functions that are non-differentiating or that can be obtained cost-effectively by contract service providers.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;During the three months ended March 31, 2012, in connection with this streamlining of operations, the Company recorded charges of $2.1 million related to severance, other termination benefits and outplacement services. The Company expects to incur an additional $0.1 million restructuring charge in the second quarter of 2012 related to severance, other termination benefits and outplacement services.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company plans to vacate two of its leased buildings in 2012 related to manufacturing operations and internal research functions. The Company did not incur any restructuring charges during the first quarter of 2012 in connection with the exit of these leased buildings as they are still in use; however, it expects to incur restructuring charges of approximately $1.2 million in the remainder of 2012, primarily related to the net present value of future minimum lease payments at the cease-use date, less potential estimated future sublease income.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;As of March 31, 2012, the Company performed an impairment analysis of property and equipment and leasehold improvements related to its manufacturing operations. Since the estimated undiscounted future cash inflows from a&amp;#160;certain group of these assets were less than the carrying value, the Company determined that&amp;#160;these assets&amp;#160;were impaired and recorded a restructuring charge of $0.8 million. Further, the Company changed the useful life of certain property and equipment and leasehold improvements impacted by XOMA&lt;font style="display: inline; font-family: Times New Roman;"&gt;'&lt;/font&gt;s plans to vacate two leased buildings. As a result, the Company recorded accelerated depreciation of $0.9 million as a restructuring charge.&amp;#160;The Company expects to incur additional restructuring charges of approximately $0.7 million in the remainder of &amp;#160;2012 related to the&amp;#160;accelerated depreciation&amp;#160;of leasehold improvements.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The current and long-term portions of the outstanding restructuring liabilities are included in accrued and other liabilities and other liabilities - long-term on the condensed consolidated balance sheets and are based upon restructuring charges recognized as of March&amp;#160;31, 2012 and December 31, 2011 in connection with the 2009 and 2012 restructuring plans. As of March&amp;#160;31, 2012, the components of these liabilities are shown below (in thousands):&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Employee Severance &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;and Other Benefits&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Facility Charges&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Asset &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Impairment &lt;font style="display: inline; font-size: 70%; vertical-align: text-top;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 52%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Balance at December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;162&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;162&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 52%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Restructuring charges&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;2,070&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,707&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;3,777&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 52%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Cash payments&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,258&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(23&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,281&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Adjustments&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;8&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,707&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(1,699&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 52%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Balance at March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;812&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;147&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;959&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;(1)&amp;#160;&amp;#160;Restructuring charges include non-cash impairments of property and equipment and leasehold improvements. However, these amounts are not included in the restructuring accrual.&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The restructuring charges the Company expects to incur in connection with the 2012 streamlining of operations are subject to various assumptions, and actual results may differ.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20120331" unitRef="U002" decimals="-3">-916478000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-13">-886053000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Contract and other-->
  <us-gaap:ContractsRevenue contextRef="c20120101to20120331" unitRef="U002" decimals="-3">8851000</us-gaap:ContractsRevenue>
  <!--Contract and other-->
  <us-gaap:ContractsRevenue contextRef="c20110101to20110331" unitRef="U002" decimals="-3">9768000</us-gaap:ContractsRevenue>
  <!--Selling, general and administrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20120101to20120331" unitRef="U002" decimals="-3">4679000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, general and administrative-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20110101to20110331" unitRef="U002" decimals="-3">5369000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Significant Accounting Policies [Text Block]-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Basis of Presentation&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The condensed consolidated financial statements include the accounts of XOMA and its subsidiaries. All intercompany accounts and transactions were eliminated during consolidation. The unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the U.S. Securities and Exchange Commission ("SEC") on March 14, 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are necessary to present fairly the Company's consolidated financial position as of March 31, 2012, the consolidated results of the Company's operations and the Company's cash flows for the three months ended March 31, 2012 and 2011. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year or future periods.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Use of Estimates&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, research and development expense, long-lived assets, restructuring liabilities, derivative instruments and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company's billing under government contracts. Under the Company's contracts with the National Institute of Allergy and Infectious Diseases ("NIAID"), a part of the National Institutes of Health ("NIH"), the Company bills using NIH provisional rates and thus are subject to future audits at the discretion of NIAID's contracting office. These audits can result in an adjustment to revenue previously reported.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Option Pricing Model ("Black-Scholes Model") used to calculate the fair value of its contingent warrant liabilities. The Company changed its assumption from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions, which was determined to be a more precise indicator for the fair value calculation of the Company's warrants.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Reclassifications&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Certain reclassifications of prior period amounts have been made to the financial statements and accompanying notes to conform to the current period presentation. Prior period presentation of contingent warrant liabilities has been reclassified from current liabilities to long-term liabilities based on the contingent nature of these obligations. These contingent warrant liabilities represent a conditional obligation of the Company to repurchase certain warrants for cash in the event of a change in control. In addition, gain or loss on revaluation of the contingent warrant liabilities included in the other income (expense) line of the condensed consolidated statement of operations in the prior period has been reclassified to the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. These reclassifications had no impact on the Company's previously reported net loss or cash flows.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Long-lived Assets&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company reviews the carrying values and depreciation estimates of its long-lived assets whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the estimated future net cash flows expected to result from the use of an asset is less than its carrying amount. Long-lived assets include property and equipment and building and leasehold improvements. During the three months ended March 31, 2012, the Company recorded an impairment loss of $0.8 million and accelerated depreciaton of $0.9 million&amp;#160;on long-lived assets in connection with the Company's 2012 streamlining plan. See &lt;font style="font-style: italic; display: inline;"&gt;Note 6: Streamlining and Restructuring Charges&lt;/font&gt; for additional disclosure on the 2012 streamlining plan.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Concentration of Risk&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Cash equivalents and receivables are financial instruments, which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents such as money market funds. The Company has not encountered such issues during 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2012, two customers represented 49% and 40% of total revenue and 63% and 37% of the accounts receivable balance.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;For the three months ended March 31, 2011, these two customers represented 51% and 44% of total revenues. As of December 31, 2011, there were receivables outstanding from these two customers representing 57% and 43% of the accounts receivable balance.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Newly Adopted Accounting Pronouncements&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In May 2011, Accounting Standards Codification Topic 820, &lt;font style="font-style: italic; display: inline;"&gt;Fair Value Measurement&lt;/font&gt; was amended to develop common requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. generally accepted accounting principles and international financial reporting standards. The Company adopted this guidance as of January 1, 2012 on a retrospective basis and this adoption did not have a material effect on the Company's consolidated financial statements.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In June 2011, Accounting Standards Codification Topic 220, &lt;font style="font-style: italic; display: inline;"&gt;Comprehensive Income&lt;/font&gt; was amended to increase the prominence of items reported in other comprehensive income. Accordingly, a company can present all nonowner changes in stockholders' equity either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The Company adopted this guidance as of January 1, 2012 on a retrospective basis and this adoption did not have a material effect on the Company's consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Income taxes-->
  <us-gaap:IncomeTaxesPaid contextRef="c20120101to20120331" unitRef="U002" decimals="-3">0</us-gaap:IncomeTaxesPaid>
  <!--Income taxes-->
  <us-gaap:IncomeTaxesPaid contextRef="c20110101to20110331" unitRef="U002" decimals="-3">15000</us-gaap:IncomeTaxesPaid>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20120331" unitRef="U002" decimals="-3">88725000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-14">62695000</us-gaap:AssetsCurrent>
  <!--Contingent warrant liabilities-->
  <us-gaap:WarrantsAndRightsOutstanding contextRef="c20120331" unitRef="U002" decimals="-3">21122000</us-gaap:WarrantsAndRightsOutstanding>
  <!--Contingent warrant liabilities-->
  <us-gaap:WarrantsAndRightsOutstanding contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-15">379000</us-gaap:WarrantsAndRightsOutstanding>
  <!--Shares used in computing basic and diluted net loss per share of common stock (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20120101to20120331" unitRef="U001" decimals="0">44353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Shares used in computing basic and diluted net loss per share of common stock (in shares)-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20110101to20110331" unitRef="U001" decimals="0">29180</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120101to20120331" unitRef="U002" decimals="-3">15771000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20110101to20110331" unitRef="U002" decimals="-3">17347000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20120331" unitRef="U002" decimals="-3">101322000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-16">78036000</us-gaap:Assets>
  <!--Other liabilities - long term-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20120331" unitRef="U002" decimals="-3">1079000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other liabilities - long term-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-17">952000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Disclosure of Compensation Related Costs, Share-based Payments [Text Block]-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;9.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Stock-based Compensation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In the first quarter of 2012, the Board of Directors of the Company approved grants under the Long Term Incentive Plan for an aggregate of 940,900 stock options and an aggregate of 343,115 restricted stock units ("RSUs") to certain employees of the Company. The options vest monthly over four years and the RSUs vest annually over three years in equal increments.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company's employees, consultants and directors based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. This model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company's historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues. The forfeiture rate impacts the amount of aggregate compensation for both stock options and RSUs. To establish an estimate of forfeiture rate, the Company considers its historical experience of option forfeitures and terminations.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The fair value of stock-based awards was estimated based on the following weighted average assumptions for the three months ended March 31, 2011 and 2010:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Three Months Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;0&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;0&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;92&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;86&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1.05&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;2.20&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" colspan="3" valign="bottom" style="width: 11%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;5.6 years&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" colspan="3" valign="bottom" style="width: 11%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;5.6 years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Stock option activity for the three months ended March 31, 2012 was as follows:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Options&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Weighted &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Average &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Exercise Price &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Weighted &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Average &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Remaining &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Contractual Life &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(in years)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Aggregate &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Intrinsic Value &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Options outstanding at December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;5,053,435&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;12.55&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;6.89&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;940,900&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1.45&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(24,730&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1.69&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Forfeited, expired or cancelled&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(167,484&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;21.65&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Options outstanding at March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;5,802,121&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;10.53&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;7.28&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;2,375&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Options exercisable at March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;3,567,292&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;14.96&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;6.45&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;867&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The valuation of RSUs is determined at the date of grant using the closing stock price. To establish an estimate of forfeiture rate, the Company considers its historical experience of forfeitures and terminations.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Unvested RSU activity for the three months ended March 31, 2012 is summarized below:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="width: 56%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Weighted-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="width: 56%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Number of&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Average Grant-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Shares&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Date Fair Value&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Unvested balance at December 31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;903,874&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1.69&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;343,115&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1.29&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(132,575&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1.69&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Unvested balance at March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,114,414&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1.57&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2012 and 2011 (in thousands):&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Three Months Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;385&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,061&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Selling, general and administrative&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;289&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;711&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;674&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,772&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!--Fair Value Disclosures [Text Block]-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;4.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies ASC 820, which establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td style="width: 27pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 87px;"&gt;&lt;div style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;Level 1 - &lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1214px;"&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td style="width: 27pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 87px;"&gt;&lt;div style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;Level 2 -&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1214px;"&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;Observable inputs other than quoted prices in active markets for similar assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td style="width: 27pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 87px;"&gt;&lt;div style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;Level 3 - &lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1214px;"&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;Unobservable inputs.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The following tables set forth the Company's fair value hierarchy for its financial assets (cash equivalents) and liabilities measured at fair value on a recurring basis as of March 31, 2012 and December 31, 2011.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Financial assets and liabilities carried at fair value as of March 31, 2012 and December 31, 2011 were classified as follows (in thousands):&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Fair Value Measurements at March 31, 2012 Using&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; width: 10%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Quoted Prices in &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Active Markets for &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Identical Assets&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Significant &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Other &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Observable &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Inputs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Significant &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Unobservable &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Inputs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(Level&amp;#160;1)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(Level&amp;#160;2)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(Level&amp;#160;3)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Money market funds &lt;font style="display: inline; font-size: 70%; vertical-align: text-top;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;50,523&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;50,523&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;U.S. government securities &lt;font style="display: inline; font-size: 70%; vertical-align: text-top;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;9,999&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;9,999&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Foreign exchange options&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;926&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;926&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;60,522&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;926&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;61,448&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Contingent warrant liabilities&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;21,122&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;21,122&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Fair Value Measurements at December 31, 2011 Using&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; width: 10%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Quoted Prices in &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Active Markets for &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Identical Assets&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Significant &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Other &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Observable &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Inputs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Significant &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Unobservable &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Inputs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(Level&amp;#160;1)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(Level&amp;#160;2)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;(Level&amp;#160;3)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Money market funds &lt;font style="display: inline; font-size: 70%; vertical-align: text-top;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;27,222&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;27,222&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Foreign exchange options&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,202&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,202&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;27,222&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,202&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;28,424&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Contingent warrant liabilities&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;379&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;379&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 45pt; font-size: 10pt; margin-right: 0pt;"&gt;(1)&amp;#160;&amp;#160;Included in cash and cash equivalents&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The fair value of the foreign exchange options at March 31, 2012 and December 31, 2011 was determined using readily observable market inputs from actively quoted markets obtained from various third party data providers. These inputs, such as spot rate, forward rate and volatility have been derived from readily observable market data, meeting the criteria for Level 2 in the fair value hierarchy.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The fair value of the contingent warrant liabilities was determined at March 31, 2012 and December 31, 2011 using the Black-Scholes Model, which requires inputs such as the expected term of the warrants, volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. A market-based volatility rate was determined to be a more precise indicator for the fair value calculation of the Company's warrants.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The fair value of the contingent warrant liabilities was estimated using the following range of assumptions at March 31, 2012 and December 31, 2011:&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 60%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 36%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;March 31,&lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;December 31, &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 36%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;40&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;102.1% - 103.2&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 36%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;0.5% - 1.05&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;0.4&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 36%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;2.7 - 4.9 years&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="right" colspan="2" valign="bottom" style="width: 10%;"&gt;&lt;div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;2.9 - 3.1 years&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The following table provides a summary of changes in the fair value of the Company's Level 3 financial liabilities for the three months ended March 31, 2012 (in thousands):&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr style="text-align: center;"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Contingent warrant liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Balance at December&amp;#160;31, 2011&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;379&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Initial fair value of warrants issued in March 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;6,390&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Reclassification of contingent warrant liability to equity upon exercise of warrants&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;(4&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Net increase in fair value of contingent warrant liabilities upon revaluation&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;14,357&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 68%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Balance at March 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;21,122&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The net increase of $14.4 million in the estimated fair value of the contingent warrant liabilities was recognized as a loss in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of operations for the three months ended March 31, 2012.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;For the three months ended March 31, 2011, the Company recognized a net decrease of $2.4 million in the estimated fair value of the contingent warrant liabilities as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <!--Deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20120101to20120331" unitRef="U002" decimals="-3">884000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Deferred revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-6156000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20120331" unitRef="U002" decimals="-3">2268000</us-gaap:OtherAssetsNoncurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-18">2632000</us-gaap:OtherAssetsNoncurrent>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20120101to20120331" unitRef="U002" decimals="-3">24227000</us-gaap:OperatingExpenses>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20110101to20110331" unitRef="U002" decimals="-3">22716000</us-gaap:OperatingExpenses>
  <!--Other liabilities-->
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-37000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <!--Other liabilities-->
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-90000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-30425000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-6320000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20120331" unitRef="U003" decimals="INF">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20111231" unitRef="U003" decimals="INF">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20120331" unitRef="U002" decimals="-3">19488000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-19">15011000</us-gaap:StockholdersEquity>
  <!--Income Tax Expense (Benefit)-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20120101to20120331" unitRef="U002" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income Tax Expense (Benefit)-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20110101to20110331" unitRef="U002" decimals="-3">15000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Foreign Currency Transaction Gain (Loss), Unrealized-->
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-376000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <!--Foreign Currency Transaction Gain (Loss), Unrealized-->
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-1619000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <!--Preferred stock, $0.05 par value, 1,000,000 shares authorized-->
  <us-gaap:PreferredStockValue contextRef="c20120331" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, $0.05 par value, 1,000,000 shares authorized-->
  <us-gaap:PreferredStockValue contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-20">0</us-gaap:PreferredStockValue>
  <!--Long-term Debt [Text Block]-->
  <us-gaap:LongTermDebtTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;7.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Long-Term Debt and Other Financings&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Long-Term Debt&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Novartis Note&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In May 2005, the Company executed a secured note agreement with Novartis (then Chiron Corporation), which is due and payable in full in June 2015. Under this note agreement, the Company borrowed semi-annually to fund up to 75% of the Company's research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50 million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus 2%, which was equal to 2.80% at March 31, 2012, and is payable semi-annually in June and December of each year. At the Company's election, the semi-annual interest payments can be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $50 million. The Company has made this election for all interest payments thus far. Loans under the note agreement are secured by the Company's interest in the collaboration with Novartis, including any payments owed to it thereunder.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;At March 31, 2012 and December 31, 2011, the outstanding principal balance under this note agreement was $14.0 million. Pursuant to the terms of the arrangement as restructured in November 2008, the Company will not make any additional borrowings under the Novartis note. Due to the structure of the secured note agreement with Novartis and since there is no liquid market for this obligation, there is no practical method to estimate fair value of this long-term debt.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Servier Loan&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In December 2010, in connection with the license and collaboration agreement entered into with Servier, the Company executed a loan agreement with Servier, which provided for an advance of up to &amp;#8364;15 million. The loan was fully funded in January 2011, with the proceeds converting to approximately $19.5 million. The loan is secured by an interest in XOMA's intellectual property rights to all gevokizumab indications worldwide, excluding certain rights in the U.S. and Japan. Interest is calculated at a floating rate based on a Euro Inter-Bank Offered Rate ("EURIBOR") and subject to a cap. The interest rate for the initial interest period was 3.22%. The interest rate has been reset to 3.83% for the six-month period from July 2011 through January 2012 and 3.54% for the six-month period from January 2012 through July 2012. Interest is payable semi-annually; however, the loan agreement provides for a deferral of interest payments over a period specified in the agreement. During the deferral period, accrued interest will be added to the outstanding principal amount for the purpose of interest calculation for the next six-month interest period. On the repayment commencement date, all unpaid and accrued interest shall be paid to Servier and thereafter, all accrued and unpaid interest shall be due and payable at the end of each six-month period. The loan matures in 2016; however, after a specified period prior to final maturity, the loan is to be repaid (i) at Servier's option, by applying up to a significant percentage of any milestone or royalty payments owed by Servier under the Company's collaboration agreement and (ii) using a significant percentage of any upfront, milestone or royalty payments the Company receives from any third party collaboration or development partner for rights to gevokizumab in the U.S. and/or Japan.&amp;#160; In addition, the loan becomes immediately due and payable upon certain customary events of default. At March 31, 2012 and December 31, 2011, the outstanding principal balance under this loan was $20.0 million and $19.4 million, respectively, using the Euro to US Dollar ("USD") exchange rate at each such date. For the three months ended March 31, 2012 and 2011, the Company recorded unrealized foreign exchange losses of $0.6 million and $1.6 million, respectively, related to the re-measurement of the loan.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The loan has a stated interest rate lower than the market rate based on comparable loans held by similar companies, which represents additional value to the Company. The Company recorded this additional value as a discount to the face value of the loan amount, at its fair value of $8.9 million. The fair value of this discount, which was determined using a discounted cash flow model, represents the differential between the stated terms and rates of the loan, and market rates. Based on the association of the loan with the collaboration arrangement, the Company recorded the offset to this discount as deferred revenue.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The loan discount is amortized under the effective interest method over the expected five-year life of the loan.&amp;#160;&amp;#160;The Company recorded non-cash interest expense of $0.3 million in the three months ended March 31, 2012 and 2011, resulting from the amortization of the loan discount. At March 31, 2012 and December 31, 2011, the net carrying value of the loan was $13.2 million and $12.5 million, respectively. For the three months ended March 31, 2012, the Company recorded an unrealized foreign exchange loss of $0.2 million related to the re-measurement of the loan discount as of March 31, 2012.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company believes that realization of the benefit and the associated deferred revenue is contingent on the loan remaining outstanding over the five-year contractual term of the loan. If the Company were to stop providing service under the collaboration arrangement and the arrangement is terminated, the maturity date of the loan would be accelerated and a portion of measured benefit would not be realized. As the realization of the benefit is contingent, in part, on the provision of future services, the Company is recognizing the deferred revenue over the expected five-year life of the loan. The deferred revenue is amortized under the effective interest method, and the Company recorded $0.3 million of related non-cash revenue during both the three months ended March 31, 2012 and 2011.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;General Electric Capital Corporation Term Loan&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In December 2011, the Company entered into a loan agreement (the "Loan Agreement") with General Electric Capital Corporation ("GECC"), under which GECC agreed to make a term loan in an aggregate principal amount of $10 million (the "Term Loan") to XOMA (US) LLC, a wholly owned subsidiary of the Company, and upon execution of the Loan Agreement, GECC funded the Term Loan. The Term Loan is guaranteed by the Company and its two other principal subsidiaries, XOMA Ireland Limited and XOMA Technology Ltd.&amp;#160;&amp;#160;As security for their obligations under the Loan Agreement, the Company, XOMA (US) LLC, XOMA Ireland Limited and XOMA Technology Ltd. each granted a security interest pursuant to a guaranty, pledge and security agreement in substantially all of their existing and after-acquired assets, excluding their intellectual property assets (such as those relating to the Company's gevokizumab and anti-botulism products). The Company incurred debt issuance costs of approximately $1.3 million in connection with the Term Loan and will make an additional payment equal to 5% of the Term Loan (the "Final Payment Fee") on the maturity date, or such earlier date as the Term Loan is paid in full. The debt issuance costs and Final Payment Fee are being amortized and accreted, respectively, to interest expense over the term of the Term Loan using the effective interest method.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Term Loan accrues interest at a fixed rate of 11.71% per annum. We are required to repay the principal amount of the Term Loan over a period of 42 consecutive equal monthly installments of principal and accrued interest, commencing on January 4, 2012, and thereafter on the first calendar day of each succeeding month.&amp;#160;&amp;#160;The Term Loan matures and is due and payable in full on June 30, 2015.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including restrictions on the ability to incur indebtedness, grant liens, make investments, dispose of assets, enter into transactions with affiliates and amend existing material agreements, in each case subject to various exceptions.&amp;#160;&amp;#160;In addition, the Loan Agreement contains customary events of default that entitle GECC to cause any or all of the indebtedness under the Loan Agreement to become immediately due and payable. The events of default include any event of default under a material agreement or certain other indebtedness. Upon an event of default, the Term Loan and other obligations under the Loan Agreement will, at the election of GECC, bear interest from and after the occurrence and during the continuation of an event of default at a rate equal to the lesser of 5.0% above the stated rate of interest or the maximum rate allowed by law.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company may voluntarily prepay the Term Loan in full, but not in part, and any voluntary and certain mandatory prepayments are subject to a prepayment premium of 3% in the first year of the loan, 2% in the second year and 1% thereafter, although mandatory prepayments in connection with entering into certain exclusive licenses, granting certain negative pledges or incurring certain collaboration-related indebtedness will not be subject to such prepayment premium.&amp;#160;&amp;#160;The Company will also be required to pay the Final Payment Fee in connection with any voluntary or mandatory prepayment. At March 31, 2012 and December 31, 2011, the outstanding principal balance under the Loan Agreement was $9.3 million and $10.0 million respectively.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In December 2011, pursuant to the loan agreement, the Company issued to GECC unregistered stock purchase warrants, which entitle GECC to purchase up to an aggregate of 263,158 unregistered shares of XOMA common stock at an exercise price equal to $1.14 per share. These warrants are immediately exercisable and will expire on December 30, 2016. The Company allocated the aggregate proceeds of the GECC Term Loan between the warrants and the debt obligation based on their relative fair values.&amp;#160;&amp;#160;The fair value of the warrants issued to GECC was determined using the Black-Scholes Model. The warrants fair value of $0.2 million is recorded as a discount to the debt obligation and is being amortized over the term of the loan using the effective interest method. If the maturity of the debt is accelerated in connection with any voluntary or mandatory prepayment, then the remaining discount amortization would be recognized immediately.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Interest Expense&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Interest expense for the Servier loan, GECC loan and Novartis note are shown below (in thousands):&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Three Months Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Servier loan&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;516&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;442&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;GECC term loan&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;417&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Novartis note&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;99&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;84&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;10&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;6&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Total interest expense&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,042&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;532&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Other Financings&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;ATM Agreement&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On February 4, 2011, the Company entered into an At Market Issuance Sales Agreement (the "2011 ATM Agreement"), with McNicoll, Lewis &amp;amp; Vlak LLC (now known as MLV &amp;amp; Co. LLC, "MLV"), under which it may sell shares of its common stock from time to time through the MLV, as the agent for the offer and sale of the shares, in an aggregate amount not to exceed the amount that can be sold under the Company's registration statement on Form S-3 (File No. 333-172197) filed with the SEC on February 11, 2011 and amended on March 10, 2011, June 3, 2011 and January 3, 2012, which was most recently declared effective by the SEC on January 17, 2012. MLV may sell the shares by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for the Company's common stock or to or through a market maker. MLV may also sell the shares in privately negotiated transactions, subject to the Company's prior approval. From the inception of the 2011 ATM Agreement through March 31, 2012, the Company sold a total of 7,572,327 shares of common stock under this agreement for aggregate gross proceeds of $14.6 million, including 2,285,375 shares of common stock sold in the first quarter of 2012 for aggregate gross proceeds of $3.3 million. Total offering expenses incurred related to sales under the 2011 ATM Agreement from inception to March 31, 2012, were $0.4 million, including $0.1 million incurred in the first quarter of 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Underwritten Offering and Amendment to Shareholder Rights Plan&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On March 9, 2012, the Company completed an underwritten public offering of 29,669,154 shares of its common stock, and accompanying warrants to purchase one half of a share of common stock for each share purchased, at a public offering price of $1.32 per share. Total gross proceeds from the offering were approximately $39.2 million, before deducting underwriting discounts and commissions and estimated offering expenses totaling approximately $2.9 million. The warrants, which represent the right to acquire an aggregate of up to 14,834,577 shares of common stock, are immediately exercisable and have a five-year term and an exercise price of $1.76 per share.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company has amended its shareholder rights agreement to provide that it will not apply to any person or entity who becomes the beneficial owner of 20% or more but less than 40% of its outstanding common stock with the prior approval of its board of directors, and its board has approved purchasers in&amp;#160;the March 2012 public offering becoming beneficial owners of 20% or more but less than 40% of its outstanding common stock as a result of their participation in the offering.&amp;#160; As a result, such ownership by any such purchaser will not trigger the provisions of the rights agreement that would give each holder of the rights the right to receive upon exercise that number of common stock equivalents having a market value of two times the exercise price.&amp;#160;&amp;#160;The board's approval in this regard only applies to purchasers in&amp;#160;such offering.&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <!--Collaborative Arrangement Disclosure [Text Block]-->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;5.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Licensing, Collaborative and Other Arrangements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; font-style: italic; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Servier - U.S. Perindopril Franchise&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;On January 17, 2012, the Company announced that it had acquired certain U.S. rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON&amp;#174; (perindopril erbumine), a currently marketed ACE inhibitor, and three fixed-dose combination ("FDC") product candidates where a form of proprietary perindopril (perindopril arginine) is combined with another active ingredient(s), such as a calcium channel blocker. The Company assumed commercialization activities for ACEON&amp;#174; in January 2012 following the transfer from Servier's previous licensee.&amp;#160;&amp;#160;In late February 2012, the Company initiated enrollment in a Phase 3 trial for perindopril arginine and amlodipine besylate, the first FDC product candidate. The trial, named PATH (&lt;font style="display: inline; font-weight: bold;"&gt;P&lt;/font&gt;erindopril &lt;font style="display: inline; font-weight: bold;"&gt;A&lt;/font&gt;mlodipine for the &lt;font style="display: inline; font-weight: bold;"&gt;T&lt;/font&gt;reatment of &lt;font style="display: inline; font-weight: bold;"&gt;H&lt;/font&gt;ypertension), is expected to enroll approximately 816 patients with hypertension to determine the safety and efficacy of the FDC versus either perindopril or amlodipine alone. Based on regulatory interaction to date, if&amp;#160;the trial generates positive results, it is expected to be the only&amp;#160;efficacy trial needed to complement&amp;#160;existing clinical data&amp;#160;and will&amp;#160;support&amp;#160;the submission of an application to the FDA seeking approval for this product candidate. Partial funding for the PATH trial was provided by Servier; the balance of study expenses, consisting primarily of costs generated by the Company's contract research organization, are expected to be paid over time from the profits generated by the Company's ACEON&amp;#174; sales.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In connection with the original agreement, the Company paid a $1.5 million license fee to Servier in the third quarter of 2010. The Company also is required to pay a royalty on ACEON&amp;#174; sales at a rate that is tiered based on sales levels and ranges from a mid-single digit to a mid-teen percentage rate. If approved, the Company also will pay a royalty on sales of the FDC product candidates in the mid-teen percentage rate. The FDC royalty rate is subject to reduction in the event of generic competition or if other intellectual property rights are required. The Company may be required to pay the following milestones: development milestones aggregating $8.5 million (assuming the Company exercises its options on the additional FDCs) and sales milestones of up to an aggregate $15.1 million, in each case for all of the FDC product candidates. The Company also may be required to make certain additional payments if the FDC product candidates receive FDA approval but certain minimum sales levels are not reached. The Company generally will be responsible for its development and commercialization expenses, but Servier has agreed to partially fund development of the first FDC product candidate.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!--Depreciation, Depletion and Amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20120101to20120331" unitRef="U002" decimals="-3">1265000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation, Depletion and Amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20110101to20110331" unitRef="U002" decimals="-3">1346000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Nature of Operations [Text Block]-->
  <us-gaap:NatureOfOperations contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;1.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Description of Business&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;XOMA Corporation ("XOMA" or the "Company"), a Delaware corporation, combines a portfolio of late-stage clinical programs and research activities to develop innovative therapeutic antibodies with its recently launched commercial operations.&amp;#160; XOMA focuses its scientific research on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.&amp;#160;&amp;#160;XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier ("Servier") through a global Phase 3 program and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also has produced the XMet platform, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators that could offer new approaches in the treatment of diabetes.&amp;#160;&amp;#160;In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier's ACEON&amp;#174; (perindopril erbumine) and certain U.S. rights to a patent-protected portfolio of fixed dose combination product candidates where perindopril is combined with other active ingredients to treat cardiovascular disease.&amp;#160;XOMA has the right to develop and commercialize one of these product candidates and options to develop and commercialize two more product candidates, all for the U.S. market.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20120331" unitRef="U002" decimals="-3">2852000</us-gaap:AccountsPayableCurrent>
  <!--Accounts payable-->
  <us-gaap:AccountsPayableCurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-21">2128000</us-gaap:AccountsPayableCurrent>
  <!--Accrued and other liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20120331" unitRef="U002" decimals="-3">6297000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued and other liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-22">10012000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20120101to20120331" unitRef="U002" decimals="-3">43000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20110101to20110331" unitRef="U002" decimals="-3">-10000</us-gaap:OtherNoncashIncomeExpense>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20120101to20120331">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20120101to20120331">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20120101to20120331">2012-03-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20120101to20120331">No</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20120101to20120331">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20120101to20120331">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20120101to20120331">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20120101to20120331">XOMA Corp</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20120101to20120331">0000791908</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20120504" unitRef="U001" decimals="0">68083980</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20120101to20120331">2012</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20120101to20120331">Q1</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20120101to20120331">10-Q</dei:DocumentType>
  <!--Prepaid expenses and other current assets-->
  <xoma:PrepaidExpensesAndOtherCurrentAssets contextRef="c20120331" unitRef="U002" decimals="-3">3674000</xoma:PrepaidExpensesAndOtherCurrentAssets>
  <!--Prepaid expenses and other current assets-->
  <xoma:PrepaidExpensesAndOtherCurrentAssets contextRef="c20111231" unitRef="U002" decimals="-3" id="Item-23">2019000</xoma:PrepaidExpensesAndOtherCurrentAssets>
  <!--License and collaborative fees-->
  <xoma:LicenseAndCollaborativeFees contextRef="c20120101to20120331" unitRef="U002" decimals="-3">1014000</xoma:LicenseAndCollaborativeFees>
  <!--License and collaborative fees-->
  <xoma:LicenseAndCollaborativeFees contextRef="c20110101to20110331" unitRef="U002" decimals="-3">5827000</xoma:LicenseAndCollaborativeFees>
  <!--Unrealized gain loss on warrants-->
  <xoma:UnrealizedGainLossOnWarrants contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-14357000</xoma:UnrealizedGainLossOnWarrants>
  <!--Unrealized gain loss on warrants-->
  <xoma:UnrealizedGainLossOnWarrants contextRef="c20110101to20110331" unitRef="U002" decimals="-3">2390000</xoma:UnrealizedGainLossOnWarrants>
  <!--Issuance and extinguishment of warrant liabilities-->
  <xoma:IssuanceAndExtinguishmentOfWarrantLiabilities contextRef="c20120101to20120331" unitRef="U002" decimals="-3">6386000</xoma:IssuanceAndExtinguishmentOfWarrantLiabilities>
  <!--Issuance and extinguishment of warrant liabilities-->
  <xoma:IssuanceAndExtinguishmentOfWarrantLiabilities contextRef="c20110101to20110331" unitRef="U002" decimals="-3">0</xoma:IssuanceAndExtinguishmentOfWarrantLiabilities>
  <!--Interest Added Principal Balances Long-Term Debt-->
  <xoma:InterestAddedPrincipalBalancesLong-TermDebt contextRef="c20120101to20120331" unitRef="U002" decimals="-3">-398000</xoma:InterestAddedPrincipalBalancesLong-TermDebt>
  <!--Interest Added Principal Balances Long-Term Debt-->
  <xoma:InterestAddedPrincipalBalancesLong-TermDebt contextRef="c20110101to20110331" unitRef="U002" decimals="-3">0</xoma:InterestAddedPrincipalBalancesLong-TermDebt>
  <!--Condensed Consolidated Financial Statement Detail Text Block-->
  <xoma:CondensedConsolidatedFinancialStatementDetailTextBlock contextRef="c20120101to20120331">&lt;div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr valign="top"&gt;&lt;td align="right" style="width: 18pt;"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;3.&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Condensed Consolidated Financial Statement Detail&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Comprehensive Loss&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Comprehensive loss is equal to net loss for both the three months ended March 31, 2012 and 2011.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Net Loss Per Share of Common Stock&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Basic and diluted net loss per share of common stock is based on the weighted average number of shares of common stock outstanding during the period.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Potentially dilutive securities are excluded from the calculation of earnings per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Three Months Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Common stock options and restricted stock units&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;5,722&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;2,638&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Convertible preferred stock&lt;/div&gt;&lt;/td&gt;&lt;td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;254&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Warrants for common stock&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;5,457&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,607&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;11,179&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;4,499&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;For the three months ended March 31, 2012 and 2011, all outstanding securities were considered anti-dilutive, and therefore the calculation of basic and diluted net loss per share was the same.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;At March 31, 2012 cash equivalents consisted of demand deposits of $14.4 million, money market funds of $50.5 million, and U.S. government securities of $10.0 million with maturities of less than 90 days at the date of purchase. At December 31, 2011, cash equivalents consisted of demand deposits of $21.1 million and money market funds of $27.2 million with maturities of less than 90 days at the date of purchase.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Foreign Exchange Options&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The Company holds debt and may incur expenses denominated in foreign currencies, which exposes it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and the Euro. The Company is required to make principal and accrued interest payments in Euros on its &amp;#8364;15.0 million loan from Servier (See &lt;font style="font-style: italic; display: inline;"&gt;Note 7: Long-Term Debt and Other Financings&lt;/font&gt;). In order to manage its foreign currency exposure related to these payments, in May 2011, the Company entered into two foreign exchange option contracts to buy &amp;#8364;15.0 million and &amp;#8364;1.5 million on January 2016 and January 2014, respectively. By having these option contracts in place, the Company's foreign exchange rate risk is reduced if the U.S. dollar weakens against the Euro. However, if the U.S. dollar strengthens against the Euro, the Company is not required to exercise these options, but will not receive any refund on premiums paid.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Upfront premiums paid on these foreign exchange option contracts totaled $1.5 million. The fair values of these option contracts are re-valued at each reporting period and are estimated based on pricing models using readily observable inputs from actively quoted markets. The fair values of these option contracts are included in other assets on the condensed consolidated balance sheet and changes in fair value on these contracts are included in other income (expense) on the condensed consolidated statements of operations.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;The foreign exchange options were revalued at March 31, 2012 and had an aggregate fair value of $0.9 million resulting in a related loss of $0.3 million for the three months ended March 31, 2012.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Accrued Liabilities&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;Accrued liabilities consisted of the following at March 31, 2012 and December 31, 2011 (in thousands):&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;March 31,&lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;December 31, &lt;/div&gt;&lt;div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;2011&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Accrued payroll and other benefits&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;2,155&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;3,007&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Accrued management incentive compensation&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;996&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;4,096&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Accrued restructuring costs&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;891&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;70&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;760&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;917&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Accrued severance payments&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;551&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;1,207&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;944&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;715&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"&gt;&lt;div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;6,297&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;"&gt;10,012&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;"&gt;Contingent Warrant Liabilities&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of XOMA's common stock at an exercise price of $1.76 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in March 2012 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At issuance, the fair value of the warrant liability was estimated to be $6.4 million using the Black-Scholes Model. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded an increase in the fair value of $14.7 million as a loss in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, 14,832,827 of these warrants were outstanding and had a fair value of $21.1 million. This increase in liability is primarily due to the excess of the market value of the Company's common stock at March 31, 2012 compared to the warrant exercise price. See &lt;font style="font-style: italic; display: inline;"&gt;Note 4: Fair Value Measurements &lt;/font&gt;for further disclosure regarding the fair value of this warrant liability.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In February 2010, in connection with an underwritten offering, the Company issued five-year warrants to purchase 1,260,000 shares of XOMA's common stock at an exercise price of $10.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in February 2010 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.3 million using the Black-Scholes Model. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.3 million as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding. See &lt;font style="font-style: italic; display: inline;"&gt;Note 4: Fair Value Measurements &lt;/font&gt;for further disclosure regarding the fair value of this warrant liability.&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"&gt;In June 2009, the Company issued warrants to certain institutional investors as part of a registered direct offering. The warrants represent the right to acquire an aggregate of up to 347,826 shares of XOMA's common stock over a five year period beginning December 11, 2009 at an exercise price of $19.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in June 2009 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.1 million using the Black-Scholes Model. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.1 million as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding. See &lt;font style="font-style: italic; display: inline;"&gt;Note 4: Fair Value Measurements &lt;/font&gt;for further disclosure regarding the fair value of this warrant liability.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</xoma:CondensedConsolidatedFinancialStatementDetailTextBlock>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:footnote xlink:label="Footnote-Item-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The condensed consolidated balance sheet as of December 31, 2011 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.</link:footnote>
    <link:loc xlink:href="#Item-1" xlink:label="Item-1_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-1_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-2" xlink:label="Item-2_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-2_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-3" xlink:label="Item-3_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-3_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-4" xlink:label="Item-4_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-4_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-5" xlink:label="Item-5_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-5_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-6" xlink:label="Item-6_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-6_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-7" xlink:label="Item-7_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-7_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-8" xlink:label="Item-8_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-8_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-9" xlink:label="Item-9_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-9_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-10" xlink:label="Item-10_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-10_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-11" xlink:label="Item-11_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-11_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-12" xlink:label="Item-12_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-12_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-13" xlink:label="Item-13_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-13_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-14" xlink:label="Item-14_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-14_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-15" xlink:label="Item-15_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-15_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-16" xlink:label="Item-16_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-16_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-17" xlink:label="Item-17_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-17_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-18" xlink:label="Item-18_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-18_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-19" xlink:label="Item-19_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-19_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-20" xlink:label="Item-20_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-20_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-21" xlink:label="Item-21_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-21_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-22" xlink:label="Item-22_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-22_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
    <link:loc xlink:href="#Item-23" xlink:label="Item-23_lbl" xlink:type="locator" />
    <link:footnoteArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-23_lbl" xlink:to="Footnote-Item-1" xlink:type="arc" />
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>xoma-20120331.xsd
<DESCRIPTION>XBRL SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<xs:schema targetNamespace="http://xoma.com/20120331" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xoma="http://xoma.com/20120331" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20120331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://xoma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" id="CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" id="CondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
        <link:definition>060100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" id="BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/CondensedConsolidatedFinancialStatementDetail" id="CondensedConsolidatedFinancialStatementDetail">
        <link:definition>060300 - Disclosure - Condensed Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>060400 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/LicensingCollaborativeAndOtherArrangements" id="LicensingCollaborativeAndOtherArrangements">
        <link:definition>060500 - Disclosure - Licensing, Collaborative and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/StreamliningAndRestructuringCharges" id="StreamliningAndRestructuringCharges">
        <link:definition>060600 - Disclosure - Streamlining and Restructuring Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/LongtermDebtAndOtherFinancings" id="LongtermDebtAndOtherFinancings">
        <link:definition>060700 - Disclosure - Long-Term Debt and Other Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>060800 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060900 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xoma.com/role/LegalProceedingsCommitmentsAndContingencies" id="LegalProceedingsCommitmentsAndContingencies">
        <link:definition>061000 - Disclosure - Legal Proceedings, Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:element name="PrepaidExpensesAndOtherCurrentAssets" id="xoma_PrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LicenseAndCollaborativeFees" id="xoma_LicenseAndCollaborativeFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="UnrealizedGainLossOnWarrants" id="xoma_UnrealizedGainLossOnWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CashPaidDuringNineMonthsEndedAbstract" id="xoma_CashPaidDuringNineMonthsEndedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IssuanceAndExtinguishmentOfWarrantLiabilities" id="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CashPaidDuringPeriodAbstract" id="xoma_CashPaidDuringPeriodAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InterestAddedPrincipalBalancesLong-TermDebt" id="xoma_InterestAddedPrincipalBalancesLong-TermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DescriptionOfBusinessAbstract" id="xoma_DescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BasisOfPresentationAndSignificantAccountingPoliciesAbstract" id="xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CondensedConsolidatedFinancialStatementDetailAbstract" id="xoma_CondensedConsolidatedFinancialStatementDetailAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CondensedConsolidatedFinancialStatementDetailTextBlock" id="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FairValueMeasurementsAbstract" id="xoma_FairValueMeasurementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LicensingCollaborativeAndOtherArrangementsAbstract" id="xoma_LicensingCollaborativeAndOtherArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Long-TermDebtAndOtherFinancingsAbstract" id="xoma_Long-TermDebtAndOtherFinancingsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncomeTaxesAbstract" id="xoma_IncomeTaxesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Stock-BasedCompensationAbstract" id="xoma_Stock-BasedCompensationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LegalProceedingsCommitmentsAndContingenciesAbstract" id="xoma_LegalProceedingsCommitmentsAndContingenciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DocumentAndEntityInformationAbstract" id="xoma_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>xoma-20120331_cal.xml
<DESCRIPTION>XBRL CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:calculationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermDebtNoncurrent" xlink:title="calculation: Liabilities to LongTermDebtNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenueNoncurrent" xlink:title="calculation: Liabilities to DeferredRevenueNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="WarrantsAndRightsOutstanding" xlink:title="calculation: Liabilities to WarrantsAndRightsOutstanding" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DeferredRevenueCurrent" xlink:title="calculation: LiabilitiesCurrent to DeferredRevenueCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LongTermDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to LongTermDebtCurrent" order="99999.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_PrepaidExpensesAndOtherCurrentAssets" xlink:label="PrepaidExpensesAndOtherCurrentAssets" xlink:title="PrepaidExpensesAndOtherCurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpensesAndOtherCurrentAssets" xlink:title="calculation: AssetsCurrent to PrepaidExpensesAndOtherCurrentAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="ReceivablesNetCurrent" xlink:title="calculation: AssetsCurrent to ReceivablesNetCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to OtherNonoperatingIncomeExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="InterestExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to InterestExpense" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_UnrealizedGainLossOnWarrants" xlink:label="UnrealizedGainLossOnWarrants" xlink:title="UnrealizedGainLossOnWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="UnrealizedGainLossOnWarrants" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to UnrealizedGainLossOnWarrants" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="RoyaltyRevenue" xlink:title="calculation: Revenues to RoyaltyRevenue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="ContractsRevenue" xlink:title="ContractsRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="ContractsRevenue" xlink:title="calculation: Revenues to ContractsRevenue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_LicenseAndCollaborativeFees" xlink:label="LicenseAndCollaborativeFees" xlink:title="LicenseAndCollaborativeFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="LicenseAndCollaborativeFees" xlink:title="calculation: Revenues to LicenseAndCollaborativeFees" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="Revenues" xlink:title="calculation: OperatingIncomeLoss to Revenues" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to SellingGeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="RestructuringCharges" xlink:title="RestructuringCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="RestructuringCharges" xlink:title="calculation: OperatingExpenses to RestructuringCharges" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to OperatingIncomeLoss" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfLongTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfLongTermDebt" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfLongTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfLongTermDebt" order="99997.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingLiabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDeferredRevenue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OtherNoncashIncomeExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OtherNoncashIncomeExpense" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AssetImpairmentCharges" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AssetImpairmentCharges" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="UnrealizedGainLossOnDerivatives" xlink:title="UnrealizedGainLossOnDerivatives" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="UnrealizedGainLossOnDerivatives" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to UnrealizedGainLossOnDerivatives" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="ForeignCurrencyTransactionGainLossUnrealized" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ForeignCurrencyTransactionGainLossUnrealized" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfFinancingCostsAndDiscounts" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_UnrealizedGainLossOnWarrants" xlink:label="UnrealizedGainLossOnWarrants" xlink:title="UnrealizedGainLossOnWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="UnrealizedGainLossOnWarrants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to UnrealizedGainLossOnWarrants" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="DebtInstrumentIncreaseAccruedInterest" xlink:title="DebtInstrumentIncreaseAccruedInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DebtInstrumentIncreaseAccruedInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DebtInstrumentIncreaseAccruedInterest" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="OtherPostretirementBenefitsPayments" xlink:title="OtherPostretirementBenefitsPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OtherPostretirementBenefitsPayments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OtherPostretirementBenefitsPayments" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationDepletionAndAmortization" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="IncreaseDecreaseInReceivables" xlink:title="IncreaseDecreaseInReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInReceivables" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInReceivables" order="14.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInOperatingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>xoma-20120331_def.xml
<DESCRIPTION>XBRL DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://xoma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" xlink:href="xoma-20120331.xsd#LegalProceedingsCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://xoma.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="xoma-20120331.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://xoma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xoma-20120331.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://xoma.com/role/LongtermDebtAndOtherFinancings" xlink:type="simple" xlink:href="xoma-20120331.xsd#LongtermDebtAndOtherFinancings" />
  <link:roleRef roleURI="http://xoma.com/role/StreamliningAndRestructuringCharges" xlink:type="simple" xlink:href="xoma-20120331.xsd#StreamliningAndRestructuringCharges" />
  <link:roleRef roleURI="http://xoma.com/role/LicensingCollaborativeAndOtherArrangements" xlink:type="simple" xlink:href="xoma-20120331.xsd#LicensingCollaborativeAndOtherArrangements" />
  <link:roleRef roleURI="http://xoma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="xoma-20120331.xsd#FairValueMeasurements" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedFinancialStatementDetail" />
  <link:roleRef roleURI="http://xoma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="xoma-20120331.xsd#BasisOfPresentationAndSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://xoma.com/role/DescriptionOfBusiness" xlink:type="simple" xlink:href="xoma-20120331.xsd#DescriptionOfBusiness" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="xoma-20120331.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="definition: StatementLineItems to StockholdersEquityAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="definition: StatementLineItems to PreferredStockParOrStatedValuePerShare" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: StatementLineItems to PreferredStockSharesAuthorized" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: StatementLineItems to CommonStockParOrStatedValuePerShare" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: StatementLineItems to CommonStockSharesAuthorized" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: StatementLineItems to CommonStockSharesOutstanding" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="8.0" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockMember" xlink:title="definition: ClassOfStockDomain to PreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/DescriptionOfBusiness" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedFinancialStatementDetail" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/FairValueMeasurements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/LicensingCollaborativeAndOtherArrangements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/StreamliningAndRestructuringCharges" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/LongtermDebtAndOtherFinancings" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://xoma.com/role/LegalProceedingsCommitmentsAndContingencies" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>xoma-20120331_lab.xml
<DESCRIPTION>XBRL LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl">Amortization of discount and final payment fee on debt and debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="UnrealizedGainLossOnDerivatives" xlink:title="UnrealizedGainLossOnDerivatives" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnDerivatives_lbl">Unrealized loss on foreign exchange options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:title="label: UnrealizedGainLossOnDerivatives to us-gaap_UnrealizedGainLossOnDerivatives_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives_lbl1" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnDerivatives_lbl1">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl1" xlink:title="label: UnrealizedGainLossOnDerivatives to us-gaap_UnrealizedGainLossOnDerivatives_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges_lbl">Restructuring charge related to long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and cash equivalents at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2">Cash and cash equivalents at the end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="IncreaseDecreaseInReceivables" xlink:title="IncreaseDecreaseInReceivables" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInReceivables_lbl">Trade and other receivables, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:title="label: IncreaseDecreaseInReceivables to us-gaap_IncreaseDecreaseInReceivables_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Legal Proceedings, Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, $0.0075 par value, 92,666,666 shares authorized, 68,076,152 and 35,107,007 shares outstanding at March 31, 2012 and December 31, 2011, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="DebtInstrumentIncreaseAccruedInterest" xlink:title="DebtInstrumentIncreaseAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl">Accrued interest on interest bearing obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:title="label: DebtInstrumentIncreaseAccruedInterest to us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1">Debt Instrument, Increase, Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1" xlink:title="label: DebtInstrumentIncreaseAccruedInterest to us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl">Discount on long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueCurrent_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:title="label: DeferredRevenueCurrent to us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueCurrent_lbl1" xml:lang="en-US" id="us-gaap_DeferredRevenueCurrent_lbl1">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl1" xlink:title="label: DeferredRevenueCurrent to us-gaap_DeferredRevenueCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueNoncurrent_lbl">Deferred revenue - long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:title="label: DeferredRevenueNoncurrent to us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Basic and diluted net loss per common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl">Effect of exchange rate changes on cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:title="label: EffectOfExchangeRateOnCashAndCashEquivalents to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtCurrent_lbl">Interest bearing obligation - current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:title="label: LongTermDebtCurrent to us-gaap_LongTermDebtCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtNoncurrent_lbl">Interest bearing obligations - long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:title="label: LongTermDebtNoncurrent to us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Revenues_lbl" xml:lang="en-US" id="us-gaap_Revenues_lbl">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:title="label: Revenues to us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Revenues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Revenues_lbl1" xml:lang="en-US" id="us-gaap_Revenues_lbl1">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="us-gaap_Revenues_lbl1" xlink:title="label: Revenues to us-gaap_Revenues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenuesAbstract_lbl">Revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:title="label: RevenuesAbstract to us-gaap_RevenuesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="OtherPostretirementBenefitsPayments" xlink:title="OtherPostretirementBenefitsPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherPostretirementBenefitsPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherPostretirementBenefitsPayments_lbl" xml:lang="en-US" id="us-gaap_OtherPostretirementBenefitsPayments_lbl">Common stock contribution to 401(k)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherPostretirementBenefitsPayments" xlink:to="us-gaap_OtherPostretirementBenefitsPayments_lbl" xlink:title="label: OtherPostretirementBenefitsPayments to us-gaap_OtherPostretirementBenefitsPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherPostretirementBenefitsPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherPostretirementBenefitsPayments_lbl1" xml:lang="en-US" id="us-gaap_OtherPostretirementBenefitsPayments_lbl1">Other Postretirement Benefits Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherPostretirementBenefitsPayments" xlink:to="us-gaap_OtherPostretirementBenefitsPayments_lbl1" xlink:title="label: OtherPostretirementBenefitsPayments to us-gaap_OtherPostretirementBenefitsPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl">Proceeds from issuance of long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:title="label: ProceedsFromIssuanceOfLongTermDebt to us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" id="us-gaap_ReceivablesNetCurrent_lbl">Trade and other receivables, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:title="label: ReceivablesNetCurrent to us-gaap_ReceivablesNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesNetCurrent_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesNetCurrent_lbl1">Receivables, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl1" xlink:title="label: ReceivablesNetCurrent to us-gaap_ReceivablesNetCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebt_lbl">Principal payments of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:title="label: RepaymentsOfLongTermDebt to us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermDebt_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebt_lbl1">Repayments of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl1" xlink:title="label: RepaymentsOfLongTermDebt to us-gaap_RepaymentsOfLongTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="RestructuringCharges" xlink:title="RestructuringCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" id="us-gaap_RestructuringCharges_lbl">Restructuring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xlink:title="label: RestructuringCharges to us-gaap_RestructuringCharges_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl">Streamlining and Restructuring Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:title="label: RestructuringAndRelatedActivitiesDisclosureTextBlock to us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" xlink:title="label: RestructuringAndRelatedActivitiesDisclosureTextBlock to us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="ContractsRevenue" xlink:title="ContractsRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractsRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractsRevenue_lbl" xml:lang="en-US" id="us-gaap_ContractsRevenue_lbl">Contract and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl" xlink:title="label: ContractsRevenue to us-gaap_ContractsRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="us-gaap_RoyaltyRevenue_lbl">Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" xlink:title="label: RoyaltyRevenue to us-gaap_RoyaltyRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense_lbl">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxesPaid_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:title="label: IncomeTaxesPaid to us-gaap_IncomeTaxesPaid_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstanding_lbl">Contingent warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:title="label: WarrantsAndRightsOutstanding to us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Shares used in computing basic and diluted net loss per share of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_PreferredStockMember_lbl">Series B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other liabilities - long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:title="label: IncreaseDecreaseInDeferredRevenue to us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl">Net loss before taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Provision for income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="ForeignCurrencyTransactionGainLossUnrealized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl">Unrealized loss on foreign currency exchange</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:title="label: ForeignCurrencyTransactionGainLossUnrealized to us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl1" xml:lang="en-US" id="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl1">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl1" xlink:title="label: ForeignCurrencyTransactionGainLossUnrealized to us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred stock, $0.05 par value, 1,000,000 shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl">Long-Term Debt and Other Financings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl1">Long-term Debt [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl1" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl">Licensing, Collaborative and Other Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl">Non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" id="us-gaap_NatureOfOperations_lbl">Description of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:title="label: NatureOfOperations to us-gaap_NatureOfOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NatureOfOperations_lbl1" xml:lang="en-US" id="us-gaap_NatureOfOperations_lbl1">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl1" xlink:title="label: NatureOfOperations to us-gaap_NatureOfOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl">Streamlining and Restructuring Charges [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:title="label: RestructuringAndRelatedActivitiesAbstract to us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNoncashIncomeExpense_lbl">Other non-cash adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:title="label: OtherNoncashIncomeExpense to us-gaap_OtherNoncashIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNoncashIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNoncashIncomeExpense_lbl1">Other Noncash Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl1" xlink:title="label: OtherNoncashIncomeExpense to us-gaap_OtherNoncashIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="dei_EntityPublicFloat_lbl">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_PrepaidExpensesAndOtherCurrentAssets" xlink:label="PrepaidExpensesAndOtherCurrentAssets" xlink:title="PrepaidExpensesAndOtherCurrentAssets" />
    <link:label xlink:type="resource" xlink:label="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" id="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl">Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer. And, aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssets" xlink:to="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl" xlink:title="label: PrepaidExpensesAndOtherCurrentAssets to xoma_PrepaidExpensesAndOtherCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl1" xml:lang="en-US" id="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssets" xlink:to="xoma_PrepaidExpensesAndOtherCurrentAssets_lbl1" xlink:title="label: PrepaidExpensesAndOtherCurrentAssets to xoma_PrepaidExpensesAndOtherCurrentAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_LicenseAndCollaborativeFees" xlink:label="LicenseAndCollaborativeFees" xlink:title="LicenseAndCollaborativeFees" />
    <link:label xlink:type="resource" xlink:label="xoma_LicenseAndCollaborativeFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="xoma_LicenseAndCollaborativeFees_lbl" xml:lang="en-US" id="xoma_LicenseAndCollaborativeFees_lbl">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Also, includes reimbursable income that occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndCollaborativeFees" xlink:to="xoma_LicenseAndCollaborativeFees_lbl" xlink:title="label: LicenseAndCollaborativeFees to xoma_LicenseAndCollaborativeFees_lbl" />
    <link:label xlink:type="resource" xlink:label="xoma_LicenseAndCollaborativeFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_LicenseAndCollaborativeFees_lbl1" xml:lang="en-US" id="xoma_LicenseAndCollaborativeFees_lbl1">License and collaborative fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndCollaborativeFees" xlink:to="xoma_LicenseAndCollaborativeFees_lbl1" xlink:title="label: LicenseAndCollaborativeFees to xoma_LicenseAndCollaborativeFees_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_UnrealizedGainLossOnWarrants" xlink:label="UnrealizedGainLossOnWarrants" xlink:title="UnrealizedGainLossOnWarrants" />
    <link:label xlink:type="resource" xlink:label="xoma_UnrealizedGainLossOnWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="xoma_UnrealizedGainLossOnWarrants_lbl" xml:lang="en-US" id="xoma_UnrealizedGainLossOnWarrants_lbl">The increases (decreases) in the market value of warrants whose gains (losses) were included in earnings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnWarrants" xlink:to="xoma_UnrealizedGainLossOnWarrants_lbl" xlink:title="label: UnrealizedGainLossOnWarrants to xoma_UnrealizedGainLossOnWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="xoma_UnrealizedGainLossOnWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_UnrealizedGainLossOnWarrants_lbl1" xml:lang="en-US" id="xoma_UnrealizedGainLossOnWarrants_lbl1">Unrealized gain loss on warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnWarrants" xlink:to="xoma_UnrealizedGainLossOnWarrants_lbl1" xlink:title="label: UnrealizedGainLossOnWarrants to xoma_UnrealizedGainLossOnWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="xoma_UnrealizedGainLossOnWarrants_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="xoma_UnrealizedGainLossOnWarrants_lbl2" xml:lang="en-US" id="xoma_UnrealizedGainLossOnWarrants_lbl2">Revaluation of contingent warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnWarrants" xlink:to="xoma_UnrealizedGainLossOnWarrants_lbl2" xlink:title="label: UnrealizedGainLossOnWarrants to xoma_UnrealizedGainLossOnWarrants_lbl2" />
    <link:label xlink:type="resource" xlink:label="xoma_UnrealizedGainLossOnWarrants_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="xoma_UnrealizedGainLossOnWarrants_lbl3" xml:lang="en-US" id="xoma_UnrealizedGainLossOnWarrants_lbl3">Revaluation of contingent warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnWarrants" xlink:to="xoma_UnrealizedGainLossOnWarrants_lbl3" xlink:title="label: UnrealizedGainLossOnWarrants to xoma_UnrealizedGainLossOnWarrants_lbl3" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CashPaidDuringNineMonthsEndedAbstract" xlink:label="CashPaidDuringNineMonthsEndedAbstract" xlink:title="CashPaidDuringNineMonthsEndedAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl1" xml:lang="en-US" id="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl1">Cash paid during the nine months ended [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringNineMonthsEndedAbstract" xlink:to="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl1" xlink:title="label: CashPaidDuringNineMonthsEndedAbstract to xoma_CashPaidDuringNineMonthsEndedAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl2" xml:lang="en-US" id="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl2">Supplemental Cash Flow Information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringNineMonthsEndedAbstract" xlink:to="xoma_CashPaidDuringNineMonthsEndedAbstract_lbl2" xlink:title="label: CashPaidDuringNineMonthsEndedAbstract to xoma_CashPaidDuringNineMonthsEndedAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:label="IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:title="IssuanceAndExtinguishmentOfWarrantLiabilities" />
    <link:label xlink:type="resource" xlink:label="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl" xml:lang="en-US" id="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl">Noncash value of warrants and rights issued or extinguished. "Equity warrants and rights outstanding" represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:to="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl" xlink:title="label: IssuanceAndExtinguishmentOfWarrantLiabilities to xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl1" xml:lang="en-US" id="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl1">Issuance and extinguishment of warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:to="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl1" xlink:title="label: IssuanceAndExtinguishmentOfWarrantLiabilities to xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl2" xml:lang="en-US" id="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl2">Issuance of contingent warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:to="xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl2" xlink:title="label: IssuanceAndExtinguishmentOfWarrantLiabilities to xoma_IssuanceAndExtinguishmentOfWarrantLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CashPaidDuringPeriodAbstract" xlink:label="CashPaidDuringPeriodAbstract" xlink:title="CashPaidDuringPeriodAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_CashPaidDuringPeriodAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_CashPaidDuringPeriodAbstract_lbl1" xml:lang="en-US" id="xoma_CashPaidDuringPeriodAbstract_lbl1">Cash paid during the period [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringPeriodAbstract" xlink:to="xoma_CashPaidDuringPeriodAbstract_lbl1" xlink:title="label: CashPaidDuringPeriodAbstract to xoma_CashPaidDuringPeriodAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="xoma_CashPaidDuringPeriodAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="xoma_CashPaidDuringPeriodAbstract_lbl2" xml:lang="en-US" id="xoma_CashPaidDuringPeriodAbstract_lbl2">Cash paid during the year for:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringPeriodAbstract" xlink:to="xoma_CashPaidDuringPeriodAbstract_lbl2" xlink:title="label: CashPaidDuringPeriodAbstract to xoma_CashPaidDuringPeriodAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_InterestAddedPrincipalBalancesLong-TermDebt" xlink:label="InterestAddedPrincipalBalancesLong-TermDebt" xlink:title="InterestAddedPrincipalBalancesLong-TermDebt" />
    <link:label xlink:type="resource" xlink:label="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl" xml:lang="en-US" id="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl">Unpaid interest added to the outstanding principal amount on long-term debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAddedPrincipalBalancesLong-TermDebt" xlink:to="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl" xlink:title="label: InterestAddedPrincipalBalancesLong-TermDebt to xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl1" xml:lang="en-US" id="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl1">Interest Added Principal Balances Long-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAddedPrincipalBalancesLong-TermDebt" xlink:to="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl1" xlink:title="label: InterestAddedPrincipalBalancesLong-TermDebt to xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl1" />
    <link:label xlink:type="resource" xlink:label="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl2" xml:lang="en-US" id="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl2">Interest added to principal balances on long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAddedPrincipalBalancesLong-TermDebt" xlink:to="xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl2" xlink:title="label: InterestAddedPrincipalBalancesLong-TermDebt to xoma_InterestAddedPrincipalBalancesLong-TermDebt_lbl2" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_DescriptionOfBusinessAbstract" xlink:label="DescriptionOfBusinessAbstract" xlink:title="DescriptionOfBusinessAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_DescriptionOfBusinessAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_DescriptionOfBusinessAbstract_lbl1" xml:lang="en-US" id="xoma_DescriptionOfBusinessAbstract_lbl1">Description of Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfBusinessAbstract" xlink:to="xoma_DescriptionOfBusinessAbstract_lbl1" xlink:title="label: DescriptionOfBusinessAbstract to xoma_DescriptionOfBusinessAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesAbstract" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract_lbl1" xml:lang="en-US" id="xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract_lbl1">Basis of Presentation and Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAndSignificantAccountingPoliciesAbstract" xlink:to="xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract_lbl1" xlink:title="label: BasisOfPresentationAndSignificantAccountingPoliciesAbstract to xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CondensedConsolidatedFinancialStatementDetailAbstract" xlink:label="CondensedConsolidatedFinancialStatementDetailAbstract" xlink:title="CondensedConsolidatedFinancialStatementDetailAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_CondensedConsolidatedFinancialStatementDetailAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_CondensedConsolidatedFinancialStatementDetailAbstract_lbl1" xml:lang="en-US" id="xoma_CondensedConsolidatedFinancialStatementDetailAbstract_lbl1">Condensed Consolidated Financial Statement Detail [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CondensedConsolidatedFinancialStatementDetailAbstract" xlink:to="xoma_CondensedConsolidatedFinancialStatementDetailAbstract_lbl1" xlink:title="label: CondensedConsolidatedFinancialStatementDetailAbstract to xoma_CondensedConsolidatedFinancialStatementDetailAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:label="CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:title="CondensedConsolidatedFinancialStatementDetailTextBlock" />
    <link:label xlink:type="resource" xlink:label="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl" xml:lang="en-US" id="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl">This element may be used to disclose further details for significant balance sheet and income statement line items, that are not presented elsewhere in the notes to the financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:to="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl" xlink:title="label: CondensedConsolidatedFinancialStatementDetailTextBlock to xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl1" xml:lang="en-US" id="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl1">Condensed Consolidated Financial Statement Detail Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:to="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl1" xlink:title="label: CondensedConsolidatedFinancialStatementDetailTextBlock to xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl2" xml:lang="en-US" id="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl2">Condensed Consolidated Financial Statement Detail</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:to="xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl2" xlink:title="label: CondensedConsolidatedFinancialStatementDetailTextBlock to xoma_CondensedConsolidatedFinancialStatementDetailTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_FairValueMeasurementsAbstract" xlink:label="FairValueMeasurementsAbstract" xlink:title="FairValueMeasurementsAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_FairValueMeasurementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_FairValueMeasurementsAbstract_lbl1" xml:lang="en-US" id="xoma_FairValueMeasurementsAbstract_lbl1">Fair Value Measurements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsAbstract" xlink:to="xoma_FairValueMeasurementsAbstract_lbl1" xlink:title="label: FairValueMeasurementsAbstract to xoma_FairValueMeasurementsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_LicensingCollaborativeAndOtherArrangementsAbstract" xlink:label="LicensingCollaborativeAndOtherArrangementsAbstract" xlink:title="LicensingCollaborativeAndOtherArrangementsAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_LicensingCollaborativeAndOtherArrangementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_LicensingCollaborativeAndOtherArrangementsAbstract_lbl1" xml:lang="en-US" id="xoma_LicensingCollaborativeAndOtherArrangementsAbstract_lbl1">Licensing, Collaborative and Other Arrangements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingCollaborativeAndOtherArrangementsAbstract" xlink:to="xoma_LicensingCollaborativeAndOtherArrangementsAbstract_lbl1" xlink:title="label: LicensingCollaborativeAndOtherArrangementsAbstract to xoma_LicensingCollaborativeAndOtherArrangementsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_Long-TermDebtAndOtherFinancingsAbstract" xlink:label="Long-TermDebtAndOtherFinancingsAbstract" xlink:title="Long-TermDebtAndOtherFinancingsAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_Long-TermDebtAndOtherFinancingsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_Long-TermDebtAndOtherFinancingsAbstract_lbl1" xml:lang="en-US" id="xoma_Long-TermDebtAndOtherFinancingsAbstract_lbl1">Long-Term Debt and Other Financings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Long-TermDebtAndOtherFinancingsAbstract" xlink:to="xoma_Long-TermDebtAndOtherFinancingsAbstract_lbl1" xlink:title="label: Long-TermDebtAndOtherFinancingsAbstract to xoma_Long-TermDebtAndOtherFinancingsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_IncomeTaxesAbstract" xlink:label="IncomeTaxesAbstract" xlink:title="IncomeTaxesAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_IncomeTaxesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_IncomeTaxesAbstract_lbl1" xml:lang="en-US" id="xoma_IncomeTaxesAbstract_lbl1">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesAbstract" xlink:to="xoma_IncomeTaxesAbstract_lbl1" xlink:title="label: IncomeTaxesAbstract to xoma_IncomeTaxesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_Stock-BasedCompensationAbstract" xlink:label="Stock-BasedCompensationAbstract" xlink:title="Stock-BasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_Stock-BasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_Stock-BasedCompensationAbstract_lbl1" xml:lang="en-US" id="xoma_Stock-BasedCompensationAbstract_lbl1">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Stock-BasedCompensationAbstract" xlink:to="xoma_Stock-BasedCompensationAbstract_lbl1" xlink:title="label: Stock-BasedCompensationAbstract to xoma_Stock-BasedCompensationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_LegalProceedingsCommitmentsAndContingenciesAbstract" xlink:label="LegalProceedingsCommitmentsAndContingenciesAbstract" xlink:title="LegalProceedingsCommitmentsAndContingenciesAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_LegalProceedingsCommitmentsAndContingenciesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_LegalProceedingsCommitmentsAndContingenciesAbstract_lbl1" xml:lang="en-US" id="xoma_LegalProceedingsCommitmentsAndContingenciesAbstract_lbl1">Legal Proceedings, Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalProceedingsCommitmentsAndContingenciesAbstract" xlink:to="xoma_LegalProceedingsCommitmentsAndContingenciesAbstract_lbl1" xlink:title="label: LegalProceedingsCommitmentsAndContingenciesAbstract to xoma_LegalProceedingsCommitmentsAndContingenciesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="xoma_DocumentAndEntityInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="xoma_DocumentAndEntityInformationAbstract_lbl1" xml:lang="en-US" id="xoma_DocumentAndEntityInformationAbstract_lbl1">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="xoma_DocumentAndEntityInformationAbstract_lbl1" xlink:title="label: DocumentAndEntityInformationAbstract to xoma_DocumentAndEntityInformationAbstract_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>xoma-20120331_pre.xml
<DESCRIPTION>XBRL PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Thomson Reuters Accelus-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://xoma.com/role/LegalProceedingsCommitmentsAndContingencies" xlink:type="simple" xlink:href="xoma-20120331.xsd#LegalProceedingsCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://xoma.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="xoma-20120331.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://xoma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xoma-20120331.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://xoma.com/role/LongtermDebtAndOtherFinancings" xlink:type="simple" xlink:href="xoma-20120331.xsd#LongtermDebtAndOtherFinancings" />
  <link:roleRef roleURI="http://xoma.com/role/StreamliningAndRestructuringCharges" xlink:type="simple" xlink:href="xoma-20120331.xsd#StreamliningAndRestructuringCharges" />
  <link:roleRef roleURI="http://xoma.com/role/LicensingCollaborativeAndOtherArrangements" xlink:type="simple" xlink:href="xoma-20120331.xsd#LicensingCollaborativeAndOtherArrangements" />
  <link:roleRef roleURI="http://xoma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="xoma-20120331.xsd#FairValueMeasurements" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedFinancialStatementDetail" />
  <link:roleRef roleURI="http://xoma.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="xoma-20120331.xsd#BasisOfPresentationAndSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://xoma.com/role/DescriptionOfBusiness" xlink:type="simple" xlink:href="xoma-20120331.xsd#DescriptionOfBusiness" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <link:roleRef roleURI="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="xoma-20120331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" />
  <link:roleRef roleURI="http://xoma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="xoma-20120331.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityPublicFloat" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="ReceivablesNetCurrent" xlink:title="ReceivablesNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="ReceivablesNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to ReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_PrepaidExpensesAndOtherCurrentAssets" xlink:label="PrepaidExpensesAndOtherCurrentAssets" xlink:title="PrepaidExpensesAndOtherCurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssets" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpensesAndOtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredRevenueCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LongTermDebtCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermDebtNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermDebtNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to WarrantsAndRightsOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockMember" xlink:title="presentation: ClassOfStockDomain to PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_LicenseAndCollaborativeFees" xlink:label="LicenseAndCollaborativeFees" xlink:title="LicenseAndCollaborativeFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="LicenseAndCollaborativeFees" xlink:title="presentation: RevenuesAbstract to LicenseAndCollaborativeFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="ContractsRevenue" xlink:title="ContractsRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="ContractsRevenue" xlink:title="presentation: RevenuesAbstract to ContractsRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RoyaltyRevenue" xlink:title="presentation: RevenuesAbstract to RoyaltyRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="Revenues" xlink:title="presentation: RevenuesAbstract to Revenues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="RevenuesAbstract" xlink:title="presentation: IncomeStatementAbstract to RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to SellingGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="RestructuringCharges" xlink:title="RestructuringCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="RestructuringCharges" xlink:title="presentation: OperatingExpensesAbstract to RestructuringCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_UnrealizedGainLossOnWarrants" xlink:label="UnrealizedGainLossOnWarrants" xlink:title="UnrealizedGainLossOnWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="UnrealizedGainLossOnWarrants" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to UnrealizedGainLossOnWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="OtherPostretirementBenefitsPayments" xlink:title="OtherPostretirementBenefitsPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherPostretirementBenefitsPayments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherPostretirementBenefitsPayments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="DebtInstrumentIncreaseAccruedInterest" xlink:title="DebtInstrumentIncreaseAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DebtInstrumentIncreaseAccruedInterest" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DebtInstrumentIncreaseAccruedInterest" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_UnrealizedGainLossOnWarrants" xlink:label="UnrealizedGainLossOnWarrants" xlink:title="UnrealizedGainLossOnWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="UnrealizedGainLossOnWarrants" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to UnrealizedGainLossOnWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AssetImpairmentCharges" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCostsAndDiscounts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="ForeignCurrencyTransactionGainLossUnrealized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ForeignCurrencyTransactionGainLossUnrealized" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="UnrealizedGainLossOnDerivatives" xlink:title="UnrealizedGainLossOnDerivatives" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="UnrealizedGainLossOnDerivatives" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to UnrealizedGainLossOnDerivatives" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherNoncashIncomeExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherNoncashIncomeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="IncreaseDecreaseInReceivables" xlink:title="IncreaseDecreaseInReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInReceivables" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="IncreaseDecreaseInDeferredRevenue" xlink:title="IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDeferredRevenue" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfLongTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfLongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to EffectOfExchangeRateOnCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsPeriodIncreaseDecrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CashPaidDuringNineMonthsEndedAbstract" xlink:label="CashPaidDuringNineMonthsEndedAbstract" xlink:title="CashPaidDuringNineMonthsEndedAbstract" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CashPaidDuringPeriodAbstract" xlink:label="CashPaidDuringPeriodAbstract" xlink:title="CashPaidDuringPeriodAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringPeriodAbstract" xlink:to="IncomeTaxesPaid" xlink:title="presentation: CashPaidDuringPeriodAbstract to IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringNineMonthsEndedAbstract" xlink:to="CashPaidDuringPeriodAbstract" xlink:title="presentation: CashPaidDuringNineMonthsEndedAbstract to CashPaidDuringPeriodAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashPaidDuringNineMonthsEndedAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashPaidDuringNineMonthsEndedAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to DebtInstrumentUnamortizedDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:label="IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:title="IssuanceAndExtinguishmentOfWarrantLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceAndExtinguishmentOfWarrantLiabilities" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to IssuanceAndExtinguishmentOfWarrantLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_InterestAddedPrincipalBalancesLong-TermDebt" xlink:label="InterestAddedPrincipalBalancesLong-TermDebt" xlink:title="InterestAddedPrincipalBalancesLong-TermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InterestAddedPrincipalBalancesLong-TermDebt" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to InterestAddedPrincipalBalancesLong-TermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/DescriptionOfBusiness">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_DescriptionOfBusinessAbstract" xlink:label="DescriptionOfBusinessAbstract" xlink:title="DescriptionOfBusinessAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessAbstract" xlink:to="NatureOfOperations" xlink:title="presentation: DescriptionOfBusinessAbstract to NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesAbstract" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationAndSignificantAccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: BasisOfPresentationAndSignificantAccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/CondensedConsolidatedFinancialStatementDetail">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CondensedConsolidatedFinancialStatementDetailAbstract" xlink:label="CondensedConsolidatedFinancialStatementDetailAbstract" xlink:title="CondensedConsolidatedFinancialStatementDetailAbstract" />
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:label="CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:title="CondensedConsolidatedFinancialStatementDetailTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CondensedConsolidatedFinancialStatementDetailAbstract" xlink:to="CondensedConsolidatedFinancialStatementDetailTextBlock" xlink:title="presentation: CondensedConsolidatedFinancialStatementDetailAbstract to CondensedConsolidatedFinancialStatementDetailTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/FairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_FairValueMeasurementsAbstract" xlink:label="FairValueMeasurementsAbstract" xlink:title="FairValueMeasurementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueMeasurementsAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/LicensingCollaborativeAndOtherArrangements">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_LicensingCollaborativeAndOtherArrangementsAbstract" xlink:label="LicensingCollaborativeAndOtherArrangementsAbstract" xlink:title="LicensingCollaborativeAndOtherArrangementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingCollaborativeAndOtherArrangementsAbstract" xlink:to="CollaborativeArrangementDisclosureTextBlock" xlink:title="presentation: LicensingCollaborativeAndOtherArrangementsAbstract to CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/StreamliningAndRestructuringCharges">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="presentation: RestructuringAndRelatedActivitiesAbstract to RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/LongtermDebtAndOtherFinancings">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_Long-TermDebtAndOtherFinancingsAbstract" xlink:label="Long-TermDebtAndOtherFinancingsAbstract" xlink:title="Long-TermDebtAndOtherFinancingsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Long-TermDebtAndOtherFinancingsAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: Long-TermDebtAndOtherFinancingsAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_IncomeTaxesAbstract" xlink:label="IncomeTaxesAbstract" xlink:title="IncomeTaxesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxesAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_Stock-BasedCompensationAbstract" xlink:label="Stock-BasedCompensationAbstract" xlink:title="Stock-BasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Stock-BasedCompensationAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: Stock-BasedCompensationAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xoma.com/role/LegalProceedingsCommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="xoma-20120331.xsd#xoma_LegalProceedingsCommitmentsAndContingenciesAbstract" xlink:label="LegalProceedingsCommitmentsAndContingenciesAbstract" xlink:title="LegalProceedingsCommitmentsAndContingenciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalProceedingsCommitmentsAndContingenciesAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: LegalProceedingsCommitmentsAndContingenciesAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%8`
M?`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`****`"BBB@`HK#\<_$3PS\/[%;K7;LF64XM;.!=TT[>
MBK_7H*X;2_$7Q=^,<S/H5PGAW1MVU[J("25N>55S]X^NW`']X]*^4S;C#+,L
MQRR^E&5?%/:E32<EYR;:C!=;RDM-;-'J83*,3B:#Q$VH4E]J6B^6[D_1,]49
MT4X9P/J:6N8\/_"3P?HFVXN[>;5+L<M?:M,;B0GU&[A?P`KIP`H"J,`#@"O<
MR^MF5:CS8RE&G+HHS<_O?)%7]+KS.+$0P\)VHR<EW:M]VK_&P4445WF`4444
M`%%%%`!1110`4444`%<U\5OB3IOPP\*2:[=IYMQ(?*L;4=9I3T'T[FNEKQGQ
M%'+\1OVF8='O8]]AX7LOM`@89#2XW`D=P6*_E7Q7'>>8[)\IITL!IB<34C1I
M-JZC*=[S:ZJ$%*5NK26Q[.1X*AB\5*=?^'3BYR\TME_V\VE\S"\`^"_$'Q/^
M(,TWC.^DFN8D677YU<@0JW*64>/NC'+8[<>M>_6UI;Z?9I9:=:QQQPQA88D&
MU5`'`XZ"O-/V6[VVU#PUK=U+)NU"3Q!</?$_>Y;Y<_AG%>H5X7A-E&!PW"\,
MRIOFJXIN<IMWDUS-)2EU:M>?>HY/LEW<58NO5S-X>6D:=DDM%LKM+MV_NV,B
MY\/:GJW_`"%O$5PB'K;Z>?)7'NPR^?<,/I65J_P?\/7]HZV6M:U8W&,QWD&M
M7!=&]?G<@_B*ZRO,?CQ\8H]$LV^'O@F3[9XAU+_1UAM_F-NK<$GT;'0=NIQ7
MM\7/A3),FJX[-J:FDK+FO*<I/X84[MRYI/1*-K/72USBRG^U,;C(T<+)I];:
M12ZN72RZW+W[._CO7/&GA>^M?$-Z+NXTG4GL_MH&#.H`(8^^#BO0*Y+X*_#D
M?#+P+;Z%<,KWDA,U](O>5NHSWQP,^U=;7=P1A\XPO"6#I9JV\0H+GN[M-ZJ+
M;U;BK1;>K:;;9AG53"5<UK2PJ_=\SM;1>J71-ZH****^I/,"BBB@`HHHH`**
M**`"O+[6W_X0K]IFYN[\;;;Q/I2I:3M]TS1D$IGUP!@=\UZA65XO\&Z%XWTL
M:7KENS!'$EO/$VV2"0='1ARI%?,\3Y-B,UH8>MA6O;8>K&K#FTC)I.,HMV=E
M*$I1O9\K:=G:QZ668RGA9U(5;\E2+C*VZO9IKO9I.W78\K\6_#OXF?"?QO=?
M$'X/6HOK'4&+W^D[<X8G)^7.6!.2".03Z5+!^TK\1G"V[?`/5'F/'RM(`6^G
ME9_6O2M&L?&>D;+*]U2WU2!3@7,RF*=5_P!K:"KGWPM;5?'83@;,L-5J5,DS
M&M@*=23E*BX4JD(RD[R]GSJ2BF[MJ,G&[Z;'KU<[PU2$8XW#PKRBK*:E*+:6
MW-:S=MM4G^9X[/+^T]\3U^R+96WA33Y.'EW?OBOIU+9^@7ZUUWPM^!_A7X8A
MM0A+WVJRJ?M&IW0RYSU"C^$?J>YKM**][*>`LKP.81S'&U:F+Q,?AJ5I<W)?
M?V<$HPAZQC?S.'%9[B:^'>'HQC2IO>,%:_\`B;O*7S=O(****^Y/$"BBB@`H
MHHH`****`"O&+3_@H1^Q_/\`M97G[#5[\9;73?BI:6T=Q'X2UFPN;*6^B>/S
M%>TDGC2*[!4-S"[\JPZJ0/9Z^%/^"Y/_``2;M/\`@H?\$[+XK_!G6?\`A%_C
MG\+BVK?#7Q;;3>0[R1D2FQFD'*QNR@J__+.0!N5+`@'VC\1?B-X!^$7@?5/B
M9\4O&6F^'O#VB6C76KZUK%XEO;6<*]7DD<A5'U/>O/OV>OVZOV5?VI?@IJ?[
M1_P6^+5M?^`](NKF"]\6ZA97&GV*_9_]=(LMW'&KQ+WE7,?!^;@U^&7PG_:U
M_;<_X.=/B%X!_P"";_Q#2#P+X*^&^GQZI^T7JVEZD@E\236MP(08XU/`=]@$
M:[E65VDR%5`/J+_@YGT!_@W^QA^SS_P3=_9ML8O"'@;X@_$>P\+WNGZ./*":
M=`J;(!CJ"[AV)SO*_-DDF@#Z0\3?\'-O_!%+PKXZD\!7O[9$%Q+#.\,^IZ;X
M4U2YL4=6Q@7$=L4<'LZ%DP,[A7V?\'?C3\)?VA/AYIWQ:^!_Q&T?Q7X:U:+S
M-/UK0K]+BWF'<!D)`8'@J<%3P0#7EWPG_P""9/["'P>_9VM/V7?#G[+G@JX\
M)0Z6MG>V6H>'+>=M1P@5YKAW0M+*YRQ<G.3P1@8_.?\`X(6:'-^P?_P6._:G
M_P""77@W5;Q?AO:B'Q-X'T>\N&E^Q;FC)"G!"CRY]AS@GRE)R:`/U,_9W_:P
M_9V_:PTC6]:_9[^*NF^)HO#>O7&B^((K-F6;3K^!RDD$T4@5XV!!QN4!ARI(
MYJ]^T/\`M'?`_P#9/^$NJ_'3]HGXD:=X4\*Z-&'O]7U.0A%).%154%I'8\*B
M`LQZ`U_.;_P3_P#B?^TE^P%^TU^T!_P5.^&4UYKWPQ\+_M!WWA7XY>"K2%V8
M:)<SR21ZJNW.6@E8<XXS@\,<;_\`P7@_:L^)/_!8KX8?$?\`:`^`WB>XLOV9
M/V>YK&STC43&R+XT\17CHK2JC8)2&-B!N`V@YQN<@`']&_@[Q=X?\?>$M,\<
M^$[_`.UZ7K.GPWNFW0C9/.@E0/&^U@&&58'!`//(KE-(_:@^`.O?M$:O^R=H
MWQ3TJY^(N@Z!!K6L>%(IB;FUL9FVQRN,8&>#MSN"NC$`,I/'?"3XN>"_@'_P
M3L\+_&WXBZDMIH7A/X1V.JZK.S`8A@TY)&`R>6(7"CNQ`')K^?/X`^/_`-L'
MX"_%OPS_`,'/'Q&UBZ_X1'XC_'"_T'Q?H:P,S1>%KDB%9R!SY2M%(J(`!FUA
M(/SXH`_IZHJEX;\1:)XO\/6/BOPWJ45YIVIV<=U8W<#ADFAD4,CJ1P05(/XU
M=H`****`"BBB@`K\NO\`@MK^V-^U7^T3X^M?^"/G_!,70]2O/'/C$)!\5_B!
M86TGV+P;I,N-\,MRHV0321G+G.]8R%4;Y5(_46F)!!'(TL<**SG+LJ@%OKZT
M`?BE^U;_`,$'_B3_`,$KO`?PM_;J_P""/MMJVJ?%'X/V$<'Q#T",R2R^/K-C
MFZE,*D[G.YU,*#F+;@%XP3W'_!4#PUXS_P""Z?\`P2W^'W[8G[$/A35+7XG_
M``D\7Q>(6^'6JVK1:C;ZA`H6\TUD;:6E1@KQXQYH48P6P/UXIL<,,.?)B5-Q
MRVU<9/K0!^4O@#_@[)_8TTKX0I9_M%_!3XH^&/C'IULEKK'PO3P9,UQ<ZD!M
M9+>1L*J,_02['`.-I(YN_P#!`?\`9/\`VJ/%O[2GQQ_X*\_MD_#:\\#>(/C=
M>)#X4\%:A"T5S8Z2KAEDEC?#1DJD**K`%@C/@;AG]2'TW3I)?/DL(&<G.]H@
M3GZXJ>@#\GO^#<KX)3^(_#?[9.A?%_X9W$WA;QI\?-6MD@UK376VU>T*RQ3!
M-X`E3YMI*Y`)ZYKJ/^"\?[&GPT_9Y_X(*^._V=_V//@8FD>'=#N;*\A\/^&[
M&24QQB\62>X?[SN>2SR,2<=3@5^G"1QQ+MC0*,YPHQ0Z)(I210RD8((R"*`/
MR._X*PZS\:OVC_V(/V:O^"3?[-.DZI<^)?C?HF@R>-;S3K5F31?#%K#`;BYN
M6QMCC:0#EB,F`KU8`GB+_@TN^&&K?!F3X)0_\%*_V@9_#T6G"#3_``OJ'B*&
M31XW0;H@;3R]GEK(`VT8QC@YYK]<%AA5Q(L*A@NT,%&0/3Z4Z@#\[_\`@W1^
M.OQIE_9=UO\`8)_:K\.:MI/Q-_9ZU@^';V'6+5HVO='+/_9]U&Q&)8]B/$'!
M.X0@YP17Z(4T11+(9EC4.P`9@.2![TZ@`HHHH`****`"BBB@`HHHH`****`"
2BBB@`HHHH`****`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">4.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Fair Value Measurements</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies ASC 820, which establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</div><div style="text-indent: 0pt; display: block;"><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 27pt;">&#160;</td><td style="width: 87px;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;">Level 1 - </div></td><td style="width: 1214px;"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt;">Quoted prices in active markets for identical assets or liabilities.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 27pt;">&#160;</td><td style="width: 87px;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;">Level 2 -</div></td><td style="width: 1214px;"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt;">Observable inputs other than quoted prices in active markets for similar assets or liabilities.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 27pt;">&#160;</td><td style="width: 87px;"><div style="display: inline; font-family: Times New Roman; font-size: 10pt;">Level 3 - </div></td><td style="width: 1214px;"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt;">Unobservable inputs.</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables set forth the Company's fair value hierarchy for its financial assets (cash equivalents) and liabilities measured at fair value on a recurring basis as of March 31, 2012 and December 31, 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Financial assets and liabilities carried at fair value as of March 31, 2012 and December 31, 2011 were classified as follows (in thousands):</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Fair Value Measurements at March 31, 2012 Using</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="padding-bottom: 2px; width: 10%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Quoted Prices in </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Active Markets for </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Other </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Observable </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Unobservable </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(Level&#160;1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(Level&#160;2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(Level&#160;3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Total</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Money market funds <font style="display: inline; font-size: 70%; vertical-align: text-top;">(1)</font></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">50,523</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">50,523</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">U.S. government securities <font style="display: inline; font-size: 70%; vertical-align: text-top;">(1)</font></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,999</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,999</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Foreign exchange options</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">926</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">926</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Total</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">60,522</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">926</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">61,448</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Liabilities:</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Contingent warrant liabilities</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">21,122</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">21,122</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 34%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Fair Value Measurements at December 31, 2011 Using</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="padding-bottom: 2px; width: 10%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Quoted Prices in </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Active Markets for </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Other </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Observable </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Unobservable </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(Level&#160;1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(Level&#160;2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(Level&#160;3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Total</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Money market funds <font style="display: inline; font-size: 70%; vertical-align: text-top;">(1)</font></div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">27,222</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">27,222</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Foreign exchange options</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,202</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,202</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 27pt; font-size: 10pt; margin-right: 0pt;">Total</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">27,222</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,202</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">28,424</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 42%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Liabilities:</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Contingent warrant liabilities</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">379</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">379</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 45pt; font-size: 10pt; margin-right: 0pt;">(1)&#160;&#160;Included in cash and cash equivalents</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair value of the foreign exchange options at March 31, 2012 and December 31, 2011 was determined using readily observable market inputs from actively quoted markets obtained from various third party data providers. These inputs, such as spot rate, forward rate and volatility have been derived from readily observable market data, meeting the criteria for Level 2 in the fair value hierarchy.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair value of the contingent warrant liabilities was determined at March 31, 2012 and December 31, 2011 using the Black-Scholes Model, which requires inputs such as the expected term of the warrants, volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. A market-based volatility rate was determined to be a more precise indicator for the fair value calculation of the Company's warrants.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair value of the contingent warrant liabilities was estimated using the following range of assumptions at March 31, 2012 and December 31, 2011:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 60%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 36%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">March 31,</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">December 31, </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 36%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected volatility</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">40</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">102.1% - 103.2</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 36%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Risk-free interest rate</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.5% - 1.05</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0.4</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 36%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected term</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2.7 - 4.9 years</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" colspan="2" valign="bottom" style="width: 10%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2.9 - 3.1 years</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table provides a summary of changes in the fair value of the Company's Level 3 financial liabilities for the three months ended March 31, 2012 (in thousands):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="text-align: center; width: 80%; font-family: times new roman; font-size: 10pt;"><tr style="text-align: center;"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Contingent warrant liabilities</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">March 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Balance at December&#160;31, 2011</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">379</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Initial fair value of warrants issued in March 2012</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,390</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Reclassification of contingent warrant liability to equity upon exercise of warrants</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(4</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Net increase in fair value of contingent warrant liabilities upon revaluation</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,357</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 68%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Balance at March 31, 2012</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">21,122</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The net increase of $14.4 million in the estimated fair value of the contingent warrant liabilities was recognized as a loss in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of operations for the three months ended March 31, 2012.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three months ended March 31, 2011, the Company recognized a net decrease of $2.4 million in the estimated fair value of the contingent warrant liabilities as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of operations.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FairValueMeasurementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_FairValueMeasurementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%
M1%]#3TY33TQ)1$%4141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97-C
M<FEP=&EO;E]O9E]"=7-I;F5S<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D)A<VES7V]F7U!R97-E;G1A=&EO;E]A;F1?4VEG;CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?1FEN86YC:3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&EC96YS:6YG7T-O
M;&QA8F]R871I=F5?86YD7T]T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W1R96%M;&EN:6YG7V%N9%]297-T<G5C='5R:6YG/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&]N9U1E<FU?
M1&5B=%]A;F1?3W1H97)?1FEN86YC/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMB87-E9%]#;VUP96YS871I;VX\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,96=A;%]0
M<F]C965D:6YG<U]#;VUM:71M96YT<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE
M971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O
M<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^
M#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C
M='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I
M;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM
M+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD
M(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\
M+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M13%'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N
M=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA>2`P-"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T
M:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^6$]-02!#;W)P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A
M;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P
M,#`W.3$Y,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!796QL
M+6MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@4F5P
M;W)T:6YG(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/D%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N
M(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8X+#`X,RPY.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R
M($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y1,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I
M;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA
M<B`S,2P-"@D),C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S4X.6%B8C-?83DT,E\T,V$U7V$U8F1?9#1B-3EA-&1F,V)F
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,U.#EA8F(S7V$Y-#)?
M-#-A-5]A-6)D7V0T8C4Y831D9C-B9B]7;W)K<VAE971S+U-H965T,#(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5404%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3D1%
M3E-%1"!#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*'5N875D:71E9"D@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<T+#@X
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#@L,S0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R861E(&%N9"!O=&AE<B!R96-E:79A8FQE<RP@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ-C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPS,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;
M,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C<T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U
M<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U
M<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M."PW,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,BPV.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PS,CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPW,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\
M+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(V.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M-C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,2PS,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW."PP,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@U,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3(X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^
M6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)U960@86YD(&]T:&5R(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#(Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DQ,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-CDU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=
M/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R
M97-T(&)E87)I;F<@;V)L:6=A=&EO;B`M(&-U<G)E;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-SDV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M+#@U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P+#8S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E("T@;&]N9RUT97)M/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#(P-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-3,Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S
M=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T
M(&)E87)I;F<@;V)L:6=A=&EO;G,@+2!L;VYG+71E<FT\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,S+#4V.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#4R-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT('=A
M<G)A;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(Q+#$R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=&AE<B!L:6%B:6QI=&EE<R`M(&QO;F<@=&5R;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-SD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\
M+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,2PX,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,RPP,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q=6ET>3H\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"`D,"XP
M-2!P87(@=F%L=64L(#$L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D
M,"XP,#<U('!A<B!V86QU92P@.3(L-C8V+#8V-B!S:&%R97,@875T:&]R:7IE
M9"P@-C@L,#<V+#$U,B!A;F0@,S4L,3`W+#`P-R!S:&%R97,@;W5T<W1A;F1I
M;F<@870@36%R8V@@,S$L(#(P,3(@86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!R
M97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3,U+#0U-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PX,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@
M9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3$V+#0W
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X.#8L,#4S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#0X.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`Q,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO
M<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P,2PS,C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<X+#`S-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ
M73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N
M/3-$=&]P/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$,R!V86QI
M9VX],T1T;W`^5&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@8F%L86YC92!S
M:&5E="!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2!H87,@8F5E;B!D97)I=F5D
M(&9R;VT@=&AE(&%U9&ET960@9FEN86YC:6%L('-T871E;65N=',@87,@;V8@
M=&AA="!D871E(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)W,@06YN=6%L(%)E
M<&]R="!O;B!&;W)M(#$P+4L@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R
M(#,Q+"`R,#$Q+CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%)04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%
M1"!"04Q!3D-%(%-(14544R`H=6YA=61I=&5D*2`H4&%R96YT:&5T:6-A;"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E<75I='DZ/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!S=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E9F5R<F5D('-T;V-K+"!S:&%R97,@875T:&]R:7IE9"`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D
M("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M,BPV-C8L-C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3(L-C8V+#8V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T
M<W1A;F1I;F<@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8X+#`W-BPQ-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-2PQ,#<L,#`W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I3044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E13($]&
M($]015)!5$E/3E,@*'5N875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY2979E;G5E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&EC96YS92!A;F0@8V]L;&%B;W)A=&EV92!F965S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#$T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#@R-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N=')A8W0@86YD(&]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX+#@U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDL-S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL.#8U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L-3DU/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A
M=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PW-S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPS-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E;&QI;F<L
M(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#8W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,S8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<G5C='5R:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<W-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R
M871I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(T+#(R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R+#<Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"PS-C(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPQ,C$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]T:&5R(&EN8V]M92`H97AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#0R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4S,BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8V-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`U
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E=F%L=6%T:6]N(&]F(&-O;G1I;F=E;G0@=V%R<F%N="!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L,S4W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,SDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,@8F5F;W)E('1A>&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S,"PT,C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-BPS,C`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R(&EN
M8V]M92!T87@@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#,P+#0R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#8L,S,U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@;F5T
M(&QO<W,@<&5R(&-O;6UO;B!S=&]C:R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-CDI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(R
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F5S('5S960@:6X@8V]M<'5T:6YG(&)A<VEC(&%N9"!D:6QU=&5D
M(&YE="!L;W-S('!E<B!S:&%R92!O9B!C;VUM;VX@<W1O8VL@*&EN('-H87)E
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#,U,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#$X
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S4X
M.6%B8C-?83DT,E\T,V$U7V$U8F1?9#1B-3EA-&1F,V)F#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S,U.#EA8F(S7V$Y-#)?-#-A-5]A-6)D7V0T
M8C4Y831D9C-B9B]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"
M6$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)
M1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("AU;F%U9&ET960I("A5
M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@;W!E<F%T:6YG(&%C
M=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,P+#0R-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8L,S,U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!
M9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@
M=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#(V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VL@8V]N=')I8G5T:6]N('1O(#0P,2AK*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`T-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S<R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R
M=65D(&EN=&5R97-T(&]N(&EN=&5R97-T(&)E87)I;F<@;V)L:6=A=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V86QU871I;VX@;V8@8V]N=&EN
M9V5N="!W87)R86YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PS-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R+#,Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<W1R=6-T=7)I;F<@8VAA<F=E(')E;&%T960@=&\@;&]N
M9RUL:79E9"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I
M>F%T:6]N(&]F(&1I<V-O=6YT(&%N9"!F:6YA;"!P87EM96YT(&9E92!O;B!D
M96)T(&%N9"!D96)T(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E5N<F5A;&EZ960@;&]S<R!O;B!F;W)E:6=N(&-U<G)E;F-Y(&5X
M8VAA;F=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!L
M;W-S(&]N(&9O<F5I9VX@97AC:&%N9V4@;W!T:6]N<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@;F]N+6-A<V@@861J=7-T;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@87-S971S(&%N9"!L
M:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&4@
M86YD(&]T:&5R(')E8V5I=F%B;&5S+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`L-C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-C4Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(T-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A
M;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,RPR,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-2PT,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V
M+#$U-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,2PV-S4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,RPR,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO
M=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-30X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@X."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN
M(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#@X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@
M:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@:7-S=6%N8V4@8V]S
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#0X,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,3(Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M(&ES<W5A;F-E(&]F(&QO;F<M=&5R;2!D96)T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C`L,3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<FEN8VEP86P@<&%Y;65N=',@;V8@9&5B=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-S$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L
M-S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L,C,Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E
M8W0@;V8@97AC:&%N9V4@<F%T92!C:&%N9V5S(&]N(&-A<V@\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U-S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&EN8W)E87-E(&EN(&-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V
M+#4T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#$T,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!T:&4@8F5G:6YN:6YG(&]F('1H
M92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X+#,T
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S<L,S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&%T('1H92!E;F0@
M;V8@=&AE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S0L.#@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L.#<T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-A<V@@<&%I9"!D=7)I;F<@=&AE('EE87(@9F]R.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY.;VXM8V%S:"!I;G9E<W1I;F<@86YD(&9I;F%N
M8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M:7-C;W5N="!O;B!L;VYG+71E<FT@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PX
M.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U86YC92!O9B!C;VYT:6YG96YT('=A<G)A;G0@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S@V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@861D960@=&\@
M<')I;F-I<&%L(&)A;&%N8V5S(&]N(&QO;F<M=&5R;2!D96)T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,Y.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0T/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T
M93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@
M("`\=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$=&]P/E1H92!C;VYD96YS960@
M8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970@87,@;V8@1&5C96UB97(@,S$L
M(#(P,3$@:&%S(&)E96X@9&5R:79E9"!F<F]M('1H92!A=61I=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&%S(&]F('1H870@9&%T92!I;F-L=61E9"!I;B!T
M:&4@0V]M<&%N>2=S($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2X\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,S4X.6%B8C-?83DT,E\T,V$U7V$U8F1?9#1B-3EA
M-&1F,V)F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,U.#EA8F(S
M7V$Y-#)?-#-A-5]A-6)D7V0T8C4Y831D9C-B9B]7;W)K<VAE971S+U-H965T
M,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$
M97-C<FEP=&EO;B!O9B!"=7-I;F5S<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<V-R:7!T:6]N(&]F($)U<VEN
M97-S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R('9A;&EG;CTS
M1'1O<#X\=&0@86QI9VX],T1R:6=H="!S='EL93TS1"=W:61T:#H@,3AP=#LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^,2XF(S$V,#L\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<SPO9&EV
M/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R
M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
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M875N8VAE9"!C;VUM97)C:6%L(&]P97)A=&EO;G,N)B,Q-C`[(%A/34$@9F]C
M=7-E<R!I=',@<V-I96YT:69I8R!R97-E87)C:"!O;B!A;&QO<W1E<FEC(&UO
M9'5L871I;VXL('=H:6-H(&]F9F5R<R!O<'!O<G1U;FET:65S(&9O<B!N97<@
M8VQA<W-E<R!O9B!T:&5R87!E=71I8R!A;G1I8F]D:65S('1O('1R96%T(&$@
M=VED92!R86YG92!O9B!H=6UA;B!D:7-E87-E<RXF(S$V,#LF(S$V,#M83TU!
M(&ES(&1E=F5L;W!I;F<@:71S(&QE860@<')O9'5C="!G979O:VEZ=6UA8B`H
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M97,N)B,Q-C`[)B,Q-C`[26X@;W)D97(@=&\@<F5T86EN('-I9VYI9FEC86YT
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S4X.6%B8C-?
M83DT,E\T,V$U7V$U8F1?9#1B-3EA-&1F,V)F#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,U.#EA8F(S7V$Y-#)?-#-A-5]A-6)D7V0T8C4Y831D
M9C-B9B]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY"87-I<R!O9B!0<F5S96YT871I;VX@86YD
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"87-I<R!O9B!0
M<F5S96YT871I;VX@86YD(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX@86YD(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/'1A8FQE(&)O
M<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL
M93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R('9A;&EG;CTS1'1O<#X\=&0@86QI
M9VX],T1R:6=H="!S='EL93TS1"=W:61T:#H@,3AP=#LG/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^,BXF(S$V,#L\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY"87-I<R!O9B!0<F5S96YT871I;VX@86YD(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY"87-I<R!O9B!0<F5S96YT871I;VX\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:&4@8V]N9&5N<V5D(&-O
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M4F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE(&9I<V-A;"!Y96%R(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$Q+"!F:6QE9"!W:71H('1H92!5+E,N(%-E8W5R
M:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*")314,B*2!O;B!-87)C
M:"`Q-"P@,C`Q,BX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA
M<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SY);B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT+"!T:&4@=6YA
M=61I=&5D(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E
M;65N=',@:6YC;'5D92!A;&P@861J=7-T;65N=',L(&-O;G-I<W1I;F<@;VYL
M>2!O9B!N;W)M86P@<F5C=7)R:6YG(&%D:G5S=&UE;G1S+"!W:&EC:"!A<F4@
M;F5C97-S87)Y('1O('!R97-E;G0@9F%I<FQY('1H92!#;VUP86YY)W,@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!P;W-I=&EO;B!A<R!O9B!-87)C:"`S,2P@
M,C`Q,BP@=&AE(&-O;G-O;&ED871E9"!R97-U;'1S(&]F('1H92!#;VUP86YY
M)W,@;W!E<F%T:6]N<R!A;F0@=&AE($-O;7!A;GDG<R!C87-H(&9L;W=S(&9O
M<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R
M,#$Q+B!4:&4@:6YT97)I;2!R97-U;'1S(&]F(&]P97)A=&EO;G,@87)E(&YO
M="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H92!R97-U;'1S('1H870@
M;6%Y(&]C8W5R(&9O<B!T:&4@9G5L;"!F:7-C86P@>65A<B!O<B!F=71U<F4@
M<&5R:6]D<RX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN
M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY5<V4@;V8@17-T:6UA=&5S/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^5&AE('!R97!A
M<F%T:6]N(&]F(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@
M=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9V5N97)A;&QY(&%C8V5P=&5D
M(&EN('1H92!5;FET960@4W1A=&5S(')E<75I<F5S(&UA;F%G96UE;G0@=&\@
M;6%K92!E<W1I;6%T97,@86YD(&%S<W5M<'1I;VYS('1H870@869F96-T('1H
M92!R97!O<G1E9"!A;6]U;G1S(&]F(&%S<V5T<RP@;&EA8FEL:71I97,L(')E
M=F5N=64@86YD(&5X<&5N<V5S+"!A;F0@<F5L871E9"!D:7-C;&]S=7)E<RX@
M3VX@86X@;VXM9V]I;F<@8F%S:7,L(&UA;F%G96UE;G0@979A;'5A=&5S(&ET
M<R!E<W1I;6%T97,@:6YC;'5D:6YG+"!B=70@;F]T(&QI;6ET960@=&\L('1H
M;W-E(')E;&%T960@=&\@8V]N=&EN9V5N="!W87)R86YT(&QI86)I;&ET:65S
M+"!R979E;G5E(')E8V]G;FET:6]N+"!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@97AP96YS92P@;&]N9RUL:79E9"!A<W-E=',L(')E<W1R=6-T=7)I;F<@
M;&EA8FEL:71I97,L(&1E<FEV871I=F4@:6YS=')U;65N=',@86YD('-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;BX@5&AE($-O;7!A;GD@8F%S97,@:71S(&5S
M=&EM871E<R!O;B!H:7-T;W)I8V%L(&5X<&5R:65N8V4@86YD(&]N('9A<FEO
M=7,@;W1H97(@;6%R:V5T+7-P96-I9FEC(&%N9"!O=&AE<B!R96QE=F%N="!A
M<W-U;7!T:6]N<R!T:&%T(&%R92!B96QI979E9"!T;R!B92!R96%S;VYA8FQE
M('5N9&5R('1H92!C:7)C=6US=&%N8V5S+"!T:&4@<F5S=6QT<R!O9B!W:&EC
M:"!F;W)M('1H92!B87-I<R!F;W(@;6%K:6YG(&IU9&=M96YT<R!A8F]U="!T
M:&4@8V%R<GEI;F<@=F%L=65S(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@
M=&AA="!A<F4@;F]T(')E861I;'D@87!P87)E;G0@9G)O;2!O=&AE<B!S;W5R
M8V5S+B!!8W1U86P@<F5S=6QT<R!M87D@9&EF9F5R('-I9VYI9FEC86YT;'D@
M9G)O;2!T:&5S92!E<W1I;6%T97,L('-U8V@@87,@=&AE($-O;7!A;GDG<R!B
M:6QL:6YG('5N9&5R(&=O=F5R;FUE;G0@8V]N=')A8W1S+B!5;F1E<B!T:&4@
M0V]M<&%N>2=S(&-O;G1R86-T<R!W:71H('1H92!.871I;VYA;"!);G-T:71U
M=&4@;V8@06QL97)G>2!A;F0@26YF96-T:6]U<R!$:7-E87-E<R`H(DY)04E$
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M9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D%T($UA<F-H(#,Q
M+"`R,#$R+"!T:&4@0V]M<&%N>2!C:&%N9V5D(&ET<R!E>'!E8W1E9"!V;VQA
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M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/E)E8VQA<W-I9FEC871I;VYS/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O
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M=&AE(&]T:&5R(&EN8V]M92`H97AP96YS92D@;&EN92!O9B!T:&4@8V]N9&5N
M<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<R!I;B!T
M:&4@<')I;W(@<&5R:6]D(&AA<R!B965N(')E8VQA<W-I9FEE9"!T;R!T:&4@
M<F5V86QU871I;VX@;V8@8V]N=&EN9V5N="!W87)R86YT(&QI86)I;&ET:65S
M(&QI;F4@;V8@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@<W1A=&5M96YT
M(&]F(&]P97)A=&EO;G,N(%1H97-E(')E8VQA<W-I9FEC871I;VYS(&AA9"!N
M;R!I;7!A8W0@;VX@=&AE($-O;7!A;GDG<R!P<F5V:6]U<VQY(')E<&]R=&5D
M(&YE="!L;W-S(&]R(&-A<V@@9FQO=W,N/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^3&]N9RUL
M:79E9"!!<W-E=',\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA
M<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SY4:&4@0V]M<&%N>2!R979I97=S('1H92!C87)R>6EN9R!V86QU
M97,@86YD(&1E<')E8VEA=&EO;B!E<W1I;6%T97,@;V8@:71S(&QO;F<M;&EV
M960@87-S971S('=H96YE=F5R(&5V96YT<R!O<B!C:&%N9V5S(&EN(&-I<F-U
M;7-T86YC97,@:6YD:6-A=&4@=&AA="!T:&4@87-S970@;6%Y(&YO="!B92!R
M96-O=F5R86)L92X@06X@:6UP86ER;65N="!L;W-S(&ES(')E8V]G;FEZ960@
M=VAE;B!T:&4@97-T:6UA=&5D(&9U='5R92!N970@8V%S:"!F;&]W<R!E>'!E
M8W1E9"!T;R!R97-U;'0@9G)O;2!T:&4@=7-E(&]F(&%N(&%S<V5T(&ES(&QE
M<W,@=&AA;B!I=',@8V%R<GEI;F<@86UO=6YT+B!,;VYG+6QI=F5D(&%S<V5T
M<R!I;F-L=61E('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@86YD(&)U:6QD:6YG
M(&%N9"!L96%S96AO;&0@:6UP<F]V96UE;G1S+B!$=7)I;F<@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,BP@=&AE($-O;7!A;GD@<F5C
M;W)D960@86X@:6UP86ER;65N="!L;W-S(&]F("0P+C@@;6EL;&EO;B!A;F0@
M86-C96QE<F%T960@9&5P<F5C:6%T;VX@;V8@)#`N.2!M:6QL:6]N)B,Q-C`[
M;VX@;&]N9RUL:79E9"!A<W-E=',@:6X@8V]N;F5C=&EO;B!W:71H('1H92!#
M;VUP86YY)W,@,C`Q,B!S=')E86UL:6YI;F<@<&QA;BX@4V5E(#QF;VYT('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9&ES<&QA>3H@:6YL:6YE.R<^
M3F]T92`V.B!3=')E86UL:6YI;F<@86YD(%)E<W1R=6-T=7)I;F<@0VAA<F=E
M<SPO9F]N=#X@9F]R(&%D9&ET:6]N86P@9&ES8VQO<W5R92!O;B!T:&4@,C`Q
M,B!S=')E86UL:6YI;F<@<&QA;BX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY#;VYC96YT<F%T
M:6]N(&]F(%)I<VL\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA
M<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SY#87-H(&5Q=6EV86QE;G1S(&%N9"!R96-E:79A8FQE<R!A<F4@
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M.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G
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M<G,@<F5P<F5S96YT960@-#DE(&%N9"`T,"4@;V8@=&]T86P@<F5V96YU92!A
M;F0@-C,E(&%N9"`S-R4@;V8@=&AE(&%C8V]U;G1S(')E8V5I=F%B;&4@8F%L
M86YC92X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,2P@
M=&AE<V4@='=O(&-U<W1O;65R<R!R97!R97-E;G1E9"`U,24@86YD(#0T)2!O
M9B!T;W1A;"!R979E;G5E<RX@07,@;V8@1&5C96UB97(@,S$L(#(P,3$L('1H
M97)E('=E<F4@<F5C96EV86)L97,@;W5T<W1A;F1I;F<@9G)O;2!T:&5S92!T
M=V\@8W5S=&]M97)S(')E<')E<V5N=&EN9R`U-R4@86YD(#0S)2!O9B!T:&4@
M86-C;W5N=',@<F5C96EV86)L92!B86QA;F-E+CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM
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M9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/DEN($UA>2`R,#$Q
M+"!!8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VX@5&]P:6,@.#(P
M+"`\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I<W!L87DZ
M(&EN;&EN93LG/D9A:7(@5F%L=64@365A<W5R96UE;G0\+V9O;G0^('=A<R!A
M;65N9&5D('1O(&1E=F5L;W`@8V]M;6]N(')E<75I<F5M96YT<R!F;W(@;65A
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M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY);B!*=6YE(#(P,3$L($%C8V]U;G1I;F<@4W1A;F1A<F1S
M($-O9&EF:6-A=&EO;B!4;W!I8R`R,C`L(#QF;VYT('-T>6QE/3-$)V9O;G0M
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,U.#EA
M8F(S7V$Y-#)?-#-A-5]A-6)D7V0T8C4Y831D9C-B9@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\S-3@Y86)B,U]A.30R7S0S835?835B9%]D-&(U
M.6$T9&8S8F8O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E
M9"!&:6YA;F-I86P@4W1A=&5M96YT($1E=&%I;#QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;F1E;G-E9"!#;VYS
M;VQI9&%T960@1FEN86YC:6%L(%-T871E;65N="!$971A:6P@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYD96YS960@0V]N<V]L:61A=&5D($9I;F%N8VEA;"!3=&%T96UE;G0@1&5T
M86EL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W
M<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQT86)L92!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQT<B!V86QI9VX],T1T;W`^/'1D(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M=VED=&@Z(#$X<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/C,N)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^0V]N9&5N<V5D($-O;G-O
M;&ED871E9"!&:6YA;F-I86P@4W1A=&5M96YT($1E=&%I;#PO9&EV/CPO=&0^
M/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&1I
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M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D-O
M;7!R96AE;G-I=F4@;&]S<R!I<R!E<75A;"!T;R!N970@;&]S<R!F;W(@8F]T
M:"!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R
M,#$Q+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F
M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/DYE="!,;W-S(%!E<B!3:&%R92!O9B!#;VUM
M;VX@4W1O8VL\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R
M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
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M9B!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R92`H:6X@=&AO=7-A;F1S*3H\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!S='EL93TS1"=W:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@=&EM97,@
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M93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M
M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E1H<F5E($UO;G1H<R!%;F1E
M9"!-87)C:"`S,2P\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B8C,38P.SPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@-38E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I
M9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^,C`Q,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I
M9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^,C`Q,3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-38E
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY#;VUM;VX@<W1O8VL@;W!T:6]N<R!A;F0@
M<F5S=')I8W1E9"!S=&]C:R!U;FET<SPO9&EV/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
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M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U-B4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@
M-38E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY787)R86YT<R!F;W(@8V]M;6]N('-T
M;V-K/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
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M;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$L-C`W/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@8F=C
M;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`U-B4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY4;W1A;#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@
M,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,2PQ-SD\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'@[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C0L-#DY/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D9O<B!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q+"!A;&P@;W5T<W1A;F1I;F<@
M<V5C=7)I=&EE<R!W97)E(&-O;G-I9&5R960@86YT:2UD:6QU=&EV92P@86YD
M('1H97)E9F]R92!T:&4@8V%L8W5L871I;VX@;V8@8F%S:6,@86YD(&1I;'5T
M960@;F5T(&QO<W,@<&5R('-H87)E('=A<R!T:&4@<V%M92X\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O
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M(&]F("0Q-"XT(&UI;&QI;VXL(&UO;F5Y(&UA<FME="!F=6YD<R!O9B`D-3`N
M-2!M:6QL:6]N+"!A;F0@52Y3+B!G;W9E<FYM96YT('-E8W5R:71I97,@;V8@
M)#$P+C`@;6EL;&EO;B!W:71H(&UA='5R:71I97,@;V8@;&5S<R!T:&%N(#DP
M(&1A>7,@870@=&AE(&1A=&4@;V8@<'5R8VAA<V4N($%T($1E8V5M8F5R(#,Q
M+"`R,#$Q+"!C87-H(&5Q=6EV86QE;G1S(&-O;G-I<W1E9"!O9B!D96UA;F0@
M9&5P;W-I=',@;V8@)#(Q+C$@;6EL;&EO;B!A;F0@;6]N97D@;6%R:V5T(&9U
M;F1S(&]F("0R-RXR(&UI;&QI;VX@=VET:"!M871U<FET:65S(&]F(&QE<W,@
M=&AA;B`Y,"!D87ES(&%T('1H92!D871E(&]F('!U<F-H87-E+CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/D9O<F5I9VX@17AC:&%N9V4@3W!T:6]N<SPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
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M<R!O;B!I=',@)B,X,S8T.S$U+C`@;6EL;&EO;B!L;V%N(&9R;VT@4V5R=FEE
M<B`H4V5E(#QF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9&ES
M<&QA>3H@:6YL:6YE.R<^3F]T92`W.B!,;VYG+51E<FT@1&5B="!A;F0@3W1H
M97(@1FEN86YC:6YG<SPO9F]N=#XI+B!);B!O<F1E<B!T;R!M86YA9V4@:71S
M(&9O<F5I9VX@8W5R<F5N8WD@97AP;W-U<F4@<F5L871E9"!T;R!T:&5S92!P
M87EM96YT<RP@:6X@36%Y(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@:6YT
M;R!T=V\@9F]R96EG;B!E>&-H86YG92!O<'1I;VX@8V]N=')A8W1S('1O(&)U
M>2`F(S@S-C0[,34N,"!M:6QL:6]N(&%N9"`F(S@S-C0[,2XU(&UI;&QI;VX@
M;VX@2F%N=6%R>2`R,#$V(&%N9"!*86YU87)Y(#(P,30L(')E<W!E8W1I=F5L
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY5<&9R;VYT('!R96UI
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M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W
M<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^5&AE(&9O<F5I9VX@97AC:&%N9V4@;W!T:6]N<R!W
M97)E(')E=F%L=65D(&%T($UA<F-H(#,Q+"`R,#$R(&%N9"!H860@86X@86=G
M<F5G871E(&9A:7(@=F%L=64@;V8@)#`N.2!M:6QL:6]N(')E<W5L=&EN9R!I
M;B!A(')E;&%T960@;&]S<R!O9B`D,"XS(&UI;&QI;VX@9F]R('1H92!T:')E
M92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3(N/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O
M/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M06-C<G5E9"!,:6%B:6QI=&EE<SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R
M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/D%C8W)U960@;&EA8FEL:71I97,@8V]N<VES=&5D
M(&]F('1H92!F;VQL;W=I;F<@870@36%R8V@@,S$L(#(P,3(@86YD($1E8V5M
M8F5R(#,Q+"`R,#$Q("AI;B!T:&]U<V%N9',I.CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\8G(@+SX\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I
M9'1H.B`X,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@-38E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,G!X('-O;&ED.R!W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXR,#$R/"]D:78^/"]T
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M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I
M9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^1&5C96UB97(@,S$L(#PO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SXR,#$Q/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W
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M)W=I9'1H.B`U-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D%C8W)U960@<&%Y<F]L
M;"!A;F0@;W1H97(@8F5N969I=',\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/C(L,34U/"]T9#X\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,RPP,#<\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI
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M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
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M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^.3DV/"]T9#X\=&0@;F]W
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M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#`Y-CPO=&0^/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R
M(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U-B4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[
M(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
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M=&]M('-T>6QE/3-$)W=I9'1H.B`U-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D%C
M8W)U960@<')O9F5S<VEO;F%L(&9E97,\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES
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M;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-S8P/"]T9#X\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXY,3<\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O
M;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@-38E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!8V-R
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M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU-3$\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$L,C`W/"]T9#X\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@8F=C
M;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`U-B4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/D]T:&5R/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`U-B4[)SX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY4;W1A;#PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
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M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$P+#`Q
M,CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\
M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY#;VYT:6YG96YT(%=A<G)A;G0@3&EA8FEL:71I97,\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY);B!-87)C:"`R,#$R
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M('=A<G)A;G1S(&ES<W5E9"!I;B!-87)C:"`R,#$R(&%S(&$@;&EA8FEL:71Y
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M<F-H(#,Q+"`R,#$R('5S:6YG('1H92!";&%C:RU38VAO;&5S($UO9&5L(&%N
M9"!R96-O<F1E9"!A;B!I;F-R96%S92!I;B!T:&4@9F%I<B!V86QU92!O9B`D
M,30N-R!M:6QL:6]N(&%S(&$@;&]S<R!I;B!T:&4@<F5V86QU871I;VX@;V8@
M8V]N=&EN9V5N="!W87)R86YT(&QI86)I;&ET:65S(&QI;F4@;V8@=&AE(&-O
M;F1E;G-E9"!C;VYS;VQI9&%T960@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,N
M($%S(&]F($UA<F-H(#,Q+"`R,#$R+"`Q-"PX,S(L.#(W(&]F('1H97-E('=A
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M8V4N(%-E92`\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I
M<W!L87DZ(&EN;&EN93LG/DYO=&4@-#H@1F%I<B!686QU92!-96%S=7)E;65N
M=',@/"]F;VYT/F9O<B!F=7)T:&5R(&1I<V-L;W-U<F4@<F5G87)D:6YG('1H
M92!F86ER('9A;'5E(&]F('1H:7,@=V%R<F%N="!L:6%B:6QI='DN/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^26X@1F5B<G5A
M<GD@,C`Q,"P@:6X@8V]N;F5C=&EO;B!W:71H(&%N('5N9&5R=W)I='1E;B!O
M9F9E<FEN9RP@=&AE($-O;7!A;GD@:7-S=65D(&9I=F4M>65A<B!W87)R86YT
M<R!T;R!P=7)C:&%S92`Q+#(V,"PP,#`@<VAA<F5S(&]F(%A/34$G<R!C;VUM
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M9F]R('1H92!W87)R86YT<R!I<W-U960@:6X@1F5B<G5A<GD@,C`Q,"!A<R!A
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M:7)A=&EO;B!O9B!T:&4@=V%R<F%N=',N($%T($1E8V5M8F5R(#,Q+"`R,#$Q
M+"!T:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N="!L:6%B:6QI='D@=V%S
M(&5S=&EM871E9"!T;R!B92`D,"XS(&UI;&QI;VX@=7-I;F<@=&AE($)L86-K
M+5-C:&]L97,@36]D96PN($%T($UA<F-H(#,Q+"`R,#$R+"!T:&4@0V]M<&%N
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M:"`S,2P@,C`Q,B!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!-;V1E;"!A;F0@
M<F5C;W)D960@82!D96-R96%S92!I;B!T:&4@9F%I<B!V86QU92!O9B`D,"XS
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M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/DEN($IU;F4@,C`P.2P@=&AE($-O;7!A;GD@:7-S=65D('=A<G)A;G1S('1O
M(&-E<G1A:6X@:6YS=&ET=71I;VYA;"!I;G9E<W1O<G,@87,@<&%R="!O9B!A
M(')E9VES=&5R960@9&ER96-T(&]F9F5R:6YG+B!4:&4@=V%R<F%N=',@<F5P
M<F5S96YT('1H92!R:6=H="!T;R!A8W%U:7)E(&%N(&%G9W)E9V%T92!O9B!U
M<"!T;R`S-#<L.#(V('-H87)E<R!O9B!83TU!)W,@8V]M;6]N('-T;V-K(&]V
M97(@82!F:79E('EE87(@<&5R:6]D(&)E9VEN;FEN9R!$96-E;6)E<B`Q,2P@
M,C`P.2!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D,3DN-3`@<&5R('-H87)E
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M;V8@=&AE('=A<G)A;G1S+B!!="!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE(&9A
M:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@;&EA8FEL:71Y('=A<R!E<W1I;6%T
M960@=&\@8F4@)#`N,2!M:6QL:6]N('5S:6YG('1H92!";&%C:RU38VAO;&5S
M($UO9&5L+B!!="!-87)C:"`S,2P@,C`Q,BP@=&AE($-O;7!A;GD@8VAA;F=E
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M(&$@9&5C<F5A<V4@:6X@=&AE(&9A:7(@=F%L=64@;V8@)#`N,2!M:6QL:6]N
M(&%S(&$@9V%I;B!I;B!T:&4@<F5V86QU871I;VX@;V8@8V]N=&EN9V5N="!W
M87)R86YT(&QI86)I;&ET:65S(&QI;F4@;V8@=&AE(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,N($%S(&]F($UA<F-H
M(#,Q+"`R,#$R+"!A;&P@;V8@=&AE<V4@=V%R<F%N=',@=V5R92!O=71S=&%N
M9&EN9RX@4V5E(#QF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@
M9&ES<&QA>3H@:6YL:6YE.R<^3F]T92`T.B!&86ER(%9A;'5E($UE87-U<F5M
M96YT<R`\+V9O;G0^9F]R(&9U<G1H97(@9&ES8VQO<W5R92!R96=A<F1I;F<@
M=&AE(&9A:7(@=F%L=64@;V8@=&AI<R!W87)R86YT(&QI86)I;&ET>2X\+V1I
M=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S,U.#EA8F(S7V$Y-#)?-#-A-5]A-6)D7V0T8C4Y831D9C-B
M9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-3@Y86)B,U]A.30R
M7S0S835?835B9%]D-&(U.6$T9&8S8F8O5V]R:W-H965T<R]3:&5E=#`Y+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!6
M86QU92!-96%S=7)E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQT86)L92!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQT<B!V86QI9VX],T1T;W`^/'1D(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M=VED=&@Z(#$X<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/C0N)B,Q-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^1F%I<B!686QU92!-96%S
M=7)E;65N=',\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY&86ER('9A;'5E(&ES(&1E
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M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=CX\
M=&%B;&4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS
M1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M='(@=F%L:6=N/3-$=&]P/CQT9"!S='EL93TS1"=W:61T:#H@,C=P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X-W!X.R<^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DQE=F5L(#$@+2`\+V1I=CX\+W1D
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M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P
M,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/CQT<B!V86QI9VX],T1T;W`^/'1D('-T>6QE/3-$)W=I9'1H.B`R
M-W!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#@W<'@[)SX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5V96P@,B`M/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$R,31P>#LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3V)S97)V86)L92!I;G!U
M=',@;W1H97(@=&AA;B!Q=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S
M(&9O<B!S:6UI;&%R(&%S<V5T<R!O<B!L:6%B:6QI=&EE<RX\+V1I=CX\+W1D
M/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=CX\=&%B
M;&4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@
M=F%L:6=N/3-$=&]P/CQT9"!S='EL93TS1"=W:61T:#H@,C=P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`X-W!X.R<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DQE=F5L(#,@+2`\+V1I=CX\+W1D/CQT
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R
M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E1H92!F;VQL;W=I;F<@=&%B;&5S('-E="!F;W)T
M:"!T:&4@0V]M<&%N>2=S(&9A:7(@=F%L=64@:&EE<F%R8VAY(&9O<B!I=',@
M9FEN86YC:6%L(&%S<V5T<R`H8V%S:"!E<75I=F%L96YT<RD@86YD(&QI86)I
M;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@
M8F%S:7,@87,@;V8@36%R8V@@,S$L(#(P,3(@86YD($1E8V5M8F5R(#,Q+"`R
M,#$Q+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/D9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S(&-A<G)I960@870@
M9F%I<B!V86QU92!A<R!O9B!-87)C:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@
M,S$L(#(P,3$@=V5R92!C;&%S<VEF:65D(&%S(&9O;&QO=W,@*&EN('1H;W5S
M86YD<RDZ/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O
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M=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C
M,38P.SPO=&0^/'1D(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P
M>"!S;VQI9#L@=VED=&@Z(#,T)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY&86ER(%9A;'5E($UE87-U<F5M96YT<R!A="!-87)C
M:"`S,2P@,C`Q,B!5<VEN9SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q,"4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[('=I9'1H.B`T,B4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[
M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^475O=&5D
M(%!R:6-E<R!I;B`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^06-T:79E($UA<FME=',@9F]R(#PO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R
M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY)9&5N=&EC86P@07-S971S/"]D
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M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^4VEG;FEF:6-A;G0@/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/8G-E<G9A8FQE(#PO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY);G!U=',\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D
M/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@
M=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY3:6=N:69I8V%N="`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^56YO8G-E<G9A8FQE(#PO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R
M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY);G!U=',\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R!W:61T:#H@,3`E.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[
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M-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXH3&5V
M96PF(S$V,#LR*3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^*$QE=F5L)B,Q-C`[,RD\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
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M,G!X('-O;&ED.R!W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@
M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E1O=&%L/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`T,B4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!<W-E=',Z/"]D
M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$P)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$P)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B
M9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@-#(E.R<^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M36]N97D@;6%R:V5T(&9U;F1S(#QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="US:7IE.B`W,"4[('9E<G1I8V%L+6%L:6=N.B!T97AT+71O
M<#LG/B@Q*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL
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M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE
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M93H@,3!P=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O
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M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-3`L-3(S
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`T,B4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY5+E,N(&=O=F5R;FUE;G0@<V5C=7)I=&EE<R`\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M<VEZ93H@-S`E.R!V97)T
M:6-A;"UA;&EG;CH@=&5X="UT;W`[)SXH,2D\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H
M.B`T,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY&;W)E:6=N(&5X8VAA;F=E(&]P
M=&EO;G,\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
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M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^.3(V/"]T9#X\=&0@
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M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^.3(V/"]T9#X\=&0@;F]W<F%P
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M.B`T<'@[('=I9'1H.B`T,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#(W<'0[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4;W1A;#PO
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXY,C8\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B0\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^+3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#1P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P
M>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z
M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXV,2PT-#@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`T,B4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO
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M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
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M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N
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M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
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M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F
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M9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
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M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C
M965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@-#(E.R<^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES
M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA
M<F=I;BUL969T.B`Q.'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H
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M(&9O;G0M<VEZ93H@,3!P=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
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M<VEZ93H@,3!P=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI
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M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M86QI9VXZ(&-E;G1E<CLG/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R!W:61T:#H@-#(E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D
M(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED
M=&@Z(#,T)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY&86ER(%9A;'5E($UE87-U<F5M96YT<R!A="!$96-E;6)E<B`S,2P@,C`Q
M,2!5<VEN9SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[('=I9'1H.B`Q,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
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M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H
M.B`T,B4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^475O=&5D(%!R:6-E<R!I
M;B`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M06-T:79E($UA<FME=',@9F]R(#PO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY)9&5N=&EC86P@07-S971S/"]D:78^/"]T9#X\
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M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H
M.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M4VEG;FEF:6-A;G0@/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
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M=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SY/8G-E<G9A8FQE(#PO9&EV/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN
M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY);G!U=',\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@
M,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY3:6=N
M:69I8V%N="`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^56YO8G-E<G9A8FQE(#PO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY);G!U=',\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H
M.B`Q,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^
M/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`T,B4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q
M-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P
M)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXH3&5V
M96PF(S$V,#LQ*3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^*$QE=F5L)B,Q-C`[,BD\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
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M,G!X('-O;&ED.R!W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@
M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/BA,979E;"8C,38P.S,I/"]D:78^/"]T9#X\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R
M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4;W1A;#PO9&EV/CPO=&0^/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@-#(E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M07-S971S.CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q,"4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q,"4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#0R)3LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TY<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M
M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/DUO;F5Y(&UA<FME="!F=6YD<R`\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M<VEZ93H@-S`E.R!V97)T:6-A;"UA;&EG
M;CH@=&5X="UT;W`[)SXH,2D\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-RPR,C(\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
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M9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^+3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT
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M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Q
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M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^+3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P
M>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
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M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
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M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$L,C`R
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M87)G:6XM;&5F=#H@,C=P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/E1O=&%L/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C<L,C(R
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M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$L,C`R/"]T
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C@L-#(T/"]T9#X\=&0@;F]W
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
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M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE
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M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
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M>6QE/3-$)W=I9'1H.B`T,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY,:6%B:6QI=&EE<SH\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES
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M;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[
M(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
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M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
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M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/"]T
M<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H
M.B`T,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY#;VYT:6YG96YT('=A<G)A;G0@
M;&EA8FEL:71I97,\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T
M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO=&0^/'1D
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M;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@=VED=&@Z(#$E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,S<Y/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXS-SD\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M(&UA<F=I;BUL969T.B`T-7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^*#$I)B,Q-C`[)B,Q-C`[26YC;'5D960@:6X@8V%S:"!A
M;F0@8V%S:"!E<75I=F%L96YT<SPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R
M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/E1H92!F86ER('9A;'5E(&]F('1H92!F;W)E:6=N
M(&5X8VAA;F=E(&]P=&EO;G,@870@36%R8V@@,S$L(#(P,3(@86YD($1E8V5M
M8F5R(#,Q+"`R,#$Q('=A<R!D971E<FUI;F5D('5S:6YG(')E861I;'D@;V)S
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M=&AE(&-R:71E<FEA(&9O<B!,979E;"`R(&EN('1H92!F86ER('9A;'5E(&AI
M97)A<F-H>2X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY4:&4@9F%I<B!V86QU92!O9B!T:&4@8V]N=&EN9V5N="!W87)R86YT
M(&QI86)I;&ET:65S('=A<R!D971E<FUI;F5D(&%T($UA<F-H(#,Q+"`R,#$R
M(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE
M<R!-;V1E;"P@=VAI8V@@<F5Q=6ER97,@:6YP=71S('-U8V@@87,@=&AE(&5X
M<&5C=&5D('1E<FT@;V8@=&AE('=A<G)A;G1S+"!V;VQA=&EL:71Y(&%N9"!R
M:7-K+69R964@:6YT97)E<W0@<F%T92X@5&AE<V4@:6YP=71S(&%R92!S=6)J
M96-T:79E(&%N9"!G96YE<F%L;'D@<F5Q=6ER92!S:6=N:69I8V%N="!A;F%L
M>7-I<R!A;F0@:G5D9VUE;G0@=&\@9&5V96QO<"X@070@36%R8V@@,S$L(#(P
M,3(L('1H92!#;VUP86YY(&-H86YG960@:71S(&5X<&5C=&5D('9O;&%T:6QI
M='D@87-S=6UP=&EO;B!I;B!T:&4@0FQA8VLM4V-H;VQE<R!-;V1E;"!F<F]M
M(&%N(&5S=&EM871E(&]F('9O;&%T:6QI='D@8F%S960@;VX@:&ES=&]R:6-A
M;"!S=&]C:R!P<FEC92!V;VQA=&EL:71Y(&]B<V5R=F5D(&]N(%A/34$G<R!U
M;F1E<FQY:6YG('-T;V-K('1O(&$@=F]L871I;&ET>2!E<W1I;6%T92!B87-E
M9"!O;B!T:&4@=F]L871I;&ET>2!I;7!L:65D(&9R;VT@=V%R<F%N=',@:7-S
M=65D(&)Y(%A/34$@:6X@<F5C96YT('!R:79A=&4@<&QA8V5M96YT('1R86YS
M86-T:6]N<RX@02!M87)K970M8F%S960@=F]L871I;&ET>2!R871E('=A<R!D
M971E<FUI;F5D('1O(&)E(&$@;6]R92!P<F5C:7-E(&EN9&EC871O<B!F;W(@
M=&AE(&9A:7(@=F%L=64@8V%L8W5L871I;VX@;V8@=&AE($-O;7!A;GDG<R!W
M87)R86YT<RX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY4:&4@9F%I<B!V86QU92!O9B!T:&4@8V]N=&EN9V5N="!W87)R86YT
M(&QI86)I;&ET:65S('=A<R!E<W1I;6%T960@=7-I;F<@=&AE(&9O;&QO=VEN
M9R!R86YG92!O9B!A<W-U;7!T:6]N<R!A="!-87)C:"`S,2P@,C`Q,B!A;F0@
M1&5C96UB97(@,S$L(#(P,3$Z/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/'1A8FQE(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#8P)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`S-B4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^36%R8V@@,S$L/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM
M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/C(P,3(\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY$96-E;6)E
M<B`S,2P@/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/C(P,3$\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
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M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M-#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T
M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/C$P,BXQ)2`M(#$P,RXR/"]T9#X\=&0@;F]W<F%P/3-$;F]W
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M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY2:7-K+69R964@:6YT97)E
M<W0@<F%T93PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N-24@+2`Q+C`U/"]T9#X\
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C`N-#PO=&0^/'1D(&YO
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M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY%>'!E
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M:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXR+C<@+2`T+CD@>65A<G,\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M/'1D(&%L:6=N/3-$<FEG:'0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/C(N.2`M
M(#,N,2!Y96%R<SPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q
M-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:&4@9F]L;&]W:6YG('1A8FQE
M('!R;W9I9&5S(&$@<W5M;6%R>2!O9B!C:&%N9V5S(&EN('1H92!F86ER('9A
M;'5E(&]F('1H92!#;VUP86YY)W,@3&5V96P@,R!F:6YA;F-I86P@;&EA8FEL
M:71I97,@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P
M,3(@*&EN('1H;W5S86YD<RDZ/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/'1A8FQE(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!W:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
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M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY-87)C:"`S
M,2P@,C`Q,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C@E
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY"86QA;F-E(&%T($1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,3$\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F
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M97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY);FET:6%L(&9A:7(@=F%L=64@;V8@=V%R
M<F%N=',@:7-S=65D(&EN($UA<F-H(#(P,3(\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
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M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-BPS.3`\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@-C@E.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY296-L87-S:69I8V%T:6]N(&]F(&-O;G1I;F=E;G0@=V%R<F%N="!L:6%B
M:6QI='D@=&\@97%U:71Y('5P;VX@97AE<F-I<V4@;V8@=V%R<F%N=',\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M*#0\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^
M/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I
M9'1H.B`V."4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/DYE="!I;F-R96%S92!I;B!F
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M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P
M>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,30L
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M:6=H=#H@,'!T.R<^0F%L86YC92!A="!-87)C:"`S,2P@,C`Q,CPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#1P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/C(Q+#$R,CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#1P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY4:&4@;F5T(&EN8W)E87-E(&]F("0Q-"XT(&UI;&QI;VX@
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\8G(@
M+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D9O<B!T:&4@=&AR964@;6]N
M=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$Q+"!T:&4@0V]M<&%N>2!R96-O9VYI
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M+V1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&EC
M96YS:6YG+"!#;VQL86)O<F%T:79E(&%N9"!/=&AE<B!!<G)A;F=E;65N=',\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY,:6-E;G-I;F<L($-O;&QA8F]R871I=F4@86YD($]T:&5R($%R<F%N9V5M
M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQI8V5N<VEN9RP@0V]L;&%B;W)A=&EV92!A;F0@3W1H
M97(@07)R86YG96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B
M;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT
M9"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@
M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXU+B8C,38P.SPO9&EV/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F=#X\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT
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M+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
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M>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D]N($IA;G5A<GD@,3<L(#(P
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M<')I;"`H<&5R:6YD;W!R:6P@87)G:6YI;F4I(&ES(&-O;6)I;F5D('=I=&@@
M86YO=&AE<B!A8W1I=F4@:6YG<F5D:65N="AS*2P@<W5C:"!A<R!A(&-A;&-I
M=6T@8VAA;FYE;"!B;&]C:V5R+B!4:&4@0V]M<&%N>2!A<W-U;65D(&-O;6UE
M<F-I86QI>F%T:6]N(&%C=&EV:71I97,@9F]R($%#14].)B,Q-S0[(&EN($IA
M;G5A<GD@,C`Q,B!F;VQL;W=I;F<@=&AE('1R86YS9F5R(&9R;VT@4V5R=FEE
M<B=S('!R979I;W5S(&QI8V5N<V5E+B8C,38P.R8C,38P.TEN(&QA=&4@1F5B
M<G5A<GD@,C`Q,BP@=&AE($-O;7!A;GD@:6YI=&EA=&5D(&5N<F]L;&UE;G0@
M:6X@82!0:&%S92`S('1R:6%L(&9O<B!P97)I;F1O<')I;"!A<F=I;FEN92!A
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M<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/DEN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@;W)I9VEN86P@86=R965M96YT+"!T:&4@0V]M<&%N
M>2!P86ED(&$@)#$N-2!M:6QL:6]N(&QI8V5N<V4@9F5E('1O(%-E<G9I97(@
M:6X@=&AE('1H:7)D('%U87)T97(@;V8@,C`Q,"X@5&AE($-O;7!A;GD@86QS
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M;6EL97-T;VYE<R!A9V=R96=A=&EN9R`D."XU(&UI;&QI;VX@*&%S<W5M:6YG
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,U.#EA
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1R96%M;&EN:6YG(&%N9"!297-T
M<G5C='5R:6YG($-H87)G97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=')E86UL:6YI;F<@86YD(%)E<W1R=6-T
M=7)I;F<@0VAA<F=E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T<F5A;6QI;FEN9R!A;F0@4F5S=')U
M8W1U<FEN9R!#:&%R9V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M/'1R('9A;&EG;CTS1'1O<#X\=&0@86QI9VX],T1R:6=H="!S='EL93TS1"=W
M:61T:#H@,3AP=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^-BXF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@
M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY3=')E86UL:6YI;F<@86YD
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M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN
M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/DEN($IA;G5A<GD@,C`Q,BP@=&AE($-O;7!A;GD@:6UP;&5M96YT960@
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M<G-O;FYE;"!B>2`X-"!P;W-I=&EO;G,L(&]R(#,T)2P@;V8@=VAI8V@@-3(@
M=V5R92!E;&EM:6YA=&5D(&EM;65D:6%T96QY(&%N9"!T:&4@<F5M86EN9&5R
M(&5L:6UI;F%T960@87,@;V8@07!R:6P@-BP@,C`Q,BX@5&AE<V4@<W1A9F8@
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY$=7)I
M;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,BP@:6X@
M8V]N;F5C=&EO;B!W:71H('1H:7,@<W1R96%M;&EN:6YG(&]F(&]P97)A=&EO
M;G,L('1H92!#;VUP86YY(')E8V]R9&5D(&-H87)G97,@;V8@)#(N,2!M:6QL
M:6]N(')E;&%T960@=&\@<V5V97)A;F-E+"!O=&AE<B!T97)M:6YA=&EO;B!B
M96YE9FET<R!A;F0@;W5T<&QA8V5M96YT('-E<G9I8V5S+B!4:&4@0V]M<&%N
M>2!E>'!E8W1S('1O(&EN8W5R(&%N(&%D9&ET:6]N86P@)#`N,2!M:6QL:6]N
M(')E<W1R=6-T=7)I;F<@8VAA<F=E(&EN('1H92!S96-O;F0@<75A<G1E<B!O
M9B`R,#$R(')E;&%T960@=&\@<V5V97)A;F-E+"!O=&AE<B!T97)M:6YA=&EO
M;B!B96YE9FET<R!A;F0@;W5T<&QA8V5M96YT('-E<G9I8V5S+CPO9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ
M(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM
M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^5&AE($-O;7!A;GD@<&QA;G,@=&\@=F%C871E('1W;R!O9B!I=',@;&5A
M<V5D(&)U:6QD:6YG<R!I;B`R,#$R(')E;&%T960@=&\@;6%N=69A8W1U<FEN
M9R!O<&5R871I;VYS(&%N9"!I;G1E<FYA;"!R97-E87)C:"!F=6YC=&EO;G,N
M(%1H92!#;VUP86YY(&1I9"!N;W0@:6YC=7(@86YY(')E<W1R=6-T=7)I;F<@
M8VAA<F=E<R!D=7)I;F<@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,B!I;B!C
M;VYN96-T:6]N('=I=&@@=&AE(&5X:70@;V8@=&AE<V4@;&5A<V5D(&)U:6QD
M:6YG<R!A<R!T:&5Y(&%R92!S=&EL;"!I;B!U<V4[(&AO=V5V97(L(&ET(&5X
M<&5C=',@=&\@:6YC=7(@<F5S=')U8W1U<FEN9R!C:&%R9V5S(&]F(&%P<')O
M>&EM871E;'D@)#$N,B!M:6QL:6]N(&EN('1H92!R96UA:6YD97(@;V8@,C`Q
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!<R!O9B!-87)C:"`S,2P@,C`Q
M,BP@=&AE($-O;7!A;GD@<&5R9F]R;65D(&%N(&EM<&%I<FUE;G0@86YA;'ES
M:7,@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N="!A;F0@;&5A<V5H;VQD(&EM
M<')O=F5M96YT<R!R96QA=&5D('1O(&ET<R!M86YU9F%C='5R:6YG(&]P97)A
M=&EO;G,N(%-I;F-E('1H92!E<W1I;6%T960@=6YD:7-C;W5N=&5D(&9U='5R
M92!C87-H(&EN9FQO=W,@9G)O;2!A)B,Q-C`[8V5R=&%I;B!G<F]U<"!O9B!T
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M;VYA;"!R97-T<G5C='5R:6YG(&-H87)G97,@;V8@87!P<F]X:6UA=&5L>2`D
M,"XW(&UI;&QI;VX@:6X@=&AE(')E;6%I;F1E<B!O9B`F(S$V,#LR,#$R(')E
M;&%T960@=&\@=&AE)B,Q-C`[86-C96QE<F%T960@9&5P<F5C:6%T:6]N)B,Q
M-C`[;V8@;&5A<V5H;VQD(&EM<')O=F5M96YT<RX\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E1H92!C
M=7)R96YT(&%N9"!L;VYG+71E<FT@<&]R=&EO;G,@;V8@=&AE(&]U='-T86YD
M:6YG(')E<W1R=6-T=7)I;F<@;&EA8FEL:71I97,@87)E(&EN8VQU9&5D(&EN
M(&%C8W)U960@86YD(&]T:&5R(&QI86)I;&ET:65S(&%N9"!O=&AE<B!L:6%B
M:6QI=&EE<R`M(&QO;F<M=&5R;2!O;B!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED
M871E9"!B86QA;F-E('-H965T<R!A;F0@87)E(&)A<V5D('5P;VX@<F5S=')U
M8W1U<FEN9R!C:&%R9V5S(')E8V]G;FEZ960@87,@;V8@36%R8V@F(S$V,#LS
M,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$@:6X@8V]N;F5C=&EO;B!W
M:71H('1H92`R,#`Y(&%N9"`R,#$R(')E<W1R=6-T=7)I;F<@<&QA;G,N($%S
M(&]F($UA<F-H)B,Q-C`[,S$L(#(P,3(L('1H92!C;VUP;VYE;G1S(&]F('1H
M97-E(&QI86)I;&ET:65S(&%R92!S:&]W;B!B96QO=R`H:6X@=&AO=7-A;F1S
M*3H\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN
M9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#)P>"!S;VQI9#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SY%;7!L;WEE92!3979E<F%N8V4@/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G
M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/F%N9"!/=&AE<B!"96YE9FET<SPO
M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P
M>#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^1F%C:6QI='D@0VAA<F=E<SPO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^07-S970@/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M<'@@<V]L:60[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^5&]T86P\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D
M/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3$\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
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M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-C(\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,38R/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E)E<W1R=6-T=7)I;F<@8VAA
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M(#$P<'0[)SXR+#`W,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT
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M.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^+3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^,2PW,#<\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
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M-3@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^
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M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T<CX\='(@8F=C
M;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`U,B4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/D%D:G5S=&UE;G1S/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^+3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
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M:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O
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M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P
M>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#$L
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M)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`U,B4[)SX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R
M9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/D)A;&%N8V4@870@36%R8V@@,S$L(#(P,3(\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED
M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXX,3(\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'@[
M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W
M:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^.34Y/"]T
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^*#$I)B,Q-C`[)B,Q-C`[4F5S=')U8W1U<FEN9R!C
M:&%R9V5S(&EN8VQU9&4@;F]N+6-A<V@@:6UP86ER;65N=',@;V8@<')O<&5R
M='D@86YD(&5Q=6EP;65N="!A;F0@;&5A<V5H;VQD(&EM<')O=F5M96YT<RX@
M2&]W979E<BP@=&AE<V4@86UO=6YT<R!A<F4@;F]T(&EN8VQU9&5D(&EN('1H
M92!R97-T<G5C='5R:6YG(&%C8W)U86PN/"]F;VYT/CQB<B`O/CPO9&EV/CQD
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M(&EN8W5R(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@,C`Q,B!S=')E86UL:6YI
M;F<@;V8@;W!E<F%T:6]N<R!A<F4@<W5B:F5C="!T;R!V87)I;W5S(&%S<W5M
M<'1I;VYS+"!A;F0@86-T=6%L(')E<W5L=',@;6%Y(&1I9F9E<BX\+V1I=CX\
M+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&]N9RU497)M
M($1E8G0@86YD($]T:&5R($9I;F%N8VEN9W,\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,;VYG+51E<FT@1&5B="!A
M;F0@3W1H97(@1FEN86YC:6YG<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M5&5R;2!$96)T(&%N
M9"!/=&AE<B!&:6YA;F-I;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@=F%L:6=N/3-$=&]P
M/CQT9"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXW+B8C,38P.SPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F=#X\9&EV('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/DQO;F<M5&5R;2!$96)T(&%N9"!/=&AE<B!&:6YA;F-I
M;F=S/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^3&]N
M9RU497)M($1E8G0\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-T>6QE.B!I=&%L:6,[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,3AP=#L@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY.;W9A<G1I<R!.;W1E/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y
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M92!I;B!F=6QL(&EN($IU;F4@,C`Q-2X@56YD97(@=&AI<R!N;W1E(&%G<F5E
M;65N="P@=&AE($-O;7!A;GD@8F]R<F]W960@<V5M:2UA;FYU86QL>2!T;R!F
M=6YD('5P('1O(#<U)2!O9B!T:&4@0V]M<&%N>2=S(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@8V]S=',@=6YD97(@
M:71S(&-O;&QA8F]R871I;VX@87)R86YG96UE;G0@=VET:"!.;W9A<G1I<RP@
M;F]T('1O(&5X8V5E9"`D-3`@;6EL;&EO;B!I;B!A9V=R96=A=&4@<')I;F-I
M<&%L(&%M;W5N="X@26YT97)E<W0@;VX@=&AE('!R:6YC:7!A;"!A;6]U;G0@
M;V8@=&AE(&QO86X@86-C<G5E<R!A="!S:7@M;6]N=&@@3$E"3U(@<&QU<R`R
M)2P@=VAI8V@@=V%S(&5Q=6%L('1O(#(N.#`E(&%T($UA<F-H(#,Q+"`R,#$R
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA
M>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I
M;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SY!="!-87)C:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$L
M('1H92!O=71S=&%N9&EN9R!P<FEN8VEP86P@8F%L86YC92!U;F1E<B!T:&ES
M(&YO=&4@86=R965M96YT('=A<R`D,30N,"!M:6QL:6]N+B!0=7)S=6%N="!T
M;R!T:&4@=&5R;7,@;V8@=&AE(&%R<F%N9V5M96YT(&%S(')E<W1R=6-T=7)E
M9"!I;B!.;W9E;6)E<B`R,#`X+"!T:&4@0V]M<&%N>2!W:6QL(&YO="!M86ME
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M<W1Y;&4Z(&ET86QI8SL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^4V5R=FEE<B!,;V%N/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P
M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/DEN($1E
M8V5M8F5R(#(P,3`L(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@;&EC96YS92!A
M;F0@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@96YT97)E9"!I;G1O('=I=&@@
M4V5R=FEE<BP@=&AE($-O;7!A;GD@97AE8W5T960@82!L;V%N(&%G<F5E;65N
M="!W:71H(%-E<G9I97(L('=H:6-H('!R;W9I9&5D(&9O<B!A;B!A9'9A;F-E
M(&]F('5P('1O("8C.#,V-#LQ-2!M:6QL:6]N+B!4:&4@;&]A;B!W87,@9G5L
M;'D@9G5N9&5D(&EN($IA;G5A<GD@,C`Q,2P@=VET:"!T:&4@<')O8V5E9',@
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M97)E<W0@<&5R:6]D('=A<R`S+C(R)2X@5&AE(&EN=&5R97-T(')A=&4@:&%S
M(&)E96X@<F5S970@=&\@,RXX,R4@9F]R('1H92!S:7@M;6]N=&@@<&5R:6]D
M(&9R;VT@2G5L>2`R,#$Q('1H<F]U9V@@2F%N=6%R>2`R,#$R(&%N9"`S+C4T
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M97)I;V0N(%1H92!L;V%N(&UA='5R97,@:6X@,C`Q-CL@:&]W979E<BP@869T
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M86XN)B,Q-C`[($EN(&%D9&ET:6]N+"!T:&4@;&]A;B!B96-O;65S(&EM;65D
M:6%T96QY(&1U92!A;F0@<&%Y86)L92!U<&]N(&-E<G1A:6X@8W5S=&]M87)Y
M(&5V96YT<R!O9B!D969A=6QT+B!!="!-87)C:"`S,2P@,C`Q,B!A;F0@1&5C
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M9F]R96EG;B!E>&-H86YG92!L;W-S97,@;V8@)#`N-B!M:6QL:6]N(&%N9"`D
M,2XV(&UI;&QI;VXL(')E<W!E8W1I=F5L>2P@<F5L871E9"!T;R!T:&4@<F4M
M;65A<W5R96UE;G0@;V8@=&AE(&QO86XN/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV
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M=&5R97-T(&5X<&5N<V4@;V8@)#`N,R!M:6QL:6]N(&EN('1H92!T:')E92!M
M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3(@86YD(#(P,3$L(')E<W5L=&EN
M9R!F<F]M('1H92!A;6]R=&EZ871I;VX@;V8@=&AE(&QO86X@9&ES8V]U;G0N
M($%T($UA<F-H(#,Q+"`R,#$R(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@=&AE
M(&YE="!C87)R>6EN9R!V86QU92!O9B!T:&4@;&]A;B!W87,@)#$S+C(@;6EL
M;&EO;B!A;F0@)#$R+C4@;6EL;&EO;BP@<F5S<&5C=&EV96QY+B!&;W(@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,BP@=&AE($-O;7!A
M;GD@<F5C;W)D960@86X@=6YR96%L:7IE9"!F;W)E:6=N(&5X8VAA;F=E(&QO
M<W,@;V8@)#`N,B!M:6QL:6]N(')E;&%T960@=&\@=&AE(')E+6UE87-U<F5M
M96YT(&]F('1H92!L;V%N(&1I<V-O=6YT(&%S(&]F($UA<F-H(#,Q+"`R,#$R
M+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y
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M;65T:&]D+"!A;F0@=&AE($-O;7!A;GD@<F5C;W)D960@)#`N,R!M:6QL:6]N
M(&]F(')E;&%T960@;F]N+6-A<V@@<F5V96YU92!D=7)I;F<@8F]T:"!T:&4@
M=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q+CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@:71A;&EC.R!T97AT
M+6EN9&5N=#H@.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY'
M96YE<F%L($5L96-T<FEC($-A<&ET86P@0V]R<&]R871I;VX@5&5R;2!,;V%N
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&)R("\^/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY);B!$96-E;6)E<B`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82!L;V%N(&%G<F5E;65N="`H=&AE("),;V%N($%G<F5E;65N
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M+"!T:&4@0V]M<&%N>2P@6$]-02`H55,I($Q,0RP@6$]-02!)<F5L86YD($QI
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M(&5Q=6%L('1O(#4E(&]F('1H92!497)M($QO86X@*'1H92`B1FEN86P@4&%Y
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M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:&4@
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M96YC:6YG(&]N($IA;G5A<GD@-"P@,C`Q,BP@86YD('1H97)E869T97(@;VX@
M=&AE(&9I<G-T(&-A;&5N9&%R(&1A>2!O9B!E86-H('-U8V-E961I;F<@;6]N
M=&@N)B,Q-C`[)B,Q-C`[5&AE(%1E<FT@3&]A;B!M871U<F5S(&%N9"!I<R!D
M=64@86YD('!A>6%B;&4@:6X@9G5L;"!O;B!*=6YE(#,P+"`R,#$U+CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G
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M=&\@=&AE(&QE<W-E<B!O9B`U+C`E(&%B;W9E('1H92!S=&%T960@<F%T92!O
M9B!I;G1E<F5S="!O<B!T:&4@;6%X:6UU;2!R871E(&%L;&]W960@8GD@;&%W
M+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y
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M(&EN('1H92!F:7)S="!Y96%R(&]F('1H92!L;V%N+"`R)2!I;B!T:&4@<V5C
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M,3(@86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!T:&4@;W5T<W1A;F1I;F<@<')I
M;F-I<&%L(&)A;&%N8V4@=6YD97(@=&AE($QO86X@06=R965M96YT('=A<R`D
M.2XS(&UI;&QI;VX@86YD("0Q,"XP(&UI;&QI;VX@<F5S<&5C=&EV96QY+CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W<'0[(&1I
M<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!M
M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^26X@1&5C96UB97(@,C`Q,2P@<'5R<W5A;G0@=&\@=&AE(&QO
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M(&%N9"!W:6QL(&5X<&ER92!O;B!$96-E;6)E<B`S,"P@,C`Q-BX@5&AE($-O
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M;V8@)#`N,B!M:6QL:6]N(&ES(')E8V]R9&5D(&%S(&$@9&ES8V]U;G0@=&\@
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M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@
M:71A;&EC.R!T97AT+6EN9&5N=#H@.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY);G1E<F5S="!%>'!E;G-E/"]D:78^/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO
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M(&%R92!S:&]W;B!B96QO=R`H:6X@=&AO=7-A;F1S*3H\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SX\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=W:61T:#H@.#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z
M(#4V)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$-B!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#(R)3LG/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:')E92!-;VYT:',@16YD
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M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I
M9'1H.B`U-B4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SXR,#$R/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$
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M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SXR,#$Q/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U-B4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M
M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY);G1E<F5S="!E
M>'!E;G-E/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$P)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#$P)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-38E.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SY397)V:65R(&QO86X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
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M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES
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M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY'14-#('1E<FT@
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M(#$P<'0[)SXT,3<\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/BT\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-38E
M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY.;W9A<G1I<R!N;W1E/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/=&AE<CPO9&EV/CPO=&0^/'1D(&%L
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M=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T
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M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C8\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O
M;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@-38E.R<^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/
M=&AE<B!&:6YA;F-I;F=S/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@:71A;&EC.R!T
M97AT+6EN9&5N=#H@.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY!5$T@06=R965M96YT/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W<'0[
M(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^3VX@1F5B<G5A<GD@-"P@,C`Q,2P@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&%N($%T($UA<FME="!)<W-U86YC92!386QE<R!!9W)E
M96UE;G0@*'1H92`B,C`Q,2!!5$T@06=R965M96YT(BDL('=I=&@@36-.:6-O
M;&PL($QE=VES("9A;7`[(%9L86L@3$Q#("AN;W<@:VYO=VX@87,@34Q6("9A
M;7`[($-O+B!,3$,L(")-3%8B*2P@=6YD97(@=VAI8V@@:70@;6%Y('-E;&P@
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M;W)M(%,M,R`H1FEL92!.;RX@,S,S+3$W,C$Y-RD@9FEL960@=VET:"!T:&4@
M4T5#(&]N($9E8G)U87)Y(#$Q+"`R,#$Q(&%N9"!A;65N9&5D(&]N($UA<F-H
M(#$P+"`R,#$Q+"!*=6YE(#,L(#(P,3$@86YD($IA;G5A<GD@,RP@,C`Q,BP@
M=VAI8V@@=V%S(&UO<W0@<F5C96YT;'D@9&5C;&%R960@969F96-T:79E(&)Y
M('1H92!314,@;VX@2F%N=6%R>2`Q-RP@,C`Q,BX@34Q6(&UA>2!S96QL('1H
M92!S:&%R97,@8GD@86YY(&UE=&AO9"!P97)M:71T960@8GD@;&%W(&1E96UE
M9"!T;R!B92!A;B`B870@=&AE(&UA<FME="(@;V9F97)I;F<@87,@9&5F:6YE
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M<'!R;W9A;"X@1G)O;2!T:&4@:6YC97!T:6]N(&]F('1H92`R,#$Q($%432!!
M9W)E96UE;G0@=&AR;W5G:"!-87)C:"`S,2P@,C`Q,BP@=&AE($-O;7!A;GD@
M<V]L9"!A('1O=&%L(&]F(#<L-3<R+#,R-R!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K('5N9&5R('1H:7,@86=R965M96YT(&9O<B!A9V=R96=A=&4@9W)O<W,@
M<')O8V5E9',@;V8@)#$T+C8@;6EL;&EO;BP@:6YC;'5D:6YG(#(L,C@U+#,W
M-2!S:&%R97,@;V8@8V]M;6]N('-T;V-K('-O;&0@:6X@=&AE(&9I<G-T('%U
M87)T97(@;V8@,C`Q,B!F;W(@86=G<F5G871E(&=R;W-S('!R;V-E961S(&]F
M("0S+C,@;6EL;&EO;BX@5&]T86P@;V9F97)I;F<@97AP96YS97,@:6YC=7)R
M960@<F5L871E9"!T;R!S86QE<R!U;F1E<B!T:&4@,C`Q,2!!5$T@06=R965M
M96YT(&9R;VT@:6YC97!T:6]N('1O($UA<F-H(#,Q+"`R,#$R+"!W97)E("0P
M+C0@;6EL;&EO;BP@:6YC;'5D:6YG("0P+C$@;6EL;&EO;B!I;F-U<G)E9"!I
M;B!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$R+CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y
M;&4Z(&ET86QI8SL@=&5X="UI;F1E;G0Z(#EP=#L@9&ES<&QA>3H@8FQO8VL[
M(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P
M<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^56YD97)W<FET=&5N($]F9F5R:6YG(&%N9"!!;65N
M9&UE;G0@=&\@4VAA<F5H;VQD97(@4FEG:'1S(%!L86X\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R
M("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/;B!-87)C:"`Y+"`R,#$R
M+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@86X@=6YD97)W<FET=&5N('!U8FQI
M8R!O9F9E<FEN9R!O9B`R.2PV-CDL,34T('-H87)E<R!O9B!I=',@8V]M;6]N
M('-T;V-K+"!A;F0@86-C;VUP86YY:6YG('=A<G)A;G1S('1O('!U<F-H87-E
M(&]N92!H86QF(&]F(&$@<VAA<F4@;V8@8V]M;6]N('-T;V-K(&9O<B!E86-H
M('-H87)E('!U<F-H87-E9"P@870@82!P=6)L:6,@;V9F97)I;F<@<')I8V4@
M;V8@)#$N,S(@<&5R('-H87)E+B!4;W1A;"!G<F]S<R!P<F]C965D<R!F<F]M
M('1H92!O9F9E<FEN9R!W97)E(&%P<')O>&EM871E;'D@)#,Y+C(@;6EL;&EO
M;BP@8F5F;W)E(&1E9'5C=&EN9R!U;F1E<G=R:71I;F<@9&ES8V]U;G1S(&%N
M9"!C;VUM:7-S:6]N<R!A;F0@97-T:6UA=&5D(&]F9F5R:6YG(&5X<&5N<V5S
M('1O=&%L:6YG(&%P<')O>&EM871E;'D@)#(N.2!M:6QL:6]N+B!4:&4@=V%R
M<F%N=',L('=H:6-H(')E<')E<V5N="!T:&4@<FEG:'0@=&\@86-Q=6ER92!A
M;B!A9V=R96=A=&4@;V8@=7`@=&\@,30L.#,T+#4W-R!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K+"!A<F4@:6UM961I871E;'D@97AE<F-I<V%B;&4@86YD(&AA
M=F4@82!F:79E+7EE87(@=&5R;2!A;F0@86X@97AE<F-I<V4@<')I8V4@;V8@
M)#$N-S8@<&5R('-H87)E+CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQB<B`O
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M)2!O<B!M;W)E(&)U="!L97-S('1H86X@-#`E(&]F(&ET<R!O=71S=&%N9&EN
M9R!C;VUM;VX@<W1O8VL@=VET:"!T:&4@<')I;W(@87!P<F]V86P@;V8@:71S
M(&)O87)D(&]F(&1I<F5C=&]R<RP@86YD(&ET<R!B;V%R9"!H87,@87!P<F]V
M960@<'5R8VAA<V5R<R!I;B8C,38P.W1H92!-87)C:"`R,#$R('!U8FQI8R!O
M9F9E<FEN9R!B96-O;6EN9R!B96YE9FEC:6%L(&]W;F5R<R!O9B`R,"4@;W(@
M;6]R92!B=70@;&5S<R!T:&%N(#0P)2!O9B!I=',@;W5T<W1A;F1I;F<@8V]M
M;6]N('-T;V-K(&%S(&$@<F5S=6QT(&]F('1H96ER('!A<G1I8VEP871I;VX@
M:6X@=&AE(&]F9F5R:6YG+B8C,38P.R!!<R!A(')E<W5L="P@<W5C:"!O=VYE
M<G-H:7`@8GD@86YY('-U8V@@<'5R8VAA<V5R('=I;&P@;F]T('1R:6=G97(@
M=&AE('!R;W9I<VEO;G,@;V8@=&AE(')I9VAT<R!A9W)E96UE;G0@=&AA="!W
M;W5L9"!G:79E(&5A8V@@:&]L9&5R(&]F('1H92!R:6=H=',@=&AE(')I9VAT
M('1O(')E8V5I=F4@=7!O;B!E>&5R8VES92!T:&%T(&YU;6)E<B!O9B!C;VUM
M;VX@<W1O8VL@97%U:79A;&5N=',@:&%V:6YG(&$@;6%R:V5T('9A;'5E(&]F
M('1W;R!T:6UE<R!T:&4@97AE<F-I<V4@<')I8V4N)B,Q-C`[)B,Q-C`[5&AE
M(&)O87)D)W,@87!P<F]V86P@:6X@=&AI<R!R96=A<F0@;VYL>2!A<'!L:65S
M('1O('!U<F-H87-E<G,@:6XF(S$V,#MS=6-H(&]F9F5R:6YG+B8C,38P.SPO
M9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,S4X.6%B8C-?83DT,E\T,V$U7V$U8F1?9#1B-3EA-&1F
M,V)F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,U.#EA8F(S7V$Y
M-#)?-#-A-5]A-6)D7V0T8C4Y831D9C-B9B]7;W)K<VAE971S+U-H965T,3,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O
M;64@5&%X97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY);F-O;64@5&%X97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@
M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R
M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/'1A8FQE(&)O<F1E<CTS
M1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W
M:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^/'1R('9A;&EG;CTS1'1O<#X\=&0@86QI9VX],T1R
M:6=H="!S='EL93TS1"=W:61T:#H@,3AP=#LG/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^."XF(S$V,#L\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY)
M;F-O;64@5&%X97,\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4:&4@0V]M<&%N>2!D
M:60@;F]T(')E8V]G;FEZ92!A;GD@:6YC;VUE('1A>"!E>'!E;G-E(&9O<B!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"!I;F-O
M;64@=&%X(&5X<&5N<V4@=V%S(&YO="!M871E<FEA;"!F;W(@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,2X@5&AE($-O;7!A;GDG<R!E
M9F9E8W1I=F4@=&%X(')A=&4@=VEL;"!F;'5C='5A=&4@9G)O;2!P97)I;V0@
M=&\@<&5R:6]D(&1U92!T;R!S979E<F%L(&9A8W1O<G,@:6YH97)E;G0@:6X@
M=&AE(&YA='5R92!O9B!T:&4@0V]M<&%N>2=S(&]P97)A=&EO;G,@86YD(&)U
M<VEN97-S('1R86YS86-T:6]N<RX@5&AE(&9A8W1O<G,@=&AA="!M;W-T('-I
M9VYI9FEC86YT;'D@:6UP86-T('1H:7,@<F%T92!I;F-L=61E('1H92!V87)I
M86)I;&ET>2!O9B!L:6-E;G-I;F<@=')A;G-A8W1I;VYS(&EN(&9O<F5I9VX@
M:G5R:7-D:6-T:6]N<RX\+V1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W1O8VLM8F%S960@0V]M<&5N<V%T:6]N/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VLM
M8F%S960@0V]M<&5N<V%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@0V]M<&5N
M<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD
M:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D
M:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQT86)L92!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<B!V86QI
M9VX],T1T;W`^/'1D(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=VED=&@Z(#$X
M<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CDN)B,Q
M-C`[/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T/CQD:78@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^4W1O8VLM8F%S960@0V]M<&5N<V%T:6]N
M/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY);B!T:&4@9FER
M<W0@<75A<G1E<B!O9B`R,#$R+"!T:&4@0F]A<F0@;V8@1&ER96-T;W)S(&]F
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M.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN
M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P
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M,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY4:&4@9F%I<B!V86QU92!O9B!S=&]C:RUB87-E9"!A=V%R9',@=V%S(&5S
M=&EM871E9"!B87-E9"!O;B!T:&4@9F]L;&]W:6YG('=E:6=H=&5D(&%V97)A
M9V4@87-S=6UP=&EO;G,@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R
M8V@@,S$L(#(P,3$@86YD(#(P,3`Z/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G=VED=&@Z(#@P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#4V)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/E1H<F5E($UO;G1H<R!%;F1E9"!-87)C:"`S,2P\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[('=I9'1H.B`U-B4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=VED=&@Z(#$P)3LG/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXR,#$R/"]D:78^/"]T
M9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P
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M,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/C(P
M,3$\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@-38E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY$:79I9&5N9"!Y:65L9#PO9&EV
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M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,#PO=&0^/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXE/"]T9#X\+W1R/CQT<B!B
M9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z(#4V)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TY<'0[(&1I<W!L87DZ(&)L;V-K
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@
M.7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^17AP
M96-T960@=F]L871I;&ET>3PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z(#$E.R!D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXY,CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXE/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
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M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U
M-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T
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M<'0[)SXQ+C`U/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B4\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES
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M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXU+C8@>65A<G,\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI
M9VX],T1R:6=H="!C;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z(#$Q)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^-2XV('EE87)S/"]D
M:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+V1I=CX\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P
M;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R
M9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/E-T;V-K(&]P=&EO;B!A8W1I=FET>2!F;W(@=&AE('1H<F5E(&UO
M;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!W87,@87,@9F]L;&]W<SH\+V1I
M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$
M,"!S='EL93TS1"=W:61T:#H@.3`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@-#(E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
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M.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,G!X('-O;&ED.R!W:61T:#H@,3`E.R<^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I
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M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY!=F5R86=E(#PO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY%>&5R
M8VES92!0<FEC92`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
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M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^5V5I9VAT960@/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D%V97)A9V4@
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E)E
M;6%I;FEN9R`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^0V]N=')A8W1U86P@3&EF92`\+V1I=CX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^*&EN('EE87)S*3PO9&EV/CPO=&0^/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R!W:61T:#H@
M,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D%G
M9W)E9V%T92`\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^26YT<FEN<VEC(%9A;'5E(#PO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SXH:6X@=&AO=7-A;F1S*3PO9&EV/CPO=&0^
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@-#(E.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@
M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL
M969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY/<'1I;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]D
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M)SXU+#`U,RPT,S4\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXQ,BXU-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C8N.#D\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
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M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SY'<F%N=&5D/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H
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M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXY-#`L.3`P/"]T9#X\=&0@;F]W<F%P
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M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
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M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`T,B4[)SX\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE
M9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
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M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F
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M9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,2XV.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F
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M9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
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M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI
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M)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
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M;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^,C$N-C4\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W
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M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I
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M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[('=I9'1H.B`T,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/D]P=&EO;G,@;W5T
M<W1A;F1I;F<@870@36%R8V@@,S$L(#(P,3(\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED
M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXU+#@P,BPQ,C$\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B0\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[('=I
M9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^,3`N-3,\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
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M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^-RXR.#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#1P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED
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M<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/<'1I;VYS(&5X97)C:7-A8FQE(&%T
M($UA<F-H(#,Q+"`R,#$R/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#L@
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M:'0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/C8N-#4\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E1H92!V86QU
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M/CQB<B`O/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#(W<'0[(&1I<W!L87DZ(&)L;V-K.R!F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^56YV97-T960@4E-5(&%C
M=&EV:71Y(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$R(&ES('-U;6UA<FEZ960@8F5L;W<Z/"]D:78^/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQB<B`O/CPO9&EV
M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/'1A8FQE(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z
M(#@P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.B`U-B4[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@
M,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A
M;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q,"4[(&1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M(#$P)3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY7
M96EG:'1E9"T\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/"]T<CX\='(^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z(#4V)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/DYU;6)E<B!O9CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,3`E.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
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M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M('=I9'1H.B`U-B4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
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M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O
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M>6QE/3-$)W=I9'1H.B`U-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#EP=#L@
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E5N=F5S=&5D
M(&)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3$\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q
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M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^.3`S+#@W-#PO=&0^
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
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M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#H@,24[(&1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/BT\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R
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M:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^*#$S,BPU-S4\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D
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M('!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2XV.3PO=&0^
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M9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`U-B4[)SX\9&EV('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y
M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN
M+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/E5N=F5S=&5D(&)A;&%N8V4@870@36%R8V@@,S$L(#(P,3(\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$L,3$T+#0Q-#PO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@=VED=&@Z(#$E.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E1H92!F;VQL;W=I
M;F<@=&%B;&4@<VAO=W,@=&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M(&5X<&5N<V4@:6YC;'5D960@:6X@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T
M960@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS(&9O<B!T:&4@=&AR964@;6]N
M=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q("AI;B!T:&]U<V%N
M9',I.CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CLG/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`X,"4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQT<CX\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R!W:61T:#H@-38E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D
M(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('=I9'1H.B`R,B4[)SX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
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M;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W
M:61T:#H@-38E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^,C`Q,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[('=I9'1H.B`Q,"4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T
M.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^,C`Q,3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$
M(V-C965F9CX\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#H@-38E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@+3EP=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&UA<F=I;BUL969T.B`Y<'0[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY297-E87)C:"!A
M;F0@9&5V96QO<&UE;G0\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL
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M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$L,#8Q/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[('=I9'1H.B`U-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C
M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z
M(#EP=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/E-E
M;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Y)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^,C@Y/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
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M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W
M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/C<Q,3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#)P>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^
M/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I9'1H
M.B`U-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#$X<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY4;W1A;"!S=&]C:RUB87-E9"!C
M;VUP96YS871I;VX@97AP96YS93PO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M>#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P
M>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C8W
M-#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P>#L@
M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[('=I
M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
M)B,Q-C`[/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DQE9V%L(%!R;V-E961I;F=S+"!#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DQE9V%L(%!R;V-E961I;F=S+"!#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE9V%L(%!R;V-E961I;F=S+"!#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B;&4@8F]R9&5R
M/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SXQ,"XF(S$V,#L\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SY,96=A;"!0<F]C965D:6YG<RP@0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&)R("\^
M/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/;B!!<')I;"`Y+"`R,#`Y+"!A
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M-C`[(%1H92!#;VUP86YY)W,@86=R965M96YT('=I=&@@1V5N96YT96-H('!R
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY/;B!!=6=U<W0@-"P@
M,C`Q,"P@82!P971I=&EO;B!W87,@9FEL960@:6X@=&AE($1I<W1R:6-T($-O
M=7)T(&]F($1A;&QA<R!#;W5N='DL(%1E>&%S(&EN(&$@8V%S92!C87!T:6]N
M960@36-#86QL('8N($=E;F5N=&5C:"P@26YC+BP@970@86PN+"!.;RX@,3`M
M,#DU-#0N)B,Q-C`[(%1H92!D969E;F1A;G1S(&9I;&5D(&$@3F]T:6-E(&]F
M(%)E;6]V86P@=&\@=&AE(%5N:71E9"!3=&%T97,@1&ES=')I8W0@0V]U<G0@
M9F]R('1H92!.;W)T:&5R;B!$:7-T<FEC="!O9B!497AA<R!O;B!397!T96UB
M97(@,RP@,C`Q,"XF(S$V,#L@5&AE(')E;6]V960@8V%S92!I<R!C87!T:6]N
M960@36-#86QL('8N($=E;F5N=&5C:"P@26YC+BP@970@86PN+"!.;RX@,SHQ
M,"UC=BTP,3<T-RU"+B!4:&4@<&5T:71I;VX@87-S97)T<R!P97)S;VYA;"!I
M;FIU<GD@8VQA:6US(&%G86EN<W0@1V5N96YT96-H+"!T:&4@0V]M<&%N>2!A
M;F0@;W1H97)S(&%R:7-I;F<@;W5T(&]F('!L86EN=&EF9B=S('1R96%T;65N
M="!W:71H(%)!4%1)5D$F(S$W-#LN)B,Q-C`[($5F9F5C=&EV92!!<')I;"`Q
M."P@,C`Q,BP@=&AE('!A<G1I97,@96YT97)E9"!I;G1O(&$@0V]N9FED96YT
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M+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B
M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE
M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/D]N($IA;G5A<GD@-RP@,C`Q,2P@82!C;VUP;&%I;G0@=V%S(&9I;&5D(&EN
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M:79E($%P<FEL(#$X+"`R,#$R+"!T:&4@<&%R=&EE<R!E;G1E<F5D(&EN=&\@
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M>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`R-W!T
M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/D]N($IA;G5A<GD@,3$L(#(P,3$L(&$@8V]M<&QA:6YT
M('=A<R!F:6QE9"!I;B!T:&4@56YI=&5D(%-T871E<R!$:7-T<FEC="!#;W5R
M="!F;W(@=&AE($1I<W1R:6-T(&]F($UA<W-A8VAU<V5T=',@:6X@82!C87-E
M(&-A<'1I;VYE9"!3>6QV:6$L(&5T(&%L+B!V+B!'96YE;G1E8V@L($EN8RXL
M(&5T(&%L+BP@3F\N(#$Z,3$M8W8M,3`P-30M34Q7+B8C,38P.R!/;B!*=6YE
M(#$S+"`R,#$Q+"!A(&-O;7!L86EN="!W87,@9FEL960@:6X@=&AE(%-U<')E
M;64@0V]U<G0@9F]R('1H92!3=&%T92!O9B!.97<@66]R:RP@3VYO;F1A9V$@
M0V]U;G1Y+B8C,38P.R!$969E;F1A;G1S(')E;6]V960@=&AE(&-A<V4@=&\@
M=&AE(%5N:71E9"!3=&%T97,@1&ES=')I8W0@0V]U<G0@9F]R('1H92!.;W)T
M:&5R;B!$:7-T<FEC="!O9B!.97<@66]R:R!O;B!.;W9E;6)E<B`S+"`R,#$Q
M+B`F(S$V,#M4:&5S92!T=V\@8V]M<&QA:6YT<R!A;&QE9V4@=&AE('-A;64@
M8VQA:6US(&%G86EN<W0@1V5N96YT96-H+"!T:&4@0V]M<&%N>2!A;F0@;W1H
M97)S(&%N9"!S965K('1H92!S86UE('1Y<&5S(&]F(&1A;6%G97,@87,@=&AE
M(&-O;7!L86EN=',@9FEL960@:6X@=&AE(%-U<&5R:6]R($-O=7)T(&]F($%L
M86UE9&$@0V]U;G1Y+"!#86QI9F]R;FEA(')E9F5R96YC960@86)O=F4N)B,Q
M-C`[($YO('1R:6%L(&1A=&4@:&%S(&)E96X@<V5T(&EN(&5I=&AE<B!C87-E
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&)R("\^/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86X[(&UA<F=I;BUL969T.B`P<'0[(&9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SY/;B!!<')I;"`X+"`R,#$Q+"!F;W5R(&-O
M;7!L86EN=',@=V5R92!F:6QE9"!I;B!T:&4@56YI=&5D(%-T871E<R!$:7-T
M<FEC="!#;W5R="!F;W(@=&AE($5A<W1E<FX@1&ES=')I8W0@;V8@36EC:&EG
M86XN)B,Q-C`[(%1H92!C87-E<R!A<F4@8V%P=&EO;F5D.B8C,38P.R!-=6YI
M>B!V+B!'96YE;G1E8V@L(&5T(&%L+BP@-3HQ,2UC=BTQ,30X.2U*0T\M4E-7
M.R!4:69E;G1H86P@=BX@1V5N96YT96-H+"!E="!A;"XL(#(Z,3$M8W8M,3$T
M.#@M1%!(+4Q*33L@0FQA:7(@=BX@1V5N96YT96-H+"!E="!A;"XL(#(Z,3$M
M8W8M,3$T-C,M4T9#+4U*2#L@86YD($UA<G-H('8N($=E;F5N=&5C:"P@970@
M86PN+"`R.C$Q+6-V+3$Q-#8R+5)(0RU-2TTN)B,Q-C`[(%1H92!C;VUP;&%I
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M="!F;W(@=&AE(%=E<W1E<FX@1&ES=')I8W0@;V8@36EC:&EG86XN)B,Q-C`[
M($]N($]C=&]B97(@,C8L(#(P,3$L('1H92!#;W5R="!G<F%N=&5D('1H92!-
M;W1I;VYS('1O($1I<VUI<W,@9FEL960@8GD@1V5N96YT96-H(&%N9"!T:&4@
M0V]M<&%N>2!I;B!A;&P@9F]U<B!A8W1I;VYS+B8C,38P.R!/;B!/8W1O8F5R
M(#,Q+"`R,#$Q+"!0;&%I;G1I9F9S(&9I;&5D(&$@3F]T:6-E(&]F($%P<&5A
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M+CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,S4X.6%B8C-?83DT,E\T,V$U7V$U8F1?9#1B-3EA
M-&1F,V)F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,U.#EA8F(S
M7V$Y-#)?-#-A-5]A-6)D7V0T8C4Y831D9C-B9B]7;W)K<VAE971S+V9I;&5L
M:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$
M(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"CPO>&UL/@T*
M+2TM+2TM/5].97AT4&%R=%\S-3@Y86)B,U]A.30R7S0S835?835B9%]D-&(U
,.6$T9&8S8F8M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Financial Statement Detail<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CondensedConsolidatedFinancialStatementDetailAbstract', window );"><strong>Condensed Consolidated Financial Statement Detail [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CondensedConsolidatedFinancialStatementDetailTextBlock', window );">Condensed Consolidated Financial Statement Detail</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">3.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Condensed Consolidated Financial Statement Detail</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Comprehensive Loss</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Comprehensive loss is equal to net loss for both the three months ended March 31, 2012 and 2011.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Net Loss Per Share of Common Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Basic and diluted net loss per share of common stock is based on the weighted average number of shares of common stock outstanding during the period.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Potentially dilutive securities are excluded from the calculation of earnings per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td nowrap="nowrap" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Common stock options and restricted stock units</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,722</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,638</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Convertible preferred stock</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">254</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Warrants for common stock</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,457</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,607</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Total</div></td><td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,179</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,499</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three months ended March 31, 2012 and 2011, all outstanding securities were considered anti-dilutive, and therefore the calculation of basic and diluted net loss per share was the same.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Cash and Cash Equivalents</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">At March 31, 2012 cash equivalents consisted of demand deposits of $14.4 million, money market funds of $50.5 million, and U.S. government securities of $10.0 million with maturities of less than 90 days at the date of purchase. At December 31, 2011, cash equivalents consisted of demand deposits of $21.1 million and money market funds of $27.2 million with maturities of less than 90 days at the date of purchase.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Foreign Exchange Options</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company holds debt and may incur expenses denominated in foreign currencies, which exposes it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and the Euro. The Company is required to make principal and accrued interest payments in Euros on its &#8364;15.0 million loan from Servier (See <font style="font-style: italic; display: inline;">Note 7: Long-Term Debt and Other Financings</font>). In order to manage its foreign currency exposure related to these payments, in May 2011, the Company entered into two foreign exchange option contracts to buy &#8364;15.0 million and &#8364;1.5 million on January 2016 and January 2014, respectively. By having these option contracts in place, the Company's foreign exchange rate risk is reduced if the U.S. dollar weakens against the Euro. However, if the U.S. dollar strengthens against the Euro, the Company is not required to exercise these options, but will not receive any refund on premiums paid.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Upfront premiums paid on these foreign exchange option contracts totaled $1.5 million. The fair values of these option contracts are re-valued at each reporting period and are estimated based on pricing models using readily observable inputs from actively quoted markets. The fair values of these option contracts are included in other assets on the condensed consolidated balance sheet and changes in fair value on these contracts are included in other income (expense) on the condensed consolidated statements of operations.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The foreign exchange options were revalued at March 31, 2012 and had an aggregate fair value of $0.9 million resulting in a related loss of $0.3 million for the three months ended March 31, 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Accrued Liabilities</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accrued liabilities consisted of the following at March 31, 2012 and December 31, 2011 (in thousands):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">March 31,</div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">December 31, </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Accrued payroll and other benefits</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,155</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,007</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Accrued management incentive compensation</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">996</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,096</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Accrued restructuring costs</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">891</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">70</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Accrued professional fees</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">760</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">917</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Accrued severance payments</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">551</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,207</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">944</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">715</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Total</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,297</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10,012</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Contingent Warrant Liabilities</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of XOMA's common stock at an exercise price of $1.76 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in March 2012 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At issuance, the fair value of the warrant liability was estimated to be $6.4 million using the Black-Scholes Model. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded an increase in the fair value of $14.7 million as a loss in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, 14,832,827 of these warrants were outstanding and had a fair value of $21.1 million. This increase in liability is primarily due to the excess of the market value of the Company's common stock at March 31, 2012 compared to the warrant exercise price. See <font style="font-style: italic; display: inline;">Note 4: Fair Value Measurements </font>for further disclosure regarding the fair value of this warrant liability.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In February 2010, in connection with an underwritten offering, the Company issued five-year warrants to purchase 1,260,000 shares of XOMA's common stock at an exercise price of $10.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in February 2010 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.3 million using the Black-Scholes Model. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.3 million as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding. See <font style="font-style: italic; display: inline;">Note 4: Fair Value Measurements </font>for further disclosure regarding the fair value of this warrant liability.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2009, the Company issued warrants to certain institutional investors as part of a registered direct offering. The warrants represent the right to acquire an aggregate of up to 347,826 shares of XOMA's common stock over a five year period beginning December 11, 2009 at an exercise price of $19.50 per share. These warrants contain provisions that are contingent on the remote occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in June 2009 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2011, the fair value of the warrant liability was estimated to be $0.1 million using the Black-Scholes Model. At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Model from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions. The Company revalued the warrant liability at March 31, 2012 using the Black-Scholes Model and recorded a decrease in the fair value of $0.1 million as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. As of March 31, 2012, all of these warrants were outstanding. See <font style="font-style: italic; display: inline;">Note 4: Fair Value Measurements </font>for further disclosure regarding the fair value of this warrant liability.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CondensedConsolidatedFinancialStatementDetailAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_CondensedConsolidatedFinancialStatementDetailAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CondensedConsolidatedFinancialStatementDetailTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element may be used to disclose further details for significant balance sheet and income statement line items, that are not presented elsewhere in the notes to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_CondensedConsolidatedFinancialStatementDetailTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 74,887<span></span></td>
        <td class="nump">$ 48,344<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
        <td class="nump">10,164<span></span></td>
        <td class="nump">12,332<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">3,674<span></span></td>
        <td class="nump">2,019<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">88,725<span></span></td>
        <td class="nump">62,695<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">10,329<span></span></td>
        <td class="nump">12,709<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">2,268<span></span></td>
        <td class="nump">2,632<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">101,322<span></span></td>
        <td class="nump">78,036<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,852<span></span></td>
        <td class="nump">2,128<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
        <td class="nump">6,297<span></span></td>
        <td class="nump">10,012<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">6,912<span></span></td>
        <td class="nump">5,695<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Interest bearing obligation - current</a></td>
        <td class="nump">2,796<span></span></td>
        <td class="nump">2,796<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">18,857<span></span></td>
        <td class="nump">20,631<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - long-term</a></td>
        <td class="nump">7,207<span></span></td>
        <td class="nump">7,539<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Interest bearing obligations - long-term</a></td>
        <td class="nump">33,569<span></span></td>
        <td class="nump">33,524<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Contingent warrant liabilities</a></td>
        <td class="nump">21,122<span></span></td>
        <td class="nump">379<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities - long term</a></td>
        <td class="nump">1,079<span></span></td>
        <td class="nump">952<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">81,834<span></span></td>
        <td class="nump">63,025<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.05 par value, 1,000,000 shares authorized</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0075 par value, 92,666,666 shares authorized, 68,076,152 and 35,107,007 shares outstanding at March 31, 2012 and December 31, 2011, respectively</a></td>
        <td class="nump">511<span></span></td>
        <td class="nump">263<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">935,455<span></span></td>
        <td class="nump">900,801<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(916,478)<span></span></td>
        <td class="num">(886,053)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">19,488<span></span></td>
        <td class="nump">15,011<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 101,322<span></span></td>
        <td class="nump">$ 78,036<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr>
        <td colspan="4"></td>
      </tr>
      <tr>
        <td colspan="4">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2011 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the portions of the carrying amounts as of the balance sheet date of long-term debt, which may include notes payable, bonds payable, debentures, mortgage loans, and commercial paper, which are scheduled to be repaid within one year or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of warrants and rights outstanding. "Equity warrants and rights outstanding" represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 00-27<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 98-5<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PrepaidExpensesAndOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer. And, aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_PrepaidExpensesAndOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DescriptionOfBusinessAbstract', window );"><strong>Description of Business [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">1.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Description of Business</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">XOMA Corporation ("XOMA" or the "Company"), a Delaware corporation, combines a portfolio of late-stage clinical programs and research activities to develop innovative therapeutic antibodies with its recently launched commercial operations.&#160; XOMA focuses its scientific research on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.&#160;&#160;XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier ("Servier") through a global Phase 3 program and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also has produced the XMet platform, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators that could offer new approaches in the treatment of diabetes.&#160;&#160;In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier's ACEON&#174; (perindopril erbumine) and certain U.S. rights to a patent-protected portfolio of fixed dose combination product candidates where perindopril is combined with other active ingredients to treat cardiovascular disease.&#160;XOMA has the right to develop and commercialize one of these product candidates and options to develop and commercialize two more product candidates, all for the U.S. market.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DescriptionOfBusinessAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_DescriptionOfBusinessAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001140361-12-023627-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-12-023627-xbrl.zip
M4$L#!!0````(`'2#J$"SFA/3=&D``.MY!``1`!P`>&]M82TR,#$R,#,S,2YX
M;6Q55`D``[R!J4^\@:E/=7@+``$$)0X```0Y`0``[#UK<^,VDM^OZOX#SI?=
M9*HDF=1;GL>6QYXD3L9CESV3[-75?8!(2$*&KP"@;>777S?`ERA*%B5Y;$\F
M5;LCD^A&=Z/1:#0:S5?_NO,]<L.$Y&'P^L!N60>$!4[H\F#Z^B"632H=S@_^
M]>8__^/5?S6;/[&`":J82\9S\G$6^C(,R!6+%2`@QX[#/`!I8N.[L?`(X`[D
M$?[DKP]F2D5'AX>WM[<M?-(*Q?2P;5F=0QY(10.''23M/1Y\7M,<7X^IS)K?
M+;6_[>C6]F@T.M1OLZ:25S4$M/;AO\_?7SLSYM-FF1[LWLT!B]3T#\W+M"F7
M8;=M#]8Q:UID`,$-DVH1MV1.:QK>')IW`&;;3<MN=NP4"&0\I33*H"94CG4/
MR8L*$)?QZD[@147S(/:K>7"5.%3SB!U""R:XDP&$P08P8=`LP3EA'"@QKZ8M
M>5E!GQ,+L0(&WH`"5P$%E#NR&DJ_J@"1W*D&@!=5S56T@BQ\4P'`[IQ9-0"^
MJ0"X"WV:`\`?+2?TL5W;ZF2M-IEK,$<)>863XTAJM;]B$Z(GRQ&.U>L#R?W(
MPSF@G\T$F[P^P`Z;:6>M.^D>D$.#2,]Q&,U`L3M%N/OZP-'M;,M684:>;INU
M9H'B:IX\RYYR%Y]/.!-$$\86N$G%<W+VZ\$;"_X;C.R1-7QU6`9.NSJLZ"OI
M*0)%#-UR_R`?H4[!QKU!LE'ZEIUBR=^5@%C@%D`Z,&!YQVX!('U:Z#I]E,AN
MO3A[5O=9"-&HF4KDT6M:W0QY\F8_\G@N2K4HCZ)^[%,>MMU^?O*PFR"2!Y)'
M9G[L9Z,I"^;'KF]^[(<S/]9S5"_K(=7KN2C5PG3;F_F)`VZ$\0G\YY(<?$9E
M+-B;1'%G5#"9HDK?%=$CKE6XVRMP)Z[TT:?KTVU1=TJH77X#XBZ+#R$^H-]*
M52BREW7I*0JX&F.ANU,6A#X/UG=XGW#+/2XC3=\6^%X6&^S[CEV7*]@A4H]$
ME+NP12(.C;BBGM[M0:-DZW&4M[R$AF?!B6E&$OVY0C<R7[L)]J*?Z7$F+G.X
M3SWP8)LP-*-.K]OKP81X=7@/^@<DU"RJ:PG5VG2FF-^$:3"RK"&8G5I$^Z%0
M_"^*;4@X(2Z7>NM#:."2"3?,S'V8[V3"&(%&+AN;M_H'ES)&IQYHETHN,5K`
M?C'Y$=`%#NSN3[#M,2P/26>R8H@6O??U@]7M#Q:9WK#;IRZ%LA.Q7@KMT7`W
M*7P*!*,>_XNYY"<*VOO#^U#*%\CM*1CE&T!TPY:8RX$0!B$N@D+S'4>VV1[T
M%YBZI[LORTN]\=F"BRLFE8@=%0L8..*`M9TR(IBGPV`J)%X83)L>@+B$2LDJ
M5`^?GOE@CP1J[XG&L.N@V`.K--\J>_GB7&P]'/?0?T+E3,]U_>/=GS&,DP?M
M9(-0!0^%F"-COU$O9F72$00F&_Y3`#Q6*90&VFJ%&G2'P\5AV*BO1^2JUG(&
MGE=WV.EVGQ6'UOT<OND,.M;SXFJ3V=3K#P>[<'7L)&L@K+-T[#'-(74<$8-5
M\#@=<P_\F&63?18X8$HE.V7FW[,@Q71I$`$)QP;-^QS+KJM2I]U>=+.V(^.I
M<%_/<#9[W?9HG]RGX.2'%,$+`DOVI6#H1Y-W=Q$+I)')A9K!1O:X<I58IB+!
M<,HF3`CF)HB`&(W&8-EU+>SW[M.$3:AXHK*HJ1CM[F"?LO@HJ&M8#36K@CD,
M[`CH$]BZ@*G[F;[*(78<Y[;='][#6Z&S+\1"O>&QK7[G/EVMXN$D]'VNT#&2
M9MT!*L!^,]A-`$VXC?!"W/>3__V((:JW7NA\_K^EE2='@HM"$46.`>$U^+V#
M]>:?GGKI\IM_3M7+Y">1:NZQUP<(UP3G>AH<$8]-U$NBG_``8UE'I-./X!%L
M\"*/SH_(&+M[22;07W-"?>[!LX_<!\8^L%MR%?HT>$E\\`=YT$1L1\1">-U>
M@@-_1&S](&DB^'26M#G0M%$_>OG?=M_25!X^!XIKT695D;;<^9J^E%[OQJ%P
MF7A]8!T0AWE>1%V3!9#\+2/JI'\GA-UR5\V0%^L?)6$H+8P`A"&,,,JLYWT+
M<J-Y`S[#*'\,:Z]YJ@E>ZG*X1UGM/(SZP2TSDAV'GKM2VK;56JV.A\I=9A_[
M?8:,OF=3ZL&2&3J,H1J!J5UKP];(XE")_"=J:O;7FJF\3@Z9.,>"'&Z"+!'S
M'[%4?#(O2;H]^)*FX2(@QY'@'ADU2-NRX/\I&&H?^N:!(K=4D@GWP&$%?P46
M.W(=ZUB^`&''0F%8[=BC/G,I/@C4'$8%F)N$(N"T@4"4>/16QEQAW!2C5H#K
M9^8*#@L"4Z"4+7+3(I@'!(N#,VL06+]:Y@WB`K?H0]@BUJC9[?;MWK!%/LY8
M@4",+0AT<N!/']1@2O$$HH@/J09-B6@PS]=LX`IXH)['ID"/5$".RGSRN7XY
MH=S#!5"%(`41--)6D0C=N-@:U_PI#"CH'6N0,2RZS@P%`U"":I%,!(W=&+=*
MN`8ZC'JHM`UR*\)@.HD]6-.IFA4\BH0;S$IR,;S%@S]B@0MS2C$0-:,WC(2.
MSD_!&`M(6C`9>WI0U$PP!F`Z#A^#M_`]44"8GBSDED-G5\>7'\]^.TZ,QZ#[
MLBQ9R=AG"<Z'C,#AF'#H`]^!9X?A?B/*"%T3#F2XU*=3)EODFF/`%'@`>=$\
M=)YAE8;L,6/!HEY)4")H!CJ%(H19C-M=?*%"#*('L3\&N0!G!LH!R4B4@F0W
MP-+<_%LPA889W2KO$80O0X^[.D:E)>:$L$;A"08\B#+;TB(YHF//,P)E12[,
M.!0H3]0/A()RRU]@[HO4T6<CHIW&E!'3/Y],-AG0@C3>32;,T4-E)KL]Q-EN
MM\WTB*C06TB<,D*/"="",SJ8F,-"&(%KII3'='?'4U`N_4O-*/8.(DK(3$83
MC)?/I<0IK&F+!/LC=CG.#V`$&";C&'@*6"9:/5*@72A^Q+)H54IFISS.B*@$
M@`A)$")%CA>[J:)Q">.3,4(S1N#YK]S["U1LV1@UEJS1U4]-VVKVK#:8I#(M
MB:GY7A:P:QED6%'1\'0LL4&H"2[S`[0[((U_7YP?-\SL2@XGX*&G%[\)8T;%
M)K&1DQ;>*I;&\R(CMS,./1=MX9AYG&$`'!#0*/*XHYTV&'EH!8SZ5&$69M&]
MJ.0T1Z0'<M$.@]D'A&.F11#"F&.RGCEC`26#X=:3V(6=(\9&$B#`XY,;/@U%
M&$MOWMK>RZY>2FNYLL]T28^G0`CIZEENX9H>,:6M\?*2#ELUL[)E2_HIS%!H
ME:[HL(.#O_1:KJ=5OI"?.R<XF5?.&?@7YPM,%FO4ZW;+<\6,.T6#:BBBT%R!
MF4`BKI@?@B.?*"3Y!!,$6EPKL-6R3#-.)&ST(12X?@;Y>T!DR`?.KUFDF%Y'
M.D8N97H$=IFL+C@M:C/:.0)6G9NF!?9WT'QKEM1,\JFO`J9,ZF51+P'S^KX+
M%5SJ^1]K!K-%`8S.LUT4M"%#P7_]!G5K<[;CQKQNV.*)V+)?:!!3F"8#K9WV
M/1N47>U$I9F#F4OOG?S=(]L^^6U@X:Q'7<[W*-K!D\O>XN83/O$KY1K'DLJR
MD[KUQ@TF[H1AUCN:Y#&8Q&]6XQE;C;^M$Y0:#K09^[(<18.AS8(SBW'<JPW'
M]=R[P3C(RD!'R4\""X+N@VU9O6[S_/WO1:U&AF+8Z-B=C;B!^0[N#"N1KYE#
MVE'&_Q.*SPW`&X(/-DWM0+'+T]P_2UVC=+.VNUN64H">V0?`77#,[.(&_*.>
M!NHVW&3_7=NB/@&#^@$D*=`N8ER"S*!;':P`K<*N&#<1(;1Q>[-L:PQ;T5[M
M8*Z^[1"?N'$TB_<PM2434.*BJM^"NFYA'M]1J<H3_1QTB$_IBN@<%06#>51H
M<AX'_*^2R4R-92\UE'9W.&K^<G+1O+K^';!RT!)P),H;M12L70`;-D\O?VZ^
M_^7\)7D+/)<#/Q4@_4[S^L>3YODO/[_4ZGE.A9QM`-9N7OT,8+^>+PG@Z[1G
M&#$UZJ0'6&N2$C20)CV@ULKQ.]M,GT"A+QP5XA+2[J<Z;42%Z*88B$]6K_,0
M=4U;E5/C6R9R6+!\*,^BJ'%U3_FBCL:PHO].YFU<9L':BO#&<10Q'0(@^KS`
MA!RJ9EH^'`8B6\KY'1C]$RZ<F"]%1+\M$O<O$E6_"YENM7(;%O(JP*&1"AXV
MB+E*06@,5`N=M_P#C+%Y^J(JFR(,KA'R6K<XSL$VR"6UBZDAUL&;4;NO_UMD
M:44'7YK^BJS1!Z0?-`9O)>G-6AT&+@IP6XQ`?V@-^G:OO8:#0@]?GH4-!J'3
MLS$M?+`3"]]9+4#1P]@`IF;$L'4?M1LPM/B_91UKD/ZP`9)K@.CT%._T&D!%
M`W!428,J7(G!`B6&U\"<,B?9463F&``C$[GPYFODMGWR=L]>S,0J(_V*Q5,K
M"QPS[_J=S4152"T%!T378EC*KRNT25IL-7SV<-A;3'5<1KQONFK)K0MR6TKW
M6T/C*=YB.@OPGH;)-TA3`QLD2=R%)QBFDTND(V@.F<(E4"G0S@G7H\7D\HTZ
M?3SNZN;-E@9J1^X^!=1<_0*^TEM>Z_DJ0*0`6]T"&`Y'HS6<5'13X"+Q^:\P
M/0,MVXJIDC9,VNTRC?LC:+9(;A7N!Z.QUI3NX26+46\K>H5Y3YKFKA4HD'\/
MR1_"P-E!LH-VZ8K82O0/3&PM$?>!\%ZGK,'W$?Z62NZ8NZ#<BW$[%L#>'KQ^
M?7R+F^AL!=?^F!MZ'A7FI5Z%EURS=Q1VSL%47C*A':?3!&\M(]HILMD&*V.U
M^J.<KQ5]/`&NUAK/"J[:[<VY,B=2N$7%(D<TP(N(&$HUO_71/VRO9TND:["+
MR;L$Z`I@+H+J&TX[+G4%U:O3ZZ-R6/?^T&#1H]N*3^T`-DV*7)9MB*D3S-PI
M*3.HU>$M-C\IMMYML/JE.V_5G3PTS36O@0P&[3I$@_L1^HQ\I'>;WO4P$`#P
M@#<[JD/CCYUY_BSS)K[=^/A:;WP,_R87/G(3]>TRQZ:SOAA/=[FK$Z`%<\)I
M`+#$G&-HJ2HP_,GZE!THF#L#X`"J&>;ON#KQ:2ER5($`<P^P)Q^6>'V0O2E&
MNWRBS;+<(L2O71R=$C3QL-($_CD!8T!,.2D,^2>_W)BEEP$$]D\=%0I,R9@Q
MO8%(#E8"JG"92W+.\V[#"`LGZ5,A9'$<2QXP*<VI57K:HTE-,>ML)3^4BD@8
M?#[A#@V4!^(%E(XRZ4":_"3]7'=X0T5VPP3/4[@#XM/W'`K](*T@/Y@A`<$+
M`M+EZ7%3K?.+=>MUP0U(8AWOJGV5]'UZ0WG':]56MUVZJKJ`?F]DU?.=>IW-
MJ'J_^LK^^BH$&X18[&&GNRJLMRL!M7;+`_!_.U:[5X<8/6G0G5=+@>-"*W#[
MM:L\`Z//A#3MMPO46G:GW5Y%864_#TUV+1D/#]X,AE:GOQT'V>08,ZIK[X1C
M6(#,)J))G!6AZ#"8?F3"Q]#=+L&U]F!4(GL9\<-36DO:H_U1+=>%KXHX=PRT
M=3J]_F@EP171J@>FN5[).DLST.[68>`#4Z;TS:7)2M#9&#]\DCH]Y07)ZIR1
M8W0/*DT@H$`,*8*W<X0^"S+0''+'9:PS'/07U6GSKI\(PS5KT'7+9QG[9_A,
MUZ;?BN$,=&\CW.QUAYOP6]'S$^&W9O!N.'QH?B^,B[T-OQGH_L;7MON#WB8<
M5_3]1#BN.<+:Q]T#PWA64,&%V6U@S<.=#X5AD[`T-#GZ'8FI*;4^+&0;T+*F
M>MNEV:!65(#:K(R;@2_7]-FU[E&_URWE7]3H_`FQ77,=L^Q]L)U/["1$9<J0
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M#SZS^)[^<,%F+!4#<OO+;KJ_K\=@I_8VP6IO,$:KN`);H<S=/`9[BLBD[U:4
MA4V;7GHT4+`+>9>VQJWM=N<BG67E6MG%@Y-<+VIL`_WM@;4-_:G'HD)R[$`+
M,+<IH+Z$A\RD9ST:>HFM!,/',(%?V>^.,Z4<5]R\XZ?!;;V)5(XJ;L'M5;&T
M,@SZRN3L0D.,;.UR#<2R2WNB2MP/16*]6=/&6=,I'6#?1V^4JA#8VO>9K3VM
ML+5YV[TN&`.[+.#J;AZ6YJV_++(!N85OHRS35WBYGV^W=`:#04F@RWWLD;H=
M)+<I7=J$726?DRF$P3?,5EW`!98EP90C^I;%^ASRV;YT%NNWC-FO,6.V_S?)
MF+W&XH^^QX/<?A8M:F)O'R67%IE(H;(V/`!:V7TBJE;BQ0'%-H_0U:ILS"=L
M4<_RLFCMK&A?FC*LO]".CHVN52*+Z@1N5YXEF]:Q,Y7Z3`D97:FZH&W`#7Y0
M$=-C3<T7#)]%+"`8EYZ$3JQO+>E(6Q,/V/1!51A%H5"ZJC@PG!1EF;*;\#/_
M*_;IV&0@*RQ+SO^,,:-9\7'HSLVW'6]84I?<93?,"Y,M#(VRQ+I64N5UB<ZL
M2#1R@=7=DT]&8AF4[]."K0'SD)QAET2AY(D@0D$ZW7_H6H1&)KVVJ7C#/.XG
MA<6Y[S.7PT]OGM65$<RGJ`&BV)!*4^<%*S.9*C9M3;)D,!AT,LF)D[GLH36,
M->B)":0L9C:C)R;3<C>QXI[.`]>>CL!$9="F&'.:C2Q",:5!^L5,3.*^G.&I
M:T=3C<$T)AS,[\[$GM3"U\5M`SW*&3>Z,(O`*K=`*=-9WY,X2(C7Z=,8%@W"
MH.GRB2XFI'BB!,*\=V!@QHR$8P62TO%NJ9I9ACCP.Y[GC$@F;K"R3E+59O."
MB74FY==>%NS4J,%&EP'TQQT<G!5F_'5U(5,&<XW=*%H;O)@@$+&3;#.@[7?M
MEDV`+P]1%KXF:3+[]0<6S!<2</N'>H;MQNEQEZZ'%2N0E6,.PA*M*%4:PF-+
MQT10.&8B8O6CPL<*OK,6:*CXS&7ZS0)@`'K\$ZRI,A\GT+<D]DCV-QW>Z0H,
MVG8]S#?409.$123Q!$#AVJ(O;(YC[NFOR>"8ED>O9!P7+XFL,6^+VI;>PTE5
M;5ZI4V"J\\DWX4*J);VJG&^PT-SQ]/,08*N7^#)5W^;:VL+H>+KD6"S!%YJ%
MMZB>#:RNM30EJFG$CS=$8&+ON&^6L^_L5CN;*\FTR)>VA/)&88TJB%??R&'X
M014@'+3>G+KA)SYB?4T')@KW8]^P1+(`$%6F0A@^;0(CNFQF`UKA)?90,5-C
M&/,4?=U3@DW&8X/(7&#Z-K7J3ZUC::K>+BX#19,.4P3<!A]=F4#?A3+?WH6_
MJ#>77,-'E<<-^B\]0'CK`6$%UH1EIO9LIC,X=5=-R\+79PK#CS6:35627!?P
MKCSHP<0+;Y/C)YI[^0X0AQ^7GHHPCO*)93YB;'P[K6O@HP1).=SDZZQ)\::B
M0%QF++ZN/4A5WDL1:?Y48S=RTS)T\T6R[%\G2Q&NF59KF,[!%ODQUK5V%\DP
M5_"-YPE3!C\YY/&).2--V*T_+.:NF_'1T5'>;?.E->S[A2V6K#3@90O7(L?Y
M=W)6>!C4<9B'>L)P<P`&Q^'99^%!?*/,A*6?W%D2="&$L-Z5R/V(34VHU1JL
M-:%YS^4%"IKF+U?QF+?0-1RKAO*;,=S.STCOR^A)DAU*X!96NPG)/=-B-;9%
MG?"*E]$$R[>AN)].:ECE'P7S2E?7EI\6;OK@YMI4>T7IF-H4A8]?C:FG3]OE
MC+'$`T4"3!6+.%KA^,K\,G&Z6=6K0:YBZXO,K7)A\+MS&B)1\/+^W,SQU;TU
MLL*V89`>$B7N4$G"$IP>]+S!\NO\'JPF*J%G^>+H,>Z,ZR!B*2+\1</`*V*?
M671X'"H5^EFG"5U-\QBF7'2W7>=YM=KE(.S#]5T12ZT*\2U0XX0H_0#K$H$;
M?RMH]/K`_+M22B:FGQ$ZAGW=9R27Z/EW;P3=P0"<J!U;7N)^K['E=W[DA7/&
MR'6ZI24;ZOB39"?_U'::@[K^8&##D5\^('@DK?W_]KZTN7$<2?O[1.Q_X'J[
MHET1DEK4:?=T=X3KFO%L75.NFMF-C8TW:`FR.4V1:AYV>7_]FP=`@A1U61=I
M(V)Z2I9((`$D$HD\GC1[J(),]PZ$.($_K/;$&)8S++<+EKO`"V:M)?5E9D58
M[X+)W0Q1+8*3*G9'CJ<&2`.+@QFW?&J_7.[1,]O1;,?=,O-7+&;\A/A,"QB(
M0^OZ!I8Y"'\]^8_12(C)I"2N9.GM0EYI^IT7CXDR:9YON;CGFUS_7\D+M!//
M7W/7CS%9,1/V"VU`I5:T3:];:\N)^<G6:'H$"3\\JF>:];3K\\=UW=SA)MMN
M$I:M@V&+`[.%/>@8QC",8>2%88NG(R\6*&3WMVXLGK(Z]J7,6V'TL)V3L).=
MU&FTA^WJ[R7#(T?D$7,(&_Y8>AHWANVAX1'#(TMHZ#:&PQKPR/,UHA%NG`KL
M--I:-7?1J=WH],\JLXU>&MZH$&]TNH8Q#&,8]=WPQ^:'RIE=&28IRHY=FM%*
M_;)UTM(NQAAOO2,=;=EL'(Z?5\066!78<IN06#F1?>!5-HQ79\;;Y=W",)YA
MO$V4D-T:$?>PU(^\U1BFJS#3#<[/Z\5TN[50%@GNU4TAUF+_\LG0NU>/>]79
MMT"*-0XPBW[W&W?]L(Z-2-N->F+O,N[CP`ML>*Z6/&?W]JF6&)XS/'?8^[_A
M.,-Q\[2=]_>I!^]S@2M3='XOR+0X%X\#<5ETY7FIS63ZJ31F,RV8CLB`C-.3
M)@`^#CZH9?U5`5U)T)TIH@%%$G\PSJ%NQ'/XD(3#X7@,D8+#V]U*;0N<LBFB
M\]HD+%_C[3!3RG%%XF68.@M10^S.$K!!QOM(KO\%[S&$4.@&"0*B1<ET)O$(
M"?@$B&&XGL0C>"G$;$-(RCE8G++/"\#-U\0<3\'/+T:C9)IX$KUGXH[<$F![
M!L)\ZX0XVDA[Y0V_\:AZ!\US>]`;GA7PXU=UM6?"-ZN"P"5L!^U^][&C>!U(
M'-$46&>N3J5\(I+5^[:$[#\[Z^=+)!;;WR5IF^'UGP\'9^N1=B4\V'DW#>M&
M^+#M/-Y.8P3N@ZW@($QKD5;YRE_X!=@E%[G'=U/5L#<8YNO(K-?K$<:UV<KT
MNX/MQ@7'@`N,[\"!"9L!CT$4FY\##S8#2.%E%16T=[-7U9NI/-MO#84#%Q\P
M%1-,%8/JH/MWGDD5@U>.!`K]S+BP3@HOOD)\+9F4RMS7JED;IG3*JS,]1P!V
M+$=-G+B^XQ,"?H2%-R4,JKRPXI7$8:Z,5.V`M%X!W$,B=^S"%03!R"\(A3D6
MX4A>>=+W"$4_=/S(D4CYQ5H"$B4Z(XM`7Y'FQ'>2L;N0S%OG#N2T$(CT*F9.
MF*),@N@F;Q;=JYQL6\V@HY$[\V!>I1KD$:%B%F=WY6\^]4AU2+&L0\CC<J<:
M$:Z/F,#9-DXO<*[/%R95G^`=/`9KT_R[*GI0.A!&Q947CO1&53K`M*?LSL>E
M!9)(A"D^YW**J5FX8XZQ+@']@7,010K!>NFD3ZB6`58E$"-!`*`3H!B>>1!.
MV"(A%N+7WH,R3F@O1[=!XHVQ!`)US[?@?TF0<6ULDH#5G*K/G!_$F;$E7<ZL
M<,2%[^.E^(M`-%,$$U6+\Y_IH+2AR`H!<T@H#7C(TQ?B6^NJ95T)N-5G.*9O
MOS,\,?8^=2,L5V&=GER]?7WR$CMF%ZO=D_4PGJM8NN05"F:@WS-P,33HW`BN
MU1GG!,!CQ!=L;[CBI)&>#7H5;A)D5_%AZT.//NX*M)0@\"T9Q_07N/X)6=4$
M[A"L,0.;1,&[3QPWA&;R;+:`/E5@10>9M8IHK]J;RG8C=W36?@&TO]`YFA<E
M"+CDZ95E+Q1,K<U"5\D.C8""!0HMC&H^$``?N`<T&+R=*6K5NR29T/H4C-#J
ME6ZS!%9&WVOPO<0QAY[<8+P:OOGY:#+?(IK6MQ+^?4XG?"[2XBL?.G`,ICCG
M"W8_;B0\[1"7<@<J0"BHLFND22<NI?%[!LHO\:8S.ZRL!T2E?>26P&,'0::G
MJ3[%6/D-'=*Y`0^RQ8N<`6SMD%;=$A6A97U"#03$6?,FP/%=H][;T$D5B.%/
M)*+6EA',4I)L0M=)3)L:=3+&84>!%$1"1V9',P@\C4W>.V&(-Y92NB6>-LY"
M(ZLD4JQA)4?68'AO#V3'.)V.A8CB#6@B=.]8U+"JE:D!5!*]R7#?J(1"\YHJ
MJ2SQ^'MQ)E`E@F,A"!%8D2@#G9:BH=`\Z:=F=D8G!_;\70#'SL0(;VX:;CE,
M%DPV>F[F^`"!R$'E%7<\EZP`18%/IH:$8/'I!'##43)%:/61D*6%-#',IQ%R
M-OU"2TTR%5@19^I?R?A&SL=UD,0EE1PTKF/WDH8EKA6PBDD]0]'NS%#MQ*,.
M2TKP,*,@":D`T<4B+X,59==:K8A7I.V7!MP?D"VBP@%V[9+Y3\[)#19`\].Z
MS62Q;<'V5/.5.W7YYTPQ^^C(J@67P"ENG,0D1^&B(L(;]K5=^E1Y"]?VC1L)
M8HW3DX^7%Y=O3E["GK-@\*H034ES-)M_%8X''>)K?\67=+</#B8"S1P'!#]S
M):](EE)(I49\F\QY=N1I2-I/6A\&]WTHE/`C,K61L[<()EVHNX9\&XN.\1K1
M]<C75!SL2NU;D*UW.!54T89E585.X0.7A2F&09;7'B$Q0JX]^.,N`%')8,C:
MW4R>**\P]*!Y-;H-\.3YQ+]]!H&#J_8A&`L/."C_$'T+]X4DDO+7\4;DZ6$5
M"E3/K+P0+?-2^9R7@OH`-&*Y;HR?[E)L6AL6R]:\M"2IBZ<JB$OMT>`:"W[Q
MT[+B(.UHCV01OP1C<O1WTE[3?G"@V@-8R]%%I1K)E&,$60[T9Q5;<,+Q9NIC
M$28\*H25%2'3S1!*N;]WHEQ)&Q+.#NC+(=]Q7:JO1`INH&FPV?2K=9';,B^6
M%)4[V$F[,=T?6YO](D8><!P=#K0.SU7$O)9%BL+BA'!$B`N,QG>A5&',K$%3
M!XUS@319+#"+H-)+;(@[CFTCK,6Q`L%OJW(OLJN99BQMH7S*J-!_HB)+2\4-
M$!LQK=GXU,Y5?>:4CT"K\Z+_D),%6I^^0P=D6A4EN(:E546S^/A;06$HU#6>
MBH>F-8ZRE@K;F0_+&2@_5$)459E*!1'*!EF&BPMVW6'CJ'!)>2NO)G$8>"W0
M(M+"2@WK!AN"UT&K)W4TE$J[1L2*T13-7JRJ<6$XZU1JVR\M#'C26BPSJ:1L
M5+CYRX9SK%F^RI*W"H-8,8#'4Z;6>WXGW3IH%915O1039<*Y1..AZGV\"J%F
M3*F0(G1L`?X^NZ]=<*FWRDS-\:IR(B.)^ZCTQL4W7ZU`FW;QE(4[BU=@4$V$
MC_%]+$.8&4F$L'E#OR4JY43P!4ZZ!@2;W?`J=\U7<BQQ`Y=-N+7ERA@2K[NY
M*EC8>:'BH+R.X.;0+(RIZDN"D2X8:;WFA*U6>-L@:MQ(*S'(MQ(Y37R\M:SW
M<[.@[+A+XB-5R;REP9*;U0`NK[8W/VF%,H7JS)TO6#=?DR_3Y>"W^=5?$!R8
M":[Y,$$L*89>"#%748+9&3__#/,.^V<TC_I!_/P15`1K\+-UI;>+@\H'M>J%
M7E3L*!U]6IG`S$"EA.X"BJLC.XXM5E\'/EY:,MOF%S?ZO3K3<V#=&&4,;G00
MH9J;;R3@BVN\&Z.U1/=MII9`=:M+J^;"V9Z:5?*JW$B?<=K.HU``"ULAS'P#
M+5/W`AU(J)H`*6.\@>)/K.=)Y6]4I%19M4#$B`=I*\0RRN/"#1PU)Y3.PN="
MKNC;I7?I.IN63G[6_L'2^4JMLV,J/*U9&M7ZH716YVX@^+7,UB^M^5B^!8TI
M&`H9^#ISM=`OO/9A<0^,!%,%6G:H72G@R=[Y"R*AUWY!:BV62<G9]@==?J`[
M?*'TWC1F(B-'E;5\MDRP[F+8*MQ@\9+T;;DDO?DE2>MQECC\\2HE.&Q%%T)Z
M$53-Q+V@?WRJ/Y0$=&NVY,<^':%=V+H7XX"\='J@7!CX\)GM>\_V*G*)(24/
MDENUV;E"]G3"<01B=)S>BZVOP<P=66>==N/QVN([-(#^@PR@'T#M!E4/5R"O
M%:)IU9GR7H4#5[K_T#DW)9%+@CB+*II2.[2;,NLJ;A?\4:J4^&LN^(H<7=KS
MTXR8J"P:C*)U2CR_Y2YBBG7#T]E7SI],ZV"3`9NSY33GCWA'LFM\"Y>?&]`@
M&&&!I,S?'#_!8!(5@H%#@1;C,$"_(ODWV;W'#B+\@*WAD,<NA3K)P"T++V@A
MTB/8USQGY5@9+U,A.7/P;?.WQ!<;[IO.5OL&UR44<,..<(TOR3ZW=-<`+Z*K
M6$CC6X!N"N0CLAV(:929KM"$2%:_4:X/M@$6(O,<2\5IHG<P-82"ONN#0+WW
M1<[@0/X:O%C#B?8CJ;OHKG&EB1$:PWWI*1ME@O[4G*VNC""+`BOIM(PXJ$-0
M'`*RJQ@EM`4T'GT:.VMYMMUZ^2AIZ@LSCQ4[WT543&WAW[[B3Y\==[QE\I&6
MGE-H>"?$;)8Q9/=S^4*+"+J0P22OV=M0I(E_EC\^*LGP[&S8R9.2:W,WA&R6
M--@[^6W0&9RO0]7KI=;X(I'_E#X.3`%%(1I]TG3?QTQ>!P;6R9&YK(M#4+W9
M3/=/?NL6$O+6&L#5K8.19.33)S/?=);$*FZ+8XG&KI?D/!$S#*C!]Z0H1>6)
M/>BG*)NIQ9=S8R>U6HPOT.Y[(SXF>*?Y-'G#C3,9RQ=QB8"P]8EIG_S6ZW7[
M76TF-NN[?I.S5&`5)Z=S;I^UMY^<+PLBZ>8SD_DY8,,WV5.[24*U^\.A7<A'
M7M+;GFG?\-@8=GO#1]#.XK-<:C]*]`'1W8+LX]8>U^5F<FMP\MOPK-T=+.O^
M$^EUNF^V24X*"YWS1:KHX??9LQ\#?[3%H6JW"U)U<?M[IW>SF1V>_';>[VQ*
M^QO-4S(AU5*%K5H2:P&^C%!](,D@PUL_R_HB2[.;LZ8_3?2&9;O4+#7Z"MM4
M31XH[?G8!J6-HZED[6V3D/RD$Y+/GTE"\I46*Z_+AEWG&S_"V+/1SJBGT8G#
M]L(HMOY(G!#$"LK^+/C@5>"$8W)%N*$8Q4%83`+#J'P,;QA;-QQYEB408!"%
M]16#Z"[)NXGFCL^>X[.'WK><FYM0W,C0WO->NP&GK=27@UF65%9\LMOK-FR[
MSYD9[HB#L?`E/!PQ9O[+U;?HY"6Y5:5G5$QG7O`@1)%XMN2HSNZ@07;J8#H>
M1KQ,@B2DI+`LO0T;YR<=2N%4C[)+B)_%'O](R!D\"M>T:QKN7!'4)$."HEP^
MC4K=89;RO%SBC:Q\9CGW9#[5`U4SNUG*&IR1F7BQHYS\XY3ET\!/+0HI-?-+
M>V`NOE#G8M6_FXOM5FD4DJEI\\CLC/D8?0J_QVY<=.9C@'Z:!^;Z<"^-<@DL
M62@4[CW)\4Q+HSQ%`",:W.CWY@1YF'P,R.!H!H5.`QPU"%DWNBW&X^=Z*J0E
M8'HKVF@Y<%YPIJN*(O;'::H([A/YM7)#XGREJ?WEV5#%.1;?18CA\;",,U`F
MFZK#$5IC/4_+4<W&S>M6.AX]T+\0]YNQCD99L=%L-LF67&SCP14>C/#.<3U2
MI^#K?)K?UY!<1P_6_XDP:(Z"9(;I&Q2-P1T`OT^$2X%PW`.%E?)D<Q`;1;RE
M<C.W:7"S7`?Q;8FP1?&V?,T+/2]:]:5+)Q<M:TK*5]H<,I#6",Q'"<Q\+HXN
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M':.V5DV\OM7=\/42JGEZ4H-==R5M]NIUD0Q_`'O<@G7IMP8<$636I%9KLDUX
M8<Z]NSA^\U$^Z,-&$USE8IBXRM[#VL[_#N>.1C*H(%H9`K"/Q-Y=^-K/C^AK
M[W6,R_!9N6L8C'?%>;&S$KZ'7^):\-Z./&)UYT65'&AM)FRK-0B9V5CK,;R5
ML:V$T5WOH7P6(2>/&0EG)-S1N=%(N(J,X8N8.HS$6>=1J#K.F-'PWIW4>TD0
ML8#NR2^-J#:B^NCL>)%FLM1Y4UV"@'!]Q`]AM+HZC^64,/B#)'+\\5,5$GOQ
MV/;62`0XNDM!&B)RN*)./`](6B_+]C-RU/4;[7ZWT>M6QX^[ALOAF3ET?SBB
MA[_3ZM>*-8P,.3R3#%IGYX9'JLLC1Y0?S>KSQ1ZB06JANOT%H23$>LD@SVW'
M5$&J2J2;ZF^@9ZN758%+[%:O5OJ989&#L\@R&@RC&$:I):,\7Y.;<O.;--Z*
M;J/33J\Q[%9'<7MIF*,ZS&&W!K6RE1@6,<>P813#*%6RLJT*A:^\"O>.`2W%
MF'!67:RC2J7;"8-T)R:YW3K$'\OQ!P0#.@2)N]$.[<&PT3OK53;Z81N=T;!=
M5=FN`XKG+@V%!UYIPWQU9KZ]*"J&`PT'/A\.W*V]LTAYKVX:](*XPWQJ\1[T
MZ%YU=C208HV#Y-H3U=W2BVC<4>CB6;O3L#OV'K?TGM=[V[U:T>4];-#2X3G/
M;K?ZW=ISG9%\=95\PU;GK/;L9X1>O81>I]$=[M."L,\EWJ?UN;:ZLZR%15@W
M1G=^7B=(M]$?#!N=G:+CFF.D*BQ8Y6/$[K7.=XF]:W3GRK!=+23?8+<!TT;H
M587[JBSTS@;#FO+<HS`N]X'16)7"F7=Z_5ZJ\KQ1P=Z1%]!G+JDZ0Z2N_==1
MW44!U;5Q1@]<</.P'/#-QXK!@@K@/@;LU,42S%-H'+H:6]?""^YKBWBZL^JB
M&T004G'$W880K@]]>L`HQC4P3C6HGKV34[5HPD.L$7^Q=T2FNB,N*7"\YG*+
MT>$Y:./U6U3#]?F))\/Z:['^QX0PCH))[5G?,%5EF$KA=!(\P_,6JJ9*]A;[
MX*DC/1(\M$'`-ZQX?%9\@Z::=XX;,ESGT^3)YUN5,+7Y7#L>IF@]'N#2Y$AN
M0L)N4)3:W<;9<)?95B:3]LF@T]4C&?^YEBO<!*#NF>V9*DC6;J_;L&T#/F:X
M9+F([=17Q#X#Y?8?I-H:&5O-W5,#^%S#'X8_#J6]KC((5U[:IL`OVPM<DVM>
MU5SS4[O;:?3WFBOSW!%>CHX&L;Z`7T98-<P63Q/&H!;G09EI^1%Y6"8<O*;)
M"';#MGN-GKU/-#"3D7#(J=K*FKV,GD>?%7V3>I`+ELYW5X.8<\PZF`2>%]Q3
M$@%%:D>WP7UDQ4'L>)Q*T+QV(H'>^>E,^!$G*&`2@!\)N&>/O`2#T:D4H\"L
M@3'^,*;\`=2"'3R#HAC^F<(`(\P9"&8BY`P!:_WP=DPN0&^HE:_Z:$+<3;C3
MHV),!MO&E'362,BO9$S)5]IK'WBOO<WOM>4Z847N`292\.CA6<\T'&OUM:FN
M6\0P7M49;T4<6%T9[_GZ1[^(2-"YBZKM6-P)+YBACFP\II6*Y.J>F4`4PQBE
M%K;V8)<`H<9+NG^9>P5W<AA`P[H1O@@=CV2O,YZZOAO%:)2X6Q%C7Q]'EO&?
ME@`-[K2:N(&)-ZRW-HU#>Y]@TL:QNLT18I]M9#1?RS1NO*M/$&QKL--T'^-.
M-3RWSC5C.*PKENJA_:QEGW_Y*8F:-XXS^_F-&R%&6A**3Y/7FLC^(CST4KX.
MHCBBW.]7*-4_.P_DL?P*-+W"SG_[MS]9UB__WFQF^;A6UF1D_0\^:=&C_]ML
M\M.J:WR%WM!>2!M&7RF._(N8_'HR0AMSVV[;<4"?NEW[Y#<Y32N.QG(<N]6F
MR\<XE-<W76[L%:\"'-]F"DCI%&\$5L<>9!8NJ?-X?6>RW=[*FYP*CSB8E>AS
M$I&VT.79#N?J@.S8:RT1'PO/R_J-4Q-2'X2#`H>DV9(A&SS.XO3=T?01".>$
M$3@CBE8A;$WXY,36?9!XB+9HA6(DW#MX9@+[S8K8SH2(FTX4B1B+L,X<=VS%
M@16'CA]-1&@YEN<ZUZZ'.(^NC\_2_O<>^!'$@(3[Q+6([X7PD=#?H:&9$\;N
MR)TY&$PC$4&GV0(3.FC+^JHA>3JSF>?"O%Q<O;;..NV&=7_KCFXS6%!$[@2J
MG:FX#\+?*22'&\0!3+)Y(%.9_L6M*T)T8#SP5,"L!*$;P]SR++G^+`$:DXC#
M@S)TTUB,;GWWCT1$+444S'`T"MUKIJ6L"[YIX=L4ON"AOX2BB;B;!G[D@6'?
M$S>,8&[N`PN.\Q3+%!NXCD1XQX4)$*X4GO4<>#3QLU\:/)ZI\X`+2_3#LLE)
MUJGC_K"'6`^DVGM,4O[4D'**_98GE3M$\IW0+EYY+RB$2@U!12T3P<M]&'/2
MH)3X]\A(EFTUK>6G06&N.G9O`5&EDNP1A/T]"3!TCF1-1/(!,6&%E`,<.N<B
M'Q$J+TF9",6,DBFPY><`>(\M[0WC[IIQ.]8*(+>#\^VG3,+*$R``Z8AAGG#`
M_;$&4T<N=.>$E6'I9?<7P]"[9NAN]23Q-TTWD#Q=.<E:53VZ),(\LE`AAIT>
MW^J(\S]&Y8H?G7,H&ES?\4=N=M:=CIP(U-@_$A=>P;O-2U+I-&&A=#:"SM<:
M!RW2084]"4G'!=42='R'M,F2J/,Y0*Z5N/9/=3'?%9>@.-\C!V9T;KK7GUGK
M7J"Z#AIYY$Y<OG`Q]T2;QOWOS5JSJ3EK%\D"YU5)%L`J=,\PXMEN[QJ1LMNK
M:23J`KO2?'JI]0VKD2P_RBOB_ZYLM/0N0J.74O18N?*D:MX;^;B#P'P#V*M;
M;3ZG%]S-M(1J#>:"+^<?M,MYG8=SF5K++DA]-6>3$1A'9\HK(`WN.B.LY5;G
MS?6)C'RU'D%FY*GS,"[)0&5DFY%M1V?%IR+;<@;@.@_DB<N&"F9(Y$C:;2*S
MN;B;B_L.SJIG>C:=DKLQFR3[Y9,5BX8-Z\.&'<.&A@V/SX9=PX:&#8\`38:I
ME4^3\W90`KJW!N+<X1`6-G`CD+5]+F)CK6UY0,22-?:??OO:-SE5PQ$Q:V36
MR*R16:/GL$9[`:4[UO&]&;K%A\`7#RK9;)+XXX@,6_CZ\F!O;GN(['(G0O*S
MJU'1>.)@)N\:TM2";Z43;O#NJ@)KUF\W^IUN]?>HX8W#\T8-BH(9MC!L8=BB
M$FQ1EY-D#U6PZZ'K?6M=M:R;`-0UG[`#(DR)XDP>H_,=?*=N2<).MNQYX_R\
M!D65#8\<D4?,:6_XP_"'X8\G?L;L%_:V&'M6?67Q71`*(,42WT>WCG\CK&!&
M-=RV5^4,:/4>2-S)5JU]N*CAP)ISX'EG8%BO6NOZ7%AOEWJL83S#>,]`YNVS
MUE"O`AHSPRVMJS&O$<VX[4083/Y-2=M-'0CT;-05E-^P75W9;K\'@^$YPW.'
MU8(-QQF.*SE<[4:O=U93MEO?:KPZ@&#'3H>2!&7C!#F6$Z1.T="&40RC&$8Q
MC&(8Q3!*-9SP=0S-W#:+]GV&L[XBE=9L+;.UC`PVC&(8Q3"*813#*)5CE/V&
M5E;!4;Q9:.5K>`Y&@"DX]TX8(ERJ5E5G+65/UN@U5NZZ6+GK[U<Q+&=8SK"<
M8;EEM'7LAOT$`F4,WQF^.XH/^;@%1$WIPE4.](/$5I<8B5<*"5.Z<*/2A?.5
M2$WU0E.]L!9A]D9$;BLB3<$>M9"F>F%UAV.J%QZ;,",PGFR%+U.]L"+#>.(5
MRHQLJP\K/A799JH7&MFPTSNYJ5%HKN>'/9&>Z0ED:A0>GS##AJ9&H6'#*K*A
MJ5%HV-#4*-SE`IL:A<O7]?@![:9NUR-%IUDCLT9FC<P:/9TU,C4*38W"YUI9
MJC-L='8:WFLR(I\,;YCR(X8M#%L8MGA:)\D^D;5-+9JC>=L?:4.MP$70E&/8
MK50WC%=5QK,;G?8^4PD-\QGF,U+/,%ZU&*_.4N_IXPN90C3YG?!L<0YV?7TU
M)1H,VQW_<#!<9[CN*>)7&8ZK%\=USAJ]3J^F;+>NR7AU1(`I1%.9^)MGC1MK
M&,4PBF$4PRB&40RC5,/_7L]H2U.*QFRN*FTNPRB&40RC&$8QC&(8I1IZW4[B
M*JO@*#:%:(R-^ZE[50S+&98S+&=8;AEMW>&Y83K#=(;I-E:+=UF")M_=:AC2
M?R51[$X>-D8`^DJC_PBC_U*B$_?ZF^C$F`J>T9U^NO1'7C(68T3)'SG1K>7X
M8_X@_DA<6%0L+5*5&>-PT2VFK+W)C'V]%=8$:ZW<4:V58&+%^,V"G"TLO_+!
M"4>WJO9*AZ9ROB++O1-98Q&+<`KW\[&58($6*Q3.&.BW-(A;B0O@$EJL-0'^
MMQPJ!0"/_<$%#J:R)D!P'3O4&#UUYX1ND$1`K1N.8;N%\8,U=F+'FH7!G0NR
M(VI9,+9(R+8;5I0`V4!6-`MB*W1BT<!APM5I3'_10.X"SXGQ!O5@W3IWPKH6
MPH=QA$"0['?Q&+#WAC45`F]E-(NC$"ZFH>M@/Q8!HED=9,$X/^>WK@AQ3A]:
MV[.@MW'=J.HRX6CI!;?(8NMR)K,BMO\*#Y7FU>@V\*"Y#\%8>`WK_M:%-D*4
M"Z&(%&,JWL'7Q/>9&"%C8M>*5DD@L)G&0DA`Z$:_-R>A0#Z$%T3$O)=G3LL)
M!?1Q_2_!93#P11@WL(4'K":)L2(WP[AV?,=[B-R('OU7,K[!ZDA6',",`)L%
MLY9U49R/!A'Z.IC.'/_!XGT-$A%Z3T>DTQY%R90VO>+8DNF2&Q;D!/#0%#<1
M3(?6R+430:O0Q*T;Q4%(!3'@`QSE,ZQ:HC_*^XF?_J]/'RY^C*P$>#'T'G"Y
M^"48GJ._D_::]H-T:@^XTYGGJIVKELAR86CPY?4#=83#"P6BUR%1=]@<\/Q(
M\(3"&Q$*))!],*5RJS>Y/ZTC$B`%A@1JKV$IK2G(4FA:C%Q:[S',`LP%R82"
M((#I&278)HQ$\I5<KA^CE/P="(FG<TZM(2(4DXRUG3\)/"^XIR.)3[>)QN]K
M'W)S[M2ZE/D;5*7,7W>PK2I<5Y!L4[:!P:'4-MN,^ZLU")00R\WM%4G$>PS3
MFMU4'T;,G5`UWU'VT]Q1>PE-PV.T.J%I"];T[?PE8P<^2A,4L(^@@%Z[,L$`
M+PQC["=28S>YI>U.RWYA->&K;JLZR%Q%IMEEX$B=9.Z7<N.3D;LUV5[M5I\V
M5ZO=K^S>,AQSS).ZW=IEQNM!I.YSTG71&%PO:9NGYQ&7[`TNT7(''.#JN>B>
MV1J">.VUSJT'X83[JE9YY%B32C#/DV"6<V"6;LNN([-4)$:D1#(?P8V4>G_8
M>2(C!B++L:)D"B\^H$.(':11B;]^SC7'KOVN-7%]QQ^YCI=S0BE'7WR+BO@4
M"+V-+.%C.$K!RW1*?05)Y/CCZ&7]W$ME=D7)SV=;N9S6HG1[=]3@K$JZQ?KF
MTFTR`8Q]OSYF\;RX,`;RM2\-U=K8"U;WE>/!Z2$P^D`Y<K)94C$':UTFGED:
MW1$K$NPV:+@&:7-UVE"7/IQ_H(SE5;=B&!CH7"Q75\O4Y[F]JF#F&C2ZY]7Q
M29G#:][3($:>$T44GJKB%Y<$YSU@="2&M<*G9!9@H+D(*4!2VZ%F,U9S,YY6
MQ^3\<H]'77UNB@OVY$=*K!B%PJ'`X\(YN")TEG9E*/!QVM#;;T93/F`/).[&
MB]]K=/O#RMXA#WGF+LO;J\6FUVZ1FY@+MIT;D[1ZE*35CMVP:UM28$\^B<V-
MWE7);_'U`QN.Z!_L7JMG05>>EH:5Y;,\*ATF%*/@Q@=ZQIC/YEA>$*4^#NVX
M7T-#0#5:ZQ@F#9.BX!,=4T1A%,,_F$@5X8/!3(0.9]BL[1-9F>VT6.Z66FOG
M%VC!>M24C=ZM.;%V/AM0YPIBP['0V+"S4RXDMKMQ7/_@;#?'3&6??_DIB9HW
MCC/[^1V,[!\XL#=N-()]DH0B^@I+^PJ7\+=_^Y-E_?+OS>8;,1%A"+W",(2?
MB&:3?U*M7,H-_4;.Z*6OWOC"+]"`H=DO8O+KR0B9OFVW[3B@3]VN?6(EOLN_
M?FNW.R>X-C#W7O3K2;-[\MO96:_=;F=4K^QOCY3;*>7V&I0W!W9_\$C:/\'R
MAYBT)^*H2#?]=D$_?0S\40+O`P_-S_)J"CN=P5F.P-*F=TB4;7=6$66YXU]/
M+H&_F_894#CH=C:AD/>"?V-AB!+LG'DZU1/J@2W9L]/K=(9Y"HL][)2ZS5@0
M:+,'ZU)'JZN)HM7[A5Y)6]20>+><U&9WN&+?+.SY,,/94!"<M[<>#KP33(5U
M^A[TF9><\,UN\03YZ5.F>EP+!+>PWK+Q\8.(;X.Q=>G?P8E&1T;#DDU]=;X+
M^.OM]SAT0+%W?0P,P8T'7^+6@M;#``Y%:/Y21E>73"&TA"2]`X(R>C)R7A$U
M_!QU^,'U@Q`H4TU>^.-\*TPXTZV1O35'M7N=?G$5#D6\6<5%J[CIB4JGP9$7
M$91*4#P9LZ&!T"Q2/<3PIC',M1-&%G1O1;=.*%X69YO?OL*7/SOAI_`*E;DQ
MZ6&?17B%[ZQSEG?UN;G\^.[DMW:KW1[VLZE9HZ,C#JE$$]CMD.BIV\!#J)P?
MU4:ZB./0O4XXZBL.+&@%EK8X'OU5^>)CM"O[O'>65Z_F&SX0N9OI7>=`>Q]W
MY)JT9Z)(*3;6Z2OABXD;S_%*NA'ED_*Y+<7[G$28ZV"OQ&XFQ>RR<V@QP>\D
M5M5KTG5'#];7#+3%^@O>,_DX:5C??%`G/+SE%@<BVU!-:"U@`_AZ]N[VNEM>
MX]RD[^H,>L.#R1[8Y]N/^G.HKJQ2$O\`$K"?R>.&93>@%_R/17%D.0D<4V'9
M\-/&:.?^@Q%X'B'&M$&5-'D\VC>2:9WVV@-Y'_@W3<*^>B.N8^M_T"1BD4WD
M?XMDXJ-?X4E\,+6<K-P_OTD;6PW,;8>V2/))QWZ&-!)[?>`?.+&V"L-6;H0X
MF)4XUF3:1Z'+LQW.U=;+N'ZL[;"U.+EAL>NL?N.DW?PUW<T(=,66@7><S.#?
M+(O#J;@+IUJ3>]1YX5'@`S];;@R_CG8\5PN*%ZP_61^#.R>,7>@AF$]1?RYN
MP$N,1GVPX!;?SWMHQ'<Q2F+RST3P"?4(/T#4TIM0,%;AO1O?6NDDGL++H![>
MNB$HA*^#<!;P??^E@KB$9\8)0TW.G`<Z5S!&*/$\_/=OB2_03]1O@0()APWB
MK$:%'O,$PJ$4!O>HWHBIVW1\/R'P2KB531+H(YGAQV'_Q7SZ%*@Z@GQ32(O$
MKZ01$4HO7&DQ-!`U0781C8(HEN"0A%XYPOOWM1R>11ZCFY(9:2#U%';X?22`
MS!_Z;=VIY=S`L&X(_3%T0>[-',]RID'BQZW4,*00)HM/J"%Y@0,-C49A(@A$
M,'*_-\D%9[V_?/7IBS7SDLCJO%`K0.B$?\`T(56=UEG[Q7S41H,F`:9>K5%^
M=M5*Y?`)@1KA0!N8ID@XH/GI%IX@/9N73VLO`XF`SJ0Y"@:$();C,0-:XAM!
M$D<Q=(@FL^),-)`BSQ4)02HRQ+)LK(&./P\$HL)173SCUC@0Q&PE:T7`J2G3
MW4);4V<LF#W5R,B]['AE`XIO80DF."_O8;$4&R$YA=U$B*QRHUT_%*8P;5=Z
M,/,L6&`[E\"G<;:0XI02VBLPI2ZM3RB(DN.YNVN7R3F';UL.TME8PK/7,E8J
M623A:(MB%(;&?I^3,$H<!MLE3SL<[Y&2`+KTH6"+*`Z344Q<!+P"3,'4@7P_
MRXO/>VB?6'[J_"Z(4U"K1WY"0DFVHBZF,6PJZI'FEO4F$8JDM%-%UEHG!DY?
MY.)\$#]:U#)LYC\25X%PR[@-%\&X@0V<5(RDC\]"O,0CSN^4;?(H<!5,;S%4
MP&6!P)?),6A(=8KV8!KVKE9MJX)>B?#.!8Y!<5>CV:V(+I:*$[11T.$V"GQ?
MGC*T?>C<=T=D)V5]):>-I'N-\DE)"L".H#?ERBQ4\UB;R&_6]!W6(&3F^I@/
M/'AZ?$<"#787ZULLUL^Z@]Z?[7[^"*7F4;ZARO=`2AH+J;\YH`R$#U)ZIH.$
MOO`L)A?5G0@9Y#ZPG!G\\)WV-[3R@WW>*NL'=KIVF.(7V@DJX;[Q*P]/<%1%
MH-&90$Q_6I2(>@(!>2/N@M_=_TNFSK6"TB9WX'T0>N-[F(H&J@SRN!U!`V@)
ME4W(L_I;ZZI%*_4W!V9<4^[<*`7@9CAYQYH`\3'#1.LHXX[U-@D#?K/YRO%_
MMSY-)K2Z7_"YTY.WW[Z@PG?RDH4J`[LS?/G(F?&\Y!"YTH`X5^:L99J+"%T0
MH[A0W5:G\Z+L9=2"J%(!:M+43[=UUGV1-IKIH;(U<JS^+?%XD3%8+$AN;O65
MY].TV^KW5C:COY2V)-ONY.>W5(G]LW4+NM"=V@D%MD_!&8C%X91`NR1,$+#X
MO'8'QRL^),F+9F+D3ESF:M8X9:MX6H8*##QMDE]K2`U^G+5/9_,F:G`Z9;,$
M+EX<19>VIJ.\J^=\M*%F\UM8_9;U247*R:'RM<B7*/5C*F:!^R/Q9PZ<UKAV
M<Z.(;AT>!CT"HU!'`SY-9[@SB7$5\#'U-OXF&YUOJ'A_=/BJ(>`K=0<I\HPF
M$T!D)%QB`3EEH+$!T8$7W70!Y8K"/..$!82TX7$+;OR@,8X;2=Q]G"H@^M1]
MB63)H8*4X4(F#1)#LQE7%V!9Z>0*+$"/B`'@2'1X$,T@U6#T`48?AE88/#A>
M7%3GH5$UJ9F>EET;%IT-.(>G+E#*"/6K"$EFL/'P0K6<HD)\IW#OA*JPXC_D
MZJ;DZ8*V]$LX/N(+KE>0">.\(,X)UI_@09:M&DS[I9_JL]IJ70MT[0$+`#./
M73Y"BDQ%B4A*E(]`+0@(H07C`3F^$_:ODWAQ2<6+G=P(TG/RATX[NP=0TWC:
MI9&Q#92^,R&+US2T:@-T6,"<?;NRWE"L`)P0WZ[>P.F0EM?A`C2QW#-8;&1,
M14+6#>?EH9;']8;X=))Y\N9J^V`(N*"I_*'=&A1&F'U1'&`H^*24\C`4S:EP
M,$B6V$8SB3SKLC;$/K<4\TQAR>/"V>V!X,`U=G@3R7M67M\8X6J&M!L\LEK<
M"H^$3>0"S<!/](#O8J"3JE\S0UT`=XAVC>2KEUPOR2)Y>TK*+\3Z<Z_2,&#V
M1G3(R88F#E9RT0/`^0B7!B'@:K32Y>]^/YRUSO-J8LG=4'6DV\OF:DIE]`A9
MT@N4MGO8*E3-1YL'.NI=TM-\4K&N17R/2A/?F!T%U\<785R`2!\/&^*TY8E:
MUBN][(P31<'(S15O8=&A%.B%=LH%6Y:DU&0B-;K<C%@T$_GH[77OSIMLC/V9
MCRJU/=-I19Z?!G"W^3\2F>H$%\`U7)@IW;O2ND$*9ZXHU`0>:Z+E%6Z%$Y$7
M@R65Z4HWGQ_X36+EM#LA(W%81G>+V1B;'`_0'IR6N'5(%R#6Y3'/\ZZ:F`W/
M5DP@&0&#DW(U+QG8J`:WF<)1T\FNCOFS9H-S<,%>@EY7G8!R;C.BUC[?<ML2
MOG]<!M-^]F5]#\[4KR0\5Z#J"F=D;/$:YCCU6@:=R6M,*HC%>$Y&TAT_2R^2
MDIO6$)85%$QD6%TS3/=WMJTI8MAA*X5>`8ZVN'69<VY9]V@9!08"K74FK[)4
MS@PO"9J:N>1PR(:E?8>W'#H&<90-J3CP78@4Q_QV"Q+4%@3>Z82'8;_R7@<7
M9=SW/).2M\?I=/)K:)&FVQ1O'1`$D=P-"]<A-\=D,\,K1"-SGL$L1/*]24)F
M:CD?47[WNEFV8OZNKBWH1@*8%(TRGMA(Z#?2)9D3,SG9##TK$9(*=-7GF,T/
MUX'4#=87X'43)VN:R5?GR._73/X7KK9HO44#9.B.K-?.#`G57><617)L8$BO
MRAI40:07C.F%>VK..CYG^L98!NL$)]ZZ4%_"[9DTZ[46[O3D+V]?OSYYV9#[
MF^\3^!WW0H<\.]Y8IK,MR2>;^F(W-:5H9R8!)C-E$J`06J42DZ??KEY:[]^_
M!M$!?0=H;P_N\0X3)=<1'`D2<E:;$18R"AIIE.B"-C\1#1Z'M-_C[RD%+/#2
M/U'2W20.9M2*.:\VQQG@/>D^L`**`,O&FY))5TP:TB7*-GCE/5Q!U8%"/WP5
MHUL_\(*;!^M]/"Y5>B^D-P"/*VD!A<M?YE+4O9S%P>;FJ#"Y&Q'&MI8;FHTT
MJH:*AJ;&5\W3ZZB9@UYGGAC?L)$J?2EC5N`:G"[0(/"6"2N-QE)>.1BD^.Y&
M,<<"C-G.V71&5-YU+!-'=0\&OU/N&.&GK=.L-"T:FNG$D:Z9O/%1M]A1YT`?
MPCPDGAM-L=EQ,HJCEWE[@,L9I&/RSA)B'IG'.`0'S9$%[T_^:E+F*\NX$8D@
MR[KT>.OF!F7F3L-CLKBAK`'>;^_(%/Q9OO!."-AW@3^O$S70L$F3!;J!AR9:
MTI1D,$INDTAS-WG&E-(P/WRD?ZYSBANY%K3"J5*AS/&"M+6\%0TC0.9N>4JI
MT?7+C,+,LKA01WG&16(U!I.16.G<L$_/_2YDQ6^865"HAO8+RMU"?]2T9?V3
MUU`67::3@=PN2R._LD[S+BCXN=<A<`*2X;!0S-&DZ5'\%@@*STNQ"K3V2UPX
M#>7VH:M)YJGMZ;%BF2=';8.)&[+;"11+!]G^(7//)`B31+*&2%IHH\@&J-PV
M,BYM40QA("/3NNT&QQ$:G>E1[)P__^AF!??42/.$I#9.>7:27&7@#%>N4_:P
M,P%N@"545<9]5&WPCQ$PKL\5S+.`-8I?<KG\=6KGS``<Z71`/SQ(1S'V100O
MWTC`#A!D#9;LKIZ5BU,G':+I<8?<S9J?7FZ;CPRDUW/)&$L[8HK.Q?00Q7,G
M1%MN>OP2^<S;(X0OT7SO=Z"^!$E$,84SB0=2PNUSGJK5*S#GBV);!=J98]@2
MI)\!`2,GB3BT2X8G2N&A3^!"S8?=FI2:M\1;QJ?5/#V\I-PY_:K_R%TZ);.)
MA"K7&^N$.JTMZ]N,C'=S339*CGI^?QTEC[2"1NI-5D&=T#S.9`.FP0DSH2X]
MFE*;8JOYB'$O1CPWX\S7SX:)#&NFA'8^)>A\2+4/LB#`B#FXMM_"2-UKV#"Z
M[T"=*"EATF0Y=4`_2J;2Q8>5)UCW]IQ[(Q.W,PU.X22["SPXAV%KPV:890>U
MIL_Q@01LD\1DSDH-4JP%9TWP'4CQ.]`)"F(0JF;YC*:P8#V>)_L1/T[=A!2V
M[HNT;@@=OF2/RGF3.ND3H!H$T"\]@@2`.I*/QL"2(#>W"P@J4;-)H"+'DTQ5
MXZ%;182B7H:K*6&MATJEQP'?<2)D8KX#Z$_EC)5-9>3*B;$TG/4Z-U^D?\]/
MV4K7"#7G>)$,[<A4,[7>\XIXR<3D%QN&5C:E>XDCF!=QZ`,YUZY+[`+1(PQR
M'A`C*79@<9H50K?S9J:B\9G0X>%).K[1>W0#6H=($WBQM=$MZA@*KUKYJ8OG
M?OJ@C#/2;4H@$SJ#;L/NGQ6ZX`Q@^)EL%R,-?X(.*`TQ&[ANI)U5<`FW>QD8
M!6D$&I$DP70-0K;#`5SJ2@XW41?#Q[4IE(K\(&\@P`-MQ&ZRVWQ*AXP6E4*/
MYB(3RKKO/:-,FM7ILITI"ED<!)M#V,1QIX<,E&MR96$%8@[_7ZUP:70!OO`*
M83R;5Z/;`%0`ZP,&%O`<I"T58AMT)Z+T8;`3LBQZHCA8>:TJFA!*30+>NM8`
MY99*#2*R`6G6R'F&'BLW:?NH,$7E2\L\H[J+.?5(:;"#&DO63=C5Q,61!N)*
M'(WJ1&5U!X<]%PKF-A6$JT(W64$CH>"IVTLNV8:UP-O@'@491AO5O7#;3HJT
M;8DFK6.$]P?;0@U;:X,V5ZC2V6#7E<XZG9I6.OM*_O`/[`]_F_>'+T=CJ`AF
M_<9\D(.Q-UMIVZVTN.3L4R\2^'1+`QK&JSKCK2A/6%?&VT8V:V*X.K5#'G%I
M$.67AK6VYP'+<&U6<WSOY%2M0)U9H^JOT5Z*"%9+_JS`*O!*0BQ-\;^C%KKM
MVX/J[QS#&(=GC%YOE^6GZE,!N18"E3U0*J#9B-1JUE/MV;NLO6ADZ]/CD&;U
M^>/Y:JTYUY"1L=7<0>?GU=]"AD&.R"!GU2EJ?A`U=I7/J/)BEU#*MQ>WIBIY
M9:N2MROK0=B)'#><5U7.VZ6IZY"KO%L=?%DI\&J=$!O$E02Q#JZYEE-KV[DZ
M\D995'_^L';'C4C;S?'1:._4-'G@)39<5TNNZW?KRG-[*N6SFS3RU;$M^XV=
M7E42Z1`1OC4),[_X^B'+<SK&/%4A]^B3;[T3UZ&6G;\4\,:7.6>(+7FI4":N
M',PWN2B@X!!@=VZ.$=:&TC0^C#ZZF)K7L-Z+>S=B\'?\S_J'Y_R.$"G6*8@@
MZW<?(]>=R/KP_A_:0Z^#%L.HG,#W1:P<-Z9LRTAXGI:;Q.5WM-0DAA2$>:3T
M%OI7(H(C\=!N(ZO^(C2<[`!Q.1E1!4:=EJV@CAIS0#P2>R%?ST<"&5)J#69?
MR](U<$<8EX(Q<[*5!`BB'-ZIQ(1[%X13ZZK9M4[?N1[6V6A9W6ZW:0\[]OGP
MI36!+\<9H,G5V]?TDEIN6Z8'9OGJG+S$\<MV6W$#HR-HSRHTAZY"<\A03Z<!
MPL4*#/O#G&\Q\AQDGBSA1V+Y2%I42_900A#22J?KETTM@_$_*#3+&28_Q7&:
MGPP]P:2,):(VS.>)S,EF&-037C:72_J,Q802IV"QOB0P;3V[K];QBE%R$(W@
M8A3K``,XBT&">`'0L5P*8GLJZC-V8<PX8L3>@G8^7ER]N?B[]1<ON`8MGO<+
MX<I13CV)Z!0:`%:682WTPB5Y,&Z-;QE5G)YA=G74BPAA$&832#FHQ5G$C.+0
MO>-\.E_<!#'##^IP!@T]#39/":.:$Y0.:`8MZYW"Y<1B+#,=^6E^\Z<$+X/!
MI#W@0,<Q`^</&_UAI]'M#+6MG)L.#?XZPP(@`/YT#]Z$B)FII_EAG1P-+#I;
MY$ZC<]9O=(?]1=T1?;E\Z3^`?V/.MJ<$W)5]=[-4VI;U50Y4,J>\Y449FI$&
M[<GLE@F(DBDFH9:M!;Q4G&R">?RAK8.!9\.'[VT-%4F2L&RX1T#OJ8ER0;7H
M[D,44CX7W5!86A<H:150!E4ZYUK<UA?&K/_LK8;M>\+:"'/L>9ET0/!P3\0*
M)5>;X!E<DMQ1MI&0/<\;@\%YP^[WEJ@!#85>Q#V0H%>YLGH^-%8NN'6\"1>+
MH_;F9`/N?(8JHI_5N^,&XW042>1D:))&K6XGEP9-0J$@.E((Y+0!VLH%6+/N
M>9;1B_`CB!\,YQT"IE'Y"#5G>L9KE%8O=*,HQ>51I;#&)=*)Q#.Q<[[W3A$J
MO9AOG@(`<?(M+C[EF3.NW%R^.6>AV[W&6;<'!\&B0Z"Q,E/\UD$0(0UPE2*-
M&%6CF)[.*S(<:"NRAPWTU"$-],Q[JBD@U4O<@)$F\V2=#D<'#Y*%=%@Y=N,,
MH8/*H#`PP0,N3\0U0`C%X`'A*M,R'1G*+];C)`A+>6:]H*QPW!:(LH)0.1:5
M-.BU7R@!H0-EY':X5F%*UX/4>]>!$Q*0&FN#01@U4JQ*_HUF@M["2C%20(1X
MW&?'(%T_2`:2/E$4&S1"_I`?7K3]^"CMGU'7,QQ(1*!Q$2LDUF#<%3EZX92+
M[.T&PZ<P7;?N3&GO#*JBQITM;`QL<"/5FA1U.45DF.<19`Q.S;\AI#J4NI*A
M\N_DQ(PL+9-BE?*NI\;\1-4CS4T(PK?<(1H=-`4RA*LX2'4[@VJX#Z1%B]&=
M=6FR$.V!^.''*.,AFEC"8+@A+O(]+OOCBMQ)5&`6GN;YQ9CS$Y1\_N6G)&K>
M.,[L9RS^C(@76/KY*\B,5R@;?ONW/UG6+__>;+[.,'1@\BXT<.\W<()X`8)Q
M6_^#[UGTXO\VF_RN:C[7@/9^]GK:*<%>P1]?Q.37DQ%N@+;=MN.`/G6[]LEO
M4N[50`1NYG`JM1MN=$IP'CT;DM,4^O53ZNWV5CGUJ:DX#F8E_CLB>*[+LQW.
MU0%U^_ZRG;;0-U*_<;XG^"U@EX:5%P)XJK&A6=O.<Z;F;4WVF]O9#U`%9N7%
MDZO+5Z".:I/KG'W&LV$<P''D6>]@L49PRE0(4>7@]\NBR3%_Q71\'^Y$([+2
MLO9YZXRM%/A:X<K1S&H%/ZD^Q22`FP]C-<;N[0."7^/VN1,I9C7?XN0"\14I
M>U$B7T;6Q>NWGSY*#AWV_FR=SK0E%.%U@KA/+Q&AG<$CT>[(2@E0""]#2[?N
MM0L*J,+918@*0A-NCA'2%'2<:ZS(P8#S[]Z\/GFI2$1C]-@=$XSI/55+=O!B
M.V7(7R1!$+223E*./IIWI(^K:V!'R@;M^&SY=!3T$RAT8Q?H/XU>2HV1-%`L
M.XGHA%CRQA<>\X2:KW2AHBA!BR_A#(>H!BO,)FJ>;;AX)2_.9KYN+!KL$.E2
M(5.1(10M_/I*D>53W!$FJX0D+-?L+GT+S769B7V>P;AL*JZ4\,.``97);6!]
M)DM#%Y5AT`>1]+)YE<9Z+QB[,_SS6D0/'H&&9T8Z6-'Y]>3IH\8;EN_@W'V^
M^/I7ZQ2W+.X?M6?+0W7GD]`_T[[''_$OC=3'-GB1:S`;HK*(/[;=K[EV0^'$
MJB[28UO\:Z[%=*<'/O"Q&V457M#G0ZM<L)2<V0,++U1TL:"]<:LU@J^E^&YL
MO7<F(F;03S'!:INC%!@-U_H.K@4(%^QR,01M*?"6FDVDXP6^T(K!P5T#R[LB
M.AH%&K$#@+HGCG(G^6LI<^8-U;%``3$+(I>V,M_ZT/\5%\=_S2/`^TS66#H(
M;M$70I:K90L?^6.SAY6C9`1K0@7;@3HG^UU!`>JWHAF*U3SQ47(M#5P23I=N
M5UR667DZWKVYL&!O_Y[:MN[D3J2K6<F6^HR78WPFX>NT8E7:63PX](JEU:^S
MLJM_9AN%1-\$BJ(X&3^D-K8&0;'+@<-23ADWEBZH".FO%J%8'./'*"W[1#66
MR9`0A#>.+\4C&\L**T1E!!BX#SVAJ:T1Z)ZXRWLKBE?R4CS;.IJ7Y:4D`GB.
M8%\70'AR*62T.Z9UY=)2[1,A]!+(:1T]+(J;]\:TBX"74<"HCGD06B<MP`N]
ME"Z?!BS-6A`H.2X%`:0`E_R<A]5W51E*_R:MV@N#&#?QXN"A:_3&E0C$^&V,
M8)I:I>"0]M'E)+6+%?0Q'`39B>9(9Q(T,5BBPLC96MSQ5_FN:I<&C37@,Q=H
MR.;SS/B5XG#3MG!')+5$[*J:Q.XDA2!?4B=>+]V07SCTWBX`#\Z4E;2B<O1S
MK@AR]GUJ2R?7WIG&6J>D/"F5)PWTD):KB(V$LSR6?E;Q!*8K>IE&0$1ZCZG-
M/F?)_\'N9W[%`NK])`\P7[Z,)7Q=,D<$X:\4]/D*+1&NRQ)64=9!/`-2V8\V
MU!1F&TX?A$?/LSZL(EHP0QQ2<2%9;&)E'567'9&24:ZCI0:'CC.MKY[RQ.0U
MVNQ00'J4)"!C<EH3:L8G$?2%9U&N43FWRW3#S>R%&QCT4BOB&W3]R*JS#0O^
M\D2*(GNA0:X6C8?Z>^E;%_Y8?V>EU=!*0.NF7[^UVYT3C$N!$]6+?CUI=D]^
MLSN#?KO=SL:W3I_'&9B=#LQ>9V#=WN#Q`_M(Y5.0>S[-1"@K(2RS\_(+GR;:
MXT_)G%O',D/&!OU4;=#V,[%!OQ'1*'33V+)7""(NHIW;FI_JA80P^?,%)O&K
M$U7SY43J*B=D3WPC/.<>59I1]D9#6?&BHID3S4[-B)3I]&H.JL5-Z*C2].H"
MJIGDR+9!N@DH@CXH661`0'79F8DD!FT:K:?7P1@?I@L4ZDAI1*GG)#XJ6IJ6
M9`7I>:.[HVGDDV"4*(TV&J&]Q9U`%]G-V*>Z`%C*`+Z>@EKDR4%SP`JY5E$9
MQH'C6:NLBBB01AX6AE)7D#+ZJ5"4H-O4/48TD*:$S]\F4Z[&+4`)+J\)0/2[
MJ7I(55)BU#N=<:K`Z9423R_?-VTL5^"DXZ"`,R+F0=8@?0]$O6?5+7`QE$8I
MDZ<G\A/6`DTC2V\X?E59)N7B<I$D_R9@VT003)KP/SCJ,>Z0[!@N7[WX%H1T
M-65LSC@;,RW0C^7+0BK^K:-,+C)F^K\^B-B"71.C05JMD#23R%5`0[>V+*CM
M*,[,ED4/>;SBHDW`@I=^E'@8$BQP&+#$'W@6@U`6]!Y1P`''?^/RTR4!M?[T
MFAGKMD48+RS&@L6]Q(LB!7+B_9*N%Q'(#)P%K/K!L04<S9GG7`K:NA-:>=/,
MH%RZ)>;LW7J8NZ<<?$@P^32T-C+W1F8&7\\UD:M.-.\J`6)!>,'DQ6R#R@D5
M+GHXYZ98Z)[0"9CS."SP-V@;<^2$8Q>D4#2"M0X5=[8*V_#6*822*!%6O*]Q
MI"`+A$B444U[1]ZMES:$8244QS/?2(.NS,K62!/,_I\-[W'S"GNJ_%^,9&R@
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M9;2H9_B1M0G!3\UV-Z6EM)F4D+<<\OI/N$TW.4GN"LZM``\^S,H3H4X1/XS/
M_B<^JI[D!U=3]C%@BI8V4Z3L'VD1)LQ,"Z-Y>M(G^(%-Z2B\7NQ?<<X7@=H%
M:7HQG'8E=,@GTP?YN=7D_+>(='K*FRF21<1:KV$I;X+P89X8^EW]O)J&"ZT:
M%KVJ4Y1KJTC(%YE3"%/TT9F*>4JR!_#WU:2D%TV=A'PC<VLDT%'I@>0;B^_6
M?XJ2^9"/T!/PP&HR4)8-S^WS]EEN<?+-S!'",;]7G$QPQ4D&G[(HZ1*ZZ`UZ
M@1__E(NI+A+9;_?R4MC6I7`;#NRS]EGW_*R=(WI)'_,221>1[_#66R:3,LE&
MCZPGE?+RJ-#$0D*DA%Q!"C^U)C%_M\M(T9J8)^;KPZQ4../WJSNTV\V_Y[O$
M]])>/F-%.7><Y<5DNI,,S)*5HQ4%WX.I\[-\2QZJT84_IA-7RH\+>N%12E]W
M,.S12;YV-\<8R68*89=8\/R1PWHO7>A\N=(#6"="Y,<B'X7V<LZM=_#<MMZE
MMJTMRY)^]DWV9FIA_ZPSW(SL;S[<J#TJD7B#%W\/\]<P"D(F@>4(SQ[^"SS[
M'A[]Y/]39=YM-^%-N]?M:[0OZ^H`Q&\V[9WN>7M#TE,8!@H/^X[*1^)&M\H.
M)4=0=IVC/M3KL+9O<R]_FLBNM)O7EDLSZ)X-LM%MU',UAKO98FXY4(7]=3'&
MT+'/:<GF5QPT%EF8M].D4K68N9,?IGR9WDU?56^F+^)[VVXWU%NR-5V_W^,/
M])&K^8@AO@[0^X.Q4_")P`"ESDXP/3#4JQ36XPV:@STK\[/GAILVI+>3-I.V
MPHT\S;0JXX<W?OCJ^*>[S\0/O[$$JZ^'_OA3/9V%XE;F#J'65YVY.:S8S,\$
MZ>287O`'QM/&`4BCF+]$5]AU((.MV0L\#:@BK\A7Y&47*&J.>.A7*$S]V#SW
M$:82.0WM-FP!0V5:-XQ59ZX.RX.OG(B".C!TP4M0YJ5LER*$S`$'`)>FH?+(
MD[P&Z%Z[$R$&S&2``PN0IG20AG$2JF#M&5F[C@"[5(6E^!Q@Y`!'.=-BH%2(
M,L@VSFRA+,IQEL2"Z80RK`=G63BAC\"8VNJY"NN"XD(H10CQQ*"KINJ&`[NU
M7$%2L*+;X)XC`R1BF;9H&ET4HS*F!(I<HS([$WX@G)X2TD'^)7%*^A(&/*40
ME"")H,GHY<_'V*RRU&]!!]U,\3S;2N_4E*VJU!]?$U"W0F6A!]N6A>YT:EH6
M^BLI#A]8<7B;5QR6J_85P=S?>-T7E8NNRNZI_FYYUD74.T]S5QC&JSKCV4^3
M\9YO9<+7N:N/#(^5*01QZ%*8L`+\=9<B#56B;ORQRZ\=LMQV8]BI05UEPQ:'
M98M.8]`]JSY;/-=RVZ\#_TZ$,>6AST(Q$83T'979^4J=&-*%8[:4*:ULI.P1
MI6R_OK5@=U3KKW;58--`,71:Z2;_1RFUIC1G54MS]AN]_K"R=]-J6$`,O^VR
MBN2@75=^VV>Y\"H4@V5,X'5/"*K_L9/3X)F4V=PWC;O9GW;#'I[O<8,>9[&K
M085AN3(B>XW>>5TYKN(Q@H<-?'DGH1[6#VUCB(@%\2A4.6I14$JC$)52$D)S
MO4Y(U+W$S(B<Z>H*2L\GT.XUYOKCU-&'MUF!F>I,T6%YF^O)ZCQ,<`AZZ1V)
M\2.XN)*8$N<)0I].ZSEJ!0UA?PB%B$]HF/Q0OYU!H#*3$W+*#<+I^!2XK&T1
M:K7=:J>8J80G,T7`E/2!K+C2>=L:.P^$FXLL/Y;URU31GA86S7TC1H)B_N0X
MX?\W'VC'UBHTXJ\+QMH99G7@MB/]&&Q9P?!WD,#PF&^]_8Y5"6Z$]8F=E,]U
MU^;JN\'$(4[9->/7(C0O%0_-THF!0BQ:1AD#KH^6+YI,SBT>$985HWG!&P'C
MM3&B+[%UZ$98FRP*1HQS1?Q<:`/AB^7*$(3SQ$L0=ID=R=<BOD?TYQ0M:8Q)
MK*$ZZ*RW21CDD7L+L-D$+3Q+\])DS4C"RW%5\EH&,^Q3@Y0^BON659RS[J#W
M9[NO210O@.VGEYFP3J_$?)4#7I%\P9FB"9U#N`,8]_#G0K*<5JNG4!0>&\;W
M7K8L'8X,&`,#E%VV4!;G>,;EOK2RM!+I2HZ>X)T_.`_6BD+BB&ZEFD]7CAW_
M*8`]`61=)P\+9Q"'IO^F05P'.=2S0:YL-7S1:Q`4,T._>0\MZ]6#*O#&XYDC
M!2LG@\8N<F/Z,9H?!+$?L2PQ$</72>AIG?GN!3`51CE@OG$4:XSXU^!>P)G4
M*'LKBF$E;N+;LC<+A48B"4R=L;%6\RX;HT253FOQ*1QL;`-4P(2P_M!).'63
M:410]152YPXK];[-8+_"ULS-AHSQ9S#SE0P-.Q@60T?ZEZ'ECALR[E^4X<?-
MO<^@\4UZ;HQG-B&IARG(#:<'L(#"B/*TB&N:C8!E"0D_/A@C?GE"Z'^A<,94
M7N(Z`E%$<=NN/TM4P2)';A/KCR3`QE@N1YL2+@L<C3-H2`:54$D2HS3%;*2G
MF*D:&=&M$!(A_9:+#>!1DO:>+<.J7EV)M"6/IY<K^H]48AN-3P<;?::[@#,A
M2EE=WBU#D7%HR0652FKI%0+T59Q@&?*TCK`L+4/HIS[5%^6#A_$9Z-FTG+HU
M6?>:7*&E.[9BJW#_-`2"ZDS.@6^B<BJ\/`!$=B/+5^`HY^VY:YY)S2DD%^S"
MR_\\,PW6--P^]0#PA4DY=1J$29\PNZD2C)@[L&J^HTQ>R!.+4U8JV<QYX#*:
M*2[AM?#%9&4JR`;S\81"4W]X5,\[BONW^_T=[KS]>>D-:QR8-;J-]DX#U&H0
MBU9'4<OV?UF6&@]Z-`93A4L_(L.7D;C53`8X/Q]4?W<9#CDBA_0:[3KPB%%W
M*>L9'=@AX\E'1L^MZIXZ.[>KOZ,,AQR10X;MZC/(<U=Z9V$P$5'$!<,19=^(
MVXINID$-=I/AD&->@^SZ&AF>D8H;88@;Q?6HT$$C<JNYH?I]H^$:#EF>>MQY
M;I;=VL-04$CX]B+7X`%4%0_@O+=+;)@#K[-AO3JSWM#>I0NX`D`4.\(J>I)0
M%-M.1$43\`_K;#\\-L"@T3G?)US,GI?8<%TMN<YN-U3<:_W8;D^0%)M68JE@
M=O1K>!)6`6-&)+R=M=-\DCH6J[GT97H(1GI36NPH\'W,.%4I^8YO)4!:>!^Z
M<2P066,BT.%;S..,T%XV<>]$\P&K>ZN2M)C1J=+T+;O7..OV&OWA4"LHA#79
M?XSR=84<3*'+,D$Q'9"3KNS6<)#!=U!N7R2RSC"I#@OCSL+@SHTHU2N^Q<88
M2D0MOTRE"\44LY&#D4P=IBX<F;@GYR(.`T_E?=\'B4=I=V,W)B<,)2/"8F)V
MF#X;,.90I*.FTDHY/$5$5,!$,?C?-$B`H+18&%?XT3+-./41FWB%@J]Y-;H-
M/)BX#Y@9J0:B\!"B!*B<([]EO4F$E@2=SLU<*JZ>ANN,1D2:2E=+1R"7VM4Y
MQW(BF#B5DO2`ZY>-@3*W40+&A&F!C64IG]D[^6QMO;\<7=?YQ+WRU%(@W/6X
M)R?T7*YA17\JEI)_JUX:V!:O,LI?^BTCC=*.J>.1YT21.W&9%F)6!!808?0C
M863$#PTK($P!-TR1:/2."&7#E:5V>3+R>87:PSH%,,'9I/$T_##(\$26\TD>
M-B"=OO*NYC/&EO,@`^"/\)2FA$G7'X4"^=[U2X:'*"C#+#>>V(8JYJDMB4^F
M,Z?MV9*2R1::1-6<K<J++:3%6A<D?/(C;;"$ZC3..L,L33CE1,H:U=&*TC31
MXB!U!!2<?#?*34LVV?`#"#<0SIC8/$ZW*6:LBDBE*BN(B1R/9,G]1<E9!*K!
M!\.YC560KBUK>UB'WL_6.YR'?Q"='V"T22ASDNE(Q-;P810IDR2D"'EH;>0I
MN(8;)QPK5BON"IBI.5ZM4(;LP8_M=^(Z5$`1[?V?W(W.`+3B=OO1!W>[U6^;
MD[LB)W>.><SAO='A70*1M=4IKF,#K#C%YU#(\GS`_#,F5!R$C:""-'<!0N+Q
MPL+Z3QGS0AZW99S)8!I^2B@.1VLDQ>@`B1P'L+^!_7GO\V;7'F6@#GY:"@L2
M2-X#0?W12\BO^CMIK[G*I-H#[G3FN:K\9)&UKQ^H(QP>(L00"(I[A\T1+`[I
M`3&\$3DCJ08<3#&RQF*I7J2S`6U(Q,VIBEI$,(TK]2&C0]1,A_A;`HS2:;?/
M2U4"71$8B3!F?@3"XX0/4?CK3J`0B)!C0<F,^1B&14`T"I3Y8Y#\HSA5/7B_
MI0V#Z`==@C8E,CD2R`<8G1AY]!5H.9GAK]W>$/3SP0I%!/$242_'O"!2:^3A
M<@VT^5A:-Y/C-K%Y^WR)\G)NE)?J*"\IUQK%Y<B*BVT4%Z.XZ&Q@%)<C*BYE
MGW_YZ3OH"3^_5I/Y6IM+B;3I>%=J3M\(.,:\KZ"3O$+=X[=_^Y-E_0+C_/WG
M21#$/@SS/?QA?:>O0,3#)-W&\>SGGWZZO[]O?;\.O580WOP$LKG[$_[\$SYX
M(I^/'V;P/+1-6&<GU'BQ>?FHYUP+[]>3=_+;YB60U[1/-NA8-9CO'/2%`(Y'
M_';J02\((27\YK>KD]^^K@WM1WPV#Z`%9RY(1>'#=H&=J_8Y+J:3P"%$)A8Y
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MI;J?73WES]Z3]F>7JG]V]?0_>T\*H%VJ`=K54P'M/>F`=JD2:%=/"[3WI`;:
MI7J@73U%T-Z3)M@IU00[U=,$.WO2!#NEFF"G>II@9U^VOW+C7_4TP<Z>-,%.
MJ2;8J9XFV'FT)EBPA[^'/^#[7WY".N##_P=02P,$%`````@`=(.H0!]SN]JM
M"@``>(8``!4`'`!X;VUA+3(P,3(P,S,Q7V-A;"YX;6Q55`D``[R!J4^\@:E/
M=7@+``$$)0X```0Y`0``[5U;<]NX%7[O3/^#JGV69<7M;N.)NR/;\8YGG+7'
M<=J^=2`2LC!+`BH`V=+^^@(40(DD;I1D$]HT#XE-GOOY<'!G/OV\S+/>"Z0,
M$7S1'YV<]GL0)R1%^/FBOV`#P!*$^C__X\]_^O27P>`7B"$%'*:]R:KW-",Y
M([CW"!=<".B-DP1F@F4@B3.$?SN7?TT`@SVA!+/S)4,7_1GG\_/A\/7U]>3U
M[(30Y^&'T]/1\-]?[KXF,YB#`<*,`YS`?D_0G[/BX1U)`"\LW&)?3FBF!9P-
M2UU6"OG;0),-Y*/!Z,/@;'2R9&E?F2A?!RC1Y,L&O?)I]/'CQV'QMB05@I!#
M=.FVB%ZOMXX?)1E\A-.>_/?;XVW)O20Y.$E(/I0OAE<$IQ`SF(H?&,E0*A/T
ME8N_<X@YNY]>`3:[R<@K^X;!(D7BK3"J4,!7<WC19RB?9U`_FU$XO>A+%2)&
MHP^G9^L(_;"3FN'AO;F?2P@*,+RQ.T8]!_+G$F0RUU]G$/(W<,,F?MOZ!&3)
M(BL<O!._5U3#)8=";&F0=.0`[A7:M?Z,)!6=F6SBA%;]U2IE2YD"-BF:BR@Q
MSP#,1;,9C88PXTP_D9$9#4Y'JDW_H![_YPZ!"<H01Y"-L<@Q27Z;D2P5->OS
M?Q>(K[3.#$Q@=M$/)>>(R[#XR8==.>YUU>M<5.X\0@X0ANEG0+'HGYCH<!:Y
MQ#!,K^$4)8C7W`MG4.Z&,%3=WVI&8UJ-!*")%B]^K+2A9OE7%$.VR/-"VD`T
MF5SS3RG)G=DB.SB[9?IYKRF[QTDO1":A@D<-'5XA>IYQ]4MG.!FGHMX(KT#V
M`%!ZBZ_`''&0U<#AH5)!LE+%"H,PMP)R;Q6D$OXAGH1?D3PGN'#CGR!;P%JF
M;:]5+)JO8\VMQY&`I#8EJ&R>Q9/-!R$+4@I3:T(=%"H41HI8T^IW)R"S1B$J
MN7_U)/<]0Q$\NB(!PY-*7'R2991,$N/KP+8\L8]-[</0#BV_YS-(MTSYE>!D
M(5")ZT,S/Z'RRT48!8JW`1OLE0VX$J,N(0JKIQ%AE>#G)TCS:SCAUFR[B32"
M+43193G(&U>&;0+B&UE=JT[E$;Y`O(#6!'OI5%0<=-&E.=0G5Z8=,N(;>/T+
M4`HPE[WGH[2'W2^X7)24B\&U?(>0JO"X2:/+>@O/7(EWBXEZR'%E+N%6@N8`
MY,K<IM]S"2!)R$*$_P&LP"2#9I?<1'H!P$(4!7#K)I-`IVS(5=3%]-\B)[X1
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M-BR;C;(`EJZA:1@=[>"K`:E;(Z4P@?&5JD>80/0BY^A,-"TS@)TTY=D7(TV$
MJ0_QQIUKBX3XJI(\4RF0*/^1!?0%9/)PXIA?`4I7"#\;CSNTX=%G(,)X(@3#
M+MZZP1$H,<)91+,?=_5<EHZ[QN)Q\].P[N6=^/V=SIGZCNMVU6I%3;G%PG1X
M1UB]CS:^4QFIO>NLZFR,N!&X$A'G""\$\C<QOH130N&:[@DL(?N",*%B5GF+
M.:20R1%?5<IZTOD%\AD1;UX$29&X6G0ZT*QB_ZZ:NYVFBJD767N%G]<&JT&/
M:;[J)=Z>N#J(NZN*76"*M(Q>I1:_H\'EI-QA:'P[/MI+,VPM;\MV7GO[W0'3
M'9\ND=BPS#0@'^R*/<L\^QNF$&3H=YC^`A"65MYCO7M?0U8(J0JCF_2[PUR+
MR'4)0+>9\<W][ZLEVS#<=%#HCMM$T>%J1K$/67>C_KA<L]"/NS.8K$#&5\J2
MNMG&E]KXVLONBD(CNL1C>J6-:NYB8:7&%5^3D36$@H0S<\9LK\N[(O77<67-
M8[XU;TV^0ZZ%67K>.Y3(;EZNM9!,Q)_(.O0";Z#AV+N7LCR%YJ",*U?A3EG3
MYA01X0*5JS<BUBI?<=\@8KVBJUGC*SFER7IOP=9'U]_7>^C-^^ZN%,-,R'Q>
M?P@B$\`;ISG"B/$U\LPSLG9,^NIQ(%,$:&[DC>SHLQGI6GQQ@2E0;'RMX!$R
M**(JE]:O16/-2+$;;`9,$&TY!G321@J/-A[Z4>&1%M^^EC"8TT7"%U1X<C4#
M]-DPY+>3;%)O((DWXSY_@A)M$!*X0A=13^_K\D*Z?(.,T/6B[V#%Q3_Q[W3-
MV61=8)EZS^29=^M(EQM5E;15[%LOH;ZC7?$-,DJW5$VX%..D:>.[,!ZJRHZ@
M@2I:./H\"H&.08:OJD9S!L#P!;*X#NX\0(ID&THH!`Q>P_6_0>=WW*S.8SPV
MULY:J3QS)4Q\H.0%B=1?KKZ)I-[B&X0!3D2Q&B=B+F/Z_$%[QLW)BF#&+@\=
M)Q"F1<V]96PAOZ$F0+WY9$LM&L'TF^/'/OI.2UO;U)+V(:A7P$"5ZD"S3U5\
M.^5FH[<O!05ARL3@!%65X8^!*D<0#@ZKJJ[XQEF/<`Y6JM=UH,E'5L[C;63'
MAIQ`A_?`BUW#UJV^GV*:`.\TGB%[=/:5Z+;1+N/;1FM\[=)B_7K6ML/(RL'H
M'ED9&;OK!E63>2+C1("`0NOMI'IWV)I1=XLM&*,K<JZLDSV"$E+V#+J+;K*%
M3E.S_(,507^[?(LB:-0:W^:"Q?IRS;%M$70PNHN@D;'+M;%*HH5]\N1O::3]
MJX,[<&[6T,(YHZN#KL23?<(24@@-RM4J7;C2^":D3?-K7R#Q0L]";P5<@_[X
M8>8.P4'!U5`5WYBW:73MVU7RE$3CJT9>G+418@5?F)#C1^0.P3HH3,/TQS=4
M:7JBKJ'K=J?V8O1M=..U__V$6+$;)N3XL;M#L`Z*W3#]IM.<.U^%.>QEPD1X
M'W*/T$I7NT)HH#LVE(6ZO`>0'"H45OX6$58*&-_F`NA43M+-1[[<1-L?7#$0
M'1M$@IS=`Q\V^8'_)\`[8L-TZ^H:4O12'&D-N81GH';<PZM0'QMLVKF_!WZ\
MBB*L,C>$"D/P^N,5R>J)`LQ`(KW7/FR\JL%J%U85Y':LQP:X/0*S!_K::550
M_#$B*(YS0CGZO7#^?EIN'UT15GP4_!JQ]8REW@6V9-.=8C#;L<%OQX#LTW$&
M:U2P^^D07>G_;Z<?M$L,N5R^?W_8N!O^]X@JD#P5<(OE?0$Y_M/S3K4NH@_[
MUC#4BJ?\='80S[&A:I=0[`&O0'7ZD$=$./LJ9A;P$A3G<G,Y`RW\KP'+3:2O
M_%F(C@TZ0<[N@16;?+TV']%^3[%*\2"Z3@HYHL5!;76NG.DM?=-J41C']KJ1
MC^/8,-0^#/NN)?F4:71YSU6\:Q\WIS!!A=/BYPP6&<7I]ABNT<6%LY0]7`C+
ML2%LAT#LU;^%:-,8BVB+YDT^YA@_.ERN[0&#FEB=[XC^%[3F!LW6UX*].V\&
M6NL&6X7VV/#1QO6#;I=5U&C\Q/0_W![XJ)__]-E;'/4S:MWU6\#JA?QK(M2*
M)_\#4$L#!!0````(`'2#J$`:8Q.JA@4``!<O```5`!P`>&]M82TR,#$R,#,S
M,5]D968N>&UL550)``.\@:E/O(&I3W5X"P`!!"4.```$.0$``-5:WW.C-A!^
M[TS_!\H]$T+2:QM/W!OG5R<SSC@3YSI]NY'QVFA.2*XD+D[_^JX4<(R!&`A.
MG)?$P.K3M_NM%DGH],LR9LX/D(H*WG>#@T/7`1Z**>7SOILHCZB04O?+GS__
M=/J+Y_T%'"31,'4FC\Y])&(EN','B48`9Q"&P+")9XP9Y=][YL^$*'"P$ZYZ
M2T7[;J3UHN?[#P\/!P_'!T+._:/#P\#_YV8X#B.(B4>YTH2'X#IHWU/VYE"$
M1%N&:\V7$\DR@&-_U5>EA;GR,C//W/*"(^\X.%BJJ9M2-(]K=)*9+POVJ4_!
MR<F);Y^N3!&(O@"]YK:UU\'*>-WPL[V::A>#[#A/89:"P1W,'//_Z]WU<SL1
MDX-0Q+YYX`]A3MBM%"&`45>=BSBF.@:NU8!/SP77>!>UIZ"0@P76CPOHNXK&
M"P;9O4C"K.\::`QA<'1X_!3`3XW@_<;LQUJ$-O0(%2^`*YL/;8A6(37G=(T#
M)89[LFP7L5SSYKT/!9_CN(LO8*(QPB,=@;RB''/(A+^5A%L0VZ@F@<38``$0
M\0Z4EDFH$XG7YQ&1\W:1JP7;(J(TQ'0P&((Q,A%8Z>@/R"(QD))@!MN,;A7=
M!NC-N5\1*O\F+($;("J1[6E6`#5GA$-^B@Z;8<:58'1JWAMI.A$VUGAIL"]`
M$\K:,&W807,/SHBB:C2[E:`0QY8)E&M,YYS.:$BXQC>>2&QAN\7^VU;.5MTT
M]^8"5"CIPL"/9F<)9B*H5GPK@#K*D)5N&))SHJ(K)A[45TZ2*<6GG>7)MFYV
MX,UH8>9.&+4=NU/:3T?^G!%F)BGC"$`_P]\2B5U'H#%=NQO*M?K:J5\[=J75
M*!9A8G3&"G&))4$_7O.9D''KV=#+>.O\B`PSBNG/',MLCDJY]J<T]E,;G[`:
M&5$Q*\XFNV:R_MG2M6@=L,+?YF4LN#>%&4F8[I!C"7:WC%%$6D/L-H13Z"[X
M6B@OAG@"LDNR>=P.F$9(2H;)!+Q5(#KD6XJ^SAJ3!">R9KP-\3+7,2PU8#59
MU2%#MU5=Z+Z_UF7NS;O/OS`LDXP+$V&.`#/;#$*6*FU5GA$UL5(GRIL3LD#)
M@\`'IE5VQU37P#L,TGV%3^GM;ZL7-'H-U_AS-?7"M0"POEMM@&J:.)09^._E
MSI"2"64H(YC5O5U21X)-0:K+?Q/,OL$$EV0DU!M.-FV6NEZ_63X@S[DVD/G0
MX-C/^DC+0,N*-I,B?E$\T=KK9_8]I]B!HX53'UA(O)ON[[U;TM1.D]HA^G"I
MT*'X->0^>E>Y<4$[`RGA*3&Q#(^D]61JMQ=N08XC+,T;TC=KE`:K;J.]3(E6
M'F]/C[JP::H<[U&J6&9JD.A(2/K?\WR@-$6JC$M3HVC\`5)BBX=-4Z$(EZ;`
MK^^:`N9[@>!-2D6#%FFH:K78RXQH[NOVM*B%F>;&YWW)C2VUH89E,1<^2%6H
M[ULC[2OKP6_[I?DHT>8+J?FXN$WT$M,JU7.F'T/V:N]:Z)X#2X7__9U7"2GQ
M>S)AFS6__.'F"CE]N$LYU[8UZ\W[7^!=9ZZ?;YX*]8<12@>]4'`-2WW)K$W?
M53`W/_9!Q'-&E!K-;,8-EK1RUZ/*;E/:HMTN57YA:W!#];RNHKYGI>);M)SP
M192]6-*OT[K([4MGM;G2(*O()08[K<,5^^@;>E:J)FKX5*KI)J(MQR5('U77
M;T?[HVS^F\ZKI"VX]0IQ#=8>;LW<Y.8DI:OLO$GIVOHF]T7FS2=1+PS*PHJZ
MU)MU78M@Q75T!E(<KZ?^ANOX+O_^-I]`&IT#>",>VXY7=/0!;/NIE&XZ>O5Q
MG1V&O=[IIVX(U#@HUDU';0_.==-[X[.&'3G=X"QF-SU6'D?M*H[;C]UV%+JF
M)Y'3>FW^&()XYW]02P,$%`````@`=(.H0.&I[%+;+P``04P"`!4`'`!X;VUA
M+3(P,3(P,S,Q7VQA8BYX;6Q55`D``[R!J4^\@:E/=7@+``$$)0X```0Y`0``
M[7UKC]PX>N[W`^0_\#@!U@:J;9=]=C8SV%%0[LMN(^WNCKN]>X)!L%!+K&IE
M5&*MI&J[]]>'I"XE4;R*5%%C!TAVVM)[88G/0[Z\O?SCOWW=IN`)YD6"LI]?
M+%^_?0%@%J$XR38_O]@7)V$1)<F+?PO^Z?_\\?^>G/P)9C`/2QB#AV=P_XBV
M!<K`)[@OL0&PBB*88I43(IPFV:\_D?]Y"`L(L).L^.EKD?S\XK$L=S^]>?/E
MRY?77]Z_1OGFS;NW;Y=O_O_'J[OH$6[#DR0KRC"+X`N`Y7\JZ,,K%(4E+6%'
M_>M#GC8&WK]I?0DER+].&K$3\NAD^>[D_?+UUR)^41>1O-9PTHA_'<C7OVGY
MXX\_OJ%O6U%L*)&8;G\V_GH`5-\O1RG\!->`_/?SITNA]H]OB,2;#)97X0-,
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MJM[_\<WAEPZ_SBKO`R#,HZ;@^$_%CZTEWD0(]\J[\J3WN]<YVJKK$QE]_/I;
M4C\_`8$"*!'0LOG&&Q6V*"^3?]!X[69]D60XJL'1Y"DJRF*5Q6=)$:%]5A8L
M-PS5&K)HJ]FR1].14SJ9^93RR\14T)4&:`WB^C4(LQBLDXJ(SUN(GZPA!%@H
MA@_56_I'4A1[$LR"B-CW3%)38"&[2F=HK&FAQVLCK]Z(_CG+89@F_X#QG\(D
MNT)%<9.=X;CD"1?\";+\UI2NOYY2VI+-"OO:))9%4'TNZWF445C'0G`0`BF6
M(-1<HQPFFPS`K]$CMHWINB/(\DQ+73R@4976)Z%"L<L]+1_3@V_IJ@O1]&6)
MNV4/>$0,O"2"KPC^.K+?(N26Q\#<TF=`5Q2PO-SBR#LG/?[I8YAO!LV[7*@)
MU@1"MJ$9UZS30$SF01IVB16#3[`H\WU4[G/<N8.(O@(Y3.G\*H9'BK+-28H1
M$(.0F/$=1\EK&)G4!Q,C<>5[$9'$HC=>W)6XIDAQVA@-#\1008=DJP=<MV%4
M,H@U4:F_D9Z*)8-TG+CDDX$_&;NTS02G-]=GY]=WYV<`_W5W<W5YMKK'__BP
MNEI=GYZ#NS^?G]_?@9>?LW"/Q]0P?@5^:0S\EU_:&4$&C:_2/B5UM+L$U??F
MC:ZG8?&(1T_D/^=_W^/.-<7%+5;E:9CGS[@%_DN8[EE^&.G47U!3QY*Q6EY,
M*?L$\P?$+AOTF6OB5T9=?3L!D:%3"Q'Y`QZD_1+3#!O(HNKZU-12[W+3P-^Q
M0&DTO-F)%E9&(E,UWC$P),8F"''[^`C!`]PD648"/+2F#ZI?\ZU#5S`HF@Z[
MPP'29.!]9P[>P9+F2.B^<P7==QK0A?C==P7:=\<&[;OC@?:]J]#=R*,3K+[O
M8)7^T1%?$+`V&H"J?.LH?7]LE+[W&+1?9E$.PP*>P>J_E]DJJA8_;L/G\"&%
M^!?@)_D>QE=)^)"D>,0QF)NR,U)_YK%&+`D^SJW+L;I5"60-@(7AH)$DRY!$
ME#8.824,TH.TW\;`$GC()0SZK<4X>]WFPZ9$,VI.;G-(MI2<P37,<QB??]W!
MK"!EO\%Q3T[G'=7-B8D187.B9\1Y<Z+C=H+E4*N"F+4JVH:#6A+`2J2@K0HB
M4K.8@;<$GK0Y,86!JCG1L2=O3O1+Y(T3SE9I[8HP#1V6+X)&&;QLU%^!)`,-
M36I5RA*J7*WD_"]+1-,?/FGB<P5Y6.I/,()XR('#!'7ORI$5=J(]6>?M0L?Z
MM!'VT)$9QUG]X#X/8]CISO*#P`)DL)P;97EU+F6FH&I4_.NHR6DVL#\C,MWL
MR*$LLD.PV@`L6'PV5Q323*SHG',B5],24.'5C(U28\$IW917D(ZU"C(I33MC
MV)_F1DXE;*1,U:E0%6U%-N0<EGOVMS"-MMNDW-+9MRP^11DI(LPB7/5DJV^*
MBGT.[^'7\@,NQ*_L"O4HY6:IVE#9=K+:R-T4B]=C"B"=PS8W&%SAP7&*8V@4
M04B.V>(.N&.FFN7N&O(\GST.7\A%K3,3W$9V>C/=(TIP=*@[&TN.<^T6Y61E
M7(9I<-`#OQ!-0%4];[7R@7710OD1P>YS9$A*B[*[$A?E[C'$I%KMRT>4D[W0
MG(Y.(=GIU822#G@ML.TR(%6[4?%5IAU4`J`@$@M04!D0MD+@)8Y%JZ>O_#-2
M5>G(N':&5!,HL;R2VIX/AV[V)<DE08(+%8DXHB(6]41=TZAC?%(>#?T8$8E5
MYS,)':1F3"5>U<NX)*@B!9DZ6E(V#:S/@4[<+<&"UT/:.-KHRQB<B![:^W9Y
M*@P-_N7MZ[=O__![L`MS\$2$%N#'=XL??OB!_/^PNUF`'_YU\?8//RR6OW]'
M0\7WOU\LW_YA@6WP&!66X"/&^R-XOUP`7(>5#A[EP^T#S)NG^'^QX@Y&Y`A5
M^CP;[HGW_TCJ6<BQX:8>KA5O7.JL_)_N\QP'I0S*Q0+U;^8)6#)J:-*44^4P
MA5&?6$(7,FH)E`*:R0A$U:/Y;&Z15!W2_=A]8`]EN]`669H$#<Y&XV+SYE#`
MH^K.BP6H7_UV82`8_([!@<]![+!$@A48M:"PU7.VPB(V[3*R4'HQ0S^S8C)L
M"CVOD6A4K)0,ZC40L8Z<&S-9XSB##^5E1LX[DYFI9FFFWA]XF940HY9EBY%.
M_;4T=2PYI.5E@DUS)GYE!-.W$]0/05(_)0D=VK\?8$C/KJ.'--F$,T@J8@89
M9%&C?79JJ7>):N#O6%AU%O(8>70"4QP8$5EP$%ZTB\8+T$"XT?C6(2J(JJ;#
MJ,_8JU_(SUE8Y<Z";98L::<BD>=V*%QYIP3E>)B\(Q'[U&>GR$;0_(MT'#2C
M"<;-EF:)FQ,/94`0<E!15S+Z<53%U!/Z.0;R)NH6)-ZL0<?K#CJBH)']5@&H
MU0&X0*#?AK_:\/P)/L%L#_G3BW*AMHGG"UFSBV=V@EU-4D=R,@D5@^8=R*N7
MOKDBK4=D\M594O#D^TP06YP,(@Y;79F+<>A8=N!1OYW)9*0+G`A;S_%`F5$[
M>8T_GDY3.93CMY9=.;=L.%AV.3&I<F+`"$9WT&2"DT/`.RM:<.I6S`Q^-4BY
M<5"1T(.UZXT@YV%.\O,4MS"G6Q'.DG1?#K:?*:3J[R&4LJ2&P*Y+8LA=R&@A
MTPP^A$4258G!J\?DM%&5FG@'<Q!U-@[0O3(Q2M,PKU[2Q7_/VV94]8Z,*JE/
M&X%"ES12F_XHLU[#J+Q9G]<9I3^%);S)^`E%6!Z-4&W(9:1JRS@#9TYI:.Y7
MRDU3<T&E01(_M?G"R8U?(*J/*:&,)HSRS,HQ*$+VM<OPU\!*C]3&WOWEN"6-
M#F[#87R*MN1D,5WE83@C%VKRV`J$;#/7<LVZ9*34@S0[K5@QH#NT3LA5<C'I
M`]NW3>H)SSEGY16*3#X_DU>6*]_+)"NQZ//,+=K"-LFM^("M3.IPFI8O97]T
MEF?7\3E9B0O%H5BAIB@Y\]T]_L_'\^O[.W!S`6YNSS^M[B^QP"S3-*OJ'AE5
MU.#\*T^!.>PJMNF9-O?A5_4Y5AW1'H%$HDY8Q#<^P=RMACLUK23J024!L(CO
M_:):-3R@B;HF>%SA:PT)([,^,9!<Y@Y2.K+!T+(+HGD>W'0-+7'Z'B?8\IN*
MI]JW4><)&K3"W+=MP\N\M:9(S]XD6>9X'N1L&&H$[>Z8643GHDI"6E^6A71/
ML(]BC@WW->ZP'>3:-JSL9:>VSW^[M2ULP4RJ>R9[ZADLB5/TNLR[:Y%,U^1T
MD-EN^.YYH#F>`^*!4RL=K2#'K"IQK&6E3G'(Q_!TS_!8SV^I,M7G=R2U.9/6
M997%=#+N$:4QS`LR]5H^BYL<J?BP'1*(N\,QU\&4+9;,H2;HQ2:&;1M=.BPZ
MTK^C5U64GD_T:B."3QYEK0D)Q=44L$SBY0@`G*)UE3JS15^_':;`._^&H:9N
MO)U@;<[-O/J8II::9K,_Q1%.J:.)#G3J^+3A8G]QX.IR]>'RZO+^\OP.K*[/
MP-V?5Y_._WQS=7;^Z>YWX/P_/E_>_^>\":IY%%2[*LWXJC@FJN'5'WU1MKF'
M^9;L11>DCQ!+-*3D2=CR;VC3*=6$YJ6L$F@=IC.&IS7!29-6PC.#)-6(M+\[
MPXNA<(\"(ENS0+MPEZY<B(-YA_MS^6:G0K[1SER)H@S_Q7RVZ"HJ5L`"G<VY
M?'D1%V:S+?<:EF0KU&V.GI(8QA^>/Q?DU&E]NW"V69',3KSY07/%^GN9*%I2
M2=^5\Z&\L6L9[PR-!5B^NFYR5VN`AV>P;J1!V(K[)>,(""';RNV35M]&E\BF
MGH^*8F?S`>9NW4%X66&87D-YV\'P2Z(%DNP5:!7!ZCM$LV!2X1AP]CG1H%]2
MP93#>`/&G9>S:0ASERYCQ='>W30&S`Y&TAZL4_2E`(1SW"[-<XHJ"X2-:@W4
M,Q?FML8U#C.9S1`4^#)[PH.3$0&M1%'>)G`5IVD+.*Z.%="*78]H`$3&#@'M
MONK_\?_5DG,/9F7P41->4;%:1.?8T""XT/-1$3QU,"MQZPZ^ZF"V59Q[,#L)
MFLV"6:=PGF$PRRFI63"K8<"XXYHZF)6X/$(PJ_;NIC&0![.\+FV>P:P.PD:U
M!J.#68FM<8W#O(/9]H8]TV!6HBAO$[B*T[0%'%?'"F;%KD<T`")CPV`6-9)S
M#V9E\%$37E&Q6D3GV-`@N-#S41$\=3`K<>L.ONI@ME6<>S`["9K-@EFG<)YA
M,,LIJ5DPJV'`N..:.IB5N#Q",*OV[J8QD`>SO"YMGL&L#L)&M0:C@UF)K7&-
MPWR"V>K(YA4J./'J\-V!V=UW]J0]6'/,QX%A!=48>=JSDIQ=WHG"J0ND\0D'
M\#Z(,<AE]5U7JE&LI3-<&)HWJMOE;[=RQ1&-9NUZO?B6F^WI%N8)BMF;ZQEL
MC5%M;B<T4K6]N=#`F?.!]`CGTFL/3<U15B7U&S*6I@-K<J:$_@$/1CQ?33@&
M3,B^DIDK#0VL]*X[-/9^9$R[N]5]A&.7@%[6H32]RIW\T=%:@$JOO7,%O&Q4
M?5]Z>V1TBVYS/Q*\O0ZT4=:.K:INMLXD(!I7Z\HWP;9:WC964WEP&I1K.I,&
M<UHV@IOR$>:D+R(Y?%[6*4Q>^1[T:E<_&EE#3%2H4NU%BGI^O''MIE\XSK!5
M(E%_%ZZ$)8,X-IT'=F(?,JJ(M`(Z2.C.#'F_PTY6=4C[6_?1SQ'NXEUH:QH\
M.`N*)/9'@`&'.(<E@CKEV4ORTG,08P<(04@R#A$^`XSZW@"VI6,?US_S\-@2
MPXTAYPT98U@&V)YHG2.COF3"<V,U^/I(_N7Z(&PDNLCK:SFL/&>M#FM4M^9P
M^_+I-U5I@J9#56MS:"0$@P[1:Z;1<#:D8`VZ'$$(;.N@L3\^:)YZ'A$(ZX:#
M3G6\STKRP#J7:)Z,SX1##C:PUQ)N8GR%L&UX)S7O$NM:GJ0AG]I`/4Z>18I/
MS5I&8^J"B0.E>KV04,.#7P[=(LQG6"8YS8'^`69PG93%;?B\Y5Q$8Z#199-*
MPP6EY#ZT>:6?)E??JY)C&E:"T^ZE3Y@%99X\[)M[(/[?V^7+7WV/N`RPP7)0
MO_(X1)0K#]BHX^LX@'0WI-?WYP"+RZ;5[XN"1A8TPM\R'D4S!),`TN?@X#:O
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M.B3LZJI9./3DDX8XZ"F?;S%@RE46DYUX.S*>O88<`BI%#]23B-J33FC<,=U4
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M.H>;2>P!(MQ$.18A?IO)7=VD2R>B5&)M8RD2L^8`W_`$4;C"E9P.$E4\]$VR
M*-F%*6BD2*SM?SY)6;?(K!Y86O`U^LR069T0.@Y;4+F3L:BA[6@7+E?M1.39
M-P,<88-JAQR_S6I1YONHW)/[B4X?PWS#.>8B%FF;4YZ(-1^&1MWN8A?:E[-`
MH!;TWOA&O*3.D/XW9H$^E.Z#7&1M'OC&P[Y/,"7]ZB$1U%E21"DJ]CF\AU_+
M#^EPN=G&!(\?VB9<\D?3Z20CN]'%T*:AB=G@KLQAN,5%I:G8\/"P9PK4N)T1
M?TTQ)^+W"`Q(^*]I3=@^&)7&$Q4<AEWC"S`%"Y9,;U7S@"IW<I2"@SKXA1@`
MU,)_?=_D$(:!?MCA-WPLPR2#\7F8D^:T6$71?KNGY3Z#ZR1*AN-S786VZU0K
M6+<.*A=NPTY-;W+>:QD).L_Q`)Z^\,U=[?I'8VN(I:5*MT]"/4_^LO>10TMA
M5!;U45(&TZ+731:^P6O;K&2,09=,$=B6YA;CJ03-T\-B@.?<8*)*0GH?EDGQ
MQ4CVTGAQK?CK+M!SF);/?.CR7S;=`//2MLGOF7/:O/,L2YORH4)0/?.>)%Y0
M(TCG.S*-<$^NU^!R+'C#YQU,L<W-GV`&\S#%,=@JWN)Q(CFKCX,PP;EX,Z7Z
MN^@J6>)<SXU+_!MYE/'"P%!0RR[`II*F#7W8D_?+)$.,()L:[#-/3[_+2!./
M_IB:;+($QV-D,T<4H7U&T@+<HA1':+`0S>29*35,U52R9:J6FPGFYXP<2PFK
M;RCX$!8)72:ZQ9\%9B7-?D=9V[$"#F9`8\<SC<T`A&RJEZ&QEGZ/Q@8>CX9=
M9Q-J9B[=P':).QHY.F<T278,J`HFPJ;$JL_)+GIRDJSAWJQ)7N0+<K6+(-N7
MCFC3OTA%;9DI,>XTZE/[D7)0I1Z<WER?G5_?G9\!_-?=S=7EV>H>_^/N'O_G
MX_GU_1VXN0"GJ[L_@XNKF[_>@9>?LW`?)R6,7X%?&E.^*:D#"F1>>0S[)%H]
MSBFM>R0:9OLC2F.8%V2?;ODLI)E*L"696-":8B+3;@FF\"*GEU0YZ+[_'3U'
M43Y[3LFG4;/(M`Y8GHAT^BR16_;&D2H%VGWX%1:W8<*FD!&\K;_`X*TE!1A[
M+G'/-RT#.T\CJ',JE^2I7V"+:@9I?<X^A!G!+FZY-KR!=544L"SX9QNX[^K?
MR;RSA&G/FBE(E4F5>=9E.!W*U^F5HWI'=D@%_**57SE(XYOVD=H3Z^*4H^^Z
MEIV-.;F6C:H8CR"K9S,Y8V!>O8(AGW[]^AS`]0HC""FE,KQFR5D@R;7JLB^5
M.="&,3,LZ[55GF-&>=6)4*V.%+GB0I#/)#[\:YCG85869"-1LGDLBYM]691A
M%B?9A@&@CFC]1>2BE@20&7?)`PT_,CHHU>E^`_P/0HPOE3!(D_`A26=P\;=6
M92/S2NE31J;598[:NC\"05(@&*^>8!YNX/5^^P#SF_59DN[QTRKUH813X[0;
MFIEJVS+/S)]3,HYR+>7G"(M!]1CC$L;TRDRTW>WIU/Y#6"0179F**P,TV1FY
MM/:0D)!-B#:?'*)C88B<8(-I$\P,]9J),67P>>8$XKHA]R>>P2>8(IIG@+]Y
M1$OV<(I$)FN_1UYLW?&Y*Z4CQ9YWA7[0B%2\/0CYWONJ4]=H1)4,-J*+U9@=
MYRK[,TGF^Q$2QC/(E8EP$_4V(D[3\E9&W>8V$]K73[G;40ON8$X6IS^`7ZJG
MGM?!I/4F3)<[_,ZRY+B5M#@5;M>:Y_D([@0$=\;!T13#1%.?VC,)W<G.^4QR
MBB<*5#,#PZD`AQ.9$\Q@ZD]=]N8LYU])TLE)?BWYG(ZD]U9<'28&KO&OYRZ1
MJ`6[]P0)!%W<QL(U[;+K4WI1WKPB5J[O6^G,Q(`3FB\7D#05,[AF15[#[.TJ
MRKK@W*G"U1E<I2*Q[(TKA[./-$\VB5#IGM'ZD.0I23A.QX$?0CR$;[._"38"
M.[)6?V%K:Y;4M/0_P9YB-R62<=V%AVK?R\D#D0!=(W[;`E?@1),@I-^J6!KN
M-CU.RNB?2<YB-4=EF9A$.#KLY`A`ZQZ/VHP"U-("4%LUW]I,J//9,CU/X@F"
MVGDQ;Q;;LN])RD*&V?R7[-;K^J6KS=;4W"3;J[N6M394'Q2"]AFF''DZE]W0
M_9KA[7\>?$_!CF<JQ]WCW+'@>;9'NNU$NM_$\4:3Z7:8&&\MZ>\I6=W=G=_?
MS6&V0;V'1'?SB'C7R$RVB[1,N4HR>(G_9*<EQ0)L8]H1<-6@MB8G:519ZUH-
M:U^IV[B2-X"^FDL+.ZPR7BO+_<B"EK:5Y;:VC"5OH+X(DYQ>='>(<(13`EJR
M]==0R%JB7FI]@L&ZCC\9)=3Z`1$!5`9\A"&1H"&D7WKHU3@:43%]TDC5NOS1
ML#\UM)R-7K4\6:%JV8-51VI&(TKW$!.,!MUAS.=([C0-B^)F3:?ESM`V3#(&
MQV*!)K\51\`VP]7`I-,<5R+KTBQ7?*6`/B>3,-6%D[]4[SQS0%)G2/<K,PFO
M!K*]E%<"2SY/ZN6XTX-GL/KO9796[T3@Y\'2EC^<YE/)VY_ODWMP?.)/RYGB
M#*"&C:!Y"/+JJ?>3@9KUCD96S>#TH%R5.4^HX\?O6GHUHI8OHXMDNBOH0QD7
MB^>L5>?KY@('RB5SKEZ]6CZ'_3GR>F/7Q66?F;,DSHH/5L/Y]OP!?0=)'JYL
M4V_3%$TH*N4:P(OE;$$OLNP4^`HG4O!+=8/V-8#U>\_GV]15B@R_/L,'D4J/
M$W*[\^&%B@\J'KC'O_-]ER(/1J#O[L9$`\C/#/%:2#=`N!393J9<N%:=3;,(
MK1M#8-EM\,Y_X[4OF"4QKWZ?LR'#D)O&(VTY.]OTE"-(I:9P+"G1=#ZJ%/J:
M=GRI<FLVTI1;&VY"G=N@4PT5Z?!3JPY5`U&A$?F05.';<ZZF*U04%_BC5Z?#
M][B$=5%15GR`:Y3#3M*>CTF&\J1\OLQ*B'E$;BSN6ZF247V$Y2/";YZP"%U2
M&;8$Q_;<RS%U),].\E<=I:S.8\#CEUV=?.MXI0FNF\/8#]3N?#)\'9=S@^QA
M1P<S+S/940HQS'IVQ-_^VVIXG`T[/)1[1JW.LLTG^))(OP*$]^#@%AS\-LU2
M90U4YD#'WJ*F"J"E6N"15YF'*(^3+,R?JUU$"T`F'\E%+H@FY@=-F?^WF?-`
MG>^QG9O%[N[NNN[J:R+<GRB28[<I#N5<[59D+4^R:5'@1&OO(E=WL'N`O)G+
M#D9AI?(V,LJ^OV`_(ZO"W=;(M^OQ)CB2<8B6YC;,;W):SIAN[KF%.3VPP6Z?
MT==H[XO3T+"^0D[IP^F.&VUW\HOF]*P$IYV\4`NP"W/P1#>LD111,>[0P[R3
M2,ISMB@3?*#1%<C>7J=4[E]HI^EK1LGK!SV52$"8K'Z")/7.)R*$+LPRTW>7
MHPI.7GK?'9*P[J3IZ&5=$"LK3S_O9-S)-^ON<AZA>7,L+-GK">J/M"K+/'G8
ME\V1+]P:>$_P98,.T5TZ(^#A>=&J&G'4JV@?8`;7@UN@%5+L-06LE*OK"OIV
MM5O$'RL&9'!#^A[UY*S(D]8M!AS-X#9'3TE!#ECC01Y(VKL-FE7[.4P,B"N7
M=].!N"8$-Q[T%;@W'_!L3H<<QW-K0A\C07.8L\*OF_5]\+*6\!QWND&,=(IF
M+&1\MJ47*(?))JORBD?/]WF8%6%$IG?^%"89F;?YG.4P3)-_0/;^ES&JS>$V
M(U7;`TD&SB9HGT>XEYY9,C47'/Y=K6)533HQ4E\#$CWC1CUZQ!X]M^JC$(7L
M:YHYYV1@I7?LR=C[D8'M[N#=",<N,4V.Y=4(;G1`1PD0K7K=9`$.JM\7N$6G
M^(Z$;I^=6C\-*YVX82@DD>!F]:TEG";UI39=SCJ*S>NG]#UH!>V+9F+Q7]Z^
M?OO[P_3B`BP7;]^^)?]?)Z('X;Y\1+E_KLFJ5YC\=U`?LMR_U8E@8>K?CBUO
M++A"V>8>YMLS^%"*,A)(9>K?+Y"QY`+7Z@29!V1^9+00ZP7DU0EY!\A+FO^]
MVG%YD61A%B79QO/N('FM(H-*Z%.`*]XE@<3>5'!Q%M1(/8Q"RK*&2ME"93Y9
M`^PA(H@OQF/$:U8`LDKV@,C&AB>X(O<%;>AR["&#@:@%':'9KGL::%JO?VK[
MFJ`--O<N7Q8ULQ9<)1',"MPL+T!/M]-R=\QX;KO'X`E95S2[7JIMI+]N:NC[
MN*!VUE.,\.L0STNRWM]%<4>EDZ)F1GW-<2$MZ)>.@VFO?5A8/%ZDZ`O9R8G_
MK/;7X59OE<5M8+K"(_8G>ESE\`,$A[M=F6MZ.VMSMJV%90&<[@]R4Q9IJ^+"
M18"U3X@Z2!I]VFFN&PL@;$UX/KCN#*YH&L@PK9&EY5X3Y:24_FY=@+L<1@G=
M4HS_3B'Y`Y=]M45YF?R#/F<H;:+2W)^@I6*;VEW#R03AM8%;::9V73-!5])S
M.G43)*#Q-<7D1=?0[B4_U_9V)`"ZNT#`P*$+["W[X%N`5ICV2UWQ;QN8HHS]
M$R'39UR[BO][7Q\4N4>?(/GH20JO87DX6W*/2"=(MRS%,/[P_+F`\676GM(^
M]'ZBS.@3NFCRJT_BPC9+^P2%<ADG3U@^:<;XJ=P&'<N$AGEC^W#A,WY*_J9!
M=W-3]"%ESFS"[4D9@XZ'4":1_@3>>NGX)_LUWEKGZ["DE[H<C@4R;8U8H/[V
M/`'+=FUH<H*P6^A$UK0(E'!44T1YLJ/],UJ##_LBR6#A>2Y:4G5(]V/W"3:4
M[=)#9&D2-#B+@<7FS8&`X]OJ!0%!YR/-9S+7!A."H'4,*+P&I%&$]K@)OPV?
MR<F04VXB6+E0$Q0*A&S#.JY9IX&9S(,TM!(K!LT[L*M>>HYPY!6(3#XW$V5P
MY7MQ@L2B3]CG>QAW4EX)D2^7.X!?)&>/?[YEQQ20.E&P0*(;U*_IE`::5RXW
M=>4BPWH8<(.OPM!#9M<;0SY!')+O(]Q?5=/O]>6&RND'8[WZFQGH63)*VY-+
MAIDZE3'.S%9P5^8PW.)"-2M>/7UP^ACF&W(+3*/E.2@S!Q"RK-L^:[5-=%EL
MZ-=OVO]V<8V,T^LC7`Q7E'+=]/]\.1=7`/`L3W"L2>5+>2.`4+=.7YHU2\_A
M8=)D!G<$2"N8O2=`51><NP)X*H/[`L1VIT20NXS2*B^CP;-LT%,+-)G/7M8R
MG@^AND.0*/NT-83L!]8%C%YOT-.;&"95(XO_8-M6_.AO*TSIF-#Z(@TW[!B"
M]ZX9-_3?C43\H`0N(A>141Z>^;)!^PB09YZ#?6XM(,7'8P+ZKAA!H4#W2*"K
M!PH721&%Z7_",#_/XC/<U[&;WQ1BS:8VH9@%*D5&70%485^$5:E:T(S2JM>`
MO`=8`!`)SQO#5%6)]#\[LXE+H-&@7&[Q2(`_0]&>,.T6Y@F*^6B7RC0;J/@R
M%CCG6G0%<IEQ$<+%.D'S"E3O9@)M>;TAS<_,["#AB3>(EM@Z$IS/,US<Y[_"
M-/WW#'W)[F!8H`S&ET6QASD#,BW9^M<K9"U@+K7L"NXZ3D2P5^L&E0@@,B>_
M$B'02(%*S"\/]"H:&=9'GQ=2M88?&K:/RI._H'2?E6'^?)&D,&=7YJ4R/5X,
M9*SYP%ATRP.^<3G^>3H-[MMWH'HY![2+J@UI?F4>NAGQ/JJYMHZ*YCJ>^@1W
M9'-BMB%Y.?=\4,M%>]@6B5I#G&_8+=*E/N2`EZ@VN&^"^E8&5$)SP+^BAI%9
M3?#8P-?JDT)F^:C<H*0\Q='8!N5L,EB)1(\)C(0U`7KVW.*>9UH.]Z%&@W+Z
M!C2OYH!M?E4AK6_+0W)/N`]@CIVCXO9V_Y`FT46*0G915/B^A]G>>VO$=JRY
MQ>O0L!RMK'R#U>HYH"_F@%1>]2"-+\I#:4>TC]&!C:,B]!/<)&0=,BNOPRT+
M'9E(#Z>LB#54^P;=HI5K6PY8CDJ#V<,K0-[-`;:""D-Z'Y@'WKYT'[\\2\<-
MG'&(DH?I91;#K_\.^>&!0*8?*K,R]C%RWZ+CX)AK7!$5<W3:<+AZ!^A+@-_.
M`<JB>D.:GYD;^?;%F9"79^NX<#[<ST`O8RAN]F51AEF,`W`^MC44^D"7*MBC
M7F+>,074GA1\4!EHR5'=07)7I0JL9$%'>!9<T<$!&E-37!9)=!E**;T<>;'H
ML&1U@9^P4RP**6;!:"#E8,F(L>EZT8AO7K5LQ-,Z+!QU%T;I^WDL'8GJ$&E_
M</[R$:/`+B!Q[7D!>;64I88Y1XX+])Z<,ZAWK$X#]J$#/;BS>@/`UPNFLX,\
MKSZYH!=\>AGL.RI\X`]L'AGZ]]BL`.W=5PS`JU<.,$T,N89QQZ8*N:WH`:SD
MT3S0V?O^2/[=^!@D4BSL#IHCD/85;4."IG=OW]=8(D](QN-=F,3UWL%BE<5T
M8V$]);XJ"CBX*MY$I6SS<&NHC`2E]N\P16M<?W=>*B)3ISPXF]D([O9;<J`4
MOP7AMCECE]#<`F'\%&)0TEM^HG"7E'7J]P@5)$?!8UB"+TF:@@?8W/P3XP?E
M(S6V"XLBW-##JF6RQ?_-Z6,4U1=+T#<A*/-DLX'TY`1\PD5;T",5C=F('J:(
M0;@)DZPH`0X*R+&+@KHAV0\R")Y)V%1;SU"^Q1W+(2E"]!RE<`&2-4A1AOV\
M!OA38!^;34[WL>/?E>?/]"0'_?'X5=%\CH<PI3^_>(2P!#&67I!74;WR%=*/
MB%V6H,`?&SN$Z3/883CAM[C,,"W@%_S-(?F4`WNOVQ6TV@ZY:)!\Q:BLDNOC
M7]_FVB??'V4%ADT\^.4O=7_ZJ]?>$Z_K$QR-)&"_V=/1)M_:T-4Q6A3K#?7&
MWJS;DB6]%X`V'G5S4'2.*?9I\PU#4;#]?A(LCMN1+^BTJUS($#OK93:]@)#M
MJS4DZQ\OE;3AD<2P\PY9[4O('95J\(GT>GM(>S;<NL?5(4+:@5:CHYP<?:NG
MA4@GD,1UK@.2(0AB6S$@H,9,JWB&>Z+RF7;9Q`CN71_KDW6X+WC8E[2_0E^R
M!8A@7I++<.K>#M+IIM\5N+<J\4])R+V6%5=?@S9+-NZE#LFPR<U_Z3ZN[9+^
MB]A.DVU2=6&+RGN=L0%;PV4K:1<?H=TS?;<`)8P>,Y2BS?,";,-LOPZ;@Y2[
M'$6P*!:@0.OR"S%/?E,>QG`;YK_BCCPML(NZ#`7^&LGV89\7]$+.YDY"$J+0
MB`-'#(\01S2XJ\Z?\*\IZM]+),G;ML'"W_4!/H;INODN49K09@LW9"2D@23P
MR=%^4T4Y)!0BDCWOK3'\P\/:@.?.5X>QR(Q:_>9-HM2V:DK#$S8(;OI3#2=C
MFX)EDXR^RCT?]?)XKZ'OP_T.`22Z'<(>04Z[P\.=5<TM5C?97VG[-QB[ZHC6
M/U8N:D,`F67G7:*&,R$1E+K!_2-MPK$8:45?QK#^\U4SE"(]`!Z355?9X^;W
M2ZV.6WF$"41'B^`E29I'E+Y4@S#:4="!;3.,]-PH:\$&&59OGU0RK995:M-3
MXM)-RZSC930BE[V;,@FZVNLR&^1]0T@2M,].H#1LH9UBZ9T6EM29#+2=C8;4
M.QKZX_8K;/+ZX>HE<3X)-FM0S2>UCU-\O9L07^^FQ==[D[9*DB=2V]EH?+W_
M?O'U?D)\O7<98=)LKF$2G]$![W62P8^XCAZ+\PS'*9*K5[1URL/]*AHZ-L31
M<N&NMS=R)^20@96`R%8+(YTI&AQ$XEB4Z@!(E&:3]<D,)FAT+?8IIJ7?<LW$
MVU&PJ1<]:+;N1E[M(?J.K.3M=BF=F@M36A7D+,`7<)FMR=(0Z09F<`_/A*`4
MQ!43@7(8:5CT!.04,%D;7&7Q^5?22^^3XI'4Y,VZ[GTZ"0T9C(_2K3^1H:X-
M"XU<.9^O&.-=2$IS8T&3<VHX8T$F^^IY\H2<!:>KO;`U"^/7X,7YW_=DKIJG
M@[K;5'-8+S\7((9Y\E1-'A8PPF`F9:DFQ#?D(>F^'E$:0V:=8(?K[S$L>EHO
M]_CWINDS@+0<KZH%!Z*65$?<L=$0%#L8)>LD`KL\B6"S3AVVZPQT%\`Z#[?P
M-6CC+CJMORYAUIN?"4$&O^"?\%!6'DC!R'Q]!.O+QE!>@(=G+/>(RXT+D,-R
MGV=@A\CZ0A*FGB=VQE$2V3*EW^X9F6G;OQ'.C]HJN(D?1[EUUQ[@>++1H5R&
M/:U.\S"?$=J1(2T(,(^$:<N`T]B?4>!9PEP2=H[R[0[9[SK(GOF<PY$1+8A.
MCX1HI]%J/T:N-BQK35?P1;FS%*RHNP%@W_)4<Q)\+YKC/)XR?P:BWB0RSVD'
M077S!W:2:I&-Y_IJ@F$<U_:4B)IP)H'O;#2PW@F`1?>6KE$^JRD#2T!I31",
M!)3;Z8`,=_)XF+.*\8#H%CN,DEV8?JCV#Q=7*-N<W,-\>X8'2.QD@+EF,Q5@
MHFD5'>D[<C\-8.Q;'!H9F@H^9_6^^DH/A$21X(MNB^^<_]PUQNH]Z629F6SA
M/L&*6SHJ]CV\'0$R9%?[3-"D;^00,IDZ/B+&'0UJS9VZ0C<9T#:XIBJ@U0&-
M$FBU`%'[;B`L&LI.CV';8:R9-Z=[+T;X=H7E=QTLMVWTH4U^:.`\:)6_&T2+
MAK+3(]IIE-6Y5_-FW=RJ*1C':LDV9V+ELC:4E)IVUY-HN1'R34-;=*?I;`:R
M>O6-C*N%.98KTVLYHF/='2L^A$52W*QOJX6DL+[T_2[99&1Q)\S*^@)",@I"
M:1*)KRYS8*G^7%:6;/AFX=@=&QT40LA5:]L!M4`XW+5!5S4Z5L#!#&CLS(;K
M+G"*'`.FWTY86&U;$?N2.9Q`1EE,CXOC/PKLC)RMCB^2#'?Z29B21+ET&\L9
M+,,D%<TLV]AHIIS'V;":.1SCTN$DM8U[\23C>*M!JPNZRJ#5!JTZJ/1GTV[8
M(1`Y`P0SFSG&WF&:TZ(TGMH'<OTYO?W<IH$8&!G30G2,'*V):'TZGRNU*H:;
MIJ)O-;A_Q)$&K+8X@FWX3')D[(MJ@!XG1922LU_K?4[/0<?40D%/0A>=2*2?
MU8/$*?5AX:)M9U*RK3?!_R@6U8ZIYFRS)+D'?EVMSY)_K-O&JS7J^ZR9)1M&
MM59<;%JT5JV]<<T54QP_%/70C0_\3T#.41TYL0"HB>^<&RZZ<I?DL%T='^W8
M[;JY53$F(,F[$23YSIDA6K+WQ0RG$]`789+_A6P(_PC#8I]7<8)@N*LE6W\D
MA:P-M:6FW?5O6FZ$#-70#H@,H$*@*S6;P:5>?2/C:NGS2*K7TD7'NNLT5$FV
MZ:7X:%)@K3H)B`14&6^@E[3*S(!]ZAH3?ZXSVHSQK4AT8VXR:!47H*=*1VG5
MW>U=[=EPU0)PR`T$>)ET3(PQ"79&E,,A_[N+OHWGNG/.-D+2FVDU3-?5LJ*W
MGA.'G#9S*":RB9V@O[VGP]F#QGP8:X@69%&5##?U+!P(:>31Y194,BEV'WX5
M+N]*)-HMI1P)NQU)`X,NM\\)C4NV%@ET@NH-H*]F`WM9E2'-;\SN^1E(=_;V
MB"RY@RF]&.7D0TC'<EN2=K%:V>1#5E.Z_HE*:1LH*XR[@[6F(R'$M?2#2NHA
MK&8V#F*S@;YNU:,1]=.GA$*SI8>>!X=Q%=R$Z2U)J@K)-O."W"R4E%4L1_(I
MUB?U)!MZ+"PT\=88"U:QE[E#AW'8>.?BF&RLS8!J@H[J`G24:;S64Y\-=6U@
MAQSA@`GBS*T=`KK1)7&X\[5>^R7'1VD:Y$Z.&-$&6`,5YFX8N8K5=E@-#PYW
MQ1IX$V^.U39RN(&&4+,2[B;SF0T_C:"!QE8=_T(;F?IA`ZV^KPJ-W>]YA?_"
M#YM'^'](E(.?_`]02P,$%`````@`=(.H0*[WH.1C%@``O$L!`!4`'`!X;VUA
M+3(P,3(P,S,Q7W!R92YX;6Q55`D``[R!J4^\@:E/=7@+``$$)0X```0Y`0``
M[5W=<]LXDG_?JOL??)YGQW%RNSM)36Y*_IIRK6.K;&?F[FD*IB`)=Q2A!4G'
MWK]^`9"@1.*#`$B)A&9>\B$V&NC&#XT&T&C\]//K*CYZ@21%./ER?/;N_?$1
M3"(\0\GBRW&>GH`T0NCXY__^C[_\])\G)[_`!!*0P=G1\]O1TQ*O4IP</<`\
MHPR.)E$$8UKDA!''*/G_S^R/9Y#"(UI)DGY^3=&7XV66K3^?GG[__OW=]X_O
M,%F<?GC__NST?[[>/D9+N`(G*$DSD$3P^(C2?T[YC[<X`AEOX5;QUV<2"P8?
M3ZNZM!3L?R>"[(3]='+VX>3CV;O7='9<-I%]MJA$D+]*]*5,9Y\^?3KE7RM2
MR@@96%=B4^T='17Z(SB&#W!^Q/[^]G"C+?WIE%&<)C"[!<\PIE7RXMG;&GXY
M3M%J'4/QVY+`N9I/3$C%AFGG$]/.V=^8=G[8<#[MTKP%@\X3SD#<3SLY/[FM
M4C7=&WW7EVI-3;[K4\MT1,(]:'FKFNZ-GD*"\.PJF>V^X<VJ^FK\8P;('J`B
M5]9=@-VWVJ&IKW@%WD5X5;"]I>7C*<$1A&QF2B_P:H6R%4RR=)+,+G"2T5_I
MO(5@VBX`8TT;>/;A_<?"^/_@Q-Z]]8\9COBT05FMUC!)^5SFTU`=)_<VW=!)
M?@6?P*N?QFK%/?H3)POJ,ZPNX7-&-7R?+2&Y1@F=_YCZO;JPA:-/KQ$(5K0`
M94`Y/L`T(WF4Y83^_V()R,)/<U9L/32*(@H'Q@/',7C&U$M#+U!H8D((H`CF
MB/;2K@-W][9?`T1^!7$.OT*0YL2_F1I&[BVB0WY&!6;#+$EQC&;,>I5P`C$U
MNQGG?0DS@"Q,IMQ2QPK<)3@'*4KOYU,"4\J'FPG:78]HD:`YBD"246\=Y]RP
M36G]OI;3JQIW:2YA&A&T9NSOY^<Y12),O=JK8=030JI^HRJY`.GR.L;?TV\)
MR&>(?NT-)VW5[$":^S5;]U&M[5@<93T]R7,.8K;`>EQ"F&W83P&A52]A1N':
MWU"VJFNG<NU8%*]1C*.<]3.U$%?4)&1O-\D<DY6W-V3FM]V^]99]NJ4_U"J#
MKQFD<E<:8VWUD8#7)VJ,<52K)&8[&)BTB<1^^=U4R^29^@L@R@2CF+G47XY=
MBM#/3$"[(J?N4@G-L<5!"J-W"_QR.H.(+CC.SM@_F,1G)^_/RJV7'^A/OQ<M
M>(`+Q"I.LCNP@@T1322E2&J2N@C;4)B0NCB`1((C_6<-!_*&34EQNN:#^B1:
MHKB"T)S@E6.G8"L)MUO_^<BF@J,,'ZD98S*#Y,OQ>[;G1_G.(2'E$LT@-1<Y
MWE['[0D;%U1.`N(;.E)?_P'?E.#0T-30(=$$!@^SC%WP(7$N`7(V=H!<Y(3I
M^!JE=%K]7PC(53*[I%-7`R-M9*4*]63!(,524C^PZ)F7>/DP=KP4XOT&X_@?
M"?Z>/-+%(D[@["9-<TB4AJ6%MF9@M+3!P,=%YBX&1UM#":2/80#I5QS3%2X@
M;]<HAB15`DA#4P..1!,88,PR=@&*Q+D$R'^%`9#28C[`-29L)X0M>',U3LRD
M=4=&0QH8:JPD[N36:"HH,?37,##$D7]!I]D%)FKG5TE10TR#(C"@F.3K@H\&
MWQ(6?PL#%M/\.4;1=8Q!<T=`^[T&B=KWP`"AEZT+'&I<2S#\/0PPL&-+G/`S
MPL<E579ZGV<LJ(2=::IG&XL"]3G'6"`P_#A(WVG^,593(NS'L2-,R+Q9]EW3
M7YI.3`M58^=1H@H&0'9R^J%&R[N$RJ>PH%)$JK2#14&GA$N-+E#`Z&7M`S(U
M[F(/;_2[O$*&)\I6`Y3M3PUL%)^"@X-"HFX(*!B*3A_]SNV$MGG&D1N#IHNB
M_%8JJ?$MF'XWR>37\0V.HN='OP<KY*OB,!4;]D::A@%HT`2#"!L9NYF$!F>!
MD*Z;JS^=2JJ]I3_LX-#=)2JA&WCG('WF,N?IR0*`=8%@&&>I^*4)Y?+GWZL8
MEOMY%<4UQ2DR'-F[%"F!8%>DXPCV5\(D36EG:,15?Q3VO/%Q8!'*+4.C)!J:
MFD`2S6!RL3`Q%LI,_[KZ9XY>0`Q9<'-V`0AYHPM1'C79/"]U*2,.3^W*#&:>
MS7V'_82NVV=E%?S@U(ZU?UC&"R3/N'$=8P"L/<`(4NF>8YC>P:Q41`-;1II2
MK1J:\6+'1BA+K&A8^4=D=,:&)E9M2N`:H-G5*[N-`%,1$BY$XO(U^MZE2*DU
MNR+C18:'R)9`L>,\=&1&3Q.R:2(V3<!CAH9)"$L,-%CX1T]DTIW)P336JBJ-
MXZ52F597&QY#QT+Z#Y`IP6M(LK=I#(HU(74MUFR-0.<-R?"VDU8&UT0Z0FPX
MR-8&$3.KH8,B_9%2W-7BXM[A)%*:5"--J3\-S0A!82--&QHT/$*?4953J7(.
M'67/6KM,LNT/?H)TVCC"+3LO=9W9L-YH\A"FSUL$GE%,!>2^,S^E7^*82I,R
MLY^]:?:`7(N5VK8O-@:%F+?!V@EEH<>S(5;>2TVGX(VMLC4+#".1L)(:HL'L
M@T7'8$O9ZM9!SYC;!`W#<&T#E8CDM*V2V#),S'0;I.CHQ@\6*PD=\:+C&:Z/
M?5DV]@&^P"37F!4SD3C8U!"-'"E6LKG`1,?0WP$?R38YRUCR5&8L4>/$0"&F
M5A7%R!'2+I4+/)3<AKX_U*?WU>IUM7I;XT=$G].*83[QN"XTB@6?\V)#J5.K
M!:!M56I-'\*"L#'?:'?*6NG4\_@H=LQ\`&4KKS^>##6$ZQ!NST]:+)F)%'-]
ML"BRDK2#2=*P#W>W]C?`DJOQ/(0/:+',#'=Z;$A+#9M)@T*4@]3^N#)7$JZ[
MR0\WMA1A/A<R$FX?#FD(@\*5M<3^J#)5,?0-]UZ6,/JUBW[1$AA,]#+UXEAW
MN::N7[OL-3#:\D3%^@QEE*<F4]$SO'6J:%H#Q2;(3:88\)31!O[M4C4/&$W`
M5W(+=RFY=?-7&5^M^2Q"J:7/(\="BSPN0)!9A;L"G,QF_/P<Q%.`9C?)!5BC
M;)-J5)PAF:G$"9*.:N30L)/.!2%:CN$N]1Y8LN<$SJX`8<G!TTD4Y:L\9K>=
M+N$<14@.HK<M4$74MQ<8.9*<978!E0WS<!=[LNRM+EBKZS5ZO+3*Y((/%;,_
MX-F"M:ONOP0R53%TAJ;=!9LY!IDY!I<%AC)'Z7M9;FLJ\D\#-8HQ[AHPZAG<
MZ!=*:E]93TN`45Y<K[\,\.<M]D'=I+)Y3RR,42=N[6-3L/+C\")<Q"!-[^=\
M5$U>47-#MI6N*9A,-]SFRE93+NFP0TE#.#V!V&!1$(QD`_$K7#U+J:A-),HM
M1$$RV,1CZ`)I[U`I3WU*D=G)FX:"3<^[AD/,UMI!B2W`K9F,FSSY9IN"UP&H
MKVZAL;VUTZB.\RO6)EH^X>Y55T)1AP?>T']JYPJ)H#E);!&,=J7UA[O6\X<\
MAZ->]3WAN)SQ8X0I)#P%JW%B;2NDG&KUA4:^/^8EN_^9GKZ"<$UG7<(BQ^\D
MSY:8H']MUHE*K.F(E1B3B8/"5HNL_IB2&8=[6+AU\&EIO!Q*R`?+P9HM=ZD]
MCY];#5:`!XU21G*MM;*@E$$5G)VRE](31%H+%>`IHL,C`PX)]D?ZL(`G?FQ#
MD!T!I`HZ[BM`=.2'0>,X<@QY.T1>MO=^TE-5X76N$[)R]7M-NMT2ZTVF+08]
MN[4C/H$T'K/XG3,V6?:$NH%/$]O>3A_*2[A):+MAU3K-7E,+5=G?6JH!(_7X
M#45=JFO=YRH*K_FYOW2LMRAB&&%IAG%,FX,9(E[@-51<QFBEK'8W#92#F12M
MDK&+;'5;TN19S&,&7N%N6E$CPD5,2YDEUUW]N7+7FY]'B8,6*=H[7V80[M;2
M`WX#,7L%7M7?ZH_"8#4^CK*OC1*T]W2S>+B[.T(ZS:2DF8S&VJOJ5EOT9U4P
M\&R/;3X2;O4WZLK2\-O6V2&D\2B=X6119497^VJM=.)>LYYNP)&>0@H@]JC$
M)>VZ&/,LQ64#I>%O05O9!"/M8$.AO:^PFZ#UD:%E7XP-(]MP!\HCC"G/Q2\P
MH=+'5+S);(42Q"1G?JX:36Z%1,"`9:%QX\M+=`>@V?(/V!&%5)@\RG)"Y;Q8
M`K)0."MZDHV14I",&SL68KF9)`6W<!U72=BVJ;IMBAX['-H$<L""@M4N_-XA
MT%`XK+<XU>)!IF@B8ILB$$QHA?)!Q3:SP"\L6JR';'UZZX61@6&XT_`=3G`=
M'Z5TFI62-7VI70OZP62_23)(.U^S5M)\K8XC&E\'&PKV/8+;A*H/A5;&;%!(
M##W60)^*H9#`!3O,&GS*8?FXM+(W9Q\KXNVL:`;B,"#D)+('HMKX#V%K->=L
MWQ("0<QBN7X!*&$3ZWTBD@0V@&)#6NK,3!H&2!S$]8"(F?MN<L*/R[EQG8:M
MG1P+QN&N+3<.\#55-#O60TE.!=W$3)S#.2:PH'L"KS#]BA),^//JQ3PW269U
M+D4<TU>8+3']\D))>""&,L9AKS77XB;V5/.8A\QP76`]^/;:Q,!W!BH=E/;I
M'"9P+B7':J&JC1$%U?CQW"::(_84[#QV"L;ET-_!3+M[I/PFEJ[U;V/&@DD,
M^ZF_SB3PE+,B>YNXJG.)XCR3KK:T4)4JU%*-&1-VHEFC0\LNW$1<OT&6Q1W.
M)M3O!PMXE[.D$??S4K*V>RV>I47N?=?28X9:-U580]"Y&O^,76.-[KX`Z?(Z
MQM]'$-R]%7)?M:H]/9265$X+I2`=TH=@S9D2_()H5YZ_?:.==)-41P*3*$,O
MQ347S;ZY-X.--^+,X$^7RW>OR[^WG+PQ]WKTCEJ`44>3V?_EY7KT"3_`""<1
MBF%-O"?<;=SMLHHJ'?<NJACPZ3,*H@AQA-)_QY"/MV0V66&2H7_QWQM*=BE2
M/8AF4V2X-^=W"1OLI;&ZY=A%`XOGUVP:YF]R1O+L*C]DFF(J-Q60<(>CW/!@
M+U>K=G`=2FP?][65.%B$N^MK/P"W:I?'&>.X]KSX8N@<\)7$BNWGJ<RVF4@X
MY!JB@P6NE5;V@U5=4\(]@6-/,MXD+&*5:8NJAT`J7OD(O#C#D+P+AS*5>V%5
MYF!![*.S?3D85BWS.)WJRP+_&>RQ>WQZQX?L"I96(27AGH%-TI2J:+4&B/"<
MM<K[%F8BL=K5$!TL5*VTLA^0ZIKB?U0WM#^PO:RL4K<DBPOJG[.$09<HC7`N
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M6F#:,0D>L1ZZZA?*=@T(_B12%GP2%:OX*7AC`YD%%Q2[_UO)HENA[L)$"W4[
M)L%#W4-7_4+=K@'AGFK*$HM1K<ZS:4VO1:Y$'SQ(S1KH%X]27>$^Q*%0!9L^
M*GVXV-36DGI/7E\R>&#::J5?B!IJ#??-CUUO'WBO3?>SG^#2/.'W!?@>1K?@
M^3T$;/<1@[^;9@:<1\I:B_)U$,>"SA=B@AT+WKKIZ9:)=>7^KOLHLLE9W4]S
MZ@^W)Y,4U;KUP"'DZM9(6^2LZ'#%SH*!V:(8&0SWWFP9K/Z$)]$_<T0@;38%
M1O8VC4'"TH"PQ!\\/75#3>X%Q3NT#@7'9G!M0(`[Z,;*X!H:P=^S=:@\^"Q[
M]BKR'N7>HSM8^'KKI@_XNE3N[^<>@K]@/R/UXB\8JSNX%4<5->CK+U@P,%L4
M(X,!WZ?'$80SGA/L)DUSVD1(<;1Y7;;I)MC25Z_4M]*/S:K:]#1VUX25,374
M7;QMWUIGN)Z^6KA;G"R>(%FQ"T)66%05,(*Q7N"@T&C0Q>[@6*\TW)GD`:Y+
MU]N(PC:RZDD2'5F@B+.4NP^<Z:ORV&$*8L&C4(BWF^+MG@0+36_=]`%6E\H#
M?WZPXX+'WJ7N9<%CK"[<*).K^1Q&5!57K]$2)`OX0)5SGS`%L&>)Z5]L?^@%
MQ%"^+^=35.2^="HZ>H1VT(0;-MTJ"C<`12W1%!+$\DW7#[P;J/0I*IZ>=BHZ
M>E1VT(0;*MTJVL4C48-#<T+G#$+>Z/3P*XCE)\]=RAC!*)4)%(5FV?N`GU2#
M_WWV-4<R;0;)#A9]OW_X(^-/DGZ7"/2X7UX@\"KI/P$-=W79C0'^U.<=2N!7
MG&3+](HE%];L<3N5V8*319E="59,1E;RJ$F58C1)AW^W`J:L=7)0KNIK\YT*
M\76P(6W5#[A-GOK0-?&LO5`A>/6\`SZ8^MJ&)7;"O4FIFIJ$8=37L)N$GR.=
M@UP-IOL,9%&#?^[ZD:18%<)7%ZC%*70R4VS0L-PN,4YSHGMXM"]V6[-#-W8C
MR:'X+0%%UAQ8Y<=I:,Z:7ID[44D_J.'L!052CL1VO<B&M4M+Y%R(RA8,&.BE
M\=;$^1\+2'ME$N<H71;VKDR89[ASY%-6.#]N90\"HEWTU3]<'5O3(<@+DB[S
MEPZXXHF\&9UHIW3RC=`:Q.<@9C*E[+CQ1'/RZU&R\4RT5<G#@*RWKG8`6)>V
M[.:$>:0N;H^>E+OWVZURCT11PS[J=`G3B*!UD=3P/$^IQY^F'L\V:<R:DKW&
MB;:BK=Q`(^UP@10@HWBXGV\>16T&3&@)1&"$@F"P46O7)=A"K/I`-/+EA^<*
M?OTN\_<WQ,Y!BM+[^72[VY+9(UHD:(XB=GNBR$#!=C9PC"+FG_0V`#TJUPS/
M'CB56.C$:;A7*TSM>Z)X.(_E0&6W0N)5"\M"@YF%/J"`/953-R0=6L+?L+!L
M0:BF1_ED8^G*@+ARARYA!E#<G]%QJE:WI=:%A]A'\^/1X^&12P-T-J0;$Q]5
MC,'&=.M_W)/:&LL^GS;QA85G6T*U.]<`$7Y8_14"MD`J7J[J;5@IV6OLB!6M
M2$1NIATN+;MHUV;)J?4XK&B;\JII!QO[=GV&W82M#V5C%3S9N9EUJ"/S%D74
M$+&D/CBFB,&$I[BN$CNRC=)%W\/5OD[-&/9G4/:]#X/ASB9K;=RT;0-$O:?@
M7+)R#QQ*#F87.N``=]%.W72XMZ)P`1QJ#]6Z/&8$@A6E*C9-'R`[/HPR'DP@
M'@0:[B+=5F-XXV+FA;7>Q'8N5UVULRXWX.7"EC:VVYPN+&PU-2XKY`X(W(N:
MZE;(NA7%U46?VD.U0NSL+"N/SH19KLYO^O1KML_HY(ITSHQ;*>'!V)8:S)9L
M7XG5&0LCS9:D"IKAG`['_L)V8C9\"KM*V%C6,`]UL&X%SO8W,K>8ZE\*T5'(
M\<PC&%U5:]IG9!O2IHSCFF%-G8.=!)3R'C?YUF*W#VH6Y)E8GJ7WN7L;8YS_
MB?0`N&:\65*+$[`VZN'B6RN(\(PW5=-*CXJ_!KEY&;W*FJ<9JCUQ$T$17;D-
M&!UDAP[<M\J:\4'&9O"HV*[5AVI.;N$"Q&6J'>:2L'1/J,@QS:ZL87YT"I-^
MHQ<<*M5YV_X<A#_JPV'`S4-MZVSV#WT*5UN(;H6'<^@[0`)W5%+#ZW=O2;&5
MZ-:"?9F<\@O[@_D=])=_`U!+`P04````"`!T@ZA`-:='"H,'``!U.@``$0`<
M`'AO;6$M,C`Q,C`S,S$N>'-D550)``.\@:E/O(&I3W5X"P`!!"4.```$.0$`
M`.U;[W/:-AC^OKO]#QJ?NKLY0-)V32ZT1Q+2YHX$+M!UWWK"%J"K+7F2G)#]
M]7LE6T:`8S!D'=WQ*<)ZG_?7(\FR7N7\PRP*T0,1DG+6JC6/&C5$F,\#RB:M
M6B(]+'U*:Q_>__S3^2^>]Y$P(K`B`1H]H>&41Y(S=$\2!0I0V_=)"!!/"\_D
MF?2G),)(83$AZ@Y'1,;8)ZW:5*GXK%Z?\0@?^3RJ'S>:QXV3DR98#DE$F+KF
M(KHB8YR$JE7[*\$A'5,2U!"XRN393.8J'A\?CQY/CKB8@))&L_[G;7=@C.:R
M8*/,8"H%/JNGF,SUCK$<&:VV1T.:7J/IS4$A9=\6')F-1&A=.:GK[A&6)/=D
M13YSO'EZ>EHWO;DH**(EJBF3"C.?N/*!FH?I"+^IIYU6E+('(I=$)?&/)ORA
MGO851,J2J-B;0(FZ3D\=)(B@?@[@;`,,9]X2+B"TV#7H</V"\860'F&8,:ZP
M@J%K'F4/XYBR,<^>P#.=VS/+QST9(Y/M,^U%JR9I%(<ZE>;95)!QJZ8'BF<'
MR==8D"/PSXH('I(2<G1W'2`2QK'QK#LW;%5@X:]H61D-H(3'1"@*HV\^F.HO
M%I:/PZIA`<1/PKV.*B#CJE$!A#*ZST&%>%0U*("0\-^-1^L90@1(-S[?WZRN
ML\:3*^XG>E%OLZ##%%5/-S`Y161&40W1H%4KE<B-6K-SNMXW8,UO-)"'K`:W
MB5F`4G7(T7=>7U:RK#^1).BQ]Z:]/(\S="92AER:*IL#%T=C,2Y[:@G8CI=+
MS@+"0#$T)`]IH%_K%SC4;Y;!E!`E/S.<!%3I-Z^FJ0J@E#7@S+`V@,22C+;+
MWMU5YV[0N=*M0:][<]4>PH^+=K=]=]E!@T^=SG"`7B76PJ\'(K<@LH\%9&%*
M%(6P*K.ZB%Y#<7-WBM&K!8L'RLLISW,M>^->K+?IX,A&DW@=LI3JX\UG\V`(
M?VX[=T!S[QKU^IW[]O`&!`[S>BN2+[&<7H?\L3+'!<!2BD^VI?BR/?B$KKN]
M+P>*B_=&1/J"QMI2;WR12,J(E-FFJ+"KE*:W=C=$I1]RF0BB?\SU(#Y&5M.!
M`\O!!984YD3?"1$VH@,Z870,KQW8EOH^3V`CR29]F$P^;(I3AK8!KN'O>)4_
M8T4SY]HQFUO'$IJ;0M;6@>'2A?2:,MCB4!SFB]H549B6[8J>A:QA]625U5P_
M<@V@W(*SU*8V#FQ:-J\Q%7_@,"&W!.MLFG=:REIQUQIV7J^RH_4@HPBYF@X<
M6`ZZU(?1"ZO-)0]#/.)ZQ_A`8/7KP69=M(7`;.(24T%^#5MO5MG*E?^&%M2;
M1=(80*Z%`XN6Q8$2!$>`@-P!%_=$*I'X*A&:J*D^M<_HVT1P#6]O5WESM1JN
M%O2B3/&!KGS2<3911%=&1LI.G>R%P29VHI7+K"'I]X+)!0J](6A$6J4SI>9:
M#PQ9AFX8-,D0S^S$<1^LR?V[U=RG:&3@AR3/5RWNFQ-IV)M%,:S\SDGR,WUK
M4G]:M#:!(L]H0JZJ`PWY:D0F..P+[A.B:\42LA119=ZPL/#`KE9_C!`V_URJ
M`B@GK-DH6*>T=N2HUYN!W(!9MQ9,_(^)/*\O%4'3!XNE4ETHI5',A4)LI3+O
MEK\G&,<+->&TJM_EOE&V6*\M!-9)J*1]XLU5'<UD8*M*I>Z4E8)+W5G&Z,;.
M#A24R3?QP8%E[9T],9_\XJFR*R[._MC=F40(F%I;>.,"\U\[^T-F_K2R+SG(
MM';V@6'JR\I.S%%I<V<W)/4K.V$QNK&-`\MEZ=/TK<%@F3;GU,_XL``+A5A`
M>5J/USSVFF]W]T-5]D%M8W\QJ2H6U9FP(--Z"2[<&T2;Y,!`]"_/XG0F3G0F
M=O#B=5WH:PD;.F"DM=G77N.=UVQ4(V#E-M2&5BU`&WZS7:3%]YTVL>\B[U+@
MSC-@]<96-4^V=Z/\2MWVFPJCZV56J.QN#+CJ*X_,XA`SK+AXNH;?FZ\6KI;.
M7$E)SK);C\;'5JTO2(QI`%!]0"SM5_RE>3&JMI3$GJKI#?G7S<33FT;F8N%9
MQ&$MP^+I1I%(;QLAM&0D%56)#NRCX$EL12F(U!"C^E1-7QI2(@%Q#-("HFO5
MQC@T-QR-<`Q#@P=#8RE=*)3M&J7W"5JU@(RH>C[V]"B/F.\!YR3OFA`WY%*I
M[QUID(CL`W0I5%_`ATA)K)^9(#BD?Y/@(Z:LRZ7LL2]8'U0N\%LN]L-$JTO.
M?1BG5^9P[XXR<@N?8U/980$)VIEA)^P-Y=WXX1F(OD#TZ>^RX)^+\D;*1.=#
MWV2;Z8_-A,JI[N^-,\ZZ%(]H2!5=&-$5<3\HZWVC<BW9RV+[QC%31,#G6SN`
MD=@'=WP:XS"[,27S\U)]7.HR7`7UP_!;>$FA@.`U<GO&\!:%_8*8=]*R9QFI
M5`XOFN#;X7_D+`S)3%V$W/^V;1H<!6D>TO^J.%/V^?=9$9Y+1F&MO8#Z-7)[
M1O'FA>J"4+<![UO\[HMHM8!8%/2FB#V+U"G-%415V+MG$:0UJHOE:E=!-&LE
M]RRR"J6BHA&Y#7K/,E#V+S%%^ZN-Q/_#&$T)*CU!@5__`%!+`0(>`Q0````(
M`'2#J$"SFA/3=&D``.MY!``1`!@```````$```"D@0````!X;VUA+3(P,3(P
M,S,Q+GAM;%54!0`#O(&I3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`'2#
MJ$`?<[O:K0H``'B&```5`!@```````$```"D@;]I``!X;VUA+3(P,3(P,S,Q
M7V-A;"YX;6Q55`4``[R!J4]U>`L``00E#@``!#D!``!02P$"'@,4````"`!T
M@ZA`&F,3JH8%```7+P``%0`8```````!````I(&[=```>&]M82TR,#$R,#,S
M,5]D968N>&UL550%``.\@:E/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M=(.H0.&I[%+;+P``04P"`!4`&````````0```*2!D'H``'AO;6$M,C`Q,C`S
M,S%?;&%B+GAM;%54!0`#O(&I3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`'2#J$"N]Z#D8Q8``+Q+`0`5`!@```````$```"D@;JJ``!X;VUA+3(P,3(P
M,S,Q7W!R92YX;6Q55`4``[R!J4]U>`L``00E#@``!#D!``!02P$"'@,4````
M"`!T@ZA`-:='"H,'``!U.@``$0`8```````!````I(%LP0``>&]M82TR,#$R
M,#,S,2YX<V155`4``[R!J4]U>`L``00E#@``!#D!``!02P4&``````8`!@`:
)`@``.LD`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Presentation and Significant Accounting Policies</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Presentation</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The condensed consolidated financial statements include the accounts of XOMA and its subsidiaries. All intercompany accounts and transactions were eliminated during consolidation. The unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the U.S. Securities and Exchange Commission ("SEC") on March 14, 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are necessary to present fairly the Company's consolidated financial position as of March 31, 2012, the consolidated results of the Company's operations and the Company's cash flows for the three months ended March 31, 2012 and 2011. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year or future periods.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Use of Estimates</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, research and development expense, long-lived assets, restructuring liabilities, derivative instruments and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company's billing under government contracts. Under the Company's contracts with the National Institute of Allergy and Infectious Diseases ("NIAID"), a part of the National Institutes of Health ("NIH"), the Company bills using NIH provisional rates and thus are subject to future audits at the discretion of NIAID's contracting office. These audits can result in an adjustment to revenue previously reported.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">At March 31, 2012, the Company changed its expected volatility assumption in the Black-Scholes Option Pricing Model ("Black-Scholes Model") used to calculate the fair value of its contingent warrant liabilities. The Company changed its assumption from an estimate of volatility based on historical stock price volatility observed on XOMA's underlying stock to a volatility estimate based on the volatility implied from warrants issued by XOMA in recent private placement transactions, which was determined to be a more precise indicator for the fair value calculation of the Company's warrants.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Reclassifications</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Certain reclassifications of prior period amounts have been made to the financial statements and accompanying notes to conform to the current period presentation. Prior period presentation of contingent warrant liabilities has been reclassified from current liabilities to long-term liabilities based on the contingent nature of these obligations. These contingent warrant liabilities represent a conditional obligation of the Company to repurchase certain warrants for cash in the event of a change in control. In addition, gain or loss on revaluation of the contingent warrant liabilities included in the other income (expense) line of the condensed consolidated statement of operations in the prior period has been reclassified to the revaluation of contingent warrant liabilities line of the condensed consolidated statement of operations. These reclassifications had no impact on the Company's previously reported net loss or cash flows.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Long-lived Assets</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company reviews the carrying values and depreciation estimates of its long-lived assets whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the estimated future net cash flows expected to result from the use of an asset is less than its carrying amount. Long-lived assets include property and equipment and building and leasehold improvements. During the three months ended March 31, 2012, the Company recorded an impairment loss of $0.8 million and accelerated depreciaton of $0.9 million&#160;on long-lived assets in connection with the Company's 2012 streamlining plan. See <font style="font-style: italic; display: inline;">Note 6: Streamlining and Restructuring Charges</font> for additional disclosure on the 2012 streamlining plan.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Concentration of Risk</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents and receivables are financial instruments, which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents such as money market funds. The Company has not encountered such issues during 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2012, two customers represented 49% and 40% of total revenue and 63% and 37% of the accounts receivable balance.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three months ended March 31, 2011, these two customers represented 51% and 44% of total revenues. As of December 31, 2011, there were receivables outstanding from these two customers representing 57% and 43% of the accounts receivable balance.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Newly Adopted Accounting Pronouncements</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In May 2011, Accounting Standards Codification Topic 820, <font style="font-style: italic; display: inline;">Fair Value Measurement</font> was amended to develop common requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. generally accepted accounting principles and international financial reporting standards. The Company adopted this guidance as of January 1, 2012 on a retrospective basis and this adoption did not have a material effect on the Company's consolidated financial statements.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2011, Accounting Standards Codification Topic 220, <font style="font-style: italic; display: inline;">Comprehensive Income</font> was amended to increase the prominence of items reported in other comprehensive income. Accordingly, a company can present all nonowner changes in stockholders' equity either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The Company adopted this guidance as of January 1, 2012 on a retrospective basis and this adoption did not have a material effect on the Company's consolidated financial statements.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_BasisOfPresentationAndSignificantAccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.05<span></span></td>
        <td class="nump">$ 0.05<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="nump">1,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.0075<span></span></td>
        <td class="nump">$ 0.0075<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
        <td class="nump">92,666,666<span></span></td>
        <td class="nump">92,666,666<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
        <td class="nump">68,076,152<span></span></td>
        <td class="nump">35,107,007<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 04, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">XOMA Corp<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000791908<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,083,980<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicenseAndCollaborativeFees', window );">License and collaborative fees</a></td>
        <td class="nump">$ 1,014<span></span></td>
        <td class="nump">$ 5,827<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contract and other</a></td>
        <td class="nump">8,851<span></span></td>
        <td class="nump">9,768<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">9,865<span></span></td>
        <td class="nump">15,595<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">15,771<span></span></td>
        <td class="nump">17,347<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">4,679<span></span></td>
        <td class="nump">5,369<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
        <td class="nump">3,777<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">24,227<span></span></td>
        <td class="nump">22,716<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(14,362)<span></span></td>
        <td class="num">(7,121)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(1,042)<span></span></td>
        <td class="num">(532)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
        <td class="num">(664)<span></span></td>
        <td class="num">(1,057)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UnrealizedGainLossOnWarrants', window );">Revaluation of contingent warrant liabilities</a></td>
        <td class="num">(14,357)<span></span></td>
        <td class="nump">2,390<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before taxes</a></td>
        <td class="num">(30,425)<span></span></td>
        <td class="num">(6,320)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(15)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (30,425)<span></span></td>
        <td class="num">$ (6,335)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net loss per common stock (in dollars per share)</a></td>
        <td class="num">$ (0.69)<span></span></td>
        <td class="num">$ (0.22)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing basic and diluted net loss per share of common stock (in shares)</a></td>
        <td class="nump">44,353<span></span></td>
        <td class="nump">29,180<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 11, 12, 36<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 20<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 7<br><br> -Paragraph 18<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1(i)<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 4<br><br> -Paragraph 5A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAndCollaborativeFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Also, includes reimbursable income that occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_LicenseAndCollaborativeFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UnrealizedGainLossOnWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increases (decreases) in the market value of warrants whose gains (losses) were included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_UnrealizedGainLossOnWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Long-Term Debt and Other Financings<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_Long-TermDebtAndOtherFinancingsAbstract', window );"><strong>Long-Term Debt and Other Financings [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt and Other Financings</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">7.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Long-Term Debt and Other Financings</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Long-Term Debt</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 18pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Novartis Note</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In May 2005, the Company executed a secured note agreement with Novartis (then Chiron Corporation), which is due and payable in full in June 2015. Under this note agreement, the Company borrowed semi-annually to fund up to 75% of the Company's research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50 million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus 2%, which was equal to 2.80% at March 31, 2012, and is payable semi-annually in June and December of each year. At the Company's election, the semi-annual interest payments can be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $50 million. The Company has made this election for all interest payments thus far. Loans under the note agreement are secured by the Company's interest in the collaboration with Novartis, including any payments owed to it thereunder.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">At March 31, 2012 and December 31, 2011, the outstanding principal balance under this note agreement was $14.0 million. Pursuant to the terms of the arrangement as restructured in November 2008, the Company will not make any additional borrowings under the Novartis note. Due to the structure of the secured note agreement with Novartis and since there is no liquid market for this obligation, there is no practical method to estimate fair value of this long-term debt.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Servier Loan</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In December 2010, in connection with the license and collaboration agreement entered into with Servier, the Company executed a loan agreement with Servier, which provided for an advance of up to &#8364;15 million. The loan was fully funded in January 2011, with the proceeds converting to approximately $19.5 million. The loan is secured by an interest in XOMA's intellectual property rights to all gevokizumab indications worldwide, excluding certain rights in the U.S. and Japan. Interest is calculated at a floating rate based on a Euro Inter-Bank Offered Rate ("EURIBOR") and subject to a cap. The interest rate for the initial interest period was 3.22%. The interest rate has been reset to 3.83% for the six-month period from July 2011 through January 2012 and 3.54% for the six-month period from January 2012 through July 2012. Interest is payable semi-annually; however, the loan agreement provides for a deferral of interest payments over a period specified in the agreement. During the deferral period, accrued interest will be added to the outstanding principal amount for the purpose of interest calculation for the next six-month interest period. On the repayment commencement date, all unpaid and accrued interest shall be paid to Servier and thereafter, all accrued and unpaid interest shall be due and payable at the end of each six-month period. The loan matures in 2016; however, after a specified period prior to final maturity, the loan is to be repaid (i) at Servier's option, by applying up to a significant percentage of any milestone or royalty payments owed by Servier under the Company's collaboration agreement and (ii) using a significant percentage of any upfront, milestone or royalty payments the Company receives from any third party collaboration or development partner for rights to gevokizumab in the U.S. and/or Japan.&#160; In addition, the loan becomes immediately due and payable upon certain customary events of default. At March 31, 2012 and December 31, 2011, the outstanding principal balance under this loan was $20.0 million and $19.4 million, respectively, using the Euro to US Dollar ("USD") exchange rate at each such date. For the three months ended March 31, 2012 and 2011, the Company recorded unrealized foreign exchange losses of $0.6 million and $1.6 million, respectively, related to the re-measurement of the loan.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The loan has a stated interest rate lower than the market rate based on comparable loans held by similar companies, which represents additional value to the Company. The Company recorded this additional value as a discount to the face value of the loan amount, at its fair value of $8.9 million. The fair value of this discount, which was determined using a discounted cash flow model, represents the differential between the stated terms and rates of the loan, and market rates. Based on the association of the loan with the collaboration arrangement, the Company recorded the offset to this discount as deferred revenue.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The loan discount is amortized under the effective interest method over the expected five-year life of the loan.&#160;&#160;The Company recorded non-cash interest expense of $0.3 million in the three months ended March 31, 2012 and 2011, resulting from the amortization of the loan discount. At March 31, 2012 and December 31, 2011, the net carrying value of the loan was $13.2 million and $12.5 million, respectively. For the three months ended March 31, 2012, the Company recorded an unrealized foreign exchange loss of $0.2 million related to the re-measurement of the loan discount as of March 31, 2012.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company believes that realization of the benefit and the associated deferred revenue is contingent on the loan remaining outstanding over the five-year contractual term of the loan. If the Company were to stop providing service under the collaboration arrangement and the arrangement is terminated, the maturity date of the loan would be accelerated and a portion of measured benefit would not be realized. As the realization of the benefit is contingent, in part, on the provision of future services, the Company is recognizing the deferred revenue over the expected five-year life of the loan. The deferred revenue is amortized under the effective interest method, and the Company recorded $0.3 million of related non-cash revenue during both the three months ended March 31, 2012 and 2011.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">General Electric Capital Corporation Term Loan</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In December 2011, the Company entered into a loan agreement (the "Loan Agreement") with General Electric Capital Corporation ("GECC"), under which GECC agreed to make a term loan in an aggregate principal amount of $10 million (the "Term Loan") to XOMA (US) LLC, a wholly owned subsidiary of the Company, and upon execution of the Loan Agreement, GECC funded the Term Loan. The Term Loan is guaranteed by the Company and its two other principal subsidiaries, XOMA Ireland Limited and XOMA Technology Ltd.&#160;&#160;As security for their obligations under the Loan Agreement, the Company, XOMA (US) LLC, XOMA Ireland Limited and XOMA Technology Ltd. each granted a security interest pursuant to a guaranty, pledge and security agreement in substantially all of their existing and after-acquired assets, excluding their intellectual property assets (such as those relating to the Company's gevokizumab and anti-botulism products). The Company incurred debt issuance costs of approximately $1.3 million in connection with the Term Loan and will make an additional payment equal to 5% of the Term Loan (the "Final Payment Fee") on the maturity date, or such earlier date as the Term Loan is paid in full. The debt issuance costs and Final Payment Fee are being amortized and accreted, respectively, to interest expense over the term of the Term Loan using the effective interest method.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Term Loan accrues interest at a fixed rate of 11.71% per annum. We are required to repay the principal amount of the Term Loan over a period of 42 consecutive equal monthly installments of principal and accrued interest, commencing on January 4, 2012, and thereafter on the first calendar day of each succeeding month.&#160;&#160;The Term Loan matures and is due and payable in full on June 30, 2015.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including restrictions on the ability to incur indebtedness, grant liens, make investments, dispose of assets, enter into transactions with affiliates and amend existing material agreements, in each case subject to various exceptions.&#160;&#160;In addition, the Loan Agreement contains customary events of default that entitle GECC to cause any or all of the indebtedness under the Loan Agreement to become immediately due and payable. The events of default include any event of default under a material agreement or certain other indebtedness. Upon an event of default, the Term Loan and other obligations under the Loan Agreement will, at the election of GECC, bear interest from and after the occurrence and during the continuation of an event of default at a rate equal to the lesser of 5.0% above the stated rate of interest or the maximum rate allowed by law.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company may voluntarily prepay the Term Loan in full, but not in part, and any voluntary and certain mandatory prepayments are subject to a prepayment premium of 3% in the first year of the loan, 2% in the second year and 1% thereafter, although mandatory prepayments in connection with entering into certain exclusive licenses, granting certain negative pledges or incurring certain collaboration-related indebtedness will not be subject to such prepayment premium.&#160;&#160;The Company will also be required to pay the Final Payment Fee in connection with any voluntary or mandatory prepayment. At March 31, 2012 and December 31, 2011, the outstanding principal balance under the Loan Agreement was $9.3 million and $10.0 million respectively.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In December 2011, pursuant to the loan agreement, the Company issued to GECC unregistered stock purchase warrants, which entitle GECC to purchase up to an aggregate of 263,158 unregistered shares of XOMA common stock at an exercise price equal to $1.14 per share. These warrants are immediately exercisable and will expire on December 30, 2016. The Company allocated the aggregate proceeds of the GECC Term Loan between the warrants and the debt obligation based on their relative fair values.&#160;&#160;The fair value of the warrants issued to GECC was determined using the Black-Scholes Model. The warrants fair value of $0.2 million is recorded as a discount to the debt obligation and is being amortized over the term of the loan using the effective interest method. If the maturity of the debt is accelerated in connection with any voluntary or mandatory prepayment, then the remaining discount amortization would be recognized immediately.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Interest Expense</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Interest expense for the Servier loan, GECC loan and Novartis note are shown below (in thousands):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="6" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Interest expense</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Servier loan</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">516</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">442</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">GECC term loan</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">417</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Novartis note</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">99</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">84</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Total interest expense</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,042</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">532</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Other Financings</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">ATM Agreement</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On February 4, 2011, the Company entered into an At Market Issuance Sales Agreement (the "2011 ATM Agreement"), with McNicoll, Lewis &amp; Vlak LLC (now known as MLV &amp; Co. LLC, "MLV"), under which it may sell shares of its common stock from time to time through the MLV, as the agent for the offer and sale of the shares, in an aggregate amount not to exceed the amount that can be sold under the Company's registration statement on Form S-3 (File No. 333-172197) filed with the SEC on February 11, 2011 and amended on March 10, 2011, June 3, 2011 and January 3, 2012, which was most recently declared effective by the SEC on January 17, 2012. MLV may sell the shares by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, on any other existing trading market for the Company's common stock or to or through a market maker. MLV may also sell the shares in privately negotiated transactions, subject to the Company's prior approval. From the inception of the 2011 ATM Agreement through March 31, 2012, the Company sold a total of 7,572,327 shares of common stock under this agreement for aggregate gross proceeds of $14.6 million, including 2,285,375 shares of common stock sold in the first quarter of 2012 for aggregate gross proceeds of $3.3 million. Total offering expenses incurred related to sales under the 2011 ATM Agreement from inception to March 31, 2012, were $0.4 million, including $0.1 million incurred in the first quarter of 2012.</div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; font-style: italic; text-indent: 9pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Underwritten Offering and Amendment to Shareholder Rights Plan</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On March 9, 2012, the Company completed an underwritten public offering of 29,669,154 shares of its common stock, and accompanying warrants to purchase one half of a share of common stock for each share purchased, at a public offering price of $1.32 per share. Total gross proceeds from the offering were approximately $39.2 million, before deducting underwriting discounts and commissions and estimated offering expenses totaling approximately $2.9 million. The warrants, which represent the right to acquire an aggregate of up to 14,834,577 shares of common stock, are immediately exercisable and have a five-year term and an exercise price of $1.76 per share.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company has amended its shareholder rights agreement to provide that it will not apply to any person or entity who becomes the beneficial owner of 20% or more but less than 40% of its outstanding common stock with the prior approval of its board of directors, and its board has approved purchasers in&#160;the March 2012 public offering becoming beneficial owners of 20% or more but less than 40% of its outstanding common stock as a result of their participation in the offering.&#160; As a result, such ownership by any such purchaser will not trigger the provisions of the rights agreement that would give each holder of the rights the right to receive upon exercise that number of common stock equivalents having a market value of two times the exercise price.&#160;&#160;The board's approval in this regard only applies to purchasers in&#160;such offering.&#160;</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_Long-TermDebtAndOtherFinancingsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_Long-TermDebtAndOtherFinancingsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Streamlining and Restructuring Charges<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Streamlining and Restructuring Charges [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Streamlining and Restructuring Charges</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">6.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Streamlining and Restructuring Charges</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;</font></div></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In January 2012, the Company implemented a streamlining of operations, which resulted in a restructuring plan designed to sharpen its focus on value-creating opportunities led by gevokizumab and its unique antibody discovery and development capabilities. The restructuring plan included a reduction of XOMA's personnel by 84 positions, or 34%, of which 52 were eliminated immediately and the remainder eliminated as of April 6, 2012. These staff reductions resulted primarily from the Company's decisions to utilize a contract manufacturing organization for Phase 3 and commercial antibody production and to eliminate internal research functions that are non-differentiating or that can be obtained cost-effectively by contract service providers.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three months ended March 31, 2012, in connection with this streamlining of operations, the Company recorded charges of $2.1 million related to severance, other termination benefits and outplacement services. The Company expects to incur an additional $0.1 million restructuring charge in the second quarter of 2012 related to severance, other termination benefits and outplacement services.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company plans to vacate two of its leased buildings in 2012 related to manufacturing operations and internal research functions. The Company did not incur any restructuring charges during the first quarter of 2012 in connection with the exit of these leased buildings as they are still in use; however, it expects to incur restructuring charges of approximately $1.2 million in the remainder of 2012, primarily related to the net present value of future minimum lease payments at the cease-use date, less potential estimated future sublease income.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of March 31, 2012, the Company performed an impairment analysis of property and equipment and leasehold improvements related to its manufacturing operations. Since the estimated undiscounted future cash inflows from a&#160;certain group of these assets were less than the carrying value, the Company determined that&#160;these assets&#160;were impaired and recorded a restructuring charge of $0.8 million. Further, the Company changed the useful life of certain property and equipment and leasehold improvements impacted by XOMA<font style="display: inline; font-family: Times New Roman;">'</font>s plans to vacate two leased buildings. As a result, the Company recorded accelerated depreciation of $0.9 million as a restructuring charge.&#160;The Company expects to incur additional restructuring charges of approximately $0.7 million in the remainder of &#160;2012 related to the&#160;accelerated depreciation&#160;of leasehold improvements.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The current and long-term portions of the outstanding restructuring liabilities are included in accrued and other liabilities and other liabilities - long-term on the condensed consolidated balance sheets and are based upon restructuring charges recognized as of March&#160;31, 2012 and December 31, 2011 in connection with the 2009 and 2012 restructuring plans. As of March&#160;31, 2012, the components of these liabilities are shown below (in thousands):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Employee Severance </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">and Other Benefits</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Facility Charges</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Asset </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Impairment <font style="display: inline; font-size: 70%; vertical-align: text-top;">(1)</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Total</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Balance at December 31, 2011</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">162</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">162</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Restructuring charges</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,070</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,707</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,777</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Cash payments</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,258</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(23</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,281</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Adjustments</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,707</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,699</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 52%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Balance at March 31, 2012</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">812</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">147</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">959</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">(1)&#160;&#160;Restructuring charges include non-cash impairments of property and equipment and leasehold improvements. However, these amounts are not included in the restructuring accrual.</font><br /></div><div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The restructuring charges the Company expects to incur in connection with the 2012 streamlining of operations are subject to various assumptions, and actual results may differ.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LegalProceedingsCommitmentsAndContingenciesAbstract', window );"><strong>Legal Proceedings, Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings, Commitments and Contingencies</a></td>
        <td class="text"><div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">10.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Legal Proceedings, Commitments and Contingencies</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On April 9, 2009, a complaint was filed in the Superior Court of Alameda County, California, in a lawsuit captioned Hedrick et al. v. Genentech, Inc. et al, Case No. 09-446158. The complaint asserts claims against Genentech, the Company and others for alleged strict liability for failure to warn, strict product liability, negligence, breach of warranty, fraudulent concealment, wrongful death and other claims based on injuries alleged to have occurred as a result of three individuals' treatment with RAPTIVA&#174;. The complaint seeks unspecified compensatory and punitive damages. Since then, additional complaints have been filed in the same court, bringing the total number of filed cases to seventy seven.&#160; The cases have been consolidated as a coordinated proceeding. &#160;All of the complaints allege the same claims and seek the same types of damages based on injuries alleged to have occurred as a result of the plaintiffs' treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of all but one of the cases pending in Alameda County Superior Court.&#160; The one Alameda County case not included in this settlement agreement is Kilzer v. Genentech, Inc., et al, Case No. RG-10-502461.&#160; The Company's agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.&#160;&#160; The Company believes the claims against it to be without merit and intends to defend against them vigorously.</div><div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On August 4, 2010, a petition was filed in the District Court of Dallas County, Texas in a case captioned McCall v. Genentech, Inc., et al., No. 10-09544.&#160; The defendants filed a Notice of Removal to the United States District Court for the Northern District of Texas on September 3, 2010.&#160; The removed case is captioned McCall v. Genentech, Inc., et al., No. 3:10-cv-01747-B. The petition asserts personal injury claims against Genentech, the Company and others arising out of plaintiff's treatment with RAPTIVA&#174;.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; The Company's agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On January 7, 2011, a complaint was filed in the United States District Court for the Northern District of Texas in a case captioned Massa v. Genentech, Inc., et al., No. 4:11CV70. This complaint alleges the same claims against Genentech, the Company and others and seeks the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; Effective April 18, 2012, the parties entered into a Confidential Settlement Agreement that will result in the dismissal, with prejudice, of this case.&#160; The Company's agreement with Genentech provides for an indemnity of XOMA, and payment of legal fees and funding of this settlement agreement by Genentech, which the Company believes is applicable to these matters.</div><div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On January 11, 2011, a complaint was filed in the United States District Court for the District of Massachusetts in a case captioned Sylvia, et al. v. Genentech, Inc., et al., No. 1:11-cv-10054-MLW.&#160; On June 13, 2011, a complaint was filed in the Supreme Court for the State of New York, Onondaga County.&#160; Defendants removed the case to the United States District Court for the Northern District of New York on November 3, 2011. &#160;These two complaints allege the same claims against Genentech, the Company and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; No trial date has been set in either case. The Company's agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which the Company believes is applicable to these matters. The Company believes the claims against it to be without merit and intends to defend against them vigorously.</div><div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On April 8, 2011, four complaints were filed in the United States District Court for the Eastern District of Michigan.&#160; The cases are captioned:&#160; Muniz v. Genentech, et al., 5:11-cv-11489-JCO-RSW; Tifenthal v. Genentech, et al., 2:11-cv-11488-DPH-LJM; Blair v. Genentech, et al., 2:11-cv-11463-SFC-MJH; and Marsh v. Genentech, et al., 2:11-cv-11462-RHC-MKM.&#160; The complaints allege the same claims against Genentech, the Company and others and seek the same types of damages as the complaints filed in the Superior Court of Alameda County, California referenced above.&#160; All four cases were transferred to the United States District Court for the Western District of Michigan.&#160; On October 26, 2011, the Court granted the Motions to Dismiss filed by Genentech and the Company in all four actions.&#160; On October 31, 2011, Plaintiffs filed a Notice of Appeal in each case in the United States Court of Appeal for the Sixth Circuit.&#160; The Company's agreement with Genentech provides for an indemnity of XOMA and payment of legal fees by Genentech which the Company believes is applicable to these matters. The Company believes the claims against it to be without merit and intends to defend against them vigorously.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LegalProceedingsCommitmentsAndContingenciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_LegalProceedingsCommitmentsAndContingenciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">8.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Income Taxes</div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company did not recognize any income tax expense for the three months ended March 31, 2012 and income tax expense was not material for the three months ended March 31, 2011. The Company's effective tax rate will fluctuate from period to period due to several factors inherent in the nature of the Company's operations and business transactions. The factors that most significantly impact this rate include the variability of licensing transactions in foreign jurisdictions.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_IncomeTaxesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_IncomeTaxesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_Stock-BasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">&#160;</div><div style="text-align: center;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">9.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Stock-based Compensation</div></td></tr></table></div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In the first quarter of 2012, the Board of Directors of the Company approved grants under the Long Term Incentive Plan for an aggregate of 940,900 stock options and an aggregate of 343,115 restricted stock units ("RSUs") to certain employees of the Company. The options vest monthly over four years and the RSUs vest annually over three years in equal increments.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company's employees, consultants and directors based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. This model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company's historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues. The forfeiture rate impacts the amount of aggregate compensation for both stock options and RSUs. To establish an estimate of forfeiture rate, the Company considers its historical experience of option forfeitures and terminations.</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair value of stock-based awards was estimated based on the following weighted average assumptions for the three months ended March 31, 2011 and 2010:</div><div style="text-align: justify; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: left; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Dividend yield</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">0</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected volatility</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">92</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">86</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Risk-free interest rate</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.05</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2.20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">%</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Expected term</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" colspan="3" valign="bottom" style="width: 11%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">5.6 years</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" colspan="3" valign="bottom" style="width: 11%;"><div style="text-align: right; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">5.6 years</div></td></tr></table></div><div style="text-align: center;">&#160;</div></div><div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock option activity for the three months ended March 31, 2012 was as follows:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 90%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Options</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Exercise Price </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Per Share</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Remaining </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Contractual Life </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(in years)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Aggregate </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Intrinsic Value </div><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Options outstanding at December 31, 2011</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,053,435</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12.55</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6.89</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Granted</div></td><td align="right" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">940,900</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.45</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Exercised</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(24,730</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.69</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Forfeited, expired or cancelled</div></td><td align="right" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(167,484</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">21.65</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Options outstanding at March 31, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,802,121</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">10.53</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7.28</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,375</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 42%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Options exercisable at March 31, 2012</div></td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,567,292</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14.96</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="right" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6.45</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">867</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The valuation of RSUs is determined at the date of grant using the closing stock price. To establish an estimate of forfeiture rate, the Company considers its historical experience of forfeitures and terminations.</div><div style="text-align: left; text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br /></div><div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unvested RSU activity for the three months ended March 31, 2012 is summarized below:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="width: 56%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="width: 10%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Weighted-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="width: 56%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Number of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Average Grant-</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Shares</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Date Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Unvested balance at December 31, 2011</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">903,874</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.69</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Granted</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">343,115</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1.29</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Vested</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Forfeited</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(132,575</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">1.69</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Unvested balance at March 31, 2012</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,114,414</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; padding-bottom: 4px; width: 9%; font-family: times new roman; font-size: 10pt;">1.57</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2012 and 2011 (in thousands):</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center;"><table cellpadding="0" cellspacing="0" style="width: 80%; font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; width: 22%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; width: 10%;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">2011</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Research and development</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">385</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,061</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 9pt; font-size: 10pt; margin-right: 0pt;">Selling, general and administrative</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">289</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">711</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 56%;"><div style="text-align: left; text-indent: -9pt; display: block; font-family: times new roman; margin-left: 18pt; font-size: 10pt; margin-right: 0pt;">Total stock-based compensation expense</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">674</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,772</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_Stock-BasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_Stock-BasedCompensationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBXAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (30,425)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (6,335)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
        <td class="nump">1,265<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,346<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementBenefitsPayments', window );">Common stock contribution to 401(k)</a></td>
        <td class="nump">1,134<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,046<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">674<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,772<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest on interest bearing obligations</a></td>
        <td class="nump">394<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">231<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UnrealizedGainLossOnWarrants', window );">Revaluation of contingent warrant liabilities</a></td>
        <td class="nump">14,357<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(2,390)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Restructuring charge related to long-lived assets</a></td>
        <td class="nump">1,707<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of discount and final payment fee on debt and debt issuance costs</a></td>
        <td class="nump">467<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">298<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized loss on foreign currency exchange</a></td>
        <td class="nump">376<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,619<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized loss on foreign exchange options</a></td>
        <td class="nump">276<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash adjustments</a></td>
        <td class="num">(43)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Trade and other receivables, net</a></td>
        <td class="nump">2,168<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">10,631<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(1,651)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">247<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(3,221)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(5,429)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump">884<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(6,156)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
        <td class="num">(37)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(90)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(11,675)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(3,200)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(548)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(888)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(548)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(888)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
        <td class="nump">39,480<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">4,129<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
        <td class="nump">0<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">20,102<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of debt</a></td>
        <td class="num">(714)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">38,766<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">24,231<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
        <td class="nump">0<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(573)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
        <td class="nump">26,543<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">20,143<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of the period</a></td>
        <td class="nump">48,344<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">37,304<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the end of the period</a></td>
        <td class="nump">74,887<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">56,874<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CashPaidDuringPeriodAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
        <td class="nump">0<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">15<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on long-term debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(8,899)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_IssuanceAndExtinguishmentOfWarrantLiabilities', window );">Issuance of contingent warrant liabilities</a></td>
        <td class="nump">6,386<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_InterestAddedPrincipalBalancesLong-TermDebt', window );">Interest added to principal balances on long-term debt</a></td>
        <td class="nump">$ 398<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr>
        <td colspan="4"></td>
      </tr>
      <tr>
        <td colspan="4">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2011 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense representing the noncash expenses charged against earnings in the period to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2420-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 45, 46, 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetImpairmentCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph f<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentIncreaseAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number APB14-1<br><br> -Paragraph 31<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 21<br><br> -Paragraph 16, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Represents the aggregate of gains (losses) on transactions that are unsettled as of the balance sheet date, which is therefore an adjustment to reconcile income (loss) from continuing operations to net cash provided by or used in continuing operations. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting entity's financial statements. For certain entities, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementBenefitsPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund non-pension postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherPostretirementBenefitsPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CashPaidDuringPeriodAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_CashPaidDuringPeriodAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_InterestAddedPrincipalBalancesLong-TermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unpaid interest added to the outstanding principal amount on long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_InterestAddedPrincipalBalancesLong-TermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_IssuanceAndExtinguishmentOfWarrantLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Noncash value of warrants and rights issued or extinguished. "Equity warrants and rights outstanding" represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_IssuanceAndExtinguishmentOfWarrantLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UnrealizedGainLossOnWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increases (decreases) in the market value of warrants whose gains (losses) were included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_UnrealizedGainLossOnWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Licensing, Collaborative and Other Arrangements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicensingCollaborativeAndOtherArrangementsAbstract', window );"><strong>Licensing, Collaborative and Other Arrangements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Licensing, Collaborative and Other Arrangements</a></td>
        <td class="text"><div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">5.&#160;</div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Licensing, Collaborative and Other Arrangements</div></td></tr></table></div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; font-style: italic; text-indent: 18pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Servier - U.S. Perindopril Franchise</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On January 17, 2012, the Company announced that it had acquired certain U.S. rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON&#174; (perindopril erbumine), a currently marketed ACE inhibitor, and three fixed-dose combination ("FDC") product candidates where a form of proprietary perindopril (perindopril arginine) is combined with another active ingredient(s), such as a calcium channel blocker. The Company assumed commercialization activities for ACEON&#174; in January 2012 following the transfer from Servier's previous licensee.&#160;&#160;In late February 2012, the Company initiated enrollment in a Phase 3 trial for perindopril arginine and amlodipine besylate, the first FDC product candidate. The trial, named PATH (<font style="display: inline; font-weight: bold;">P</font>erindopril <font style="display: inline; font-weight: bold;">A</font>mlodipine for the <font style="display: inline; font-weight: bold;">T</font>reatment of <font style="display: inline; font-weight: bold;">H</font>ypertension), is expected to enroll approximately 816 patients with hypertension to determine the safety and efficacy of the FDC versus either perindopril or amlodipine alone. Based on regulatory interaction to date, if&#160;the trial generates positive results, it is expected to be the only&#160;efficacy trial needed to complement&#160;existing clinical data&#160;and will&#160;support&#160;the submission of an application to the FDA seeking approval for this product candidate. Partial funding for the PATH trial was provided by Servier; the balance of study expenses, consisting primarily of costs generated by the Company's contract research organization, are expected to be paid over time from the profits generated by the Company's ACEON&#174; sales.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 27pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In connection with the original agreement, the Company paid a $1.5 million license fee to Servier in the third quarter of 2010. The Company also is required to pay a royalty on ACEON&#174; sales at a rate that is tiered based on sales levels and ranges from a mid-single digit to a mid-teen percentage rate. If approved, the Company also will pay a royalty on sales of the FDC product candidates in the mid-teen percentage rate. The FDC royalty rate is subject to reduction in the event of generic competition or if other intellectual property rights are required. The Company may be required to pay the following milestones: development milestones aggregating $8.5 million (assuming the Company exercises its options on the additional FDCs) and sales milestones of up to an aggregate $15.1 million, in each case for all of the FDC product candidates. The Company also may be required to make certain additional payments if the FDC product candidates receive FDA approval but certain minimum sales levels are not reached. The Company generally will be responsible for its development and commercialization expenses, but Servier has agreed to partially fund development of the first FDC product candidate.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-1<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingCollaborativeAndOtherArrangementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>xoma_LicensingCollaborativeAndOtherArrangementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>xoma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>7</ContextCount>
  <ElementCount>94</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Condensed Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/CondensedConsolidatedFinancialStatementDetail</Role>
      <ShortName>Condensed Consolidated Financial Statement Detail</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Licensing, Collaborative and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/LicensingCollaborativeAndOtherArrangements</Role>
      <ShortName>Licensing, Collaborative and Other Arrangements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Streamlining and Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/StreamliningAndRestructuringCharges</Role>
      <ShortName>Streamlining and Restructuring Charges</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Long-Term Debt and Other Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/LongtermDebtAndOtherFinancings</Role>
      <ShortName>Long-Term Debt and Other Financings</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Legal Proceedings, Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xoma.com/role/LegalProceedingsCommitmentsAndContingencies</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</Log>
    <Log type="Info">Process Flow-Through: 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>xoma-20120331.xml</File>
    <File>xoma-20120331.xsd</File>
    <File>xoma-20120331_cal.xml</File>
    <File>xoma-20120331_def.xml</File>
    <File>xoma-20120331_lab.xml</File>
    <File>xoma-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
